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   ABSTRACT	  
Biomedical	  Nanocrystal	  Agents:	  Design,	  Synthesis,	  and	  
Applications	  	  by	  
Minjung	  Cho	  
In	   these	   days,	   nanomaterials	   are	   applied	   in	   a	   variety	   of	   biomedical	  applications	   including	   magnetic	   resonance	   imaging	   (MRI),	   cell	   imaging,	   drug	  delivery,	   and	   cell	   separation.	   	   Most	   MRI	   contrast	   agents	   affect	   the	   longitudinal	  relaxation	   time	   (T1)	   and	   transverse	   relaxation	   time	   (T2)	   of	   water	   protons	   in	   the	  tissue	   and	   result	   in	   increased	   positive	   or	   negative	   contrast.	   	   Here,	   we	   report	   the	  optimization	  of	  r1	  (1/T1)	  or	  r2	  (1/T2)	  relaxivity	  dynamics	  with	  diameter	  controlled	  gadolinium	  oxide	  nanocrystals	  (2~22	  nm)	  and	  iron	  based	  magnetic	  nanocrystals	  (4	  ~33	   nm).	   The	   r1	   and	   r2	   MR	   relaxivity	   values	   of	   hydrated	   nanocrystals	   were	  optimized	   and	   examined	   depending	   on	   their	   core	   diameter,	   surface	   coating,	   and	  compositions;	  the	  high	  r1	  value	  of	  gadolinium	  oxide	  was	  40-­‐60	  S-­‐1mM-­‐1,	  which	  is	  10-­‐15	   fold	   higher	   than	   that	   of	   commercial	   Gd	   (III)	   chelates	   (4.3~4.6	   S-­‐1mM-­‐1).	  	  	  Moreover,	   in	  vitro	   toxicological	   studies	   revealed	   that	  polymer	   coated	  nanocrystals	  suspensions	  had	  no	  significant	  effect	  on	  human	  dermal	  fibroblast	  (HDF)	  cells	  even	  at	  high	  concentration.	   	  Towards	  multimodal	   imaging	  or	  multifunctional	  ability,	  we	  developed	  the	  iron	  oxide/QDs	  complexes,	  which	  consist	  of	  cores	  of	   iron	  oxide	  that	  act	   as	   nucleation	   sites	   for	   fluorescent	   QDs.	   	   The	   choice	   of	   variable	   QDs	   helped	   to	  visualize	   and	   remove	   large	   iron	   oxide	   materials	   in	   a	   magnetic	   separation.	  
	  	  Additionally,	   diluted	  materials	   concentrated	   on	   the	  magnet	   could	   be	   fluorescently	  detected	   even	   at	   very	   low	   concentration.	   The	   designed	   MRI	   or	   multifunctional	  nanomaterials	  will	  give	  great	  and	  powerful	  uses	  in	  biomedical	  applications.	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Chapter 1	  
Literature Review: The Preparation 
and Biomedical Applications of 
Inorganic Nanoparticles 
1.1. 	  Introduction	  
Nanotechnology	  is	  used	  to	  describe	  materials	  with	  a	  size	  below	  100	  nm	  and	  covers	  diverse	  fields	  including	  chemistry,	  material	  science,	  bioengineering,	  and	  even	  medicine.	   Nanotechnology	   makes	   use	   of	   the	   unique	   chemical	   and	   physical	  properties	   of	   nanoscale	   materials,	   which	   cannot	   be	   acquired	   in	   bulk	   state.	   In	  particular,	  magnetic	   iron	  oxide	  nanoparticles	  below	  30	  nm	  are	  superparamagnetic	  and	  exhibit	  high	  magnetization	  but	  have	  no	  residual	  magnetization	  in	  the	  absence	  of	  an	   external	   magnetic	   field.1-­‐5	   This	   superparamagnetic	   behavior	   of	   iron	   oxide	  nanoparticles,	  combined	  with	  low	  toxicity,	  makes	  them	  useful	  as	  carriers	  for	  driving	  drugs	   to	   the	   specific	   target	   cells	   (targeted	   drug	   delivery)	   and	   is	   able	   to	   use	   in	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multiplexed	  cell	  separation.6	  	  Iron	  oxide	  magnetic	  nanoparticles	  have	  widely	  used	  as	  contrast	  agents	  for	  magnetic	  resonance	  imaging	  (MRI).	  7,8	  
Among	   various	   imaging	   technologies,	   MRI	   is	   currently	   one	   of	   the	   most	  powerful	   imaging	   tools	   since	   it	   has	   several	   advantages	   including	   high	   spatial	  resolution,	  excellent	  contrast	  in	  soft	  tissue,	  non-­‐usage	  of	  radioisotopes	  or	  X-­‐rays.	  9	  It	  monitors	  the	  response	  of	  water	  protons	  to	  external	  magnetic	  field	  and	  visualizes	  the	  contrast	  in	  the	  image.	  MRI	  is	  a	  non-­‐invasive	  method	  and	  provides	  real-­‐time	  images	  of	  internal	  anatomy	  and	  physiology	  of	  living	  organisms.	  	  However,	  there	  is	  no	  little	  difference	   in	   normal	   and	   disease	   tissues	   in	   relaxation	   time,	   additional	   chemical	  supplements	   have	   been	   used	   for	   more	   accurate	   diagnosis.	   	   The	   most	   effective	  supplement	  is	  a	  contrast	  agent	  that	  accelerates	  T1	  or	  T2	  relaxation	  time.	  	  	  	  
The	  most	  widely	  used	   clinically	  MRI	   contrast	   agents	   are	  T1	   contrast	   agents	  using	   paramagnetic	   gadolinium	   (Gd)	   chelates.10,11	   In	   particular,	   Gd-­‐DTPA	   is	   a	  popular	   agent	   whose	   applications	   are	   focused	   on	   detecting	   the	   disruption	   of	   the	  blood	   brain	   barrier	   (BBB),	   the	   degree	   of	   vascularity,	   and	   flow	   dynamics.12	  	  	  However,	  the	  Gd	  chelates	  have	  still	  very	  low	  relaxivity	  values	  (4.3~4.6	  mM-­‐1S-­‐1),	  so	  a	  high	  dosage	  must	  be	  used	  for	  MR	  enhancement.13	  	  	  In	  recent	  years,	  gadolinum	  based	  nanoparticles	   could	   be	   good	   candidates	   for	   T1	   MRI	   contrast	   agents	   because	   the	  surface	  of	  nanoparticles	  contains	  a	   large	  number	  of	  metal	   ions	  with	  high	  magnetic	  moments.	   Gadolinium	   oxide	   (Gd2O3),	   gadolinium	   fluoride	   (GdF3),	   and	   gadolinium	  phosphate	   (GdPO4)	   nanoparticles	   have	   been	   applied	   as	   T1	   MRI	   contrast	   agents	  showing	   bright	   contrast.14-­‐21	   	   In	   contrast,	   iron	   oxide	   nanoparticles	   induce	   a	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shortening	   of	   T2	   relaxation	   time	   and	   show	   a	   darker	   image.	   For	   example,	  superparamagnetic	   iron	   oxide	   nanoparticles	   with	   biocompatible	   dextran	   coating	  exhibit	  large	  r2	  relaxivity	  (~200	  mM-­‐1S-­‐1)	  and	  are	  used	  for	  tumor	  evaluations.22,23	  	  	  	  
Fluorescent	   labeling	   is	   also	   an	   important	   technique	   that	   has	   been	   widely	  applied	   to	   the	   cell	   and	   tissue	   imaging.	   Specially,	   semiconductor	   nanocrystals,	  referred	  as	  quantum	  dots	  (QDs)	  are	  well	  known	  as	  fluorescent	  labeling	  probes.24-­‐26	  The	   important	   characteristics	   of	   QDs	   are	   high	   photoluminescence	   quantum	   yield	  (PLQYs,	   20~80	   %)	   comparing	   with	   fluorescent	   dyes,	   size	   tunable	   fluorescence	  spectra,	  and	  high	  photo	  stability.	  They	  allow	  for	  multiplex	  cell	  imaging	  and	  analysis	  using	  size	  tunable	  QDs.27-­‐30	  Furthermore,	  QDs	  can	  be	  useful	  for	  in	  vivo	  cell	  imaging	  and	  targeting.	  31,32	  	  
The	   combination	   of	   different	   nanomaterials	   provides	   multifunctional	  biomedical	   applications	   such	   as	   multimodal	   imaging	   and	   simultaneous	   diagnosis	  and	  treatment.33-­‐36	  For	  example,	  the	  combination	  of	  MRI	  contrast	  agent	  (iron	  oxide,	  gadolinium	   oxide)	   and	   fluorescent	   probe	   (QDs,	   fluorescent	   dye,	   or	   rare	   earth	  dopants)	   allows	   the	   detection	   of	   cancer	   through	   pre-­‐MRI	   diagnosis	   and	   optical	  imaging	  during	  surgery.	  	  Moreover,	  the	  combination	  of	  magnetic	  nanoparticles	  and	  sensing	  probes	   can	  manipulate	   the	   carriers	  under	   the	   external	  magnetic	   field	   and	  visualize	   the	   disease	   area	   for	   the	   treatment	   simultaneously.	   	   In	   this	   chapter,	   the	  preparation	   of	   various	   nanomaterials	   and	   their	   biomedical	   applications	   are	  discussed.	  33-­‐36	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1.2. 	  Preparation	  and	  properties	  of	  inorganic	  nanoparticles	  
1.2.1. 	  Gadolinium	  based	  nanoparticles	  
Since	  Gd3+	  has	  seven	  unpaired	  electrons	  with	  a	  large	  magnetic	  moment,	  most	  T1	   contrast	   agents	   are	   Gd3+	   based	   agents.35	   	   Due	   to	   the	   toxicity	   of	   Gd3+	   ion,	   the	  contrast	  agents	  are	   in	   the	   form	  of	  complexes	  with	  chelates,	  which	  are	  most	  stable	  and	  less	  toxic.	  	  Due	  to	  interaction	  with	  blood,	  Gd-­‐chelates	  have	  short	  life	  spans	  in	  the	  body	   and	   circulate	   in	   a	   non-­‐specific	   manner.	   Moreover,	   the	   relaxivity	   (r1)	   of	   Gd-­‐chelates	   is	   relatively	   low	   (4.6	   mM-­‐1S-­‐1)	   at	   1.5	   T.12,37,38	   Very	   recently,	   gadolinium	  based	  nanoparticles	  such	  as	  gadolinium	  oxide	  (Gd2O3),	  gadolinium	  fluoride	  (GdF3),	  and	  gadolinium	  phosphate	  (GdPO4)	  are	  developed	  as	  new	  T1	  contrast	  agents	  with	  high	  relaxivity.19,39-­‐43	  
	  
Figure	   1-­‐1	   Electron	   configuaration	   and	   magnetic	   moment	   of	   metal	   ions,	   adapted	  from	  ref.	  35	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The	   Gd2O3	   nanoparticle-­‐based	   agents	   have	   been	   prepared	   with	   small	   core	  sizes	   (<	   5	   nm)	   and	   stabilizing	   biocompatible	   coatings	   of	   poly	   (ethylene	   glycol)	  (PEG)19,43,	   dextran39,	   and	   silica40	   since	   non-­‐coated	   nanoparticles	   are	   pH	   unstable	  and	   are	   not	   very	   water-­‐soluble.	   	   The	   Fortin	   and	   coworkers	   prepared	   ultra-­‐small	  gadolinium	   oxide	   nanoparticles	   stabilized	   by	   PEG.43	   The	   resulting	   Gd2O3	  nanoparticles	   had	   uniform	   size	   of	   3	   nm	   and	   they	   are	   well	   soluble	   in	   water.	   The	  relaxivity	   was	   twice	   as	   high	   as	   that	   of	   Gd-­‐DTPA.	   	   The	   Lee	   and	   coworkers	   also	  explored	  the	  ultrasmall	  Gd	  oxide	  nanoparticles	  (<	  2	  nm)	  that	  had	  a	  high	  r1	  value	  and	  obtained	   better	   contrast	   in	  vivo	  MR	   imaging.19	  Moreover,	   dextran	   stabilized	   small	  gadolinium	   oxide	   nanoparticles	   were	   synthesized	   by	   the	   reduction	   and	   co-­‐precipiation	  reaction	  of	  gadolinium	  salt	  (GdCl3)	  in	  aqueous	  media	  in	  the	  presence	  of	  dextran	  as	  a	  stabilizer.39	  Due	  to	  their	  large	  hydrodynamic	  size	  (>	  50	  nm),	  it	  is	  hard	  to	   apply	   them	   as	   MRI	   contrast	   agents	   due	   to	   the	   particle	   agglomeration	   and	  polydispersity.	  	  
GdF3	   (or	   GdF3/LaF3)	   nanoparticles	  were	   investigated	   as	   T1	   contrast	   agents	  with	  the	  surface	  functionalization	  with	  2-­‐aminoethyl	  phosphate	  group	  or	  negatively	  charged	  citrate	  group.41	  Dextran	  coated	  GdPO4	  nanoparticles	  were	  synthesized	  by	  a	  hydrothermal	   process	   in	   the	  presence	   of	   dextran.42	   These	  Gd	  based	  nanoparticles	  showed	  strong	  positive	  contrast	  effect.	  	  The	  Table	  1-­‐1	  shows	  the	  T1	  contrast	  agents	  based	  on	  the	  gadolinium	  based	  nanoparticles.	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Table	   1-­‐1	   T1	   contrast	   agents	   based	   on	   gadolinium	   based	   nanoparticles,	   adapted	  from	  ref.	  35	  	  
	  
1.2.2. Iron	  oxide	  magnetic	  nanoparticles	  
Superparamagnetic	   iron	   oxide	   nanoparticles	   (SPIOs)	   can	   serve	   as	   MRI	  contrast	   agents	   in	   diagnosis,	   heat	   mediators	   in	   hyperthermia	   treatments,	   and	  colloidal	  carriers	  for	  drug	  delivery	  targeted	  at	  cancer.4,5,44-­‐46	  Among	  several	  types	  of	  iron	  oxide,	  magnetite	  (Fe3O4)	  or	  maghemite(γ-­‐Fe2O3)	  are	  widely	  used	  for	  biomedical	  application	  because	  they	  include	  high	  magnetic	  moments,	  have	  chemical	  stability	  in	  physiological	  conditions,	  and	  low	  toxicity.4	  	  
The	   simplest	   way	   of	   synthesizing	   iron	   oxide	   nanoparticles	   is	   the	   co-­‐precipitation,	  which	  involves	  the	  simultaneous	  precipitation	  of	  Fe2+	  and	  Fe3+	  ions	  in	  basic	   aqueous	   solution.47,48	   After	   preparation,	   the	   iron	   oxide	   nanoparticles	   are	  usually	   coated	   with	   hydrophilic	   polymers	   such	   as	   dextran	   in	   order	   to	   guarantee	  their	   stability.	   	   However,	   the	   resulting	   iron	   oxide	   nanoparticles	   have	   low	  crystallinity	  and	   large	  polydispersity.	   	  Another	  method	  of	   synthesis	   is	  water-­‐in-­‐oil	  microemulsions.	   49	   	   In	   this	  method,	   a	   certain	   amount	  of	  water	   is	   added	   to	   a	   large	  
	   25	  	  
amount	   of	   non-­‐polar	   solvent	   such	   as	   oil	   and	   homogeneous	   droplets	   of	   water	   are	  stabilized	  by	  amphiphilic	  surfactants.	  	  However,	  limited	  reaction	  temperature	  leads	  to	  low	  crystallinity	  and	  low	  product	  yield.	  
In	   the	   last,	   iron	   oxide	   nanocrystals	   were	   synthesized	   by	   high	   temperature	  thermo-­‐decomposition	   of	   organometallic	   precursors	   in	   the	   presence	   of	   organic	  surfactant	   and	   solvent.50,51	   This	   method	   can	   control	   the	   nucleation	   and	   growth	  kinetics	   of	   the	   particles	   and	   offer	   high	   crystallinity,	   particle	   monodispersity,	   and	  high	  yield.	  	  These	  iron	  oxide	  nanoparticles	  can	  be	  functionalized	  with	  biocompatible	  coating	  including	  dextran	  or	  PEG	  polymers	  for	  biomedical	  applications.	  	  
1.2.3. 	  Semiconductor	  nanocrystals	  (quantum	  dots)	  
Quantum	   dots	   (QDs)	   are	   inorganic	   semiconductor	   fluorophores	   and	   have	  emerged	   as	   sensing	   probes	   for	   biomedical	   applications.26,27,32,52,53	   The	   optical	  properties	  such	  as	  absorption	  and	  emission	  spectra	  can	  be	  tunable	  from	  ultraviolet	  (UV)	  to	  near	  infrared	  (NIR)	  by	  confining	  the	  electrons	  in	  variable	  sizes	  and	  energy	  band	   gaps.53-­‐58	   For	   example,	   CdSe	   QDs	   were	   synthesized	   by	   high-­‐temperature	  decomposition	  of	  organometallic	  precursors	   in	  the	  presence	  of	  organic	  surfactants	  and	   solvents.	   59-­‐62	   	   Small	   CdSe	   QDs	   (~2	   nm	   diameter)	   show	   blue	   fluorescence	  emission	  from	  380	  to	  440	  nm,	  whereas,	  large	  QDs	  (4~6	  nm)	  emit	  red	  fluorescence	  from	  605	  to	  630	  nm.24,63	  QDs	  have	  high	  brightness	  and	  photo	  stability	  compared	  to	  the	  fluorescent	  organic	  dye.	  	  Furthermore,	  the	  PLQY	  can	  be	  enhanced	  to	  80	  %	  by	  the	  deposition	  of	  a	  shell	  of	  higher	  band-­‐gap	  QDs	  (e.g.	  ZnS	  or	  CdS)	  on	  the	  CdSe	  core.64	  	  By	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over	   coating	   with	   biocompatible	   polymers,	   QDs	   are	   widely	   used	   for	   biomedical	  imaging	  as	  a	  fluorescent	  sensing	  probe	  in	  vitro	  or	  in	  vivo.	  24,25,32,53,65-­‐67	  
1.2.4. Multifunctional	  magnetic-­‐fluorescent	  nanoparticles	  
The	  combination	  of	  a	  magnetic	  and	  a	  fluorescent	  component	  may	  provide	  a	  new	  multifunctional	   nanomaterial	   with	   a	   broad	   range	   of	   biomedical	   applications.	  	  The	  multifunctional	  magnetic-­‐fluorescent	  nanomaterials	  have	  either	  organic	  dyes	  or	  QDs	  as	  fluorescent	  domains	  and	  iron	  oxide	  or	  iron	  based	  magnetic	  nanoparticles	  as	  magnetic	  domains.	   	  There	   are	   three	   types	  of	   strategies	   to	  prepare	  multifunctional	  nanomaterials:	  1)	  the	  encapsulation	  of	  the	  magnetic	  and	  fluorescent	  domains	  inside	  one	  domain;	  2)	   the	  direct	  reaction	  between	  the	   fluorescent	  and	  magnetic	  domains	  using	  ligand	  linking;	  3)	  the	  seed	  mediated	  inorganic	  synthesis.36	  	  
First,	  in	  encapsulation,	  the	  magnetic	  and	  fluorescent	  domains	  are	  embedded	  together	   in	   a	  nano	  or	   a	  micro-­‐sized	   shell.	   	   The	   encapsulating	  materials	  have	  been	  explored	   from	   polypeptides	   to	   polyelectrolytes,	   styrene/acrylamine,	   and	   silica	  materials.68-­‐71	  	  For	  example,	  CdSe/ZnS	  QDs	  (3-­‐5	  nm)	  and	  Fe3O4	  nanoparticles	  (6	  nm)	  were	  embedded	  in	  the	  meso-­‐porous	  silica	  beads	  (3-­‐5	  um	  diameter).70	  	  This	  method	  is	   relatively	   simple	   and	   suitable	   for	   in	   vitro	   applications,72-­‐74	   but	   the	   resulting	  materials	   are	   relatively	   large	   (>100	   nm)	   and	   easily	   aggregated.	   	   In	   addition,	  magnetic	   nanoparticles	   quench	   the	   fluorescence	   of	   QDs	   through	   electron	   energy	  transfer	  when	  packed	  together	  inside	  the	  shell.75,76	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Second,	   a	   magnetic	   nanoparticle	   is	   linked	   covalently	   to	   the	   fluorescent	  probe.77-­‐82	   Simply,	   hydroxyl-­‐functionalized	   iron	  oxide	  nanoparticles	   are	   covalently	  linked	  to	  the	  NHS-­‐Cy5.5	  fluorescent	  dye	  by	  means	  of	  amino-­‐PEG	  silane	  molecules.78	  Magnetic	  nanoparticles	  are	  also	  conjugated	  with	  fluorescent	  dyes	  or	  QDs	  via	  m-­‐2-­‐3-­‐dimercaptosuccinic	   acid	   (DMSA)	   ligand	  or	   dodecylamine	   (DDA)	   cross	   linkers.77,80	  This	  method	  can	  keep	  the	  particle	  size	  small	  but	  is	  limited	  by	  low	  product	  yield	  and	  the	  complicated	  functionality	  of	  linkers.	  	  	  	  
The	   recent	   reported	   method	   for	   multifunctional	   magnetic-­‐fluorescent	  nanoparticles	   is	  based	  on	  the	  direct	  synthesis	  via	  seed	  mediation.	   	   In	   this	  method,	  QDs	  nucleate	  and	  grow	  directly	  on	  the	  surface	  of	  magnetic	  nanoparticles	  including	  iron	   oxide.83-­‐90	   	   It	   can	   be	   extended	   to	   the	   preparation	   of	   various	   hybrid	  nanostructures	  including	  metal-­‐semiconductor,	  metal	  oxide-­‐metal,	  and	  metal	  oxide-­‐semiconductor	   and	   it	   offers	   the	  products	  with	   small	   size,	   homogeneous	   structure,	  and	   tunable	   stoichiometry.91-­‐96	   	   The	   Figure	   1-­‐2	   shows	   the	   summary	   of	   types	   of	  multifunctional	  magnetic-­‐fluorescent	  nanomaterials.	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Figure	  1-­‐2	  The	  summary	  of	  multifunctional	  magnetic-­‐fluorescent	  nanocomposites	  	  
1.3. Biomedical	  applications	  of	  inorganic	  nanoparticles	  
1.3.1. Magnetic	  resonance	  imaging	  (MRI)	  
1.3.1.1. Basic	  principle	  of	  MRI	  contrast	  agents	  
Magnetic	  resonance	  imaging	  (MRI)	  is	  currently	  one	  of	  the	  most	  powerful	  and	  non-­‐invasive	   diagnostic	   tools	   and	   is	   based	   on	   nuclear	  magnetic	   resonance	   (NMR)	  with	   the	   relaxation	   of	   proton	   spins	   in	   a	   magnetic	   field.97-­‐99	   The	   contrast	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enhancement	   in	  MRI	   occurs	   from	   the	   interaction	   between	   the	   contrast	   agent	   and	  neighboring	  water	  molecules.	  	  Adding	  contrast	  agents	  help	  to	  get	  more	  specific	  and	  enhanced	  contrast	  images	  in	  MRI.	  37,38	  	  
Once	  the	  nuclei	  of	  protons	  is	  exposed	  to	  a	  strong	  magnetic	  field,	  their	  spins	  align	   in	   a	   parallel	   or	   antiparallel	   direction	   to	   the	   field.35,100	   When	   inducing	   by	   a	  resonant	   lamor	   frequency	   (ω0=	   γB0,	  where	  ω0	  =	  lamor	   frequency,	   γ=	   gyromagnetic	  ratio,	   and	   B0=	  magnetic	   field),	   the	   nuclei	   absorbs	   the	   electromagnetic	   energy	   and	  excites	   to	   the	   antiparallel	   state	   (Figure	   1-­‐3	   (a)).	   	   As	   antiparallel	   spin	   population	  increases,	   the	   longitudinal	   magnetization	   (Mz),	   which	   is	   parallel	   to	   the	   external	  magnetic	   field,	  decreases	  and	   transverse	  magnetization	   (Mxy)	   is	   generated	   (Figure	  1-­‐3	  (b)).	   	  When	  removing	  lamor	  frequency,	  the	  nuclear	  spin	  returns	  to	  their	  initial	  state.	   	   It	   is	   called	   as	   a	   relaxation.	   There	   are	   two	   relaxation	   pathways.	   First	   is	  longitudinal	   magnetization	   recovery	   (T1	   relaxation).	   	   T1	   is	   the	   time	   required	   for	  longitudinal	  magnetization	   recovering	   to	  63	  %	  of	   the	   initial	   state	   (Figure	  1-­‐3	   (c)).	  	  The	   second	   calls	   transverse	   magnetization	   decay	   (T2	   relaxation).	   	   It	   involves	   the	  induced	  magnetization	  on	  the	  perpendicular	  plane	  disappearing	  by	  the	  dephasing	  of	  spins	  (Figure	  1-­‐3	  (d)).	  	  T2	  is	  the	  time	  required	  for	  transverse	  magnetization	  to	  drop	  to	  37	  %	  of	  its	  initial	  magnitude.	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Figure	  1-­‐3	  Principles	  of	  magnetic	  resonance	  imaging	  (MRI).	  (a-­‐b)	  the	  process	  for	  the	  relaxation	  (c)	  T1	  relaxation	  (d)	  T2	  	  relaxation,	  adapted	  from	  ref.	  35,100	  
Contrast	   agents	   are	   used	   to	   improve	   the	   visualization	   of	   substances	   by	  accelerating	  their	  relaxation	  times.	  35	  The	  relaxivity	  (ri)	  is	  defined	  as	  the	  increase	  in	  relaxation	  rate	  of	  water	  protons	   (Ri)	  per	   concentration	  of	  agents	  or	   the	  slope	  of	  a	  plot	  of	  (1/Ti-­‐1/To)	  versus	  the	  concentration	  of	  agents	  (mM).	  	  
𝑅! =    1𝑇! = 1𝑇! + 𝑟!𝐶  	  
where	  Ri	   is	   the	   relaxation	   rate	  of	   the	  aqueous	   solution,	  To	   is	   the	   relaxation	  time	   of	  water	  without	   contrast	   agent,	   Ti	   is	   the	   relaxation	   time	   in	   the	   presence	   of	  contrast	  agent,	  C	  is	  the	  concentration	  of	  contrast	  agent	  (mM),	  and	  ri	  is	  its	  relaxivity	  (S-­‐1mM-­‐1).	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1.3.1.2. 	  Gd2O3	  based	  T1	  MRI	  contrast	  agents	  
The	   paramagnetic	   gadolinium	   ions	   on	   the	   surface	   of	   Gd2O3	   nanoparticles	  make	   a	   shorten	   T1	   relaxation	   time.	   The	   Bridot	   and	   coworkers	   reported	   that	  gadolinium	  oxide	  nanoparticles	  act	  as	  T1	  contrast	  agents.40	  They	  synthesized	  Gd2O3	  nanoparticles	  with	  diameters	  of	  2.2,	  3.8,	  and	  4.6	  nm,	  coated	  with	  dye	  doped	  silica	  shells	  and	  evaluated	  the	  effect	  of	  the	  size	  of	  Gd2O3	  core	  on	  the	  T1	  MR	  relaxivity.	  	  The	  r1	   relaxivities	  of	   the	  Gd2O3	  nanoparticles	  with	  2.2,	  3.8,	  and	  4.6	  nm	  core	  sizes	  were	  8.8,	  8.8,	  and	  4.4	  mM-­‐1S-­‐1	  at	  1.5	  T,	  respectively.	   	  These	  r1	  values	  are	  higher	  than	  the	  value	  of	  Gd-­‐DTPA	  (4.1	  mM-­‐1S-­‐1).12,37,38	  Moreover,	  the	  dye-­‐doped	  silica	  shell	  acts	  as	  a	  fluorescent	   probe	   as	  well	   as	   prevents	   the	   release	   of	   toxic	   Gd3+	  ion	   to	   the	   outside.	  They	   showed	   the	   use	   of	   biocompatible	   gadolinium	   oxide	   nanoparticles	  (GadoSiPEG2C)	   as	   in	  vivo	   dual	  MRI	   and	   fluorescence	   imaging	   (Figure	   1-­‐4).40	   	   The	  MRI	   and	   fluorescence	   imaging	   after	   injection	   revealed	   that	   the	   GadoSiPEG2C	  particles	  accumulated	  in	  the	  kidney	  and	  bladder.	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Figure	  1-­‐4	  T1	  weighted	  MR	  images	  and	  fluorescence	  imaging	  T1-­‐weighted	   images	   of	   rat	   a)	   before	   and	   b)	   1	   h	   after	   injection	   of	   GadoSiPEG2C;	  Fluorescence	  reflectance	  imaging	  of	  a	  mouse	  c)	  before	  and	  d)	  3	  h	  after	  the	  injection	  of	  GadoSiPEG2C	  (B:	  bladder,	  K:	  kidney),	  adapted	  from	  ref.40	  In	   2009,	   the	   Lee	   and	   coworkers	   prepared	   ultra-­‐small	   gadolinium	   oxide	  nanoparticles	  with	  an	  average	  diameter	  of	  1.0	  nm.19	  	  They	  provided	  the	  r1	  relaxivity	  value	  of	  9.9	  mM-­‐1S-­‐1,	  which	  is	  much	  higher	  than	  those	  of	  Gd	  (III)	  chelates	  (4.1	  mM-­‐1S-­‐
1)	   at	   1.5	   T.37,38	   The	   Gd	   (III)	   ions	   in	   the	   particles	   accelerates	   the	   longitudinal	  relaxation	  of	  water	  proton,	  providing	   large	  r1	  values.	  They	  also	  addressed	  the	  size	  effects	  on	  relaxivity	  and	  took	   in	  vivo	  MR	  images	  of	  a	  rat	  with	  brain	  tumor	  using	  d-­‐glucuronic	  acid	  coated	  gadolinium	  oxide	  nanoparticles.	  Figure	  1-­‐5	  showed	   in	  vitro	  cell	   toxicities	   using	   different	   cell	   lines	   and	   MR	   contrast	   enhancement	   images	   of	  brain	   tumor	  after	   injection.	   	  Moreover,	  Figure	  1-­‐6	  monitored	   in	  vivo	  MR	   images	  of	  both	  kidney	  and	  bladder	  after	  vein	  injection	  of	  the	  sample.	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Figure	  1-­‐5	  In	  vitro	  cytotoxicity	  and	  T1	  MR	  images	  of	  a	  brain	  tumor	  (a)	  In	  vitro	  cytotoxicity	  test	  of	  (i)	  DU145	  and	  (ii)	  NCTC1469	  cell	  lines.	  (b)	  In	  vivo	  T1	  MR	  images	  of	  a	  brain	  tumor	  of	  a	  rat,	  adapted	  from	  ref.	  19	  
	  
Figure	  1-­‐6	  In	  vivo	  T1	  MR	  images	  of	  a	  rat	  with	  a	  brain	  tumor.	  (a)	   Kidney,	   (b)	   bladder	   contrast	   enhancement,	   and	   (c)	   blood	   pool	   effect,	   adapted	  from	  ref.19	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Table	  1-­‐2	  shows	  the	  summary	  of	  Gd2O3	  nanoparticle	  based	  T1	  MRI	  contrast	  agents.	  The	  size	  uniformity	  of	  nanoparticle,	   low	  relaxivity,	  and	  the	  dependences	  of	  size	   and	   surface	   coating	   on	   the	   relaxation	   are	   still	   undergoing	   researches.	   	   For	  future	  clinical	  diagnosis	  and	  active	  target	  molecular	  imaging,	  the	  long-­‐term	  stability,	  long	  blood	  circulation	  time,	  and	  bio-­‐distribution	  of	  Gd2O3	  nanoparticles	  are	  essential	  to	  achieve	  ideal	  MRI	  contrast	  agent.	  
Table	  1-­‐2	  The	  summary	  of	  r1	  relaxivities	  of	  gadolinium	  oxide	  T1	  contrast	  agents	  
Sample	   Coating	   Size	  (nm)	   r1	  (mM-­‐1S-­‐1)	   B0	  Field	  (T)	   Reference	  Gd-­‐DTPA(Magnevist)	   DTPA	   -­‐	   4.1	   1.5	   ref12,37,38	  Gd-­‐DTPA-­‐BMA	  (Omniscan)	   DTPA-­‐BMA	   -­‐	   3.84	   1.5	   ref37,38	  Gd-­‐TETA	   TETA	   	   2.1	   1.5	   ref38	  PEG	  Gd2O3	   PEG	   3	   9.4	   1.5	   ref43	  PEG	  Gd2O3	   PEG-­‐dialysis	   3-­‐5	   (3	  days)	  22.8	  (6	  days)	   1.5	   ref17	  Gd2O3	   D-­‐glucuronic	  acid	   1.5	   9.9	   1.5	   ref19	  Gd2O3	   PEG-­‐silane	   2.2	   8.8	   7	   ref40	  Gd2O3	   PEG-­‐silane	   3.8	   8.8	   7	   ref40	  Gd2O3	   PEG-­‐silane	   4.6	   4.4	   7	   ref40	  Gd2O3	   PEG-­‐silane	   30	   0.1	   7	   ref43	  Gd2O3	  nanorod	   APS	  silinization	   2.5/18	   1.5	   9.4	   ref101	  Gd2O3	   DEG	   3	   2.64	   1.5	   ref102	  Gd2O3	   DEG	   60	   2.22	   1.5	   ref102	  Gd2O3	   DEG	   75	   2.05	   1.5	   ref102	  Gd2O3	   DEG	   105	   1.86	   1.5	   ref102	  Gd2O3	   SiO2	   10	   3.48	   1.5	   ref103	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1.3.1.3. Iron	  oxide	  based	  T2	  MRI	  contrast	  agents	  
Iron	  oxide	  nanoparticles	  are	   superparamagnetic,	   losing	   their	  magnetization	  in	  the	  absence	  of	  an	  external	  magnetic	  field.	   	  On	  the	  other	  hand,	  when	  applying	  an	  external	   magnetic	   field,	   they	   exhibit	   strong	   magnetization,	   which	   induces	  inhomogeneous	   local	  magnetic	   field	   and	   activates	   the	   dephasing	   of	   protons.	   As	   a	  result,	   iron	   oxide	   nanoparticles	  make	   a	   shorten	  T2	   relaxation	   time	   and	   produce	   a	  decreased	  signal	  in	  T2	  weighted	  MR	  image.35	  	  	  
The	  iron	  oxide	  nanoparticles	  are	  classified	  by	  their	  sizes;	  1)	  micrometer-­‐size	  paramagnetic	  iron	  oxide	  (MPIO,	  <	  5	  um);	  2)	  superparamagnetic	  iron	  oxide	  (SPIO,	  <	  100	  nm);	  3)	  ultra	  small	  superparamagnetic	  iron	  oxide	  (USPIO,	  <	  40	  nm).35	  The	  SPIO	  or	   USPIO	   is	   widely	   used	   as	   MRI	   contrast	   agent.104	   	   Due	   to	   the	   large	   magnetic	  moments,	   SPIO	   or	   USPIO	   can	   induce	   local	   magnetic	   field	   under	   the	   external	  magnetic	   field	  and	  thus	  yield	  an	  enhancement	   in	   the	   image.	  USPIO	  with	  diameters	  less	  than	  40	  nm	  have	  been	  clinically	  investigated	  as	  contrast	  agents	  that	  accumulate	  at	   the	   margins	   of	   brain	   tumors	   and	   offers	   prolonged	   delineation	   due	   to	   lower	  diffusion	  from	  tumor	  sites.105	  	  
The	  detection	  of	  lymph	  nodes	  is	  critical	  for	  checking	  an	  accurate	  tumor	  stage	  and	  planning	  a	  subsequent	  therapy.	  Since	  USPIO	  is	  very	  small	  (<	  40	  nm),	   they	  can	  travel	   through	   blood	   vessels	   and	   transport	   to	   lymph	   nodes	   through	   lymphatic	  vessels.105,106	   Figure	   1-­‐7	   (b)	   showed	   the	   lymph-­‐node	   metastases	   in	   patients	   with	  prostate	   cancer	   using	   USPIO.	   	   A	   SPIO	   or	   USPIO	   based	   T2	   contrast	   agent	   leads	   to	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contrast	  enhancement	  of	  tumors	  as	  well	  as	  conjugation	  with	  biological	  target	  probes,	  antibodies,	  and	  other	  imaging	  probes.	  Therefore,	   iron	  oxide	  T2	  contrast	  agents	  can	  be	  used	  for	  target	  specific	  in	  vivo	  MR	  imaging	  and	  tracking	  of	  cells.	  	  
	  
	  
Figure	  1-­‐7	  MR	  images	  of	  a	  metastatic	  lymph	  node	  using	  USPIO	  (a)	  Schematic	  diagram	  of	  an	  action	  of	  USPIO,	  (b)	  MR	  images	  of	  a	  metastatic	   lymph	  node	  and	  c)	  after	  USPIO,	  adapted	  from	  ref.105,106	  	  
	   37	  	  
1.3.2. 	  Imaging	  and	  sensing	  
1.3.2.1. Cellular	  labeling	  and	  sensing	  
Fluorescence	  imaging	  is	  widely	  used	  in	  clinical	  diagnosis.	  	  The	  Alivisatos	  and	  coworkers	  established	  the	  utility	  of	  QDs	  for	   fluorescent	   labeling.25	  The	  3T3	  mouse	  fibroblast	   cell	   was	   fluorescently	   labeled	   using	   two	   different	   CdSe/CdS	   core/shell	  nanocrystals	   (2	   nm	   green	   QDs	   and	   4	   nm	   red	   QDs).25	   Figure	   1-­‐8	   shows	   that	   the	  nucleus	   was	   labeled	   with	   green	   QDs	   and	   f-­‐actin	   filaments	   were	   labeled	   with	   red	  QDs.25	  
	  Figure	  1-­‐8	  Cross	  section	  of	  a	  dual-­‐labeled	  sample	  with	  mouse	  3T3	  fibroblast	  cell,	  adapted	  from	  ref.25	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1.3.2.2. Tumor	  targeting	  and	  sensing	  
Antibody-­‐conjugated	   QDs	   have	   allowed	   the	   real-­‐time	   tracking	   of	   single	  molecule	  on	  the	  surface	  of	  living	  cells	  with	  high	  sensitivity.	  	  The	  Nie	  and	  coworkers	  reported	   the	   development	   of	   bio-­‐conjugated	   QDs	   probes	   suitable	   for	   in	   vivo	  targeting	  and	   imaging	  of	   cancer	  cells.32	   	  They	  examined	  how	   functional	  groups	  on	  the	  QD	  probe	  affect	   targeted	   in	  vivo	   imaging.	   	  Figure	  1-­‐9	  compared	   in	  vivo	   images	  from	   three	   types	   of	   QDs	   with	   COOH,	   PEG,	   and	   PEG_PSMA	   antibody.	   With	   COOH	  probe,	  no	  tumor	  signal	  was	  observed	  and	  only	  weak	  tumor	  signal	  was	  detected	  with	  PEG	   probe	   (passive	   targeting).	   	   When	   using	   PEG-­‐PSMA	   antibody	   conjugated	   QD	  probe	   (active	   targeting),	   the	  high	   tumor	   signal	  was	   shown.	  This	   result	   shows	   that	  the	  active	  tumor	  targeting	  using	  tumor-­‐specific	  ligand	  is	  the	  most	  efficient	  probe.	  
They	  also	  explored	  in	  vivo	  imaging	  with	  multicolor	  QDs-­‐encoded	  micro-­‐bead.	  The	  0.5-­‐μm	  polymer	  beads	  were	  doped	  with	  green,	  yellow	  or	  red	  QDs	  and	  they	  were	  injected	   into	   a	   mouse	   at	   three	   different	   locations.	   Three	   different	   QDs	   encoded	  beads	   were	   fluorescently	   detected	   simultaneously	   in	   a	   mouse	   (Figure	   1-­‐10).	  Approximately	   1,000	   of	   the	  QD-­‐labeled	   cells	  were	   injected	   on	   the	   right	   flank	   of	   a	  mouse,	  while	  the	  same	  number	  of	  GFP-­‐labeled	  cells	  was	  injected	  on	  the	  left	  flank.	  	  
	   39	  	  
	  
Figure	  1-­‐9	  In	  vivo	  fluorescence	  images	  of	  tumor-­‐bearing	  mice	  using	  QD	  probes	  QD	  probes	  with	  carboxylic	  acid	  groups	  (left),	  PEG	  groups	  (middle)	  and	  PEG-­‐PSMA	  Ab	   conjugates	   (right);	  A	   color	   image	   (top),	   two	   fluorescence	   spectra	   from	  QD	  and	  animal	  skin	  (middle),	  and	  a	  spectrally	  resolved	  image	  (bottom)	  were	  obtained	  from	  the	   live	   mouse	   models	   bearing	   C4-­‐2	   human	   prostate	   tumors	   (0.5–1.0	   cm	   in	  diameter).	  The	  site	  of	  QD	  injection	  was	  observed	  as	  a	  red	  spot	  on	  the	  tail,	  adapted	  from	  ref.	  32	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Figure	  1-­‐10	  Sensitivity	  and	  multicolor	  capability	  of	  QD	  imaging	  in	  live	  animals.	  The	   comparison	   between	   QD-­‐tagged	   and	   GFP	   transfected	   cancer	   cells	   (a)	   and	  simultaneous	   in	  vivo	   imaging	  of	  multicolor	  QD-­‐encoded	  microbeads	   (b)	  The	   right-­‐hand	   images	   show	   QD-­‐tagged	   cancer	   cells	   (orange,	   upper)	   and	   GFP-­‐labeled	   cells	  (green,	  lower),	  adapted	  from	  ref.	  32	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Multifunctional	  imaging	  and	  separation	   	  
Figure	  1-­‐11	  shows	  the	  biomedical	  applications	  of	  multifunctional	  magnetic-­‐fluorescence	   nanocomposites	   via	   different	   routes.	   The	   popular	   applications	   are	  multimodal	  imaging,	  multiplexed	  cells	  separation,	  and	  targeted	  drug	  delivery.	  36	  
Figure	  1-­‐11	  Biomedical	  applications	  of	  magnetic-­‐fluorescence	  complexes.	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1.3.2.3. Multimodal	  imaging	  
The	  popular	  multimodal	  imaging	  probe	  is	  the	  superparamagnetic	  iron	  oxide	  nanoparticles	   coupled	   with	   fluorescent	   organic	   dyes.	   The	   cross-­‐linked	   iron	   oxide	  nanoparticles	  (CLIO)	  have	  been	  used	  for	  in	  vivo	  as	  well	  as	  in	  vitro	  MR	  imaging.	  The	  Josephson	   and	   coworkers	   developed	   multimodal	   imaging	   probe	   consists	   of	   CLIO	  conjugated	   with	   NRI	   fluorescent	   dye.81	   The	   optical	   imaging	   in	   the	   near	   IR	   (NIR)	  range	  from	  700	  to	  900	  nm	  allows	  the	  light	  to	  penetrate	  several	  centimeters	  into	  the	  tissue	  and	  minimizes	  the	  auto-­‐fluorescence	  of	  tissue.	  	  By	  injection	  of	  this	  probe	  into	  nude	  mice,	  the	  lymph	  nodes	  were	  darkened	  on	  MRI	  and	  detected	  by	  NIR	  fluorescent	  imaging	  (NIRF)	  at	  the	  same	  time	  (Figure	  1-­‐12).	  	  The	  Mulder	   and	   coworkers	  prepared	  quantum	  dot	  with	  paramagnetic	  Gd3+	  coating	   in	   PEG	   lipids.107	   The	   in	   vitro	   MR	   and	   fluorescent	   imaging	   capabilities	   of	  paramagnetic	  QDs	  (pQDs)	  were	  demonstrated	  for	  human	  umbilical	  vein	  endothelial	  cells	   (HUVECs).	   	   Figure	   1-­‐13	   shows	   the	   fluorescence	   imaging	   and	  T1	  MR	   image	   of	  cells	  with	  RGD-­‐pQDs	  and	  pQDs.	   	  The	  multimodal	   imaging	  probes	  could	  potentially	  map	   the	   lymph	   nodes	   or	   tumors	   with	  MRI	   prior	   to	   surgical	   resection	   and	   give	   a	  fluorescent	  imaging	  guide	  during	  surgery.	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  Figure	  1-­‐12	  MR	  and	  NIRF	  images	  from	  tissues	  of	  mice	  injected	  with	  Cy5.5-­‐CLIO	  (A)	  MR	  enhancement	  of	  lymph	  nodes	  with	  ax)	  axillary	  and	  br)	  brachial.	  	  (B)	  Contrast	  enhanced	  coronal	   image	  of	   the	  axillary	  node.	   (C)	  white	   light	  and	  (D)	  NIRF	   images,	  showing	  intense	  regions	  of	  NIRF	  in	  axillary	  and	  brachial	  nodes,	  adapted	  from	  ref.	  81	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Figure	  1-­‐13	  pQDs	  and	  their	  fluorescence	  and	  MR	  imaging	  (a)	   Schematic	   diagram	   of	   the	   preparation	   of	   QDs	   with	   a	   paramagnetic	   Gd	   (III)	  coating.	   (b)	   Fluorescence	   imaging	   of	   HUVEC	   incubated	   with	   RGD-­‐pQDs	   and	   bare	  pQDs.	   (c)	   T1-­‐weighted	   image	   of	   cells	   incubated	  with	  RGD-­‐pQDs,	   pQDs,	   or	  without	  contrast	  agent,	  adapted	  from	  ref.	  107	  
	  
1.3.2.4. Magnetic	  enrichment,	  manipulation,	  and	  separation	  
The	   enrichment,	   manipulation,	   and	   separation	   of	   different	   biomolecules	  including	  enzymes,	  proteins,	  and	  genes,	  which	  are	  present	  in	  a	  blood	  are	  important	  for	   the	   early	   diagnosis	   and	   detection	   of	   disease.36	   Moreover,	   the	  manipulation	   of	  tumor	  in	  tissue	  is	  crucial	  for	  the	  treatment.	  	  A	  multifunctional	  magnetic-­‐fluorescent	  nanoprobe	  would	  be	  able	  to	  operate	  the	  enrichment	  of	  specific	  target	  molecules	  or	  cells	   by	   the	   application	   of	   external	  magnetic	   field.	   	   At	   the	   same	   time,	   fluorescent	  domain	  would	  act	  as	  a	  sensing	  code	  to	  distinguish	  target	  molecules.	   	  For	  example,	  silica/iron	  oxide/fluorescein	  (FITC)	  nanocomposites	  were	  functionalized	  with	  anti-­‐
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CD-­‐10	   antibody	   and	   specifically	   targeted	   with	   floating	   SP	   tumor	   cells	   (Figure	  1-­‐14).108	  	  By	  applying	  an	  external	  magnetic	  field,	  the	  tumor	  cells	  were	  moved	  to	  the	  area	  where	  the	  magnet	  was	  located.	  	  
	  
Figure	  1-­‐14	  Magnetic-­‐fluorescent	  nanocomposites	  for	  cell	  separation	  SP2/0	  floating	  cells	  have	  been	  labeled	  with	  silica	  coated	  CoFe2O4–FITC	  NPs.	  	  Optical	  microscopy	   images	   taken	   (A)	   before	   and	   (B)	   after	   applying	   an	   external	  magnetic	  field	  show	  how	  the	  cells	  moved	  under	  the	  magnetic	  attraction,	  adapted	  from	  ref.	  108	  	   Recently,	   using	   Fe3O4/CdSe@GSH	   nanoparticles,	   the	   Xu	   and	   coworkers	  demonstrated	   the	   intracellular	  manipulation	   by	   applying	   a	  magnetic	   field	   (Figure	  1-­‐15).109	  The	  Fe3O4/CdSe@GSH	  nanoparticles	  were	  mainly	  distributed	  in	  the	  cytosol	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without	   magnetic	   field.	   But	   after	   applying	   a	   strong	   magnet	   for	   8	   hours,	   the	  nanoparticles	   were	   aggregated	   on	   the	   side	   of	   the	   cell	   nearest	   the	   magnet.	   	   This	  intracellular	  manipulation	  can	  be	  used	  to	  move	  and	  control	  the	  tumor	  sites	  for	  the	  treatment.	  	  
	  
Figure	  1-­‐15	  	  Magnetic	  manipulation	  of	  HEK293T	  cells	  with	  Fe3O4-­‐CdSe@GSH	  HEK293T	  cells	  are	   incubated	  with	  the	  Fe3O4-­‐CdSe@GSH	  nanoparticles	  and	  pEGFP-­‐N1	  vectors,	  these	  fluorescence	  images	  were	  taken	  of	  the	  cell	  (A)	  without	  a	  magnetic	  field	  and	  (B)	  under	  a	  magnetic	  field	  for	  8	  hours,	  adapted	  from	  ref.109	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1.4. 	  Conclusion	  and	  future	  outlook	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Chapter 2	  
    Tutorial Review: The Synthesis and 
Characterization of Fundamental and 
Multifunctional Nanomaterials  
2.1. Introduction	  
Nanotechnology	   is	   a	   fast-­‐growing	   area,	   which	   currently	   involves	   usage	   of	  various	  nanomaterials	  in	  modern	  science	  and	  technology.	  	  Magnetic	  and	  fluorescent	  inorganic	   nanoparticles	   are	   of	   particular	   importance	   due	   to	   their	   broad	   range	   of	  potential	   applications.104	   	   For	   instance	   magnetic	   iron	   oxide	   nanoparticles	   can	   be	  used	   as	   contrast	   agents	   in	   magnetic	   resonance	   imaging	   (MRI).35	   For	   the	   MRI	  contrast	   agent,	   gadolinium	   oxide	   nanoparticles	   are	   also	   used	   for	   brighter	  contrast.101	  And	  also	  external	  magnetic	  fields	  could	  get	  multiplexed	  cell	  separation	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using	   magnetic	   nanoparticles	   and	   bring	   nanoparticles	   to	   a	   specific	   site	   thereby	  acting	  as	  site-­‐specific	  drug	  delivery	  vehicles.6	  	  
Fluorescent	   semiconductor	   nanocrystals	   (QDs)	   have	   a	   strong	   characteristic	  spectral	  emission,	  which	  is	  tunable	  to	  a	  desired	  energy	  by	  selecting	  variable	  particle	  size	   and	   compositions.	   As	   a	   fluorescent	   probe,	   QDs	   have	   important	   biomedical	  applications	   including	   in	   vivo	   cell	   targeting,	   imaging,	   and	   multiplexed	   biological	  detection.25,53	   However,	   there	   are	   still	   many	   questions	   for	   the	   toxicity	   of	   QDs	  containing	   Cd,	   Pb,	   Hg,	   Te,	   and	   Se.	   	   These	   elements	   are	   toxic	   and	   can	   damage	   the	  tissues.	   	   In	   recent	   years,	   rare	   earth	   (RE)	   nanoparticles	   are	   proposed	   as	   attractive	  candidates	  for	  imaging.110	  RE	  ions,	  composed	  of	  the	  lanthanide	  (Ln)	  series	  (terbium	  (Tb),	   europium	   (Eu),	   erbium	   (Er),	   and	   ytterbium	   (Yb))	   exhibit	   sharp	   fluorescent	  spectra	   (4f	   or	   4f-­‐5d	   transition)	  with	  multicolor	   emission	   and	   photostability.	  Most	  importantly,	  RE	  nanoparticles	  have	  lower	  toxicity	  compared	  to	  QD	  probes.	  	  
A	   combination	   of	  magnetic	   and	   fluorescent	   properties	   in	   a	   nanocomposite	  would	   have	   great	   advantages	   such	   as	   multimodal	   imaging	   probe	   and	   magnetic	  separation	   with	   optical	   imaging.36,111,112	   For	   multimodal	   imaging	   and	   separation	  with	  fluorescence	  detection,	  iron	  oxide/quantum	  dot	  or	  fluorescent	  dye	  complexes	  are	   generally	   prepared.112	  Moreover,	   RE	   ions	   (Tb	   or	   Eu)	   doped	   gadolinium	   oxide	  nanoparticles	  are	  also	  used	  for	  multimodal	  imaging	  probe.	  113	  
In	   this	   chapter,	   we	   explore	   the	   preparation	   of	   a	   variety	   of	   nanomaterials	  including	   QDs,	   iron	   oxide	  magnetic	   nanocrystals,	   gadolinium	   oxide	   nanoparticles,	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magnetite	   quantum	   dot	   complexes,	   and	   rare-­‐earth	   ion	   (Eu3+)	   doped	   gadolinium	  oxide	  nanoparticles	  and	  their	  characterizations	  for	  the	  evaluation	  of	  nanomaterials.	  	  
2.2. Experimental	  sections	  
2.2.1. Materials	  
Cadmium	  oxide	  (CdO,	  powder	  99.99	  %),	  zinc	  oxide	  (ZnO,	  99.99	  %),	  lead	  (III)	  oxide	   (PbO,	   99.99	  %),	   selenium	   (Se,	   99.99	  %),	   tellurium	   (Te,	   99.99	  %),	   sulfur	   (S,	  99.5	   %),	   iron(III)	   oxide,	   hydrated	   (FeO(OH),	   catalyst	   grade,	   30-­‐50	   mesh),	  	  gadolinium	   nitrate	   hexahydrate	   (Gd(NO3)3⋅6H2O,	   99.99	   %),	   europium(III)	   nitrate	  hydrate	  (Eu(NO3)3⋅5H2O,	  99.99	  %),	  oleic	  acid	  (technical	  grade,	  90	  %),	   ,	  stearic	  acid	  (98.5	   %),	   trioctylphosphine	   oxide	   (TOP,	   technical	   grade	   90	   %),	   hexadecylamine	  (HDA,	  98	  %),	   trioctylphosphine	  oxide	  (TOPO,	  99	  %),	  octadecylamine	  (ODA,	  97	  %),	  1-­‐octadecene	  (1-­‐ODE,	  technical	  grade	  90	  %)	  were	  all	  purchased	  from	  Sigma-­‐Aldrich.	  	  All	  nanocrystals	  were	  synthesized	  under	  ultra-­‐high	  purity	  nitrogen	  (N2	  ,	  99.99	  %).	  Hexanes	   (95	   %),	   acetone	   (99	   %),	   ethanol	   (99.5	   %),	   and	   methanol	   (99	   %)	   were	  obtained	  from	  Sigma-­‐Aldrich.	  All	  chemicals	  were	  used	  as	  received.	  	  
2.2.2. 	  Synthesis	  of	  semiconductor	  nanocrystals	  (QDs)	  
2.2.2.1. Synthesis	  of	  CdSe	  QDs	  
CdSe	  semiconductor	  nanocrystals	  were	  prepared	  using	  a	  modified	  synthetic	  protocol	   from	   literature.63	   For	   a	   typical	   reaction,	   CdO	   (0.192	   g)	   and	   stearic	   acid	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(0.85	  g)	  were	  mixed	  into	  50	  ml	  three	  neck	  flask	  and	  heated	  to	  200	  °C	  under	  N2	  flow	  to	   obtain	   a	   colorless	   clear	   solution.	   After	   cooling	   down	   to	   room	   temperature,	  hexadecylamine	  (HDA)	  (1.875	  g),	  TOPO	  (1.875	  g),	  and	  1-­‐ODE	  (10	  g)	  were	  added	  into	  the	  flask.	  	  The	  mixture	  was	  reheated	  to	  283	  °C.	  	  	  At	  this	  temperature,	  0.356	  g	  of	  10	  %	  Se-­‐TOP	   (Se	   (0.64	   g)	   in	   TOP	   (8	   mmol))	   diluted	   with	   toluene	   (0.06	   g)	   and	   1-­‐ODE	  (1.375	  g)	  was	  swiftly	  injected	  into	  reaction	  flask.	  The	  reaction	  was	  allowed	  to	  cool	  down	   to	   250	   °C	   to	   grow	   CdSe	   QDs.	   	   At	   various	   time	   intervals	   (10	   sec	   to	   5	   min)	  aliquots	  mixture	  was	  taken	  out	  using	  syringe	  and	  quenched	  in	  chloroform.	  	  	  	  
2.2.2.2. Synthesis	  of	  CdS	  QDs	  
The	   synthesis	   of	   CdS	   QDs	  was	  modified	   by	   reported	  method.114	   	   CdO	   (0.0384	   g),	  oleic	  acid	  (0.338	  g),	  and	  1-­‐ODE	  (total	  volume	  12	  g)	  were	   loaded	   into	  50	  ml	   three-­‐neck	  flask	  and	  heated	  to	  300	  °C	  under	  N2	  flow.	  	  At	  this	  temperature,	  a	  solution	  of	  S-­‐ODE	   (0.15	  mmol,	  0.006	  g	  S	   in	  ODE	  6	  g)	  was	   swiftly	   injected	   into	   the	  hot	   solution.	  	  After	  injection,	  the	  temperature	  was	  allowed	  to	  cool	  down	  to	  250	  °C	  for	  the	  growth	  of	  CdS	  QDs.	  	  At	  various	  time	  intervals	  (10	  sec,	  30	  sec,	  1	  min,	  5	  min,	  10	  min),	  aliquots	  with	  a	  needle	  tip	  were	  removed	  and	  diluted	  with	  cool	  hexanes.	  	  	  
2.2.2.3. Synthesis	  of	  CdTe	  QDs	  
CdTe	  QDs	  was	  prepared	  via	  a	  modified	  reported	  procedure.63	  CdO	  (0.0384	  g),	  oleic	  acid	  (0.338	  g),	  and	  1-­‐ODE	  (total	  12	  g)	  were	  added	  into	  50	  ml	  three	  neck	  flask	  and	   heated	   to	   200	   °C	   under	   N2	   flow.	   	   At	   280	   °C,	   0.174	   g	   Te-­‐TOP	   10	  %	   solution,	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prepared	  by	  dissolving	  42.2	  mg	  of	  Te	   in	  0.8	  ml	  TOP	  and	  diluted	  with	  5	  ml	  1-­‐ODE,	  was	  quickly	  injected	  into	  the	  hot	  reaction	  mixture.	  After	  injection,	  the	  temperature	  was	  allowed	  to	  cool	  to	  250	  °C	  for	  the	  growth	  of	  CdTe	  QDs.	  	  
2.2.2.4. 	  Synthesis	  of	  CdSe@CdS	  and	  CdSe@ZnS	  QDs	  
To	  synthesize	  core/shell	  QDs,	  CdSe	  QDs	  were	  first	  prepared	  and	  purified.	  The	  procedure	   for	   the	   synthesis	  of	   core/shell	  CdSe@CdS	  QDs	  and	  CdSe@ZnS	  QDs	  was	  modified	  by	  the	  reported	  reference.62	  The	  CdS	  or	  ZnS	  shell	  was	  deposited	  onto	  the	  CdSe	   QDs	   by	   introducing	   the	   calculated	   amounts	   of	   Zn	   and	   S.	   The	   cadmium	  precursor	  solution	  (0.04	  M)	  was	  prepared	  by	  dissolving	  CdO	  (0.615	  g)	  in	  oleic	  acid	  (10.83	  g)	  and	  1-­‐ODE	  (108	  ml)	  at	  250	  °C.	  The	  zinc	  precursor	  solution	  (0.04	  M)	  was	  made	  by	  dissolving	  ZnO	  (0.39	  g)	  in	  oleic	  acid	  (10.83	  g)	  and	  1-­‐ODE	  (108	  ml)	  at	  250	  °C.	   	   The	   sulfur	   stock	   solution	   (0.04	  M)	  was	   prepared	  by	   dissolving	   sulfur	   powder	  (0.128	   g)	   in	   1-­‐ODE	   (100	  ml)	   at	   200	   °C.	   	   Both	   precursor	   solutions	  were	   prepared	  under	   the	   N2	   flow.	   The	   Zn	   or	   Cd	   precursor	   solution	   needs	   pre-­‐heating	   to	   ensure	  complete	  dissolution	  before	  injection.	   	  For	  each	  injection	  to	  make	  a	  shell,	  a	  certain	  amounts	  of	  stock	  solution	  were	  taken	  by	  syringe.	  	  	  
Following	   the	   reference,	   the	   successive	   ionic	   layer	   adsorption	   and	   reaction	  (SILAR)	  method	  is	  based	  on	  the	  alternating	   injection	  of	  Cd	  or	  Zn	  and	  S	  precursors	  into	   the	   solution	   containing	   purified	   CdSe	   QDs	   for	   the	   growth	   of	   CdSe/CdS	  core/shell	   or	   CdSe/ZnS	   core/shell	   QDs.62	   The	   amount	   of	   cadmium/zinc	   or	   sulfur	  precursors	  required	  for	  each	  layer	  was	  calculated	  by	  the	  number	  of	  surface	  atoms	  of	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a	  given	  size	  of	  a	  core/shell	  QDs.	  	  The	  average	  thickness	  of	  one	  monolayer	  of	  CdS	  was	  0.35	  nm,	  so	  additional	  layer	  growth	  would	  increase	  the	  diameter	  of	  a	  nanocrystal	  by	  0.7	   nm.	   	   In	   a	   typical	   reaction	   with	   3.7	   nm	   core,	   2.13	   X	   10-­‐3	   mmol	   of	   Cd	   and	   S	  precursor	  is	  needed	  for	  the	  first	  layer	  of	  the	  shell	  growth,	  and	  an	  additional	  2.85	  X	  10-­‐3	  mmol	  of	  Cd	  and	  S	  completes	  the	  growth	  of	  the	  second	  layer.	  	  
CdSe	  QDs	  (3.5	  nm,	  1	  X10-­‐4	  mmol	  of	  particles)	  dissolved	  in	  2	  ml	  hexanes	  were	  mixed	   with	   1.5	   g	   ODA	   and	   5	   g	   1-­‐ODE	   in	   a	   25	   ml	   three	   neck	   flask.	   	   To	   remove	  hexanes,	   the	  reaction	  mixture	  was	  allowed	  to	  preheat	  at	  100	  °C	  or	  vacuum.	   	  Then,	  under	   N2	   atmosphere,	   the	   mixture	   was	   further	   heated	   to	   240	   °C	   for	   making	  core/shell	   QDs.	   	   The	   Cd	   or	   Zn	   precursor	   solution	   (0.04	  M)	  was	   injected	  with	   the	  volume	  of	   0.49	  ml	   and	   stirred	   for	   5	  min	   at	   this	   temperature	   (240	   °C).	   Amount	   of	  solution	   required	   for	   subsequent	   injection	   was	   calculated	   using	   the	   method	  described	  above.	  After	  5	  min,	  0.49	  ml	  of	  the	  sulfur	  precursor	  solution	  was	  injected	  to	   the	  mixture	  and	  stirred	   for	  10	  min	   for	   the	   first	   layer	  of	  CdS	  or	  ZnS	  shell.	   	  After	  that,	  the	  reaction	  mixture	  was	  cooled	  down	  to	  room	  temperature	  and	  purified	  using	  methanol	  and	  acetone	  three	  times.	  	  
2.2.2.5. Synthesis	  of	  PbSe	  QDs	  and	  PbSe@PbS	  QDs	  
The	   PbSe	   QDs	   was	   prepared	   via	   a	   modified	   procedure.115	   Typically,	   PbO	  (0.892	  g,	  4	  mmol),	  oleic	  acid	  (2.825	  g,	  10	  mmol),	  and	  1-­‐ODE	  (total	  weight	  was	  16	  g)	  were	   loaded	   to	   the	   three	  neck	   flask	   and	  heated	   to	  180	   °C	  under	  N2	   flow	  until	   the	  solution	  becomes	  colorless.	  	  Then	  6.4	  g	  of	  Se-­‐TOP	  10	  %	  solution,	  prepared	  by	  0.64	  g	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of	  Se	  (8	  mmol)	  in	  6.4	  g	  TOP	  was	  quickly	  injected	  into	  the	  solution	  at	  180	  °C.	  	  Then,	  the	  reaction	  mixture	  was	  cooled	  down	  to	  150	  °C	  for	  the	  growth	  of	  PbSe	  QDs.	   	  The	  aliquots	  of	  reaction	  mixture	  were	  collected	  using	  syringe	  for	  getting	  various	  sizes	  of	  PbSe	  QDs	  (10	  sec	  (3-­‐5	  nm	  core	  size)	  and	  800	  sec	  (9	  nm)).	  	  
2.2.3. 	  Synthesis	  of	  iron	  oxide	  nanocrystals	  
The	   iron	   oxide	   magnetic	   nanocrystals	   were	   synthesized	   following	   the	  previous	  work.51	  	  	  Experimentally,	  0.178	  g	  of	  FeO(OH)	  was	  added	  with	  	  2.26	  g	  oleic	  acid	  and	  5	  g	  of	  1-­‐ODE	  into	  three	  neck	  flask	  and	  heated	  to	  120	  °C	  	  for	  3	  hours	  to	  make	  first	  iron	  oleates	  and	  finally	  refluxed	  to	  320	  °C	  for	  2	  hours.	  	  
2.2.4. Synthesis	  of	  gadolinium	  oxide	  nanocrystals	  
2	   mmol	   of	   gadolinium	   nitrate	   hexahydrate	   was	   mixed	   with	   oleic	   acid	   (4	  mmol)	  and	  1-­‐ODE	  (5	  g)	  into	  three	  neck	  flask	  and	  stirred	  for	  2	  hours	  at	  110	  °C	  until	  the	  Gd	  precursor	  was	  completely	  dissolved	   in	   the	  solvent	  as	  Gd-­‐oleate	  precursors.	  	  After	   increasing	   the	   temperature	   from	   110	   to	   290	   °C,	   the	   reaction	   mixture	   was	  refluxed	  at	  290	  °C	  for	  3-­‐18	  hours.	   	  After	  the	  reaction	  is	  done,	  the	  temperature	  was	  cooled	   down	   to	   room	   temperature.	   Finally,	   the	  gadolinium	   oxide	   nanoparticles	   (5	  nm)	  were	  prepared	  and	  stored	  in	  hexanes.	  To	  make	  larger	  nanoparticles	  (8,	  11,	  13,	  and	  22	  nm),	  the	  oleylamine	  (2,	  6,	  8,	  and	  12	  mmol)	  and	  more	  3	  g	  1-­‐ODE	  were	  added	  into	   the	   gadolinium-­‐oleate	   mixture	   (2	   mmol	   gadolinium	   nitrate	   hexahydrate,	   4	  mmol	   oleic	   acid,	   5	   g	   1-­‐octadecene)	   after	   heating	   at	   110	   °C	   for	   2	   hours	   and	   then	  refluxed	   at	   290	   °C	   for	   3-­‐18	   hours.	   For	   making	   smaller	   2	   nm	   gadolinium	   oxide	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nanoparticles,	  the	  refluxed	  reaction	  temperature	  was	  increased	  from	  290	  to	  320	  °C	  with	  the	  amount	  of	  gadolinium	  nitrate	  hexahydrate	  (2	  mmol),	  oleic	  acid	  (4	  mmol),	  and	  1-­‐ODE	  (5	  g).	  
2.2.5. Purification	  of	  nanocrystals	  
The	   resulting	   colloidal	   solution	   (5	  mL)	  was	   centrifuged	  with	  methanol	   (20	  mL)	   and	   acetone	   (20	   mL)	   at	   4150	   rpm	   for	   30	   minutes	   and	   redispersed	   with	  hexanes.	  This	  purification	  was	  repeated	  six	   times	  resulting	   in	  purified	  nanocrystal	  solutions	  with	  minimal	   residual	   surfactants.	   The	   resulting	   nanocrystal	   solution	   is	  stored	  in	  hexanes	  and	  ready	  for	  further	  synthesis	  and	  characterization.	  
2.2.6. Synthesis	  of	  iron	  oxide/CdSe	  QD	  complexes	  
For	   the	   synthesis	   of	   iron	   oxide/CdSe	   QD	   complexes,	   the	   iron	   oxide	  nanocrystals	   were	   first	   prepared	   and	   purified.	   	   Using	   iron	   oxide	   nanocrystals	   as	  seeds,	  the	  QDs	  were	  nucleated	  and	  grown	  onto	  the	  surface	  of	  iron	  oxide.	   	  CdO	  (0.3	  mmol),	   ODA	   (11	  mmol),	   and	   ODE	   (40	  mmol)	  were	   added	   in	   a	   50	  mL	   three	   neck	  flask.	   This	   mixture	   was	   ramped	   to	   200	   °C	   and	   held	   there	   for	   one	   hour	   under	  nitrogen	   (N2)	   flow.	   	   After	   cooling	   down	   to	   room	   temperature,	   1	   mL	   iron	   oxide	  nanocrystal	  solution	  stored	   in	  hexanes	  at	   the	  concentration	  of	  6,000	  mg/L	  Fe	  was	  injected	  into	  the	  mixture	  and	  the	  mixture	  was	  heated	  to	  100	  °C	  for	  30	  minutes	  for	  the	   evaporation	   of	   hexanes	   completely.	   Afterwards,	   the	   reaction	   mixture	   was	  allowed	   to	   heat	   at	   280	   °C	   for	   one	   hour	   under	   nitrogen	   (N2)	   flow.	   Se	   (0.9	   mmol)	  dissolved	  in	  trioctylphosphine	  (TOP,	  2	  ml)	  was	  slowly	  injected	  into	  the	  solution	  with	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the	  speed	  of	  0.4	  ml/min	  at	  lower	  temperature	  220	  °C	  and	  the	  temperature	  was	  set	  to	  250	  °C	  allowing	  to	  grow	  CdSe	  QDs	  on	  the	  iron	  oxide	  surface.	  Aliquots	  of	  reaction	  mixture	   at	   the	   different	   time	   intervals	   from	   1	   to	   25	   min,	   gave	   iron	   oxide/QD	  complexes	  emitting	  distinctive	   fluorescence	  colors	   from	  green	  to	  red.	  The	  aliquots	  of	  growth	  solution	  were	  quenched	  with	  hexanes	  and	  further	  purified.	  The	  Figure	  2-­‐1	  shows	  the	  synthesis	  setup	  for	  nanocrystals.	  	  
2.2.7. Synthesis	  of	  iron	  oxide/PbSe	  QD	  complexes	  
For	   the	   reaction	   of	   iron	   oxide/PbSe	  QD	   complexes,	   PbO	   (0.15	  mmol),	   oleic	  acid	   (0.8	  mmol),	   and	   1-­‐ODE	   (10	   g)	  were	  mixed	   and	   heated	   to	   180	   °C	   for	   1	   hour.	  	  After	   cooling	   down	   to	   room	   temperature,	   ODA	   (4	   g)	   and	   preformed	   iron	   oxide	  nanocrystal	  solution	  (0.1	  mmol	  Fe3O4	  in	  2	  ml	  hexanes,	  6,000	  mg/L	  Fe)	  were	  injected	  into	  the	  reaction	  mixture.	  	  After	  evaporation	  of	  hexanes	  using	  vacuum	  or	  heating	  at	  100	  °C	  for	  30	  minutes,	  the	  reaction	  was	  reheated	  to	  180	  °C.	  At	  this	  temperature,	  the	  Se	  (0.9	  mmol)	  dissolved	  in	  trioctylphosphine	  (TOP,	  2	  ml)	  was	  slowly	  injected	  to	  the	  mixture.	  The	  PbSe	  QDs	  were	  grown	  on	  the	  surface	  of	  iron	  oxide	  at	  150	  °C	  for	  30	  min.	  The	  resulting	  iron	  oxide/PbSe	  QDs	  complexes	  were	  purified	  with	  methanol/acetone	  several	  times	  and	  were	  kept	  in	  hexanes.	  	  
2.2.8. Synthesis	  of	  Eu	  (III)	  doped	  gadolinium	  oxide	  nanoparticles	  
2	  mmol	  of	  gadolinium	  nitrate	  hexahydrate	   	   (0.9	  g)	  and	  0.5	  mmol	  europium	  nitrate	  hydrate	   (0.2	  g)	  were	  mixed	  with	  oleic	  acid	   (4	  mmol)	  and	  1-­‐ODE	  (5	  g)	   into	  three	  neck	  flask	  and	  stirred	  for	  2	  hours	  at	  110	  °C	  for	  making	  Gd/Eu	  oleates.	   	  After	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increasing	  the	  temperature	  from	  110	  to	  290	  °C,	  octadecylamine	  (6	  mmol,	  1.6	  g)	  was	  added	   and	   the	   reaction	  mixture	  was	   refluxed	   at	   290	   °C	   for	   3-­‐18	  hours.	   	   After	   the	  reaction	   is	   done,	   the	   temperature	  was	   cooled	  down	   to	   room	   temperature.	   Finally,	  the	  europium	   doped	   gadolinium	   oxide	   nanoparticles	   (12	   nm)	  were	   prepared	   and	  further	   purified	  with	  methanol	   and	   acetone	   by	   centrifugation	   at	   4150	   rpm	   for	   30	  minutes	   three	   times.	   By	   changing	   the	   reflux	   time,	   monomer	   concentration,	  surfactant	   (oleic	  acid	  and	  oleylamine)	  ratio	  and	  Gd/Eu	  ratio,	   the	  particle	  diameter	  was	  varied	  from	  2	  to	  15	  nm.	  	  
	  
Figure	  2-­‐1	  Nanoparticle	  synthesis	  setup	  	  
	   58	  	  
	  
2.2.9. Instruments	  and	  characterization	  
2.2.9.1. Absorbance	  detection	  	  
Ultraviolet-­‐visible	   absorption	   spectrometer	   (Varian	   Cary	   5000	   UV-­‐visible-­‐NIR)	  was	  used	  for	  the	  absorbance	  of	  QDs.	  	  
2.2.9.2. 	  Photoluminesccence	  detection	  
Photoluminescence	   (PL)	   spectra	   of	   quantum	  dots	   or	   iron/oxide	  QD	   complexes	  were	   recorded	  on	  a	   Jobin	  Yvon	  Spex	  Fluorolog	  3	   fluorescence	   spectrophotometer.	  The	   absolute	   photoluminescence	   quantum	   yield	   (PLQY)	   was	   calculated	   by	   the	  gradient	  method	  of	  comparing	  the	  PL	  integrated	  intensity	  of	  the	  CdSe	  QDs	  and	  that	  of	   the	   solution	   of	   rhodamine	   6G	   (R6G)	   in	   ethanol.	   The	   absorption	   spectra	   of	   iron	  oxide/QDs	  complexes,	  CdSe	  QDs,	  and	  R6G	  were	  recorded	  at	  480	  nm	  excitation,	  with	  the	  optical	  intensities	  of	  all	  samples	  below	  0.10	  absorbance.	  The	  following	  equation	  was	  used	  to	  calculate	  the	  quantum	  yield.	  116,117	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experiment	   are	   equal	   to	   the	   values	   of	   the	   standard	   sample.	   nr	   and	   nx	   are	   the	  refractive	   indicies	   of	   the	   solvents.	   Ethanol	   (n=1.359)	   and	   hexanes	   (n=1.372)	   are	  used	  in	  this	  study.	  Dx	  and	  Dr	  are	  the	  PL	  integrated	  intensities	  excited	  at	  480	  nm	  of	  the	  CdSe	  QDs	  and	  R6G.	  	  
2.2.9.3. Transmission	  electron	  microscopy	  (TEM)	  
TEM	   specimens	   were	   carried	   out	   by	   JEOL	   2100	   field	   emission	   gun	   TEM	  operating	   at	   200	   kV	   with	   a	   single	   tilt	   holder.	   The	   TEM	   sample	   was	   made	   by	  evaporating	   one	   drop	   of	   purified	   solution	   in	   hexanes	   on	   ultra	   thin	   carbon	   type-­‐A	  400	   mesh	   copper	   grids	   (Ted	   Pella	   Inc.).	   Energy-­‐filtering	   transmission	   electron	  microscopy	  (EFTEM)	  provides	  the	  gatan	   imaging	  filter	  (GIF)	  mapping,	  which	  gives	  the	   chemical	   information	   from	   the	   nanostructured	   regions.	   For	   the	   analytical	  technique,	  energy-­‐dispersive	  x-­‐ray	  spectrometry	  (EDXS)	  was	  performed	  to	  get	   the	  chemical	   composition	   from	   the	   complex	   area.	   The	   size	   and	   size	   distribution	   data	  were	   obtained	   by	   counting	   over	   500	   individual	   nanocrystalline	   particles	   using	  Image-­‐Pro	  Plus	  5.0	  (Media	  Cybernetics,	  Inc.,	  Silver	  Spring,	  MD).	  	  
2.2.9.4. X-­‐ray	  diffraction	  (XRD)	  
The	  XRD	  patterns	  were	  recorded	  using	  a	  Rigaku	  D/Max	  Ultima	  II	  with	  a	  zero	  background	  sample	  holder	  and	  analyzed	  by	  JCPDS	  card.	  The	  2θ	  range	  was	  measured	  from	  10	  to	  80	  degree	  with	  Cu	  Kα	  radiation.	  The	  X-­‐ray	  was	  generated	  at	  40	  KV	  and	  40	  mA.	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2.3. Results	  and	  discussions	  
The	  core	  CdSe	  QDs	  and	  core/shell	  CdSe@ZnS	  QDs	  were	  prepared	  by	  thermo-­‐decomposition	  in	  the	  presence	  of	  organic	  surfactants	  and	  1-­‐ODE.	   	  The	  size	  tunable	  CdSe	  QDs	  have	  multiple	   fluorescent	   colors	   from	  blue	   to	   red	  under	   the	  UV	   light	   as	  shown	  in	  Figure	  2-­‐2.	  And	  the	  TEM	  image	  (Figure	  2-­‐3)	  shows	  the	  monodisperse	  CdSe	  QDs	   with	   the	   growth	   for	   180	   sec.	   The	   size	   of	   CdSe	   QDs	   was	   3.4	   ±	   0.4	   nm.	   	   The	  photographs	  of	  size	  tunable	  CdS	  and	  CdTe	  QDs	  are	  also	  in	  Figure	  2-­‐4	  and	  Figure	  2-­‐5.	  	  Moreover,	   the	  PbSe	  QDs	   emitted	   in	  Near	   IR	   region	  were	  prepared	   and	   showed	   in	  Figure	  2-­‐6.	  
	  Figure	  2-­‐2	  The	  CdSe	  QDs	  excited	  by	  UV	  light	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  Figure	  2-­‐3	  The	  TEM	  image	  of	  CdSe	  QDs	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  Figure	  2-­‐4	  Size	  tunable	  CdS	  QDs	  under	  the	  day	  light	  and	  UV	  light	  
	  Figure	  2-­‐5	  Size	  tunable	  CdTe	  QDs	  under	  the	  day	  light	  and	  UV	  light	  	  
	  Figure	  2-­‐6	  Size	  tunable	  PbSe	  QDs	  by	  taking	  aliquots	  at	  different	  time	  intervals	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When	   taking	   aliquots	   at	   the	   different	   time	   intervals,	   the	   absorbance	  spectrum	  is	  red-­‐shifted.	  	  The	  CdSe	  QDs	  were	  red	  shifted	  from	  557	  nm	  to	  589	  nm	  at	  the	  different	   time	  growth	   from	  10	  sec	   to	  180	  sec	  as	  shown	  in	  Figure	  2-­‐7.	  The	  size	  dependent	  emission	  spectra	  of	  QDs	  can	  be	  explained	  by	  quantum	  confinement	  and	  band	  gap	  energy	  theory118.	  	  The	  exciton	  transition	  shifted	  to	  higher	  energy	  with	  an	  increase	  of	  molar	  absorption	  coefficient	  as	  QD	  diameters	  decreased.	  The	  Figure	  2-­‐8	  shows	   that	   the	  absorbance	   (529	  nm)	  and	  photoluminescence	   (540	  nm)	  spectra	  of	  CdSe	  QDs	   (2	  nm	  size,	   green	  emission).	  The	  absorbance	  of	  CdS	  QDs	  and	  CdTe	  QDs	  confirmed	   the	   red	   shift	   from	  352	   to	  378	  nm	  and	  593	  nm	   to	  689	  nm,	   respectively	  (Figure	  2-­‐9	  and	  Figure	  2-­‐10).	   	  Moreover,	   the	  PbSe	  QDs	  absorb	  near	   IR	  region	  and	  were	   red-­‐shifted	  over	  1800	   to	  2200	  nm	  with	  different	  growth	   time	   (Figure	  2-­‐11).	  	  The	   Table	   2-­‐1	   shows	   the	   summary	   of	   wavelength	   (nm)	   and	   full	   width	   at	   half	  maximum	  (FWHM).	  
	  
Figure	  2-­‐7	  The	  absorbance	  of	  CdSe	  QDs	  at	  the	  different	  time	  intervals	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Figure	  2-­‐8	  The	  absorbance	  and	  photoluminescence	  (PL)	  spectra	  of	  CdSe	  QDs.	  
	  
Figure	  2-­‐9	  The	  absorbance	  of	  CdS	  QDs	  at	  the	  different	  time	  intervals	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Figure	  2-­‐10	  The	  absorbance	  of	  CdTe	  QDs	  at	  the	  different	  time	  intervals	  
	  
Figure	  2-­‐11	  The	  absorbance	  of	  PbSe	  QDs	  at	  the	  different	  time	  intervals	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Table	  2-­‐1	  The	  absorbance	  wavelength	  and	   full	  width	  at	  half	  maximum	  (FWHM)	  of	  QDs	  
	   CdSe	  QDs	   	   CdS	  QDs	   	   CdTe	  QDs	  λmax	   FWHM	   λmax	   FWHM	   λmax	   FWHM	  
30s	   557nm	   28nm	   30s	   352nm	   32nm	   15s	   593nm	   	  3onm	  
45s	   575nm	   30nm	   60s	   361nm	   30nm	   60s	   641nm	   28nm	  
180s	   579nm	   28nm	   180s	   371nm	   26nm	   180s	   663nm	   32nm	  
420s	   584nm	   26nm	   300s	   375nm	   26nm	   300s	   679nm	   34nm	  
3000s	   589nm	   28nm	   600s	   378nm	   24nm	   600s	   689nm	   36nm	  	  
The	  core	  QDs	  can	  be	  used	   for	  making	  core/shell	  QDs	   to	   improve	  PLQY	  and	  prevent	  toxic	  Cd	  leakage	  to	  the	  outside.	  	  When	  ZnS	  shell	  deposited	  on	  the	  CdSe	  QDs,	  the	   wavelength	   of	   absorbance	   and	   PL	   spectra	   was	   red-­‐shifted	   as	   depicted	   in	   the	  fluorescent	   colors	   under	   UV	   light	   (Figure	   2-­‐12).	   	   The	   TEM	   images	   (Figure	   2-­‐13)	  verified	  the	  change	  of	  size	  from	  3.6	  nm	  to	  4.3	  nm	  after	  capping	  ZnS	  shells.	  The	  XRD	  data	   confirmed	   that	   the	   peak	   positions	   of	   CdSe	   QDs	   and	   CdSe/ZnS	   QDs	   were	  matched	  with	  reference	  (Figure	  2-­‐14).	  The	  references	  were	  taken	  from	  JCPDS	  card	  02-­‐0330	  and	  01-­‐0667.	  
	   67	  	  
	  
Figure	   2-­‐12	   The	   photograph	   of	   CdSe	   QDs	   (green	   emission)	   and	   CdSe/ZnS	   QDs	  (organe	  emission)	  	  
	  
Figure	  2-­‐13	  The	  CdSe	  QDs	  (3.6	  nm,	  left)	  and	  CdSe/ZnS	  QDs	  (4.3	  nm,	  right).	  The	  inset	  indicated	  the	  high	  resolution	  images	  showing	  crystal	  lattice	  fringes.	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Figure	  2-­‐14	  The	  XRD	  pattern	  of	  CdSe	  QDs	  and	  CdSe@ZnS	  QDs	  	  
The	  iron	  oxide	  nanocrystals	  were	  prepared	  by	  thermo-­‐decomposition	  in	  the	  presence	   of	   FeOOH	   precursor	   with	   oleic	   acid	   and	   ODE	   solvent.	   	   By	   changing	   the	  molar	   ratio	   between	   FeOOH	   precursor	   and	   oleic	   acid	   from	   1:3	   to	   1:5,	   the	   core	  diameters	   of	   iron	   oxide	   nanocrystals	  were	   changed	   from	  8	   to	   17	  nm.51	   	   The	  TEM	  images	  shows	  the	  diameters	  of	  monodisperse	   iron	  oxide	  nanocrystals	  were	  10.2	  ±	  1.2	  nm	  and	  17.5	  ±	  1.3	  nm	  (Figure	  2-­‐15	  and	  Figure	  2-­‐16).	  	  The	  high	  resolution	  TEM	  image	  shows	  that	  iron	  oxide	  nanoparticles	  has	  crystalline	  structure	  showing	  lattice	  fringes	   (Figure	   2-­‐17).	   	   And	   also	   XRD	   confirmed	   that	   the	   diffraction	   peaks	   of	   iron	  oxide	   nanoparticles	   were	   matched	   with	   the	   iron	   oxide	   reference	   peaks	   (Figure	  2-­‐18).	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Figure	  2-­‐15	  TEM	  image	  of	  iron	  oxide	  nanocrystals	  with	  the	  size	  of	  10.2	  nm	  	  
	  
Figure	  2-­‐16	  TEM	  image	  of	  iron	  oxide	  nanoparticles	  with	  the	  size	  of	  17.5	  nm	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Figure	  2-­‐17	  The	  high	  resolution	  TEM	  image	  of	  iron	  oxide	  nanocrystals	  (10	  nm)	  	  
	  
Figure	  2-­‐18	  The	  XRD	  pattern	  of	  iron	  oxide	  nanoparticles.	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Based	   on	   the	   iron	   oxide	   nanoparticle	   synthesis,	   the	   multifunctional	   iron	  oxide/QDs	  complexes	  were	  prepared	   in	  a	  reaction	   that	  relied	  on	   the	  nucleation	  of	  CdSe	   QDs	   or	   PbSe	   QDs	   on	   preformed	   iron	   oxide	   nanocystals.	   Monodisperse	   iron	  oxide	  nanocrystals	  were	  used	  as	  seeds	  for	  the	  nucleation	  sites	  of	  QDs.	  By	  controlling	  growth	  time	  from	  1	  to	  25	  minutes,	  the	  size	  tunable	  iron	  oxide/CdSe	  QDs	  complexes	  were	  synthesized	  with	  multiple	  fluorescence	  colors	  from	  green	  to	  red.	  (Figure	  2-­‐19)	  	  The	   Figure	   2-­‐20	   shows	   very	   uniform	   pincushion	   iron	   oxide/CdSe	   QD	   complexes	  using	  12	  nm	  iron	  oxide	  seeds	  by	  thermo-­‐decomposition.	  Figure	  2-­‐21	   indicated	  the	  iron	   oxide/PbSe	   QDs	   complexes	   using	   18	   nm	   iron	   oxide	   nanocrystals	   by	   high	  temperature	  thermo-­‐decomposition.	  The	  gatan	  image	  filter	  (GIF)	  analytical	  mapping	  confirmed	   that	   the	  CdSe	  or	  PbSe	  QDs	  nucleated	  directly	  at	   the	   interface	  with	   iron	  oxide	  core	  (Figure	  2-­‐22	  and	  Figure	  2-­‐23).	  
	  
Figure	  2-­‐19	  Size	  tunable	  iron	  oxide/CdSe	  QDs	  complexes	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Figure	  2-­‐20	  The	  TEM	  image	  of	  iron	  oxide/CdSe	  QD	  complexes	  	  
	  
Figure	  2-­‐21	  The	  TEM	  image	  of	  iron	  oxide/PbSe	  QDs	  complexes	  using	  iron	  oxide	  10	  nm	  (A)	  and	  18	  nm	  (B)	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Figure	  2-­‐22	  The	  GIF	  mapping	  of	  iron	  oxide-­‐CdSe	  QDs	  complexes	  (A)	   frame	   image,	   (B)	   Fe	   (red)	   mapping,	   (C)	   Cd(green)	   mapping,	   and	   (D)	   mixed	  image	  (Fe	  :	  red,	  Cd:	  green)	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Figure	  2-­‐23	  The	  GIF	  mapping	  of	  iron	  oxide-­‐PbSe	  QDs	  complexes	  (A)	  frame	  image,	  (B)	  Fe	  (white)	  mapping,	  (C)	  Pb	  (yellow)	  mapping,	  	  and	  (D)	  mixed	  image	  (Fe	  :	  red,	  Cd:	  yellow)	  	  
The	   gadolinium	   oxide	   nanoparticles	   (11	   nm)	   were	   synthesized	   by	  thermodecomposition	   of	   gadolinium	   nitrate	   hexahydrate	   in	   the	   presence	   of	   oleic	  acid	  and	  ODE	   (Figure	  2-­‐24).	   	  Based	  on	   the	  gadolinium	  oxide	   synthesis,	  we	   simply	  prepared	   europium	   (Eu3+)	   doped	   gadolinium	   oxide	   nanoparticles	   for	   multimodal	  imaging	  probe.	  By	  controlling	  reaction	  parameters	  (e.g.	  reaction	  time,	  concentration	  of	  monomer,	  the	  ratio	  of	  Gd/Eu,	  the	  ratio	  of	  oleic	  acid/oleylamine),	  the	  diameter	  of	  europium	   doped	   gadolinium	   oxide	   nanoparticles	   was	   tunable	   from	   2	   to	   15	   nm	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(Figure	   2-­‐25).	   	   The	   ratio	   between	   oleic	   acid	   and	   oleylamine	   or	   the	   ratio	   between	  gadolinium	  and	  europium	  nitrate	  hydrate	   is	   important	  parameter	   to	  make	  a	  wide	  size	   range	   (Figure	   2-­‐26).	   When	   increasing	   the	   oleylamine	   and	   europium	   nitrate	  precursors,	   the	   size	   was	   dramatically	   increased	   because	   more	   labile	   gadolinium	  promoted	   the	   particle	   growth.	   	   The	   GIF	   mapping	   reveals	   that	   the	   europium	   and	  gadolinium	  elements	  were	  mixed	  in	  a	  nanoparticle	  structure	  (Figure	  2-­‐27).	  	  
	  
Figure	  2-­‐24	  The	  TEM	  image	  of	  gadolinium	  oxide	  nanoparticle	  (11	  nm)	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Figure	  2-­‐25	  TEM	  images	  of	  europium	  doped	  gadolinium	  oxide	  nanoparticles	  The	  diameter	  of	  nanoparticle	  was	  2.1	  ±	  0.4	  nm	  (A),	  	  6.0	  ±	  0.7	  nm	  (B),	  	  8.2	  ±	  0.9	  nm	  (C),	  	  11.4	  ±	  1.6	  nm	  (D),	  	  13.2	  ±	  2.0	  nm	  (E),	  and	  15.5	  ±	  2.4	  nm	  (F),	  respectively.	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Figure	  2-­‐26	  The	  reaction	  parameters	  for	  size	  tunability	  (A)	   the	   ratio	   of	   oleic	   acid	   (OA)/oleylamine	   (OAM)	   and	   (B)	   the	   ratio	   of	   Gd/Eu	  precursor	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Figure	  2-­‐27	  The	  GIF	  mapping	  of	  europium	  doped	  iron	  oxide	  nanoparticle	  (A) frame	   image,	   (B)	   Gd	  mapping,	   (C)	   Eu	  mapping,	   and	   (D)	   Gd	   and	   Eu	  mixed	  mapping	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2.4. Conclusions	  
In	   this	   tutorial	   chapter,	   the	   various	   inorganic	   nanoparticles	   including	  quantum	   dots,	   iron	   oxide	   nanoparticles,	   gadolinium	   oxide,	   iron	   oxide/QD	  complexes,	   and	   europium	   doped	   gadolinium	   oxide	   nanoparticles	   have	   been	  prepared.	  These	  inorganic	  fundamental	  and	  multifunctional	  nanocrystals	  have	  size	  tunable	   optical	   or	   magnetic	   properties.	   Therefore,	   the	   preparation	   of	   various	  nanomaterials	  gives	  great	  possibilities	  towards	  a	  variety	  of	  biomedical	  applications	  including	  MRI,	  cell	  imaging,	  manipulation,	  separation,	  and	  toxicological	  study.	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Chapter 3	  
    High r1 Relaxivity Dynamics for 
Gadolinium Oxide Nanoparticle MR 
Contrast Agents  
In	  this	  work,	  uniform	  gadolinium	  (Gd)	  oxide	  nanoparticles	  ranging	  from	  1.8	  to	   22	   nm	   were	   prepared	   using	   the	   thermal	   decomposition	   of	   gadolinium	   salts.	  	  Particles	   could	   be	   transferred	   to	   water	   using	   oleic	   acid	   bilayers,	   octylamine	  modified	  poly	  (acrylic	  acid)	  (PAA-­‐OA),	  and	  lauryl	  acrylate	  (LA)-­‐poly	  (2-­‐acrylamido-­‐2-­‐methyl-­‐1-­‐propanesulfonic	   acid)	   (PAMPS)	   (PAMPS-­‐LA)	   copolymers.	   	   Because	   of	  the	   control	  over	  both	  particle	   size	  and	   surface	   chemistry,	   it	  was	  possible	   to	   study	  how	  the	  longitudinal	  relaxivity	  (r1)	  of	  gadolinium	  oxide	  nanoparticle	  was	  affected	  by	  both	   variables.	   	   Particle	   diameter	   had	   only	   a	  moderate	   effect	   on	   relaxivity;	   larger	  particles	  were	  not	  as	  effective	  on	  average	  as	  smaller	  ones,	  an	  observation	  attributed	  to	  the	  fact	  that	  in	  larger	  particles	  there	  are	  fewer	  surface-­‐available	  gadolinium.	  	  On	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the	   other	   hand,	   surface	   chemistry	   was	   a	   key	   parameter	   for	   maximizing	   the	  relaxivity,	   as	   this	   interface	  will	   define	   the	   access	   of	  water	   to	   the	   particle	   surface.	  	  PAA-­‐OA	   and	   PAMPS-­‐LA	   coatings	   were	   the	   best	   coating.	   The	   highest	   r1	   value	  observed	  was	  58.2	  S-­‐1mM-­‐1,	  a	  value	  15	  fold	  higher	  than	  Gd(III)-­‐chelates13	  (4.3~4.6	  S-­‐
1mM-­‐1)	  at	  1.41	  T.	  Moreover,	   in	  vitro	   cell	   toxicological	  studies	  revealed	  that	  various	  gadolinium	   oxide	   suspensions,	   especially	   PAMPS-­‐LA	   coated	   nanocrystals,	   had	   no	  significant	   effect	   on	   human	   dermal	   fibroblasts	   (HDF)	   up	   to	   300	   μM.	   This	   work	  illustrates	  that	  surface	  engineered	  gadolinium	  oxide	  nanoparticles	  may	  be	  a	  strong	  candidate	  for	  MRI	  contrast	  agents	  that	  offer	  r1	  relaxivities	  in	  excess	  of	  commercially	  available	  agents.	  
3.1. Introduction	  
Magnetic	  Resonance	  Imaging	  (MRI)	  has	  emerged	  as	  a	  powerful	  noninvasive	  imaging	   technique	  because	   it	  allows	  non-­‐invasive	   in	  vivo	  examination	  of	  biological	  samples	   with	   excellent	   spatial	   resolution.97-­‐99	   Because	   there	   is	   little	   difference	  between	  normal	  and	  diseased	  tissue	  in	  MRI,	  contrast	  agents	  are	  an	  important	  way	  to	  gather	  more	  specific	  information	  about	  the	  health	  of	  a	  patient.37,38	  They	  work	  by	  either	  shortening	  the	  longitudinal	  relaxation	  time	  (T1)	  or	  the	  transverse	  relaxation	  time	   (T2)	   of	   water	   protons.	   Two	   contrast	   agents	   in	   use	   clinically	   are	   gadolinium	  (Gd)-­‐based	  chelates	  and	  iron	  oxide	  nanoparticles.12,37,119-­‐124	  Gadolinium	  chelate	  MR	  contrast	  agents	  are	  positive	  contrast	  agents	  because	  they	  shorten	  T1	  relaxation	  time	  leading	   to	   increase	   signal	   intensity.	   	   Gadolinium-­‐diethylenetriaminepentaacetate	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(Gd-­‐DTPA,	  Magnevist®)	  is	  the	  most	  popular	  clinical	  agent;	  it	  can	  be	  used	  to	  enhance	  tissue	  pathology,	  detect	   leaks	   in	   the	  blood-­‐brain	  barrier	   (BBB),	   and	   in	   some	  cases	  identify	  physiological	  changes	  in	  tissue.12	  	  	  
Iron	  oxide	  nanoparticles	  induce	  a	  shortening	  of	  T2	  relaxation	  time,	  resulting	  a	  reduction	  of	  signal	  and	  negative	  contrast.	  Dextran	  coated	  superparamagnetic	  iron	  oxide	  nanoparticles	  (SPIOs)	  possess	  very	  large	  transverse	  relaxivity	  (r2	  =	  100~200	  mM-­‐1S-­‐1)	  and	  are	  used	  specifically	   in	  the	  evaluation	  of	  the	  tumors.7,22,23,104,105,125-­‐127	  Following	   intraveneous	   injection,	   80	   %	   of	   injected	   dose	   of	   SPIOs	   is	   taken	   up	   by	  macrophages	  in	  the	  liver	  and	  the	  rest	  portion	  of	  SPIOs	  is	  taken	  up	  by	  those	  in	  spleen	  or	   bone	  marrow.7,127	   The	   reticuloendothelial	   system	   (RES)	   macrophage-­‐mediated	  uptake	  SPIOs	  has	  been	  used	  to	  detect	   liver	  tumors	  or	  their	  accumulation	   in	   lymph	  node	   has	   been	   used	   to	   diagnose	   lymph	   node	   metastases.105,106,128,129	   Specially,	  ultrasmall	   superparamagnetic	   iron	   oxide	   nanoparticles	   (USPIOs)	   with	   diameters	  less	   than	  40	  nm	  have	  been	   clinically	   investigated	   as	   contrast	   agents	   because	   they	  offer	  prolonged	  delineation	  due	  to	   lower	  diffusion	   from	  tumor	  sites	  and	   increased	  internalization	  by	  tumor	  cells.105	  	  As	  blood-­‐pool	  agents,	  they	  are	  readily	  distributed	  in	   the	   intravascular	   extracellular	   space	   and	   transported	   to	   lymph	   nodes	   through	  lymphatic	  vessels.7,105,126,127	  	  
Each	   of	   these	   contrast	   agents	   has	   strengths	   and	   weaknesses	   in	   medical	  applications.	  	  Iron	  oxide	  nanoparticles	  are	  particularly	  well	  suited	  for	  molecular	  and	  cellular	   imaging.	   	   Because	   they	   concentrate	   a	   large	   number	   of	  magnetic	   ions	   in	   a	  small	   volume,	   they	   offer	   a	   high	   signal	   to	   noise	   ratio	   which	   translates	   into	   high	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anatomic	  resolution.123,130	  Moreover,	  because	  they	  are	  formed	  as	  nanoparticles	  they	  have	   longer	   blood	   circulation	   times	   and	   increased	   retention	   by	   cells.	   	   In	   contrast,	  gadolinium	  chelates	  T1	  agents	  are	  rarely	  used	  in	  high	  sensitivity	  applications	  such	  as	  cellular	  imaging	  and	  tracking	  because	  they	  are	  rapidly	  cleared	  and	  poorly	  taken	  up	  by	   cells.	   131	   	   Therefore,	   iron	   oxide	   nanoparticles	   have	   emerged	   for	   MRI	   contrast	  agents	   suitable	   for	  molecular/cellular	   labeling.	   However,	   the	   negative	   T2	   contrast	  agent	   based	   on	   iron	   oxide	   nanoparticles	   have	   significant	   drawbacks	   in	  MRI.	   	   The	  resulting	   dark	   contrast	   image	   is	   easily	   confused	   with	   the	   signal	   from	   bleeding,	  calcification,	  and	  susceptibility	  artifacts,	  and	  as	  a	  result	  can	  be	  quite	  misleading	   in	  diagnoses.123	   	   For	   these	   more	   practical	   reasons	   the	   FDA	   approved	   brighter	   Gd	  chelates	  including	  Magnevist®	  and	  OmiscanTM	  are	  generally	  the	  choice	  of	  clinicians	  for	   MR	   enhancement	   of	   brain	   tumor,	   blood	   vessels,	   central	   nervous	   system,	   and	  other	  abnormal	  structures	  or	  lesions.132-­‐141	  
It	  would	  be	  of	  great	  value	  to	  develop	  a	  T1-­‐based	  contrast	  agent	  that	  had	  the	  advantages	  of	  a	  nanoparticle	  form	  with	  the	  benefits	  of	  the	  gadolinium	  r1	  relaxivity.	  Gadolinum	  is	  the	  material	  of	  choice	  for	  this	  application	  as	  it	  has	  seven	  unpaired	  4f	  electrons,	  providing	  a	  large	  electric	  magnetic	  moment	  and	  high	  total	  electronic	  spin	  (S	  state,	  S=7/2).37	   	   	   If	   the	  S	  value	   is	  high,	  a	  slow	  electron	  spin	  relaxation	  of	  S-­‐state	  electrons	   will	   closely	   match	   the	   slow	   water	   proton	   spin-­‐relaxation.	   Thus,	   S	   state	  electrons	  can	  induce	  the	  longitudinal	  water	  proton	  relaxation.37,38,142	  However,	  free	  gadolinium	  in	  biological	  systems	  can	  be	  toxic	  hence	  the	  use	  of	  Gd-­‐chelates	  is	  limited	  by	   toxicity	   for	   higher	   doses.	   A	   number	   of	   studies	   have	   reported	   out	   on	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nephrologenic	  system	  fibrosis	  (NSF)	  issue	  and	  other	  potential	  side	  effects	  from	  the	  use	  of	  Gd-­‐chelates	  above	  recommended	  doses	  (0.1	  mmol	  Gd/kg	  of	  body	  weight).	  143-­‐
147	  
Such	  a	  material	  could	  provide:	  1)	  positive	  (brighter)	  contrast	  so	  as	  to	  provide	  accurate,	   reliable	   information	   for	   clinical	   decisions;	   2)	   high	   relaxivity	   values	  with	  the	  injection	  of	  a	  small	  dose;	  3)	  a	  nanoparticle	  form	  to	  allow	  for	  cellular	  uptake	  and	  accumulation	   as	  well	   as	   longer	   circulation	   times;	   4)	   easy	   surface	  modification	   for	  efficient	   labeling	  with	   target	  molecules;	   and	   5)	   low	   toxicity	   to	  minimize	   potential	  side	  effects.	  	  	  	  	  
Given	   the	  potential	   there	  has	  been	   recent	   interest	   in	  producing	  gadolinium	  containing	   nanoparticles	   for	   use	   as	   contrast	   agents.17,19,40,43,101,102,113,148-­‐154	  	  Gadolinium	  oxide,	  one	  of	   the	  rare	  earth	  sequioxide	  nanoparticles,	  was	  synthesized	  using	   high	   boiling	   polyalcohol	   solution	   (polyol	   method).14,17,40,43,102,148,155-­‐158	   It	   is	  direct	  precipitation	  in	  a	  high	  boiling	  point	  of	  diethylene	  glycol	  (DEG),	  which	  acts	  as	  a	  surface	  capping	  agent	  for	  preventing	  particle	  agglomeration.	  The	  amount	  of	  NaOH	  in	  the	   reaction	   controlled	   the	   reaction	   yield	   resulting	   in	   gadolinium	   oxide	  nanoparticles	  in	  the	  range	  of	  2	  to	  5	  nm.	  Based	  on	  the	  polyol	  method,	  the	  Tillement	  group	  only	  showed	  different	  sizes	  of	  gadolinium	  oxide	  nanoparticles	   (2.2,	  3.8,	  and	  4.6	   nm)	   by	   controlling	   the	   reaction.40	   Another	   synthesis	   approach	   is	   the	  decomposition	   of	   rare-­‐earth	   complexes	   in	   the	   presence	   of	   fatty	   acid	   or	   organic	  ligands	   in	   high	   boiling	   point	   solvent.101,113,152-­‐154,159,160	   Single	   crystalline,	  monodisperse	  nanostructures	   including	  ultrathin	  nanoplates,	  nanorings,	  nanorods,	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and	  nanodisks	  were	  synthesized	  and	  the	  sizes	  were	  from	  3	  to	  20	  nm.	  For	  example,	  Holloway	   group	   demonstrated	   the	   shape	   of	   gadolinium	   oxide	  were	   changed	  with	  spheres,	   plates,	   and	   curved	   rods	   by	   depending	   on	   the	   synthesis	   factors	   including	  metal	  precursors,	  surfactants	  and	  their	  ratio.152	  Using	  decomposition	  method,	  there	  was	  no	  report	  in	  size	  control	  of	  gadolinium	  oxide.	  	  
Based	  on	  polyol	  method,	  gadolinium	  oxide	  nanoparticles	  showed	  r1	  relaxivity	  values	   (<	   9.5)	   and	   act	   as	   MRI	   contrast	   agent	   in-­‐vitro.17,43,102,148	   Very	   recently,	  ultrasmall	   gadolinium	   oxide	   nanoparticles	   were	   used	   for	   in-­‐vivo	   contrast	   agents	  with	   r1	   relaxivity	   values	   (<15).19,40,103,161-­‐163	   	   The	   Lee	   and	   other	   research	   groups	  considered	   the	   toxicity	   of	   the	   gadolinium	   oxide	   nanoparticles.19,103,162-­‐164	   For	  example,	   Lee	   group	   demonstrated	   the	   d-­‐glucuronic	   acid	   coated	   lanthanide	   doped	  gadolinium	   oxide	   was	   not	   toxic	   from	   5	   μM	   to	   279	   μM	   of	   Gd(III)	   ions.19,163	  While	  promising	  the	  extent	  to	  which	  gadolinium	  nanoparticle	  r1	  can	  be	  optimized	  so	  that	  they	  can	  compete	  with	  existing	  clinical	  contrast	  agents	  remains	  an	  open	  question.	  	  
	  	  	  	  In	   this	   work,	   we	   reported	   a	   study	   of	   how	   the	   diameter	   and	   surface	  chemistry	  of	   gadolinium	  oxide	  nanoparticles	   affect	   their	   r1	   relaxivity.	   	  Gadolinium	  oxide	  nanoparticles	   prepared	   in	   organic	   solvents	  were	   transferred	   to	  water	   using	  different	   phase	   transfer	   agents	   with	   high	   yields	   (~80	   %).	   	   Core	   diameters	   and	  different	  surface	  coatings	  of	  gadolinium	  oxide	  nanoparticles	  affect	  the	  MR	  relaxivity	  values	  since	  the	  number	  of	  Gd	  metal	  ions	  in	  a	  nanoparticle,	  water	  proton	  exchange	  rate,	   and	   rotation	   are	   dependent	   on	   both	   variables.	   Optimized	   gadolinium	   oxide	  nanoparticles	  exhibit	  10-­‐15	  fold	  higher	  r1	  relaxation	  than	  that	  of	  Gd-­‐DTPA	  (4.3	  ~	  4.6	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mM-­‐1S-­‐1)	  at	  1.41	  T.12,13	  Moreover,	   the	  gadolinium	  present	   in	   the	  particles	   is	  not	  as	  labile	  as	  Gd-­‐chelates.	   	  For	  example,	  a	  screen	  of	  acute	  toxicity	  with	  HDF	  cells	   found	  low	  to	  no	  toxicity	  up	  to	  350	  μM	  (LD50)	  in	  contrast	  to	  5.7mmol/kg	  of	  body	  weight	  of	  Gd-­‐DTPA	  (LD50).	  	  	  	  
3.2. Experimental	  sections	  
3.2.1. Chemicals	  
Gadolinium	  nitrate	  hexahydrate	  (Gd(NO3)3⋅6H2O,	  99.99	  %),oleic	  acid	  (OLAC,	  technical	  grade	  90	  %),	  oleylamine	  (OLAM,	  technical	  grade	  70	  %),	  1-­‐octadecene	  (1-­‐ODE,	  technical	  grade	  90	  %),	  poly(acrylic	  acid)	  (PAA,	  Mw=1800),	  octylamine	  (OA,	  99	  %),	   acrylic	   acid	   2-­‐Acrylamido-­‐2-­‐Methylpropane	   sulfonic	   acid	   copolymer	  (AA/AMPS),	   lauryl	  acrylate	  (LA,	  technical	  grade	  90	  %),	  dulbecco’s	  modified	  eagle’s	  medium	   (DMEM),	   fetal	   bovine	   serum	   (FBS),	   penicilin-­‐streptomycin	   (PS),	   and	  trypsin-­‐EDTA	  were	   purchased	   from	   Sigma-­‐Aldrich.	   The	   synthesis	  was	   under	   high	  purity	  nitrogen	  (N2,	  99.99	  %)	   flow.	  Methanol	   (99.8	  %),	  acetone	   (99.5	  %),	  hexanes	  (98.5	   %),	   sodium	   bicarbonate	   (99.7	   %),	   and	   dimethylformamide	   (DMF,	   99.8	   %),	  nitric	  acid	  (HNO3,	  70	  %)	  and	  hydrogen	  peroxide	  (H2O2,	  30	  %)	  were	  purchased	  from	  Fisher	   Scientific;	   1-­‐ethyl-­‐3-­‐[3-­‐dimethylaminopropyl]	   carboiimide	   hydrochoride	  (EDC)	   was	   purchased	   from	   Thermo	   Scientific;	   The	   CellTiter	   96®	   Aqueous	   One	  solution	  Cell	  Proliferation	  Assay	  (MTS	  assay)	  was	  purchase	  from	  Promega;	  Human	  derman	  fibroblast	  (HDF)	  cells	  were	  purchased	  from	  Cambrex.	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3.2.2. Synthesis	  of	  gadolinium	  oxide	  (Gd2O3)	  nanoparticles	  
2	   mmol	   of	   gadolinium	   nitrate	   hexahydrate	   was	   mixed	   with	   oleic	   acid	   (4	  mmol)	   and	   1-­‐octadecene	   (5	   g)	   and	   stirred	   for	   2	   hours	   at	   110	   °C	   until	   the	   Gd	  precursor	  was	   completely	   dissolved	   in	   the	   solvent	   as	  Gd-­‐oleate	   precursors.	   	   After	  increasing	  the	  temperature	  from	  110	  to	  290	  °C,	  the	  reaction	  mixture	  was	  refluxed	  at	  290	  °C	  for	  3-­‐18	  hours.	  After	  the	  reaction	  is	  done,	  the	  temperature	  was	  cooled	  down	  to	  room	  temperature.	  The	  resulting	  colloidal	  solution	  (5	  mL)	  was	  centrifuged	  with	  methanol	  (20	  mL)	  and	  acetone	  (20	  mL)	  at	  4150	  rpm	  for	  30	  minutes	  and	  redispersed	  with	   hexanes.	   This	   purification	   was	   repeated	   six	   times	   resulting	   in	   purified	  gadolinium	   oxide	   nanoparticle	   solution.	   	   Finally,	   the	   Gd2O3	   nanoparticles	   (5	   nm)	  were	  prepared	  and	  stored	  in	  hexanes.	  To	  make	  larger	  Gd2O3	  nanoparticles	  (8,	  11,	  13,	  and	  22	  nm),	  the	  oleylamine	  (2,	  6,	  8,	  and	  12	  mmol)	  and	  more	  3	  g	  1-­‐octadecene	  were	  added	  into	  the	  gadolinium-­‐oleate	  mixture	  (2	  mmol	  gadolinium	  nitrate	  hexahydrate,	  4	  mmol	  oleic	  acid,	  5	  g	  1-­‐octadecene)	  after	  heating	  at	  110	  °C	   for	  2	  hours	  and	   then	  refluxed	  at	  290	  °C	  for	  3-­‐18	  hours.	  For	  making	  smaller	  2	  nm	  Gd2O3	  nanoparticles,	  the	  refluxed	  reaction	  temperature	  was	  increased	  from	  290	  to	  320	  °C	  with	  the	  amounts	  of	  gadolinium	  nitrate	  hexahydrate	  (2	  mmol),	  oleic	  acid	  (4	  mmol),	  and	  1-­‐octadecene	  (5	  g).	  
3.2.3. Oleic	  acid	  coated	  Gd2O3	  nanoparticles	  
The	  oleic	  acid	  coated	  Gd2O3	  nanoparticles	  were	   followed	  and	  modified	  by	  a	  previously	  published	  procedure.165	   	  A	  specific	  amount	  of	  oleic	  acid	  (from	  30	  μL	   to	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300	  μL)	  was	  introduced	  to	  1	  mL	  of	  Gd2O3	  nanoparticles	  solution	  dispersed	  in	  ethyl	  ether	  (1,500	  -­‐	  4,000	  mg/L	  of	  Gd	  ion	  concentration).	  	  After	  stirring	  for	  24	  hours,	  ultra	  pure	  water	   (Milipore,	   18.2	  MΩ·cm)	   or	   0.1	  M	   sodium	   bicarbonate	   (pH	   9)	   solution	  was	   introduced	   and	   stirred	   for	   2	   hours.	   Then	   a	   probe	   sonicator	   (UP	   50H,	   Dr.	  Hielscher)	   was	   used	   with	   60	   %	   amplitude	   for	   10	   minutes	   for	   the	   dispersion	   in	  water.	  	  The	  Gd2O3	  aqueous	  solution	  was	  further	  stirred	  for	  1	  day	  to	  evaporate	  ethyl	  ether	   completely	   by	   opening	   the	   cap.	   The	   purification	   of	   water-­‐soluble	   Gd2O3	  nanoparticles	   was	   carried	   out	   using	   ultracentrifugation	   (optima	   L-­‐90K	  ultracentrifuge,	  Beckman	  coulter)	  at	  40,000	  rpm	  for	  3	  hours	  twice	  and	  followed	  by	  syringe	  filteration	  (pore	  size	  of	  0.45	  uM,	  Whatman	  NYL).	  The	  resulting	  clear	  brown	  aqueous	  solution	  was	  acquired	  after	  purification.	  To	  calculate	   the	   transfer	  yield	  of	  oleic	   acid	   coating,	   the	   concentrations	   of	   gadolinium	   ion	   were	   compared	   in	   both	  original	   and	   transferred	   solution.	   	   Finally,	   Gd2O3	   nanoparticles	  were	   dispersed	   in	  ultra	  pure	  water.	  	  
3.2.4. Octylamine	  (OA)	  modified	  poly	  acrylic	  acid	  (PAA)	  (PAA-­‐OA)	  polymer	  
synthesis	  
The	  preparation	  of	  PAA-­‐OA	  polymer	  and	  PAA-­‐OA	  coated	  Gd2O3	  nanoparticles	  followed	   a	   previously	   published	   procedure.166	   To	   make	   PAA-­‐OA	   copolymer,	   first	  PAA	  (0.6	  g,	  0.33	  mmol)	  was	  dissolved	  in	  DMF	  (10	  g).	  	  After	  stirring	  for	  10	  minutes,	  EDC	  (0.58	  g,	  3	  mmol)	  was	  added	  to	  the	  PAA/DMF	  solution,	  and	  octylamine	  (0.5	  mL,	  3	  mmol)	  was	  sequentially	  introduced	  to	  the	  PAA/EDC/DMF	  solution.	  	  After	  stirring	  overnight,	   rotavap	   was	   used	   to	   remove	   DMF	   and	   keep	   the	   PAA-­‐OA	   solution	   in	   a	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vacuum.	  	  	  The	  final	  PAA-­‐OA	  solution	  (15	  mg/mL)	  was	  redispersed	  in	  chloroform	  (40	  mL).	  	  	  
3.2.5. PAA-­‐OA	  coated	  Gd2O3	  nanoparticles	  
The	   varied	   amounts	   of	   PAA-­‐OA	   polymer	   from	   1	   to	   7	  mL	  were	  mixed	  with	  1mL	  Gd2O3	  nanoparticle/chloroform	  solution	   (typically	  1,500	   to	  4,000	  mg/L	  of	  Gd	  ion	   concentration).	   The	   mixed	   solution	   was	   stirred	   for	   24	   hours	   and	   then	  evaporated	   the	   chloroform	   by	   using	   vacuum	   or	   air.	   	   After	   adding	   0.05	  M	   sodium	  bicarbonate	  solution	  (10	  mL),	  a	  probe	  sonicator	  with	  60	  %	  amplitude	  was	  used	  for	  10	   minutes.	   The	   resulting	   solution	   was	   purified	   with	   ultracentrifugation	   (40,000	  rpm	  for	  3	  hours,	  twice)	  and	  filtered	  out	  with	  syringe	  filter	  (0.45	  uM,	  Whatman	  NYL).	  The	   clear	   brown	   Gd2O3	   nanoparticle	   solution	   was	   acquired	   and	   completely	  dissolved	  in	  ultrapure	  MQ	  water.	  	  
3.2.6. Poly	  (acrylic	  acid	  2-­‐Acrylamido-­‐2-­‐Methylpropane	  sulfonic	  acid)	  	  
(PAMPS)-­‐	  lauryl	  acrylate	  (LA)	  (PAMPS-­‐LA)	  polymer	  synthesis	  
The	  PAMPS-­‐LA	  polymer	  is	  synthesized	  by	  copolymerization	  of	  30	  g	  of	  AMPS	  	  (0.1447	  mol,	   207.23	   g/mol)	   and	  22.5	  mL	  of	   LA	  monomers	   (240.38	   g/mol,	   0.0827	  mol)	  in	  300	  mL	  of	  DMF	  solution	  under	  UV	  light.	  	  The	  polymer	  solution	  can	  be	  used	  to	  coat	  nanocrystals	  directly	  without	  further	  purification.	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3.2.7. PAMPS-­‐LA	  coated	  Gd2O3	  nanoparticles	  
The	  varied	  amounts	  of	  PAMPS-­‐LA	  polymer	  from	  1	  to	  7	  mL	  were	  mixed	  with	  1mL	  nanocrystal/ethyl	   ether	   solution	   (typically	   1,500	   to	   4,000	  mg/L	   of	  metal	   ion	  concentration).	   	   When	   the	   solution	   was	   cloudy	   after	   adding	   certain	   amounts	   of	  polymer,	   more	   DMF	   solution	   helped	   to	   get	   a	   clear	   mixture	   solution.	   The	  nanocrystal/polymer	  solution	  was	  stirred	  for	  24	  hours.	  	  After	  adding	  ultra	  pure	  MQ	  water,	  the	  solution	  was	  kept	  to	  stir	  for	  another	  24	  hours	  and	  allowed	  to	  evaporate	  ethyl	   ether	   via	   air.	   	   The	   resulting	   solution	   was	   purified	   with	   ultracentrifugation	  (40,000	   rpm	   for	   3	   hours,	   twice)	   and	   filtered	   out	   using	   syringe	   filter	   (0.45	   uM,	  Whatman	   NYL).	   	   The	   clear	   nanocrystal	   solution	   was	   acquired	   and	   completely	  dissolved	  in	  ultra	  pure	  MQ	  water.	  
3.2.8. 	  MRI	  relaxivity	  measurements	  
MR	  relaxivity	  measurement.	  Various	  concentration	  of	  Gd2O3	  (0.01	  ~2	  mM)	  was	   prepared	   by	   dilution	   from	   the	   stock	   solution	   of	   Gd2O3	   nanoparticles	   capped	  with	  oleic	   acid,	  PAA-­‐OA,	   and	  PAMPS-­‐LA	  polymers	   for	  MR	  relaxivity	  measurement.	  To	  measure	   r1	   and	   r2	   of	  Gd2O3	  nanoparticles,	   the	  MR	   relaxometer	   (NMR	  analyzer,	  mq	   60,	   Bruker)	   at	   1.41T	   was	   used.	   The	   r1	   and	   r2	   values	   were	   calculated	   by	  determining	   the	   slope	   of	   1/T1	   or	   1/T2	   (s-­‐1)	   at	   varying	   TR	   and	   TE	   values	   against	  gadolinium	  concentration	  (mM).	  
MR	  phantom	  imaging.	  To	  image	  phantoms	  in	  MR,	  a	  MRI	  clinical	  3T	  scanner	  was	   used.	   T1	  weighted	   contrast	   enhancement	  was	   performed	   running	   a	   standard	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spin-­‐echo	  (SE)	  sequence	  with	  500	  ms	  TR	  and	  23	  ms	  TE.	  The	  voxel	  size	   is	  0.4	  X	  0.4	  mm	   and	   slice	   thickness	   was	   1	   mm.	   	   For	   this	   measurement,	   the	   different	  concentration	   of	   Gd2O3	   aqueous	   solutions	   (oleic	   acid,	   PAA-­‐OA,	   PAMPS-­‐LA)	   were	  used	  and	  compared	  the	  contrast	  with	  Magnevist®	  (Gd-­‐DTPA)	  at	  same	  concentration	  
3.2.9. Cell	  culture	  and	  MTS	  assay	  
Cell	   Culture:	   Human	   derman	   fibroblast	   (HDF)	   were	   used	   and	   cultured	   in	  Dulbecco’s	  Modified	   Eagle’s	  Medium	   (DMEM)	  with	   10%	   fetal	   bovine	   serum	   (FBS)	  and	  1	  %	  penicilin-­‐streptomycin	  (PS).	  The	  cells	  were	  lifted	  by	  trypsin-­‐EDTA	  and	  re-­‐suspended	  in	  media	  (DMEM	  with	  10%	  FBS	  and	  1%	  PS)	  solution	  for	  the	  passaging.	  	  	  
Cell	  Viability	  test	  (MTS	  assay):	  	  To	  determine	  the	  cell	  toxicity	  depending	  on	  their	   sizes	  and	  surface	  coatings	   (oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA),	   the	  standard	  colorimetric	  assay,	  MTS	   (CellTiter	  96,	  Promega)	  was	  used.	   	  HDF	  cells	  were	  placed	  and	   grown	   in	   96	   well	   culture	   plates	   with	   over	   80	   %	   confluency.	   	   Each	   set	   was	  prepared	  with	  different	  concentration	  of	  Gd2O3	  nanoparticle	  solutions	  (0-­‐500	  uM).	  One	   set	   was	   treated	   as	   a	   blank	   (no	   nanoparticles)	   and	   last	   set	   was	   used	   for	   the	  untreated	   control	   (ethanol).	   	   The	   treated	   cells	   with	   Gd2O3	   nanoparticle	   aqueous	  solution	   were	   incubated	   for	   24	   hours.	   	   The	   solution	   was	   then	   suctioned	   out	   and	  replaced	  with	  100	  uL	  fresh	  media	  (DMEM	  with	  FBS	  10	  %	  and	  1	  %	  PS)	  solution	  and	  20	  uL	  MTS	  agent	  to	  each	  well.	  	  After	  incubating	  for	  1	  hour	  at	  37	  °C	  and	  5	  %	  CO2,	  the	  absorbance	   at	   490	   nm	   of	   the	   solution	   was	   measured	   with	   a	   plate	   reader	  (SPectraMax,	  M2,	  Molecular	  devices).	  	  The	  experiment	  was	  repeated	  three	  times	  for	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the	  average.	  The	  LD50,	  which	  gives	  the	  lethal	  dose	  required	  for	  half	  of	  the	  cells	  to	  die,	  was	  calculated	  by	  the	  percentage	  of	  the	  cell	  viability.	  	  	  
3.2.10. Instruments	  and	  characterization	  
Transmission	   electron	   microscope	   (TEM).	   	   To	  measure	   the	   diameter	   of	  the	  Gd2O3	  nanoparticles	  a	  JEOL	  2100	  field	  emission	  TEM	  operating	  at	  200	  kV	  with	  a	  single	  tilt	  holder	  was	  used.	  	  TEM	  sample	  was	  prepared	  by	  evaporation	  of	  one	  drop	  of	  Gd2O3	  nanoparticle	   solution	  on	   the	  ultrathin	  400	  mesh	   copper	   grids	   (Ted	  Pella	  Inc.).	   The	   size	   and	   size	   histograms	   of	   Gd2O3	   nanoparticles	   were	   calculated	   by	  counting	  over	  500	  particles	  with	  Image-­‐Pro	  Plus	  5.0	  (Media	  Cybernetics,	  Inc.,	  Silver	  Spring,	  MD).	  
X-­‐ray	   diffraction	   (XRD).	   	   X-­‐ray	  powder	  diffraction	  of	  Gd2O3	  nanoparticles	  was	   carried	   out	   using	   a	   Rigaku	   D/Max	   Ultima	   II	   with	   a	   zero	   background	   sample	  holder.	  The	  X-­‐rays	  were	  generated	  at	  40	  KV	  and	  40	  mA	  and	  the	  range	  of	  2θ	  was	  10	  to	  80	  degrees.	  For	  reference	  the	  JCPDS	  card	  was	  used.	  
X-­‐ray	   photoelectron	   spectroscopy	   (XPS).	   	  XPS	  data	  was	  recorded	  by	  PHI	  quantera	  with	  a	  monochromatic	  aluminium	  38.6	  W.	  An	  x-­‐ray	  source,with	  an	  x-­‐ray	  spot	   size	   (200	   um)	   with	   a	   pass	   energy	   of	   26	   eV	   at	   45°	   was	   used	   for	   the	  measurement.	  
Dynamic	   light	   scattering	   (DLS)	   and	   zeta	   potential.	   	   The	   hydrodynamic	  size	   (nm)	   and	   zeta	   potential	   (mV)	   of	   oleic	   acid	   and	   PAA-­‐OA	   coated	   Gd2O3	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nanoparticles	  were	  measured	  by	  Malvern	  Zetasizer	  Nanoseries	  (Malvern,	  UK).	  	  The	  measurement	  was	  repeated	  five	  times	  for	  the	  average.	  	  
Inductive	  coupled	  plasma-­‐optical	  emission	  spectroscopy	  (ICP-­‐OES).	   	  To	  measure	   the	   gadolinium	   concentration	   in	   a	   nanoparticle,	   Perkin	   Elmer	   ICP-­‐OES	  equipped	  with	  auto	  sampler	  was	  used.	  The	  preparation	  of	  sample	  for	  ICP-­‐OES	  was	  prepared	  by	  acid	  digestion	  using	  nitric	  acid	   (HNO3,	  70	  %)	  and	  hydrogen	  peroxide	  (H2O2,	  30%).	  	  
Total	  organic	  carbon	  (TOC).	   	  A	  Shimadzu	  TOC-­‐L	  was	  used	  to	  measure	  the	  carbon	  concentration	  for	  surface	  functionalized	  gadolinium	  nanoparticles	  in	  water.	  	  Three	   replicates	   of	   each	   sample	   were	   prepared	   by	   adding	   1	   ml	   of	   the	   stock	  nanoparticle	   sample	   and	  diluting	   to	  8.5	  mL	  with	  Milli-­‐Q	  18	  MΩ	  pure	  water.	   	   Each	  sample	  was	  run	  on	  a	  total	  nonpurgeable	  organic	  carbon	  (NPOC)	  assay	  with	  triplicate	  50	   μL	   injections.	   The	   calibrations	   from	   0.5	   to	   60	   ppm	  were	   prepared	   using	   TOC	  standard	  solution	  (Sigma-­‐Adrich)	  with	  high	  R2	  (0.998)	  value.	  
Calculation	  of	  grafting	  density	  (GD).	  	  The	  calculation	  of	  grafting	  density	  (σ)	  was	   calculated	   from	   TOC	   data	   using	   the	   equation	   below,	   similar	   to	   previously	  published	  method.167	  	  	  	  	  
𝜎 = 𝐶 ∗𝑀𝑊!𝑀𝑊! ∗ 𝐶! ∗ 𝑁𝑃 ∗ (4𝜋𝑟!"#$! )	  
The	   nonpurgeable	   organic	   carbon	   concentration	   ([C])	   from	   TOC	   analysis	  must	  be	  converted	   from	  mg/L	  (ppm)	  to	  mol/liter	  (molarity)	  by	  considering	  molar	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mass	  of	  carbon	  (12,010	  mg/mol).	  To	  determine	  the	  number	  of	  polymer	  molecules	  the	   carbon	   concentration	   is	   multiplied	   by	   the	   molecular	   weight	   of	   the	   monomer	  (MWn)	   and	  divided	  by	   the	  polymer	  molecular	  weight	   (MWp)	   times	   the	  number	   of	  carbons	  per	  monomer	  (Cn).	  By	  dividing	  by	  the	  molar	  concentration	  of	  nanoparticles,	  [NP],	  and	  the	  surface	  area	  of	  the	  particle	  the	  resulting	  grafting	  density	  is	  achieved.	  	  	  
3.3. 	  Result	  and	  discussions	  
3.3.1. 	  Synthesis	  of	  size	  tunable	  gadolinium	  oxide	  nanoparticles	  
A	  central	  goal	  of	  this	  work	  was	  to	  examine	  how	  particle	  diameter	  and	  surface	  coating	   affects	   the	   relaxivity	   of	   (Gd2O3)	   nanoparticles	   in	   aqueous	   suspensions.	  	  Towards	  that	  end,	  we	  adapted	  synthetic	  methods	  used	  to	  form	  uniform	  metal	  oxide	  nanocrystals	   in	   organic	   solutions	   to	   gadolinium	   oxide	   synthesis.	   	   This	   synthesis	  proceeds	   via	   the	   thermal	   decomposition	   of	   gadolinium	   nitrate	   precursors	   in	   the	  presence	   of	   organic	   surfactants	   (oleic	   acid	   or	   the	   mixture	   of	   oleic	   acid	   and	  oleylamine)	  (Schematic	  	  3-­‐1).	  	  Decomposition	  occurs	  at	  high	  temperature	  (290	  °C).	  
In	   a	   typical	   reaction,	   a	   Gd-­‐oleate	   precursor	   was	   first	   prepared	   by	   heating	  gadolinium	  nitrate	  hexahydrate	  and	  oleic	  acid	  at	  110	  °C	  for	  two	  to	  three	  hours.	  This	  pre-­‐treatment	  led	  to	  much	  better	  particle	  uniformity	  than	  reported	  before,	  perhaps	  because	   of	   the	   ordering	   of	   the	   fatty	   acid	   chains.168	   This	   treatment	   resulted	   in	   a	  black-­‐brownish	  Gd-­‐oleate	  complex,	  which	  was	  then	  refluxed	  system	  at	  290	  °C	  under	  N2	   for	   three	   to	  eighteen	  hours.	   	  The	  Gd2O3	  nanoparticles	  are	  nearly	  monodisperse	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with	   narrow	   diameter	   distributions	   (<15	   %)	   (Figure	   3-­‐1,	   Figure	   3-­‐2,	   and	   Figure	  3-­‐3).	  	  Moreover,	  they	  can	  be	  formed	  with	  a	  wide	  range	  of	  diameters,	  from	  1.8	  to	  22	  nm,	   by	   tailoring	   the	   reflux	   time,	   temperature,	   precursor	   concentration,	   and	  surfactant	   type	   and	   amount.	   Transmission	   electron	   microscopy	   (TEM)	   shows	  gadolinium	   oxide	   nanoparticles	   with	   different	   core	   diameters	   from	   1.8	   to	   22	   nm	  (Figure	  3-­‐1).	  
	  
Schematic	  	  3-­‐1	  Schematic	  diagram	  of	  Gd	  oxide	  synthesis	  Schematic	  diagram	  and	  photographs	  showing	  the	  synthesis	  of	  Gd2O3	  nanoparticles	  based	   on	   thermodecomposition	   of	   gadolinium(III)	   nitrate	   hexahydrate	   in	   the	  presence	  of	  organic	  surfactant	  (oleic	  acid	  and	  oleylamine)	  and	  1-­‐octadecene.	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  Figure	  3-­‐1	  TEM	  images	  of	  Gd2O3	  nanoparticles	  TEM	  images	  of	  Gd2O3	  nanoparticles	  ranging	  from	  1.8	  nm	  to	  22	  nm.	  The	  diameter	  of	  Gd2O3	   nanoparticles	   (A-­‐F)	   are	   1.79	  ±	   0.23,	   5.02	  ±	   0.45,	   7.95	  ±	   0.82,	   10.82	  ±	   1.75,	  13.18	  ±	  2.09,	  and	  21.97	  ±	  2.78	  nm,	  respectively.	  	  The	  scale	  bars	  are	  50	  nm	  except	  A	  (20	  nm).	  The	  histograms	  for	  the	  size	  distribution	  of	  Gd2O3	  nanoparticles	  are	  shown	  in	  Figure	  3-­‐2.	  
	   97	  	  
	  
Figure	  3-­‐2	  The	  histograms	  of	  Gd2O3	  nanoparticles	  The	   histograms	   of	   Gd2O3	   nanoparticles	   ranging	   from	   1.8	   to	   22	   nm.	   	   The	   average	  diameters	  with	  standard	  deviataion	  are	  (A)	  1.79	  ±	  0.23	  nm,	  (B)	  5.02	  ±	  0.45	  nm,	  (C)	  7.95	  ±	  0.82	  nm,	  (D)	  10.82	  ±	  1.75	  nm,	  (E)	  13.18	  ±	  2.09	  nm,	  and	  (F)	  21.97	  ±	  2.78	  nm,	  respectively.	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Figure	  3-­‐3	  XRD	  and	  XPS	  data	  of	  Gd2O3	  nanoparticles	  A)	  XPS	  data	  of	  Gd2O3	  nanoparticles	  (11	  nm	  diameter)	  showing	  Gd	  4d3/2	  	  at	  146.2	  eV	  	  and	  (B)	  XRD	  Data	  of	  Gd2O3	  nanoparticles	  with	  diameter	  11	  nm	  and	  22	  nm.	  For	  the	  references,	  JCPDS	  Gd2O3	  monoclinic	  (#	  43-­‐1015)	  and	  cubic	  (#	  43-­‐1014)	  were	  used.	  	  
The	   shape,	   morphology,	   crystal	   structure,	   and	   composition	   of	   Gd2O3	  nanoparticles	   were	   evaluated	   by	   transmission	   electron	   microscopy	   (TEM),	   X-­‐ray	  photoelectron	   spectroscopy	   (XPS),	   and	   X-­‐ray	   diffraction	   (XRD)	   measurement	  (Figure	  3-­‐1	  and	  Figure	  3-­‐3)	   In	  the	  TEM	  images,	  the	  Gd2O3	  nanoparticles	  appear	  as	  ultrathin	  nanoplates	  or	  nanodisks;	  in	  the	  case	  of	  plates/discs	  they	  can	  be	  visualized	  both	  parallel	  to	  the	  underlying	  carbon	  coated	  copper	  grid	  as	  well	  as	  perpendicular	  and	   standing	   on	   their	   edge	   (Figure	   3-­‐1).	   When	   perpendicular	   it	   was	   possible	   to	  measure	  edge	  thicknesses	  on	  the	  order	  of	  1.1	  to	  1.2	  nm.	  Sometimes	  the	  plates/discs	  would	   stack	  on	   top	  of	   each	  other,	   giving	   very	  dark	   contrast	   in	   the	   images.	  Due	   to	  high	   oxophilicity,	   the	   oleic	   acid	   ligand	   was	   strongly	   bound	   to	   the	   gadolinium	  nanoparticles	   rather	   than	   oleylamine.169	   The	   capped	   oleic	   acid	   ligand	   prevented	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self-­‐aggregation	   of	   nanoparticles	   via	   inter-­‐particle	   dipolar-­‐dipolar	   repulsive	   force,	  and	  was	  well	  dispersed	  in	  non-­‐polar	  solvent	  (1-­‐octadecene)	  with	  good	  dispersibility	  (side	   to	   side).160	   When	   adding	   only	   oleic	   acid,	   the	   nuclei	   of	   gadolinium	   oxide	  underwent	  a	  fast	  growth	  and	  finally	  they	  would	  form	  dynamically	  stable	  nanoplates	  with	  smaller	  size.160	  Increasing	  the	  amount	  of	  oleylamine	  with	  oleic	  acid,	  resulted	  in	  particle	  size	  increase	  from	  8	  to	  22	  nm.	  Gd2O3	  nanoparticles	  above	  11	  nm	  in	  diameter	  typically	   aligned	  parallel	   to	   the	   surface	  without	   a	   preferred	  direction	   to	  minimize	  their	  surface	  energy	  due	  to	  interfacial	  tension	  (self	  assembled	  face	  to	  face	  behavior)	  (Figure	  3-­‐4).	  The	  formation	  of	  gadolinium	  oxide	  nuclei	  with	  oleylamine	  prefered	  a	  slow	   growth	   and	   they	   transformed	   to	   a	   thermodynamically	   stable	   nanodisks.40	  When	  changing	  the	  reaction	  conditions	  including	  time,	  concentration,	  temperature,	  and	  surfactant	  ratio,	  the	  average	  diameter	  of	  nanoplates/nanodisks	  increased	  from	  1.8	   to	  22	  nm,	  but	   their	   thickness	   remained	   constant	   (~1.1	  nm).	  Over	   the	   last	   few	  years,	   others	   have	   observed	   that	   gadolinium	   oxide	   and	   rare	   earth	   doped	   Gd2O3	  nanoparticles	  often	  form	  unusual	  shapes	  including	  nanorings,	  nanoplates,	  and	  ultra-­‐narrow	  nanorods.	  However,	  those	  reactions	  proceeded	  at	  lower	  temperatures	  using	  gadolinium	  acetate	  hydrate	  or	  gadolinium	  acetylacetonate	  hydrate	  precursors	  with	  no	  size	  tunability.101,113,152-­‐154	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Figure	  3-­‐4	  The	  TEM	  image	  of	  22	  nm	  diameter	  gadolinium	  oxide	  nanodisks	  In	  the	  TEM	  images,	  some	  ultrathin	  nanodisks	  were	  aligned	  parallel	  with	  face-­‐to-­‐face	  direction.	  From	  GIF	  mapping,	  these	  nanodisks	  have	  gadolinium	  in	  a	  nanoparticle.	  	  The	   chemical	   composition	   and	   structure	   of	   the	   products	   were	   consistent	  with	   Gd2O3	   nanoparticles.	   	   X-­‐ray	   photoemission	   spectroscopy	   (XPS)	   found	   Gd	   4d	  3/2	  and	  Gd	  4d	  5/2	  features	  at	  146.2	  eV	  and	  141	  eV,	  respectively	  (Figure	  3-­‐3	  (A)).	  This	   corresponds	   to	  an	  oxidation	  state	  of	  Gd	   in	  keeping	  with	  Gd3+.	  The	  crystalline	  structure	  of	  Gd2O3	  nanoparticle	  was	  determined	  by	  x-­‐ray	  diffraction	   (XRD)	  of	   two	  different	  diameters	  of	  Gd2O3	  nanoparticles.	   	  As	   is	  apparent	   in	   the	  data	  (Figure	  3-­‐3	  (B)),	   the	   peaks	   are	   quite	   broad	   as	  would	   be	   expected	   for	   this	   plates/disks	   (<	   1.2	  nm).152,154,159	   By	   overlapping	   the	   reference	   peaks	   using	   JCPDS	   card,	   the	   Gd2O3	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nanoparticles	   contained	   both	   cubic	   and	   monoclinic	   structures.152	   	   Larger	   22	   nm	  diameter	  Gd2O3	  nanoparticles,	  had	  more	  intense	  monoclinic	  features.	  	  
Diameter	   control	   was	   best	   achieved	   through	   control	   over	   the	   type	   and	  amount	   of	   surfactant	   (oleic	   acid/oleylamine),	   though	  monomer	   concentration	   and	  temperature	   also	  played	   a	   role	   (Figure	  3-­‐5).	  Most	   particle	   growth	  occurs	   through	  the	   dissolution	   and	   reformation	   of	   particles	   rather	   than	   from	   soluble	  monomers.	  	  Smaller	   particles	   have	   higher	   surface	   energies	   or	   chemical	   potentials.	   Thus,	   they	  dissolve	   and	   grow	   faster	   than	   the	   large	   ones,	   leading	   size	   focusing	   effect,	   as	  described	   by	   the	   Gibbs-­‐Thomson	   equation.170-­‐172	   	   When	   gadolinium	   (III)	   nitrate	  hexahydrate	   reacted	  with	  oleic	  acid	  at	  110	   °C,	   the	   intermediate	  gadolinium	  oleate	  precursor	   was	   generated.	   When	   refluxed	   to	   high	   temperature	   at	   290	   °C,	   the	  nucleation	   and	   subsequent	   growth	   of	   gadolinium	   oxide	   undergo	   with	   selective	  addition	  of	  oleylamine.	  The	  Yan	  group	  proposed	   the	   formation	  mechanism	  of	   rare	  earth	  oxide	  nanocrystals	  (RE2O3)	  via	  two	  steps	  of	  rare-­‐earth	  oleates	  and	  subsequent	  decomposition	  of	   catalyzed	  oleylamine.160	  The	  ultrathin	  nanoplates	  and	  nanodisks	  RE2O3	   nanocrystals	   were	   produced	   by	   fast	   growth	   with	   [100]	   facets	   and	   slow	  growth	   of	   [111]	   facets,	   respectively.	   The	  molar	   ratio	   of	   oleic	   acid	   and	   oleylamine	  was	   very	   important	   to	   control	   the	   diameter	   of	   gadolinium	   nanoparticles	  (nanoplates/nanodisks).	  	  	  
As	   the	   amounts	   of	   oleylamine	   increased	   from	   0	   to	   12	   mmol,	   the	   particle	  diameters	  of	  Gd2O3	  nanoparticles	  increased	  from	  5	  to	  22	  nm	  with	  fixed	  amounts	  of	  gadolinium	  nitrate	  hexahydrate	  (2	  mmol)	  and	  oleic	  acid	  (4	  mmol)	  (Figure	  3-­‐1	  and	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Figure	  3-­‐5).	   	   In	  contrast,	  as	   increasing	  the	  amounts	  of	  oleic	  acid	  from	  4	  to	  8	  mmol	  with	  2	  mmol	  gadolinium	  nitrate	  hexahydrate,	  the	  particle	  diameters	  were	  decreased	  from	   10	   to	   7	   nm.	   The	   high	   ratio	   of	   organic	   surfactants	   between	   oleic	   acid	   and	  oleylamine	  (4:0	  to	  4:12)	  may	  result	   in	  more	   labile	  gadolinium;	  as	  the	  particles	  are	  more	   soluble,	   growth	   increased.	   Increasing	   concentration	   of	   precursors	   (Gd	  nitrate/oleic	   acid/oleylamine)	   from	  2/4/6	   to	   40/80/120	  produced	   larger	   particle	  diameters	  from	  11	  to	  22	  nm.	  	  Likewise,	  reducing	  the	  amounts	  of	  1-­‐octadecene	  from	  15	  g	  to	  4	  g	  with	  2	  mmol	  gadolinium	  nitrate	  hexahydrate	  also	  the	  particle	  diameter	  increased	   from	   7	   to	   13	   nm.	   Higher	   concentration	   of	   precursors	   increased	   higher	  monomer	  concentration	  and	  allowed	  particle	  growth.	  	  
Under	   a	   fixed	   concentration	   of	   precursor	   (gadolinium	   nitrate/oleic	  acid/oleylamine	  =	  4/12/12)	  and	  reflux	  time	  (6	  hours),	  as	  the	  temperature	  increased	  from	   260	   to	   320	   °C,	   the	   particle	   size	   was	   not	   changed	   significantly.	   Without	  oleylamine,	   as	   increasing	   temperature	   (290	   to	   320	   °C),	   the	   particle	   diameter	  was	  reduced	   from	  5	   to	  1.8	  nm.	  High	   temperature	  may	  cause	  a	  higher	   concentration	  of	  nuclei	  and	  decreasing	  the	  growth.	  The	  reflux	  time	  is	  not	  a	  significant	  factor	  for	  the	  size	   change.	   The	   synthetic	   parameters	   related	   to	   the	   size	   control	   of	   gadolinium	  oxide	  are	  described	  in	  Figure	  3-­‐5.	  	  In	  summary,	  to	  get	  highly	  monodisperse	  particles	  requires	  first	  that	  the	  Gd-­‐oleate	  complex	  be	  stabilized	  for	  several	  hours	  at	  110	  °C;,	  second	   that	   the	   reaction	   temperatures	  be	  high	   -­‐	  260	   to	  320	  °C;,	   and	   finally	  a	   long	  reflux	  time	  to	  fully	  sharpen	  size	  distributions	  as	  small	  particles	  dissolved	  and	  added	  to	  larger	  particles.	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Figure	  3-­‐5	  Important	  parameters	  for	  size	  tunability	  The	   size	   controllable	   Gd2O3	   nanoparticles	   by	   changing	   synthetic	   parameters	   (A)	  oleylamine,	   (B)	   oleic	   acid,	   (C)	   concentration	   of	   precursors,	   (D)	   ODE,	   (E)	  temperature,	  and	  (F)	  reflux	  time;	  As	  increasing	  the	  amounts	  of	  oleylamine	  (A),	  the	  particle	   sizes	   were	   increased	   from	   5	   to	   22	   nm.	   As	   increasing	   oleic	   acid	   (B),	   the	  particle	  sizes	  were	  decreased	  from	  10	  to	  7	  nm.	  When	  increasing	  high	  concentration	  of	   precursors	   or	   reducing	   ODE	   amounts,	   the	   particle	   sizes	  were	   increased	   due	   to	  higher	   monomer	   concentration.	   The	   temperature	   (E)	   and	   (F)	   did	   not	   show	   any	  significant	  size	  change.	  	  
3.3.2. Phase	  transfer	  of	  gadolinium	  oxide	  nanoparticles	  	  
To	   evaluate	   Gd2O3	   nanoparticles	   as	   T1	   MR	   contrast	   agents,	   the	   Gd2O3	  nanoparticles	  need	  to	  be	  transferred	  to	  water	  with	  biocompatible	  coatings.	   	  These	  coatings	  must	  perform	   two	   seemingly	  opposite	   functions:	   first,	   they	  must	  prevent	  the	  release	  of	  toxic	  Gd(III),	  which	  is	  a	  major	  cause	  of	  NSF143-­‐147,	  but	  at	  the	  same	  time	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allow	  for	  facile	  access	  of	  water	  to	  the	  surface	  gadolinium	  atoms.	   	  We	  evaluated	  two	  very	  different	  surface	  coatings	  for	  these	  reasons.	   	  One	  relied	  on	  the	  formation	  of	  a	  dense	  and	  thin	  oleic	  acid	  bilayer,	  while	  the	  others	  employed	  PAA-­‐OA	  and	  PAMPS-­‐LA	  co-­‐polymers.165,166,173	   In	   all	   cases,	   the	   original	   organic	   layer	   present	   at	   the	  nanoparticle	   interface	  was	  not	  disturbed.	   Figure	  3-­‐6	   illustrates	   the	  phase	   transfer	  process	  using	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  copolymers.	  	  In	  the	  case	  of	  the	  oleic	  acid,	  the	  bilayer	  forms	  and	  a	  free	  acid	  group	  is	  present	  at	  the	  surface.	  	  The	  PAA-­‐OA	  and	  PAMPS-­‐LA	  on	   the	  other	  hand	  wrap	   the	  organic	   ligands	   to	   the	  particle	   leaving	  the	  PAA	  or	  PAMPS	  to	  impact	  stability	  in	  aqueous	  solutions.	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Figure	  3-­‐6.	  Phase	  transfer	  of	  Gd2O3	  nanoparticles	  Schematic	  diagram	  of	  phase	  transfer	  method	  of	  ligand	  exchange	  using	  oleic	  acid	  and	  polymer	  encapsulation	  using	  PAA-­‐OA	  and	  PAMPS-­‐LA.	  	  	  
The	  transfer	  of	  particles	  via	  bilayers	  was	  reported	  previously	  for	  iron	  oxide,	  and	   the	   process	   is	   similar	   in	   this	   work.165	   	   What	   results	   are	   materials	   with	   very	  small	  hydrodynamic	  diameters	  (<	  30	  nm)	  because	  of	   the	  small	   length	  of	  oleic	  acid	  (e.g.	  1.97	  nm).	  Such	  a	  rigid	  and	  dense	  bilayer	  coating	  is	  very	  effective	  for	  dispersing	  nanoparticles	   in	   water,	   and	   it	   can	   be	   applied	   for	   a	   wide	   range	   of	   core	   diameters	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(Figure	  3-­‐7).	   	  The	  phase	   transfer	   efficiency	   (~50	  %)	  was	   found	  by	   comparing	   the	  concentration	   of	   Gd(III)	   in	   hexanes	   to	   that	   found	   in	   the	   water.	   	   Several	   factors	  controlled	  the	  efficacy	  of	  the	  phase	  transfer	  process.	  	  If	  the	  amount	  of	  phase	  transfer	  agents	   (oleic	   acid,	   PAA-­‐OA,	   and	   PAMPS-­‐LA)	   were	   not	   large	   enough	   to	   cover	   the	  hydrophobic	   surface	  of	  Gd2O3	  nanoparticles,	   then	   transfer	   efficiencies	  would	  drop	  substantially	   (10	   -­‐	   30	  %).	   	   Also,	   low	   yields	   (10	   -­‐	   40	  %)	  were	   observed	  when	   too	  much	  phase	  transfer	  agent	  was	  added.	  Both	  oleic	  acid	  and	  amphiphilic	  co-­‐polymers	  can	   form	   micelles	   above	   the	   critical	   micelle	   concentration.	   Under	   the	   optimal	  conditions	  with	   amounts	  of	   phase	   transfer	   agents,	   the	  best	   transfer	   efficiencies	   of	  oleic	   acid,	   PAA-­‐OA,	   and	   PAMPS-­‐LA	   were	   40~50	   %,	   70~80	   %,	   and	   70-­‐80	   %,	  respectively	  (Figure	  3-­‐7).	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Figure	   3-­‐7	   The	   phase	   transfer	   yields	   of	   oleic	   acid,	   PAA_OA	   and	   PAMPS-­‐LA	   coated	  Gd2O3	  nanoparticles	  (A)	   The	   photograph	   of	   oleic	   acid	   coated	   Gd2O3	   nanoparticles	   with	   different	   sizes	  from	  1.8	  nm	  to	  22	  nm	  and	  phase	  transfer	  efficiency	  (%)	  of	  oleic	  acid	  coating	  when	  using	   various	   amounts	   of	   oleic	   acid	   (30-­‐300	  uL)	   in	   1ml	   Gd2O3	   nanoparticle/ethyl	  ether	   solution	   (1.5~4	   mg/ml).	   (B)	   The	   photograph	   of	   PAA-­‐OA	   coated	   Gd2O3	  nanoparticles	  ranging	  from	  1.8	  nm	  to	  22	  nm	  diameters	  and	  phase	  transfer	  efficiency	  (%)	  using	  various	  amounts	  of	  PAA-­‐OA	  solutions	  (1	  to	  7	  ml,	  15	  mg/ml	  PAA-­‐OA)	  with	  1	  mL	  Gd2O3	  nanoparticle/ethyl	  ether	  solution	  (1.5~4	  mg/ml).	  (C)	  The	  photograph	  of	  PAMPS-­‐LA	  coated	  Gd2O3	  nanoparticles	  ranging	  from	  1.8	  nm	  to	  22	  nm	  diameters	  and	  phase	  transfer	  efficiency	  (%)	  using	  various	  amounts	  of	  PAMPS-­‐LA	  solutions	  (1	  to	  6	  ml)	   with	   1	   mL	   Gd2O3	   nanoparticle/ethyl	   ether	   solution	   (1.5~4	   mg/ml).	   The	  concentrations	  of	  Gd2O3	  nanoparticles	  were	  analyzed	  by	  ICP-­‐OES.	  	  
PAA-­‐OA	  and	  PAMPS-­‐LA	  copolymers	  represent	  a	  very	  different	  kind	  of	  surface	  coating	  as	  compared	  to	  the	  OA	  bilayers.	   	  These	  amphiphilic	  polymers	  contain	  both	  hydrophobic	   tails	   and	  hydrophilic	   COOH	  or	   SO3H	  groups;	   the	   rationale	   is	   that	   the	  hydrophobic	   tail	   surrounds	   the	   hydrophobic	   Gd2O3	   nanoparticles,	   while	   the	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hydrophilic	  chain	  transfers	  them	  into	  water.	  This	  process	  does	  not	  require	  a	  direct	  ligand	  exchange	  of	  the	  nanoparticle	  surface	  coating,	  but	  rather	  encases	  the	  particles	  in	   another	   thicker	   layer	   of	   polymer.	   	   As	   a	   result,	   PAA-­‐OA	   or	   PAMPS-­‐LA	   polymer	  coated	  Gd2O3	  nanoparticles	  are	  larger	  in	  hydrodynamic	  diameter	  (core	  size	  22	  nm,	  oleic	  acid	  coating	  43	  nm,	  PAA-­‐OA	  coating	  47	  nm,	  PAMPS-­‐LA	  coating	  49	  nm).	  	  
An	  important	  characteristic	  for	  both	  surfaces	  is	  the	  number	  of	  surface	  agents	  per	   particle;	   very	   densely	   covered	   surfaces	   should	   be	   less	   accessible	   to	  water	   for	  example,	  and	  led	  to	  less	  lower	  r1	  relaxivity	  in	  MRI.	  Previously,	  the	  surface	  coverage	  of	  polymers	  was	  determined	  by	  total	  organic	  carbon	  analysis	  (TOC).167	  The	  grafting	  density	   is	  strongly	  dependent	  on	  the	  molecular	  weight	  of	  polymers	  and	  decreased	  as	  molecular	  weight	  increased.	  A	  high	  molecular	  weight	  polymer	  has	  lower	  grafting	  density,	  and	  could	  offer	  more	  surface	  access.	  Using	  TOC	  measurement,	  we	  examined	  the	  grafting	  density	  of	  these	  transfer	  agents.	  The	  molecular	  weights	  of	  these	  agents	  of	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  are	  283,	  2783,	  4615	  g/mol,	  respectively	  (Table	  3-­‐1).165,166	  With	  5	  nm	  gadolinium	  oxide	  nanoparticles,	  the	  grafting	  densities	  of	  oleic	  acid,	  PAA-­‐OA,	  PAMPS-­‐LA	  were	  8.67,	  0.86,	  and	  0.94,	  respectively	  (Figure	  3-­‐8).	  These	  grafting	  densities	  of	  polymers	  are	  strongly	  related	  to	  the	  permeability	  and	  diffusion	  time	  of	  MR	  relaxivity.	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Table	  3-­‐1	  The	  grafting	  densities	  of	  phase	  transfer	  agents	  Iron	  oxide	   Polymer/nm2	  (grafting	  density)	  Size	   OA	   PAA-­‐OA	   PAMPS-­‐LA	  Molecular	  weight	  (theoretical)	   283	   2783	   -­‐	  Molecular	  weight	  (experimental)	   	   	   4615	  5	  nm	   8.67	   0.86	   0.94	  	  
	  
Figure	  3-­‐8	  The	  grafting	  densities	  of	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  	  
The	   dynamic	   light	   scattering	   (DLS)	   and	   zeta	   potential	   studies	   as	   well	   as	  visual	   changes	   for	   the	   stability	   confirmed	   that	   the	   Gd2O3	   nanoparticles	   were	   not	  aggregated	   and	   stable	   in	   aqueous	   suspension.	   DLS	   measures	   the	   hydrodynamic	  diameter	   using	   4	  mW	  He-­‐Ne	   laser	   at	   633	   nm	   and	   noninvasive	   173°	   back	   scatter	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geometry.	  	  When	  the	  particles	  are	  illuminated	  with	  a	  laser,	  the	  intensity	  of	  scattered	  light	   fluctuates	   at	   a	   rate	   dependent	   on	   the	   size	   of	   the	   particles.	   	   Particles	   in	   a	  suspension	   undergo	   Brownian	   motion	   and	   smaller	   particles	   moves	   more	   rapidly	  than	  the	  larger	  one.	  	  The	  intensity	  of	  fluctuations	  gives	  the	  velocity	  of	  the	  Brownian	  motions,	  or	  the	  diffusion	  coefficient	  D,	  the	  hydrodynamic	  size	  of	  the	  particle	  can	  be	  used	  by	  Stokes-­‐Einstein	  relationship.	  174,175	  	  
𝐷(ℎ) =    𝑘𝑇6𝜋𝜂𝐷	  
Where	   D	   is	   the	   diffusion	   coefficient,	   k	   is	   the	   Boltzmann	   constant,	   T	   the	  absolute	   temperature,	  𝜂	  is	   the	   velocity,	   and	  D	   (h)	   is	   the	   hydrodynamic	   radii.	   	   The	  hydrodynamic	  size	  measures	   the	  radii	  of	  a	   sphere	   that	  diffuse	  at	   the	  same	  rate	  as	  the	   molecule.	   	   This	   sphere	   includes	   a	   hydration,	   which	   means	   the	   process	   of	  attraction	   between	   the	   molecules	   of	   a	   solvent	   and	   the	   molecules	   of	   a	   substance	  dissolved.	  Thus,	  the	  attracted	  molecules	  increase	  the	  radii.	  	  
DLS	   and	   zeta	   potential	   studies	   as	  well	   as	   visual	   observation	   indicated	   that	  once	   phase	   transferred,	   the	   Gd2O3	   nanoparticles	   remained	   non-­‐aggregated	   and	  stable	   in	  aqueous	  suspension	  (Figure	  3-­‐9	  (A)).	  The	  hydrodynamic	  sizes	  of	  all	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  coated	  Gd2O3	  nanoparticles	  ranged	  from	  23	  to	  49	  nm	  (Figure	  3-­‐9	   (A)).	  The	  hydrodynamic	   sizes	  by	  DLS	   increased	  as	   expected	  when	   the	  core	   diameters	   increased	   from	   1.8	   nm	   to	   22	   nm,	   and	   there	   was	   no	   evidence	   of	  aggregation.	   Both	   oleic	   acid	   and	  PAA-­‐OA	   capped	  Gd2O3	  nanoparticle	   solution	  with	  COOH	  ligands	  had	  large	  negative	  charges	  (-­‐60~-­‐80	  mV)	  that	  varied	  with	  diameters	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Table	   3-­‐2	   The	   hydrodynamic	   size	   and	   zeta	   potential	   of	   gadolinium	   oxide	  nanoparticles	  with	  various	  coatings	  
	   Hydrodynamic	  size	  (nm)	   Zeta	  Potential	  (mV)	  Core	  Size	  (nm)	   Oleic	  acid	   PAA-­‐OA	   PAMPS-­‐LA	   Oleic	  acid	   PAA-­‐OA	   PAMPS-­‐LA	  1.8	   23.55±	  2.25	   26.78±	  3.31	   32.45±	  2.78	   -­‐77.40±0.66	   -­‐61.47±1.72	   -­‐69.43	  ±	  2.46	  5	   22.25±	  2.47	   28.12	  ±	  2.77	   34.86	  ±	  3.47	   -­‐82.07±3.86	   -­‐62.03±2.43	   -­‐69.9	  ±	  2.34	  8	   30.67±	  3.22	   32.18±	  3.23	   38.87	  ±	  4.22	   60.40±2.17	   -­‐65.33±0.5	   -­‐60.57	  ±	  1.33	  11	   33.38	  ±	  2.59	   35.03	  ±	  3.35	   39.12	  ±	  3.59	   -­‐77.20±3.5	   -­‐65.63±1.02	   -­‐68.43	  ±	  1.73	  13	   34.14±	  3.72	   38.89	  ±	  4.49	   41.88	  ±	  4.72	   -­‐64.65±4.24	   -­‐63.65±3.43	   -­‐67.23	  ±	  2.98	  22	   43.35±	  4.79	   47.05±	  5.43	   49.25±	  5.79	   -­‐63.33±1.34	   -­‐68.5±0.46	   -­‐64.53	  ±	  3.46	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Figure	  3-­‐10	  The	  stability	  of	  gadolinium	  oxide	  suspensions	  at	  25	  °C	  and	  37	  °C	  The	   stability	   test	   of	   (A)	   oleic	   acid,	   (B)	   PAA-­‐OA,	   and	   (C)	   PAMPS-­‐LA	   coated	   Gd2O3	  nanoparticles	  at	  room	  temperature	  (RT)	  and	  body	  temperature	  (37	  °C)	  from	  3	  h	  to	  4	   weeks.	   	   The	   stability	   data	   were	   based	   on	   the	   photographs	   and	   the	   changes	   of	  hydrodynamic	  size	  (nm)	  for	  long-­‐term	  duration	  (4	  weeks).	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Figure	   3-­‐11	   The	   stability	   of	   gadolinium	   oxide	   suspensions	   with	   different	   buffer	  conditions	  The	   stability	   test	   of	   (A)	   oleic	   acid,	   (B)	   PAA-­‐OA,	   and	   (C)	   PAMPS-­‐LA	   coated	   Gd2O3	  nanoparticles	  at	  different	  buffer	  conditions	  including	  PBS	  buffer,	  borate	  buffer	  (BB),	  DMEM	  1	  media	  solution	  with	  nanoparticles	  in	  water	  (1:1	  v/v	  ratio),	  and	  DMEM2	  cell	  media	  solution	  with	  nanoparticle	  solution	  in	  water	  (2:1	  v/v	  ratio).	  The	  stability	  data	  were	   based	   on	   the	   visible	   change	   (photographs)	   and	   the	   differences	   of	  hydrodynamic	  size	  (nm)	  for	  long-­‐term	  duration	  (up	  to	  4	  weeks).	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Figure	  3-­‐12	  The	  stability	  of	  gadolinium	  oxide	  suspensions	  with	  different	  pH	  The	   stability	   test	   of	   (A)	   oleic	   acid,	   (B)	   PAA-­‐OA,	   and	   (C)	   PAMPS_LA	   coated	   Gd2O3	  nanoparticles	   at	  different	  pH	  conditions	   from	  3,	  4.8,	  6.6,	  7.6,	   and	  10.	  The	   stability	  was	  determined	  from	  the	  photographs	  and	  changes	  of	  hydrodynamic	  size	  for	  long-­‐term	  duration	  (up	  to	  4	  weeks)	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Table	   3-­‐3	   The	   hydrodynamic	   size	   stability	   of	   gadolinium	   oxide	   nanoparticle	  suspensions	  
	   Hydrodynamic	  size	  (√	  :	  stable,	  X	  :	  non-­‐stable,	  r:	  little	  stable)	  	   Temperature	   Buffers	   pH	   NaCl	  (M)	  	   25C	   37C	   PBS	   BB	   DMEM	  (1:1)	   DMEM	  (2:1)	   3	   4.8	   6.6	   7.6	   10	   0.01	   0.05	   0.1	   0.5	  Oleic	  acid	   √	   √	   Î	   √	   r	   r	   Î	   r	   √	   √	   √	   √	   √	   √	   Î	  PAA-­‐OA	   √	   √	   √	   √	   √	   √	   Î	   r	   √	   √	   √	   √	   √	   √	   √	  PAMPS-­‐LA	   √	   √	   √	   √	   √	   √	   √	   √	   √	   √	   √	   √	   √	   √	   √	   	  	  
3.3.3. 	  MR	  relaxation	  dynamics	  of	  Gd2O3	  nanoparticles	  
The	   contrast	   agents	   can	   be	   evaluated	   by	   their	   relaxivity,	   or	   how	  much	   the	  relaxation	   rates	   of	   water	   protons	   are	   increased	   in	   the	   presence	   of	   the	   contrast	  agents	  (e.g.	  gadolinium	  oxide)	  at	  a	  given	  concentration.	  	  The	  relaxivity	  (ri)	  is	  defined	  as	  the	   increase	   in	  relaxation	  rate	  per	  concentration	  of	  paramagnetic	  agents,	  or	  the	  slope	  of	  a	  plot	  of	  relaxation	  rate	  (Ri	  (S-­‐1)=	  1/Ti)obs	  versus	  the	  concentration	  of	  agent	  (mM)	  (eq.1).38,142,176	   	  Total	  paramagnetic	  relaxation	  enhancement	  can	  include	  both	  an	   inner	   sphere	   component	   (Solomon-­‐Bloembergen	   Equation)	   from	   the	   proton	  relaxation	  of	  a	  solvent	  molecule	  (e.g.	  water)	  directly	  coordinated	  to	  the	  Gd(III)	  and	  an	  outer-­‐sphere	  component	  from	  solvent	  in	  the	  second	  coordination	  sphere	  and	  the	  bulk	  solvent.	  38,142,176	  	  (eq.2)	  
𝑅! = 1𝑇! !"# = 1𝑇! !"#$#%&'(")  (!.!.!"!"#) + 𝑟! 𝐺𝑑       𝑖 = 1,2             𝑒𝑞. 1 	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1𝑇! ! = 1𝑇! !""#$  !"!!"! + 1𝑇! !"#$%  !"!!"!   𝑖 = 1.2    (𝑒𝑞. 2)	  
The	  inner	  sphere	  contribution	  is	  due	  to	  the	  direct	  interaction	  between	  the	  Gd	  electron	  spins	  and	  water	  protons,	  whereas	  outer	  sphere	  relaxation	  arises	  from	  the	  interactions	   between	   the	   Gd	   electrons	   spin	   and	   bulk	   water	   protons	   that	   are	  randomly	  diffusing.	  	  	  	  
In	   order	   to	   examine	  whether	  Gd2O3	  nanoparticles	   could	   be	   applied	   as	   a	  T1	  MRI	   contrast	   agent,	   we	   measured	   the	   longitudinal	   relaxation	   time	   (T1)	   and	  transverse	   relaxation	   time	   (T2)	   of	   various	   nanoparticle	   suspensions.	   Figure	   3-­‐14	  shows	  the	  r1	  and	  r2	  relaxivity	  values	  for	  both	  PAA-­‐OA	  and	  PAMPS-­‐LA	  capped	  Gd2O3	  nanoparticles	  with	  1.8	  nm	  and	  5	  nm	  core	  diameters.	  	  These	  parameters	  were	  found	  by	  plotting	  1/T	  as	  a	  function	  of	  the	  Gd	  (III)	  concentration,	  and	  calculating	  the	  r1	  and	  r2	   by	   obtained	   from	   the	   slope.17,19	   The	   r1	   relaxivity	   values	   of	   PAMPS-­‐LA	   capped	  Gd2O3	  nanoparticles	  with	  1.8	  and	  5	  nm	  were	  58.16	  and	  56.01	  S-­‐1mM-­‐1,	  respectively	  (Figure	   3-­‐14).	   	   In	   addition,	   the	   r1	   relaxivities	   PAA-­‐OA	   capped	  Gd2O3	  nanoparticles	  with	  1.8	  nm	  and	  5	  nm	  were	  47.20	  and	  43.76	  S-­‐1mM-­‐1.	  	  Specifically,	  the	  r1	  relaxivity	  of	  1.8	   nm	  PAMPS-­‐LA	   coated	  Gd2O3	  nanoparticles	   is	   15	   times	   higher	   than	   that	   of	   Gd-­‐DTPA	   (4.6	   S-­‐1mM-­‐1)13	   at	   1.41	   T.	   This	   r1	   value	   is	   also	   six	   times	   higher	   than	   those	  reported	  r1	  values	  of	  PEG	  coated	  gadolinium	  oxide	  (8.8	  ~	  9.4	  mM-­‐1S-­‐1)	  with	  2.2	  nm	  core	  size40,43	  or	  d-­‐glucuronic	  acid	  coated	  gadolinium	  oxide	  (9.9	  mM-­‐1S-­‐1)	  with	  1	  nm	  core	  at	  1.41	  T.19	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Figure	  3-­‐14	  Plots	  of	  the	  R1	  and	  R2	  of	  gadolinium	  oxide	  suspensions	  (A)	   and	   (B)	   Plots	   of	   the	   r1	   and	   r2	   of	   PAMPS-­‐LA	   coated	   Gd2O3	  nanoparticles	   as	   a	  function	  of	  Gd(III)	   ion	  concentration.	   (C)	  and	   (D)	  Plots	  of	   the	   r1	  and	  r2	  of	  PAA-­‐OA	  coated	  Gd2O3	  nanoparticles	  as	  a	  function	  of	  Gd(III)	  ion	  concentration.	  	  The	  r1	  and	  r2	  values	  were	  determined	  from	  the	  slopes.	  	  	  
	  
The	   r1	   and	   r2	   relaxivity	   values	   of	   Gd2O3	  nanoparticles	  with	   various	   surface	  coatings	  and	  core	  diameters	  were	  shown	  in	  Table	  3-­‐4.	  	  These	  values	  were	  obtained	  from	  the	  slope	  of	   the	  plot	  of	  1/T	  as	  a	   function	  of	  Gd	  (III)	  concentration.	   	  Based	  on	  these	   values,	   the	   graphs	   on	   the	   effect	   on	   r1,	   r2,	   and	   r2/r1	   ratios	   were	   plotted	   as	  function	  of	  the	  core	  diameters	  of	  Gd2O3	  nanoparticles	  and	  surface	  coatings	  including	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Table	  3-­‐4	  The	  	  r1	  and	  r2	  relaxivities	  and	  r2/r1	  ratios	  of	  various	  Gd2O3	  nanoparticles	  from	  the	  slopes	  of	  the	  plot	  of	  1/T	  and	  concentration	  of	  Gd	  ions.	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Figure	  3-­‐15	  Plots	  of	  r1	  and	  r2	  depending	  on	  the	  core	  diameters	  and	  surface	  coatings	  (A)	  Plot	  of	  r1	  values	  of	  PAMPS-­‐LA	  and	  PAA-­‐OA	  coated	  Gd2O3	  nanoparticles	  (B)	  Plot	  of	   r1	   values	   of	   different	   core	   diameters	   of	   Gd2O3	  nanoparticles	   depending	   on	   the	  surface	   coatings	   (oleic	   acid,	   PAA-­‐OA,	   PAMPS-­‐LA)	   (C)	   Plot	   of	   r1	   values	   of	   different	  coatings	  of	  Gd2O3	  nanoparticles	  depending	  their	  core	  sizes.	  (D)	  Plot	  of	  r2/r1	  ratios	  of	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  Gd2O3	  nanoparticles.	  	  	  	  
The	   observed	   high	   relaxivity	   of	   surface	   coated	   Gd2O3	  nanoparticles	   can	   be	  explained	   from	   the	   important	   parameters	   (e.g.	   electron	   spin	   of	   metal	   ion	   (S),	  strength	   of	   magnetic	   dipole	   moment	   (M),	   number	   of	   surface	   metal	   ions	   (N),	   and	  internal	  flexibility	  (diffusion),	  and	  rotation)	  of	  the	  inner/outer	  sphere	  relaxation.	  	  In	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inner	   sphere	   contribution,	   the	   relaxivity	   (r1	   and	   r2)	   is	   proportional	   to	   S(S+1)	   by	  dipole-­‐dipole	   interaction	   modulated	   by	   the	   reorientation	   of	   the	   nuclear	   spin-­‐electron	   vector	   and	   scalar	   interactions	   influenced	   by	   electron	   spin	   relaxation	   and	  water	   proton	   exchange.142	   	   Due	   to	   high	   S	   state	   of	   Gd	   (III)	   (S=7/2),	   Gd2O3	  nanoparticles	   have	   higher	   relaxivity.16,38,180	   Second,	   Gd2O3	   nanoparticles	   have	   no	  magnetic	   dipole	   (𝜇)	   due	   to	   the	   paramagnetic	   spin	   structure.	   Since	   the	   strength	   of	  magnetic	  dipole	  moment	  (𝑀)	  of	  Gd2O3	  nanoparticle	  is	  zero	  the	  transverse	  relaxation	  (1/T2)	  can	  be	  minimized	  by	  reducing	  the	  fluctuation	  of	  local	  magnetic	  field.	  	  So,	  the	  r2/r1	  ratio	  can	  be	  retained	  to	  be	  small	  (1~3).	  	  
The	   r1	   relaxivities	  with	   core	   diameters	   (d)	  were	   related	   to	   the	   number	   of	  surface	  metal	   ions	  (N)	   interacting	  with	  water	  protons.	   	  Gd2O3	  nanoparticles	  have	  a	  high	  surface	  to	  volume	  ratio,	  as	  the	  core	  diameter	   is	  smaller.	   	   In	  contrast	  with	  Gd-­‐DTPA	  (N=1),	  Gd2O3	  nanoparticles	  concentrate	  a	  large	  number	  of	  Gd	  surface	  ions	  (N)	  possessing	  high	  electron	  spin	  (S=	  7/2)	  in	  a	  small	  volume.	  	  Since	  Gd2O3	  nanoparticles	  are	   ultrathin	   nanoplates/nanodisks,	   high	   number	   of	   Gd	   surface	   ions	   significantly	  induces	  and	  accelerates	   the	   longitudinal	   relaxations	  of	   the	  water	  proton.19	   	  As	   the	  core	  diameter	  of	  Gd2O3	  nanoparticles	  get	  smaller,	  the	  number	  of	  surface	  Gd	  ions	  in	  a	  certain	  volume	  increases	  so	  that	  it	  gets	  a	  higher	  relaxivity.	   	  In	  2009,	  the	  Lee	  group	  reported	  the	  dependence	  of	  r1	  relaxivity	  (9.9	  to	  0.1)	  with	  diameters	  (1.1	  to	  30	  nm),	  combining	   other	   reference	   works.19	   With	   size	   tunable	   ultrathin	   gadolinium	  nanoplates/nanodisks	   by	   the	   control	   of	   reaction,	   we	   confirmed	   that	   diameter	  controlled	  Gd2O3	  nanoparticles	  (1.8	  to	  22	  nm)	  had	  high	  r1	  relaxivity	  and	  those	  values	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of	  Gd2O3	  nanoparticles	   in	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  coatings	  decreased	  as	  the	  core	  size	  increased	  (Figure	  3-­‐15).	  	  The	  Table	  3-­‐5	  shows	  the	  r1	  and	  r2	  relaxivities	  values	   of	   gadolinium	  oxide	   nanoparticles	   obtained	   by	   the	   relaxation	   rate	   (1/T1	  or	  1/T2)	  per	  concentration	  of	  Gd	  atoms	  and	  per	  number	  of	  particles.	  
Table	  3-­‐5	  The	  r1	  and	  r2	   relaxivities	  of	  gadolinium	  oxide	  nanoparticles	  obtained	  by	  the	  relaxation	  rate	  per	  concentration	  of	  Gd	  atoms	  and	  number	  of	  particles	  	  
Coating	   Core	  diameter	  	  (nm)	  	   Relaxivity	  based	  on	  concentration	  of	  Gd	  atoms	   Relaxivity	  based	  on	  number	  of	  particles	  	  	   	  	   r1(mM-­‐1S-­‐1)	   r2(mM-­‐1S-­‐1)	   r1(mM-­‐1S-­‐1)	   r2(mM-­‐1S-­‐1)	  Gd-­‐DTPA	   -­‐	   4.3	   4.9	   4.3	   4.9	  Oleic	  acid	   2	   7.20	   20.0	   5.9E+09	   1.6E+10	  Oleic	  acid	   5	   6.19	   13.2	   3.2E+10	   6.8E+10	  Oleic	  acid	   8	   5.36	   12.8	   7.0E+10	   1.7E+11	  Oleic	  acid	   11	   4.87	   10.8	   1.2E+11	   2.7E+11	  Oleic	  acid	   22	   2.95	   6.8	   1.0E+11	   2.4E+11	  PAA-­‐OA	   2	   45.0	   82.3	   3.7E+10	   6.8E+10	  PAA-­‐OA	   5	   41.4	   77.8	   2.1E+11	   4.0E+11	  PAA-­‐OA	   8	   35.0	   69.6	   4.6E+11	   9.2E+11	  PAA-­‐OA	   11	   30.4	   65.1	   7.6E+11	   1.6E+12	  PAA-­‐OA	   22	   20.4	   32.6	   7.1E+11	   1.1E+12	  PAMPS-­‐LA	   2	   54.1	   74.3	   4.4E+10	   6.1E+10	  PAMPS-­‐LA	   5	   49.2	   76.0	   2.5E+11	   3.9E+11	  PAMPS-­‐LA	   8	   40.5	   64.6	   5.3E+11	   8.5E+11	  PAMPS-­‐LA	   11	   35.0	   63.8	   8.7E+11	   1.6E+12	  PAMPS-­‐LA	   22	   27.9	   51.0	   9.7E+11	   1.8E+12	  	  
Moreover,	   the	   surface	   coating	   would	   affect	   relaxivity	   dynamics	   regarding	  with	  the	  internal	  flexibility	  (diffusion)	  and	  rotation.	  The	  oleic	  acid	  (small	  molecular	  weight,	   Mw=283	   g/mol)	   coated	   Gd2O3	  nanoparticles	   has	   much	   lower	   r1	  relaxivity	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values	  than	  PAA-­‐OA	  (Mw	  =	  2783	  g/mol)	  and	  PAMPS-­‐LA	  (Mw	  =4615	  g/mol)	  coated	  Gd2O3	  nanoparticles.	   The	   longitudinal	   relaxation	   is	   dependent	   on	   the	   rotation	   and	  rotational	   correlation	   time   (𝜏𝑅) .38,142,181	   When	   the	   rigid	   and	   small	   oleic	   acid	  introduces	   to	   coat	   the	   surface	   of	   the	   Gd2O3	  nanoparticle,	   the	   proton	   relaxivity	   is	  limited	  by	   the	   fast	   rotation.	  The	  rotation	   is	  generally	  decreased	  by	   the	   increase	  of	  molecular	  weight	   of	   polymer.	   	  Moreover,	   the	   large	   polymer	   coating	   increases	   the	  internal	  flexibility	  and	  permeability	  that	  are	  important	  parameters	  for	  the	  exchange	  rate	   of	   the	  water	   proton	   and	   diffusion	  with	   bulk	  water.	   Therefore,	  more	   flexible,	  larger	   molecular	   weight	   PAA-­‐OA	   and	   PAMPS-­‐LA	   coated	   Gd2O3	   nanoparticles	   can	  accelerate	  water	  proton	  relaxation.	  	  	  
These	  factors	  (rotation,	  flexivitiy,	  and	  diffusion)	  affected	  the	  relaxivity	  values	  and	   resulted	   in	   15	   fold	   higher	   r1	   relaxivity	   than	   commercial	   Gd-­‐DTPA	   and	   6	   fold	  higher	  than	  that	  reported	  for	  other	  Gd2O3	  nanoparticles.19	   	  T1	  weighted	  MR	  images	  clearly	   confirmed	   that	   r1	   maps	   were	   not	   only	   dose,	   surface,	   and	   size	   dependent	  (Figure	  3-­‐16).	   	  At	   the	  same	  concentration,	  T1	  weighted	  MR	   images	  of	  PAA-­‐OA	  and	  PAMPS-­‐LA	   capped	   Gd2O3	   were	   much	   more	   brighter	   than	   those	   of	   oleic	   acid	  gadolinium	   nanopartices	   or	   the	   commercial	   Gd-­‐DTPA.	   	   Moreover,	   small	   size	   of	  PAMPS-­‐LA	  capped	  Gd2O3	  nanoparticles	  has	  more	  brighter	  T1	  weighted	  images	  than	  those	  of	  large	  size.	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Figure	  3-­‐16	  The	  T1	  weighted	  MR	  phantom	  images	  of	  gadolium	  oxide	  with	  different	  coatings	  (A)	  and	  different	  core	  diameters	  (B)	  
	  
The	  r1	  relaxivity	  were	  also	  measured	  in	  various	  relevant	  media	  after	  both	  1	  day	  and	  4	  weeks	  (Figure	  3-­‐17	  and	  Table	  3-­‐6).	  	  For	  most	  conditions,	  there	  was	  little	  to	   no	   change	   in	   r1	   relaxivity.	   	   The	   notable	   exceptions	   were	   PBS	   and	   cell	   media	  solution	  (DMEM	  with	  10	  %	  FBS	  and	  1	  %	  PS).	   	   In	  these	  conditions,	  the	  r1	  relaxivity	  values	  were	  decreased.	  The	  decreasing	  r1	  values	   in	  PBS	  and	  DMEM	  may	  be	  due	  to	  particle	   agglomerations	   and	   non-­‐specific	   protein	   binding	   effect,	   respectively.182,183	  The	  non-­‐specific	  protein	  itself	  may	  interfere	  the	  hydration	  of	  the	  inner	  water	  proton	  exchange	   and	   outer	   sphere	   diffusion	   so	   that	   the	   relaxivity	   was	   limited	   by	   fast	  rotation.	  This	  is	  a	  challenge	  common	  for	  all	  nanoparticle-­‐based	  contrast	  agents,	  and	  it	  will	  become	  more	  of	  an	  issue	  for	  in-­‐vivo	  MR	  imaging.	  Some	  reports	  mentioned	  that	  the	  relaxivity	  values	  can	  be	  improved	  when	  targeting	  with	  specific	  protein	  or	  linking	  with	  multiple	   targets.182,183	  The	  effects	  of	   the	  protein	  association	  on	  MR	  relaxivity	  values	  are	  the	  subject	  of	  ongoing	  studies.	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Table	  3-­‐6	  The	  r1	  stability	  at	  various	  conditions	  
	   r1	  relaxivity	  (√	  :	  stable,	  Î	  :	  non-­‐stable,	  r:	  little	  stable)	  	   Temperature	   Buffers	   pH	   NaCl	  (M)	  	   R.T.	   37C	   PBS	   BB	   DMEM	  (1:1)	   DMEM	  (2:1)	   3	   4.8	   6.6	   7.6	   10	   0.01	   0.05	   0.1	   0.5	  Oleic	  acid	   √	   √	   Î	   √	   r	   Î	   Î	   √	   √	   √	   √	   √	   √	   √	   Î	  PAA-­‐OA	   √	   √	   r	   √	   r	   r	   Î	   √	   √	   √	   √	   √	   √	   √	   √	  PAMPS-­‐LA	   √	   √	   r	   √	   √	   r	   √	   √	   √	   √	   r	   √	   √	   √	   √	  	  
3.3.4. 	  In	  vitro	  toxicological	  study	  using	  MTS	  assay	  
Full	   toxicological	   studies	   are	   beyond	   the	   scope	   of	   this	   paper,	   but	   these	  materials	   were	   screened	   in	   an	   acute	   in-­‐vitro	   assay	   designed	   to	   evaluate	   whether	  substantial	  leaching	  of	  gadolinium	  may	  occur	  in	  these	  system.	  	  In-­‐vitro	  cell	  screens	  such	   as	   the	   ones	   employed	   here	   have	   been	   used	   to	   evaluate	   new	   materials	   for	  potential	  issues,	  and	  in	  particular	  for	  comparing	  materials	  under	  development.	  The	  information	   is	  not	   valuable	   as	   an	   absolute	   indicator	  of	   toxicology.	   	   Following	  past	  work,	   we	   have	   performed	   the	   MTS	   colorimetric	   assay	   using	   human	   dermal	  fibroblast	  (HDF)	  cells.	  	  It	  has	  been	  reported	  that	  Gd	  oxide	  nanoparticle	  was	  not	  toxic	  up	  to	  5	  uM	  Gd	  (III)	  concentration.19	  	  Here	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  coated	  Gd2O3	  nanoparticles	  with	  11	  nm	  core	  diameter	  had	  no	  effect	  on	  cells	  up	  to	  0.1	  to	  0.3	  mM	   concentration	   (Figure	   3-­‐18).	   Comparing	   with	   oleic	   acid	   coated	   Gd2O3	  nanoparticles,	   the	   PAA-­‐OA	   and	   PAMPS-­‐LA	   coated	   Gd2O3	  nanoparticles	   were	  more	  stable	  and	  less	  toxic.	  	  	  From	  the	  LD50	  value	  that	  can	  give	  the	  lethal	  dose	  required	  for	  half	  of	  the	  cells	  to	  die,	  the	  percentages	  of	  cell	  viability	  were	  calculated.	  	  The	  LD50	  of	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oleic	  acid	  ,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  coated	  nanoparticles	  were	  120	  μM,	  270	  μM,	  and	  350	  μM,	  respectively.	  The	  Gd-­‐DTPA	  (Magnevist®)	  had	  no	  toxicological	   issues	  up	  to	  500	  μM.	  However,	  due	  to	  low	  relaxivity	  (4.3	  mM-­‐1S-­‐1),	  it	  needs	  higher	  dosage	  (0.2	  –	  0.6	   mL/kg	   of	   body	   (0.1	   mmol	   Gd/kg))	   for	   the	   enhancement	   in	   MRI.184-­‐187	   The	  recommended	   dosage	   was	   0.2	   mL/kg	   of	   body	   (0.1	   mmol	   Gd/kg)	   for	   the	  administration.	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Figure	  3-­‐18	  In	  vitro	  cytotoxicity	  using	  Human	  Dermal	  Fibroblast	  (HDF)	  cells	  (A)	  Cell	  viability	  (%)	  exposed	  to	  Gd-­‐DTPA	  using	  mitochondrial	  activity	  (MTS)	  assay	  for	  24h	  (B)	  Cell	  viability	  data	  when	   introduced	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  Gd2O3	  nanoparticles	  (8	  nm	  core	  diameter)	  using	  MTS	  assay.	  	  (C)	  Core	  size	  effects	  of	  PAA-­‐OA	  Gd2O3	  nanoparticles	  (D)	  core	  size	  effects	  of	  PAMPS-­‐LA	  Gd2O3	  nanoparticles	  The	  cells	  were	  alive	  up	  to	  500	  uM	  of	  Gd-­‐DTPA.	  	  The	  LD50	  of	  oleic	  acid,	  PAA-­‐OA,	  and	  PAMPS-­‐LA	  coated	  Gd2O3	  nanoparticles	  were	  120	  uM,	  270	  uM,	  and	  350	  uM	  of	  Gd(III),	  respectively.	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Chapter 4	  
    The r2 relaxation dynamics for iron 
oxide and ferrite nanocrystals 
depending on their size, coating, and 
composition 
In	   this	   work,	   we	   have	   prepared	   size	   controlled	   iron	   oxide	   (Fe3O4)	  nanocrystals	   ranging	   from	   4	   to	   33	   nm	   and	   different	   types	   of	   ferrite	   nanocrystals	  (e.g.	  AlFe2O4,	  NiFe2O4,	  ZnFe2O4,	  MnFe2O4,	  and	  MnZnFeO4).	   	  These	  size	  tunable	   iron	  oxide	   and	   ferrite	   nanocrystals	   are	   rendered	   water-­‐soluble	   by	   applying	   various	  phase	   transfer	   agents,	   including	  oleic	   acid	   (OA),	   octylamine	  modified	  poly	   (acrylic	  acid)	   (PAA-­‐OA),	   lauryl	   acrylate	   (LA)-­‐poly	   2-­‐acrylamido-­‐2-­‐methylpropane	   surfonic	  acid	  (PAMPS)	  (PAMPS-­‐LA),	  and	  poly	  (maleic	  anhydride-­‐alt-­‐1-­‐octadecene)	  (PMAO)-­‐poly	   (ethylene	   glycol)(PEG)	   (PMAO-­‐PEG),	   to	   their	   surfaces.	   The	   r2	   magnetic	  resonance,	  (MR)	  relaxivity	  values	  for	  hydrated	  iron	  oxide	  magnetic	  nanocrystals	  are	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strongly	   related	   to	   the	   core	   sizes	   (magnetic	   moments),	   hydrodynamic	   size	  (magnetic	   size	   regime),	   surface	   coatings	   (grafting	   density,	   molecular	   weight,	   and	  permeability),	   compositions	   (magnetic	   moments);	   the	   highest	   r2	   relaxivity	   is	  achieved	  using	  a	  33	  nm	  iron	  oxide	  particle	  capped	  with	  an	  oleic	  acid	  bilayer,	  which	  had	  a	  measured	  value	  of	  510	  S-­‐1mM-­‐1.	  	  In	  vitro	  cell	  toxicological	  studies	  were	  used	  to	  evaluate	   the	   various	   polymer	   coated	   iron	   oxide	   T2	   contrast	   agents,	   showing	   that	  none	   of	   the	  materials	   had	   a	   significant	   effect	   on	   human	   dermal	   fibroblasts	   (HDF)	  even	   at	   high	   concentration	   (e.g.	   6000	   uM).	   	   By	   designing	   the	   relaxivity	   dynamics	  with	  their	  sizes,	  surface	  coatings,	  and	  types,	  it	  will	  give	  an	  efficient	  T2	  iron	  oxide	  MRI	  contrast	  agents	  offering	  high	  r2	  relaxivity	  and	  low	  toxicity.	  
4.1. Introduction	  
Biomedical	  imaging	  has	  received	  enormous	  attention	  for	  their	  diagnostic	  and	  analytical	   ability	   at	   molecular	   level.	   Representative	   biomedical	   imaging	   tools	  include	   computed	   X-­‐ray	   tomography	   (CT),	   magnetic	   resonance	   imaging	   (MRI),	  optical	   imaging	  (OI),	  positron	  emission	  tomography	  (PET),	  single-­‐photon-­‐emission	  computed	   tomography	   (SPECT),	   and	   ultrasound	   (US).188,189	   These	   imaging	  techniques	  are	  non-­‐invasive	  and	  provide	  real-­‐time	  visualization	  of	  cellular	  functions	  and	  molecular	  interactions	  of	  living	  organisms.	  They	  are	  used	  to	  diagnose	  diseases	  such	   as	   cancer	   and	   give	   biological	   or	   functional	   information	   for	   pre-­‐clinical	  evaluations.	  	  Each	  imaging	  modality	  has	  its	  own	  advantages	  and	  disadvantages	  and	  a	  single	  imaging	  technique	  can	  not	  possess	  all	  required	  capabilities	  for	  diseases.	  	  In	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particular,	  MRI	  is	  the	  most	  widely	  used	  non-­‐invasive	  medical	  imaging	  technique.1	  It	  can	   give	   anatomic	   images	   of	   soft	   tissue	  with	   high	   spatial	   resolution	   and	   combine	  morphological	   and	   functional	   imaging.	   Therefore,	   MRI	   is	   one	   of	   the	   strongest	  imaging	   tools	   and	   will	   play	   as	   a	   molecular	   and	   cellular	   imaging	   probe.	   However,	  because	   of	   its	   inherent	   low	   sensitivity,	   there	   is	   a	   small	   difference	   in	   contrast	  between	  normal	  and	  abnormal	  tissues.	   	  To	  improve	  the	  sensitivity	  and	  visibility	  in	  MR	  images,	  nanotechnology	  has	  been	  called	  upon	  to	  develop	  chemical	  supplements,	  referred	  to	  as	  contrast	  agents.35	  	  
Magnetic	   nanocrystals	   can	   accelerate	   spin-­‐spin	   relaxation	   times	   for	   water	  protons	   by	   inducing	   a	   local	   magnetic	   field	   and	   thus	   reduce	   T2	   relaxation	   and	  produce	   darker	   images.190-­‐194	   Among	   various	   magnetic	   nanocrystals,	   iron	   oxide	  nanocrystals	  have	  been	  widely	  used	  as	  T2	  MRI	  contrast	  agents	   for	   strong	  contrast	  effect	   and	   improved	   biocompatibility.195,196	   Therefore,	   several	   superparamagnetic	  iron	   oxide	   nanocrystals	   (SPIOs)	   have	   been	   clinically	   approved	   for	   imaging	   liver	  tumors	   and	   metastatic	   lymph	   nodes.123	   For	   example,	   Ferridex	   and	   Combidex	   are	  approved	  for	   the	  detection	  of	   liver	   lesions	  and	   imaging	  of	   lymph	  node	  metastases.	  The	  iron	  oxide	  nanocrystals	  contain	  thousands	  of	  Fe	  atoms	  that	  can	  generate	  several	  orders	  of	  magnitude	  higher	  signal	  contrast.	  Current	  developments	  in	  SPIO	  synthesis	  are	  to	  yielding	  materials	  useful	  for	  advanced	  MRI	  contrast	  agents	  that	  possess	  high	  relaxivity,	  optimized	  surface	  coating,	  and	  longer	  blood	  circulation	  time.100,197	  Target	  specific	   functionalized	   SPIOs	   can	   be	   used	   as	   in	   vivo	   MR	   tracking	   and	   molecular	  markers	  related	  to	  the	  diseases.	  123	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Significant	   advances	   in	   synthesis	  of	   iron	  oxide	  magnetic	  nanocrystals	  using	  thermo-­‐decomposition	   has	   provided	   particles	   with	   better	   uniformity	   and	   high	  crystallinity	  over	  a	  broad	  range	  of	  sizes,	  from	  4	  to	  100	  nm.50,51,171,198,199	  	  The	  size	  and	  composition	   of	   iron	   oxide	   nanocrystals	   regulate	   their	   magnetization	   (µ)	   and	   MR	  relaxation	   (R2=1/T2=	   1/T0	   +	   r2	   [Fe]).	   Moreover,	   T2	   MR	   signal	   enhancements	   are	  highly	   dependent	   on	   hydrodynamic	   size	   related	   to	   the	   agglomeration	   and	   surface	  coating	  (thickness,	  chemical	  composition,	  grafting	  density).181,200-­‐202	  	  
The	   size	   of	   iron	   oxide	   nanocrystals	   controls	   their	   magnetic	   moment	  (paramagnetic,	  superparamagnetic,	  ferromagnetic	  properties)	  as	  well	  as	  their	  blood	  circulation	   time	   and	   bio-­‐distribution.	   The	   r2	   relaxivity	   of	   superparamagnetic	   iron	  oxide	  increases	  with	  increasing	  particle	  size	  (<30~50	  nm)	  due	  to	  the	  fast	  diffusion	  in	   motional	   averaging	   regime	   (MAR).200,202,203	   Small	   particles	   of	   iron	   oxide	  nanocrystal	   (<50	  nm)	  have	   longer	  plasma	  circulation	   time	  and	  are	   regarded	  as	  or	  molecular	   imaging	   probes	   for	   applications	   such	   as	   lymph	   node	   imaging,	   because	  they	   are	   easily	   distributed	   in	   the	   intravascular	   and	   extracellular	   space.35,100,201,204	  	  However,	   large	   magnetic	   nanocrystals	   are	   generally	   more	   polydisperse	   and	  aggregate	   in	  solution	  due	  to	   their	   large	  magnetic	  moments.	  And	  also,	   the	  diffusion	  effect	   of	   large	   nanocrystals	   is	   small	   and	   it	   is	   regarded	   as	   randomly	   distributed	  stationary	   objects	   (static	   dephasing	   regime,	   SDR).	   	   In	   SDR,	   although	   they	   exhibit	  high	   r2	   relaxivity,	   they	   are	   independent	   on	   their	   size.	   Their	   ferromagnetic	   dipole	  interaction	  causes	  the	  poor	  colloidal	  stability	  and	  large	  aggregation	  so	  that	  they	  are	  not	  suitable	  for	  in	  vivo	  molecular	  imaging	  probes	  due	  to	  their	  very	  short	  circulation	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time.202,204-­‐208	  In	  recent	  work,	  embedded	  multiple	  core	  iron	  oxides	  into	  large	  matrix	  like	   silica	   or	   polymers	   can	   control	   the	   ferrimagnetic	   dipole	   interaction	   and	  increased	  the	  r2	  relaxivity	  due	  to	  the	  increasing	  number	  of	  particles	  within	  a	  given	  aggregate.	   However,	   these	   aggregates	   become	   too	   large	   size	   problem	   and	   the	   r2	  value	   is	   still	   not	   maximized.72,204,208,209	   Therefore,	   dispersed,	   non-­‐aggregated	  magnetic	   nanocrystals	   with	   high	   r2	   relaxivity	   are	   strongly	   desired	   for	   in	   vivo,	  targeted	  MR	  imaging.	  	  
To	   produce	   disperse	   iron	   oxide	   nanocrystal	   suspensions,	   as-­‐synthesized	  hydrophobic	  materials	  should	  be	  transferred	  to	  aqueous	  solution.	  Surface	  coatings	  need	  to	  be	  biocompatible,	  allow	  the	  materials	  to	  possess	  good	  colloidal	  stability	  and	  not	   increasing	   the	   hydrodynamic	   diameter	   in	   vivo	   applications.	   Various	   surface	  modification	   methods	   such	   as	   ligand	   exchange	   and	   polymer	   encapsulation	   have	  been	  developed.181,210-­‐214	  For	   ligand	  exchange,	  hydrophobic	   ligands	   initially	  bound	  to	   the	   surface	   of	  magnetic	   nanocrystals	   are	   displaced	  with	   hydrophilic	  molecules	  exposed	   to	   the	   surrounding	   water	   using	   carboxylic	   acid	   and	   dopamine.215,216	  Although	   ligand	   exchange	   method	   is	   simple,	   excess	   ligands,	   desorption	   or	  incomplete	  coverage	  can	  cause	  a	  decrease	  in	  the	  colloidal	  stability.	  	  
Another	   method	   requires	   encapsulation	   of	   the	   particles	   in	   silica	   shells	   or	  polymers	  via	  sol-­‐gel,	  reverse	  microemulsion,	  or	  van	  der	  Waals	  interaction.181,210-­‐214	  For	   example,	   phosphine	   oxide-­‐poly(ethylene	   glycol)	   (PO-­‐PEGs),	   1,2	   distearoyl-­‐sn-­‐glycero-­‐3-­‐phosphoethanolamine-­‐N-­‐[methoxy(polyethyleneglycol)copolymer	  (DSPE-­‐mPEG),	   poly(D,L-­‐lactide-­‐co-­‐glycolide)	   (PLGA),	   	   and	   poly(glycolide)	   (PGA)	   polymers	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have	   been	   used.181,210-­‐212	   These	   polymer	   encapsulated	   magnetic	   nanocrystals	   are	  very	   stable	   in	   water	   but	   their	   hydrodynamic	   size	   is	   relatively	   larger	   than	   that	   of	  ligand	   exchange	   method.	   The	   thickness,	   grafting	   density,	   molecular	   weight,	   and	  composition	   of	   the	   surface	   coatings	   can	   strongly	   affect	   the	   T2	   MR	   relaxivity,	   by	  altering	   the	   translational	   diffusion	   of	   water	   molecules	   in	   the	   inhomogeneous	  magnetic	   field.193,200,203	   Surface	   coatings	   can	   hinder	  water	   diffusion	   or	   immobilize	  near	   water	   molecules	   by	   forming	   hydrogen	   bonds.	   181,208	   Therefore,	   different	  surface	  coatings	  of	  iron	  oxide	  nanocrystals	  with	  same	  core	  size	  can	  have	  different	  T2	  relaxivity.181,208	  	  
Lastly,	   magnetic	   properties	   of	   iron	   oxide	   nanocrystals	   can	   be	   changed	   by	  their	  compositions.100,217,218	  The	  Fe2+	  can	  be	  replaced	  with	  Mn2+,	  Zn2+,	  Ni2+,	  and	  Co2+	  in	   the	   inverse	   spinel	   structure	   and	   the	  magnetic	   properties	   of	  MnFe2O4,	   ZnFe2O4,	  NiFe2O4,	   CoFe2O4,	   and	   Fe3O4	   were	   investigated.218	   As	   compositions	   of	   magnetic	  nanocrystals	   changed	   from	   NiFe2O4,	   to	   MnFe2O4,	   the	   magnetic	   moments	   and	   r2	  relavivity	   values	   changed.	  The	   effects	   of	   size,	   surface	   coating,	   and	   composition	  on	  the	  relaxivity	  are	  very	  important	  and	  needed	  to	  be	  understood	  for	  getting	  best	  MR	  contrast	  agents.	  
Here,	   we	   have	   prepared	   very	   uniform	   and	   mono-­‐disperse	   iron	   oxide	  nanocrystals	   with	   a	   wide	   range	   of	   size	   from	   4	   nm	   to	   33	   nm	   by	   thermo-­‐decomposition	  method.	  Moreover,	  different	  compositions	  of	  iron	  oxide	  nanocrystals	  (e.g.	   AlFe2O4,	   MnFe2O4,	   ZnFe2O4,	   MnZnFeO4)	   were	   simply	   prepared	   by	   adding	  different	  metal	  ion	  precursors	  in	  the	  synthesis.	  	  These	  size	  tunable	  hydrophobic	  iron	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oxide	  nanocrystals	  were	   transferred	   to	  water	   using	   various	  phase	   transfer	   agents	  and	   evaluated	   for	   colloidal	   stability	   and	   hydrodynamic	   size.	   	   Various	   sizes,	  compositions,	   and	   coatings	   of	   iron	   oxide	   nanocrystals	   were	   investigated	   and	  optimized	   for	   MR	   relaxivity	   dynamics.	   	   Moreover,	   these	   iron	   oxide	   nanocrystals	  were	   examined	   in	   vitro	   toxicological	   effects	   with	   human	   dermal	   fibroblast	   (HDF)	  cells	  based	  on	  the	  size,	  surface	  coating,	  and	  composition.	  	  
4.2. 	  Experimental	  sections	  
4.2.1. 	  Chemicals	  
Iron	   oxide	   hydrated	   (FeO(OH),	   catalyst	   grade,	   30-­‐50	   mesh),	   aluminium	  hydroxide	  (Al(OH)3,	  reagent	  grade),	  nickel	  tetrahydrate	  (Ni(OCOCH3)2·4H2O,	  98	  %),	  manganese	   chloride	   tetrahydrate	   (MnCl2·4H2O,	   99	   %),	   zinc	   acetate	  (Zn(OCOCH3)2·4H2O,	   99.99	   %),	   oleic	   acid	   (technical	   grade	   90%),	   oleylamine	  (technical	  grade	  70%),	  oleyl	  alcohol	  (technical	  grade,	  85	  %),	  1-­‐octadecene	  (1-­‐ODE,	  technical	   grade	   90%),	   poly(acrylic	   acid)	   (PAA,	   Mw=1800),	   and	   octylamine	   (OA,	  99%),	   poly(maleic	   anhydride-­‐alt-­‐1-­‐octadecene)	   (PMAO,	   Mn=30,000-­‐50,000),	  poly(ethylene	  glycol)	  (PEG)	  methyl	  ethers	  (mPEG-­‐NH2)	  (Mw=	  2,000),	  acrylic	  acid	  2-­‐Acrylamido-­‐2-­‐Methylpropane	   sulfonic	   acid	   copolymer	   (AA/AMPS),	   lauryl	   acrylate	  (LA,technical	  grade	  90	  %)	  were	  purchased	   from	  Sigma-­‐Aldrich.	  The	  samples	  were	  synthesized	   was	   under	   a	   flow	   of	   high	   purity	   nitrogen	   (N2,	   99.99	   %).	   Aluminium	  oleate,	  methanol	  (99.8	  %),	  acetone	  (99.5	  %),	  hexanes	  (98.5	  %),	  sodium	  bicarbonate	  (99.7	   %),	   and	   dimethylformamide	   (DMF,	   99.8	   %),	   nitric	   acid	   (HNO3,	   70%)	   and	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hydrogen	  peroxide	  (H2O2,	  30%)	  were	  purchased	  from	  Fisher	  Scientific;	  1-­‐ethyl-­‐3-­‐[3-­‐dimethylaminopropyl]	   carboiimide	   hydrochoride	   (EDC)	   was	   purchased	   from	  Thermo	   Scientific;	   CellTiter	   96®	   Aqueous	   One	   solution	   Cell	   Proliferation	   Assay	  (MTS	   assay)	   was	   purchase	   from	   Promega;	   Human	   derman	   fibroblast	   (HDF)	   was	  purchase	   from	   Cambrex;	   Dulbecco’s	   Modified	   Eagle’s	   Medium	   (DMEM,	   ATTC,	  Mannassa,	   VS),	   fetal	   bovine	   serum	   (FBS),1%	  penicillin-­‐streptomycin	   (PS),	   trypsin-­‐EDTA	  were	  purchased	  from	  Sigma-­‐Aldrich.	  	  	  
4.2.2. Synthesis	  of	  size	  tunable	  iron	  oxide	  nanoparticles	  
Magnetic	   iron	   oxide	   nanocrystals	   were	   synthesized	   using	   modified	  procedure	  of	  previously	  published	  work.51	  	  0.178	  g	  of	  FeO(OH),	  2.26	  g	  oleic	  acid	  and	  5	  g	  1-­‐ODE	  were	  mixed	  in	  a	  100	  ml	  three	  neck	  flask	  and	  heated	  to	  120	  °C	  for	  2	  hours	  to	  remove	  residual	  water	  and	  further	  heated	  to	  240	  °C	  for	  30	  minutes	  to	  synthesize	  iron	  carboxylate,	  iron-­‐oleate.	  	  Then,	  the	  reaction	  mixture	  was	  heated	  at	  320	  °C	  for	  2	  hours	  under	  N2	  condition.	  	  To	  purify	  the	  resulting	  black	  colloidal	  nanocrystals,	  20	  ml	  of	  methanol	  and	  20	  mL	  acetone	  were	  added	  to	  5	  mL	  resulting	  colloidal	  solution	  and	  centrifuged	   at	   4150	   rpm	   for	   30	  minutes.	   The	   precipitates	   at	   the	   bottom	  were	   re-­‐dispersed	  using	  hexanes	  and	  this	  process	  was	  repeated	  six	  times.	  Finally,	  10	  nm	  iron	  oxide	   nanocrystals	   were	   purified	   and	   dispersed	   in	   hexanes.	   For	   16	   nm	   Fe3O4	  nanocrystals,	  the	  molar	  ratio	  between	  FeO(OH)	  and	  oleic	  acid	  was	  changed	  from	  1:3	  to	  1:5	  with	  all	  other	  conditions	  remaining	  the	  same.	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To	  produce	  smaller	  iron	  oxide	  nanocrystals	  (<5	  nm),	  iron	  oleate	  was	  used	  as	  the	  iron	  precursor.	  	  Iron	  oxyhydrate	  (FeO(OH),	  20	  mmol,	  1.8	  g),	  oleic	  acid	  (80	  mmol,	  22.4	  g)	  and	  1-­‐ODE	  (60	  g)	  were	  mixed	  in	  a	  three	  neck	  flask	  and	  heated	  to	  240	  °C	  for	  4	  hours.	   	  After	  purifying	   iron	  oleate	  precursor,	   the	   resulting	  black	   colloidal	   solution	  was	   stored	   in	   hexanes.	   	   4	   nm	   iron	   oxide	   nanocrystals	   were	   prepared	   using	   iron	  oleate	  (0.015	  mmol,	  0.009	  g)	  and	  oleic	  acid	  (0.3	  mmol,	  0.08	  g)	  in	  5	  g	  ODE	  at	  320	  °C	  for	  3	  hours	  under	  the	  N2	  flow.	  	  The	  largest	  iron	  oxide	  nanocrystals	  (33	  nm),	  required	  a	  higher	  molar	  concentration	  of	  FeO(OH),	  oleic	  acid,	  and	  ODE.	  FeOOH	  (50	  mmol,	  4.5	  g),	  oleic	  acid	   (200	  mmol,	  56	  g),	  and	  1-­‐ODE	  (40	  mmol,	  10	  g)	  were	   firstly	  heated	   to	  240	  °C	  for	  2	  hours	  and	  further	  heated	  to	  320	  °C	  for	  12	  hours.	  	  
4.2.3. Aluminum	  iron	  oxide	  (AlxFe3-­‐xO4)	  nanocrystals	  
4	  nm	  aluminium	  iron	  oxide	  nanocrystals	  were	  synthesized	  by	  decomposition	  of	  	  iron	  oleate	   (0.05	  mmol)	  and	  aluminum	  oleate	   (0.02	  mmol)	  as	  metal	  precursors	   in	  the	  presence	  of	  oleic	  acid	  (2	  mmol)	  as	  a	  surface	  stabilizer	  in	  1-­‐ODE	  (5	  g)	  at	  320	  °C	  for	  2	  hours.	  	  10	  and	  15	  nm	  aluminum	  iron	  oxide	  nanocrystals	  were	  synthesized	  by	  using	  iron	  oxyhydrated	  (FeO(OH))	  and	  aluminum	  hydroxide	  (Al(OH)3).	  Specifically,	  10	  nm	  aluminum	  ferrite	  nanocrystals	  were	  prepared	  by	  heating	  0.7	  mmol	  FeO(OH),	  0.3	   mmol	   Al(OH)3,	   3	   mmol	   oleic	   acid,	   and	   5	   g	   ODE	   at	   320	   °C	   for	   1	   hour.	   15	   nm	  aluminum	  iron	  oxide	  nanocrystals	  were	  obtained	  from	  the	  same	  conditions	  used	  to	  make	  the	  10	  nm	  aluminum	  iron	  oxide	  nanocrystal	  except	  changing	  to	  4	  mmol	  oleic	  acid.	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4.2.4. 	  Manganese	  and	  zinc	  oleate	  synthesis	  
Metal	   oleates	   (Mx+(oleate)x	   ,	   (M=	   Zn,	   Mn,	   and	   Al)	   were	   prepared	   as	   starting	  precursor	  materials	  to	  make	  various	  ferrite	  (MxFe3-­‐xO4,	  M=	  Zn,	  Mn,	  Al)	  nanocrystals.	  Manganese	  oleate	  was	  synthesized	  by	  heating	  manganese	  chloride	  (10	  mmol,	  1.25	  g)	  with	  oleic	  acid	  (20	  mmol,	  5.64	  g)	   in	  10	  g	  of	  ODE	  at	  180	  °C	   for	  2	  hours.219	   	  Zinc	  oleate	  was	   prepared	   by	  mixing	   zinc	   acetate	   (10	  mmol,	   1.83	   g)	   and	   oleic	   acid	   (20	  mmol,	  5.64	  g)	  in	  10	  g	  of	  ODE	  at	  210	  °C	  for	  2	  hours.220	  These	  metal	  oleate	  precursors	  were	  purified	  with	  20	  ml	  of	  ethanol	  and	  20	  ml	  of	  acetone	  then	  centrifuged	  at	  4150	  rpm	  for	  30	  minutes	  then	  re-­‐dispersed	  in	  5	  ml	  hexanes.	  The	  purification	  process	  was	  repeated	  three	  times.	  	  
4.2.5. Manganese	  iron	  oxide	  (MnxFe3-­‐xO4)	  nanocrystals	  	  
Manganese	  iron	  oxide	  nanocrystals	  were	  prepared	  from	  the	  mixture	  of	   iron	  oleate	  (0.03	  mmol)	  and	  manganese	  oleate	  (from	  0.0003	  to	  0.03	  mmol)	  in	  the	  presence	  of	  oleic	  acid	  (2	  mmol)	  and	  ODE	  (5	  g)	  and	  heated	  to	  320	  °C	  for	  2	  hours.	  
4.2.6. 	  Zinc	  iron	  oxide	  (ZnxFe3-­‐xO4)	  nanocrystals	  
The	  mixture	  of	  iron	  oleate	  (0.03	  mmol)	  and	  zinc	  oleate	  (from	  0.0003	  to	  0.03	  mmol)	  were	  used	  with	  oleic	  acid	  (2	  mmol)	  and	  ODE	  (5	  g)	  and	  heated	  at	  320	  °C	  for	  2	  hours.	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4.2.7. 	  MnZnFe	  oxide	  (MnZnFeO4)	  nanocrystals	  
The	  mixture	   of	   iron	   oleate	   (0.03	  mmol),	  manganese	   oleate	   (0.015	  mmol),	   and	  zinc	  oleate	  (from	  0.015	  mmol)	  were	  used	  with	  2	  mmol	  of	  oleic	  acid	  in	  5	  g	  of	  1-­‐	  ODE	  at	  320	  °C	  for	  2	  hours.	  The	  resulting	  nanocrystals	  were	  9.0	  ±	  0.6	  nm	  in	  diameter.	  
4.2.8. 	  Oleic	  acid	  bilayer	  coating	  
The	   oleic	   acid	   coated	   nanocrystals	   were	   modified	   by	   the	   previously	  published	  procedure.165	  	  Briefly,	  oleic	  acid	  (from	  30	  uL	  to	  300	  uL)	  was	  introduced	  to	  1	  mL	  of	  nanocrystals	  solution	  dispersed	  in	  ethyl	  ether	  (1,500	  -­‐	  4,000	  mg/L	  of	   iron	  concentration).	  After	  stirring	  for	  24	  hours,	  ultra	  pure	  water	  (MILLIPORE,	  18.2	  MΩ)	  or	   0.1	   M	   sodium	   bicarbonate	   (pH	   9)	   solution	   was	   introduced	   and	   stirred	   for	   an	  additional	  2	  hours.	  	  Then	  the	  sample	  was	  probe	  sonicated	  (UP	  50H,	  Dr.	  Hielscher)	  at	  60	   %	   amplitude	   for	   10	   minutes	   to	   help	   disperse	   the	   material	   in	   water.	   	   The	  nanocrystal	  solution	  was	  stirred,	  uncovered	   for	  1	  day	  to	  completely	  evaporate	   the	  residual	  ethyl	  ether	  organic	  solvent.	  The	  purification	  of	  water-­‐soluble	  nanocrystals	  was	   carried	  out	  using	  ultracentrifugation	   (optima	  L-­‐90K	  ultracentrifuge,	  Beckman	  coulter)	  at	  40,000	  rpm	  for	  3	  hours	  twice	  followed	  by	  syringe	  filteration	  (pore	  size	  of	  0.45	  uM,	  Whatman	  NYL).	  The	  resulting	  aqueous	  solutions	  were	  acquired	  after	  these	  ultracentrifugation	   and	   syringe	   filtration	   steps.	   To	   calculate	   the	   transfer	   yield	   of	  oleic	  acid	  bilayer	  coated	  materials,	  the	  concentrations	  of	  metal	  ion	  were	  determined	  using	  ICP-­‐OES	  for	  the	  original	  and	  aqueous	  solutions.	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4.2.9. Octylamine	  (OA)-­‐modified	  poly(acrylic	  acid)	  (PAA-­‐OA)	  coating	  
PAA-­‐OA	   polymer	   and	   PAA-­‐OA	   coated	   nanocrystals	   were	   prepared	   by	   the	  published	  procedure.166	  To	  make	  PAA-­‐OA	  polymer,	  first	  PAA	  (0.6	  g,	  0.33	  mmol)	  was	  dissolved	   in	  DMF	  (10	  g).	   	  After	  stirring	   for	  10	  minutes,	  EDC	  (0.58	  g,	  3	  mmol)	  was	  added	   to	   PAA/DMF	   solution,	   and	   octylamine	   (0.5	   mL,	   3	   mmol)	   was	   sequentially	  introduced	   to	   PAA/EDC/DMF	   solution.	   	   After	   stirring	   overnight,	   the	   rotavap	   was	  used	  to	  remove	  DMF	  while	  keeping	  the	  PAA-­‐OA	  solution	  under	  vacuum.	   	  The	  final	  PAA-­‐OA	  solution	  (15	  mg/mL)	  was	  dispersed	  in	  chloroform	  (40	  mL).	  	  
PAA-­‐OA	   polymer	   solutions	   from	   1	   to	   7	   mL	   were	   mixed	   with	   1mL	  nanocrystal/chloroform	   solution	   (typically	   1,500	   to	   4,000	   mg/L	   of	   metal	   ion	  concentration).	   	  The	  mixed	  solution	  was	  stirred	   for	  24	  hours	  and	  then	  chloroform	  was	   allowed	   to	   evaporate	   using	   vacuum	   or	   air.	   	   0.1	   M	   sodium	   bicarbonate	   was	  added	  for	  every	  10	  mL	  of	  solution	  then	  it	  was	  sonicated	  using	  a	  probe	  sonicator	  (60	  %	   amplitude)	   for	   10	   minutes.	   The	   resulting	   solution	   was	   purified	   with	  ultracentrifugation	   (40,000	   rpm	   for	   3	   hours,	   twice)	   and	   filtered	   out	   with	   syringe	  filter	   (0.45	   uM,	   Whatman	   NYL).	   The	   nanocrystal	   solution	   was	   acquired	   and	  completely	  dissolved	  in	  ultrapure	  MQ	  water.	  138	  
4.2.10. 	  Poly	  (acrylic	  acid	  2-­‐Acrylamido-­‐2-­‐Methylpropane	  sulfonic	  acid)	  	  
(PAMPS)-­‐	  lauryl	  acrylate	  (LA)	  (PAMPS-­‐LA)	  coating	  
The	   PAMPS-­‐LA	   polymer	   was	   synthesized	   by	   copolymerization	   of	   30	   g	   of	  AMPS	   (0.1447	  mol,	   207.23	   g/mol)	   and	   22.5	  mL	   of	   LA	  monomers	   (240.38	   g/mol,	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0.0827	  mol)	  in	  300	  mL	  of	  DMF	  solution	  under	  UV	  light.	   	  The	  polymer	  solution	  was	  used	  to	  coat	  nanocrystals	  directly	  without	  further	  purification.	  	  
The	   varied	   ratios	   of	   PAMPS-­‐LA	  polymer	  per	  nanocrystal	  were	  prepared	  by	  adding	   1	   to	   7	   mL	   (15	   mg/ml)	   were	   mixed	   with	   1mL	   nanocrystal/ethyl	   ether	  solution	  (typically	  1,500	  to	  4,000	  mg/L	  of	   iron	  concentration).	   	  When	  the	  solution	  was	  cloudy	  after	  adding	  excess	  polymer	  DMF	  was	  added	  to	  the	  solution	  to	  solubilize	  the	  polymer.	  The	  nanocrystal/polymer	  solution	  was	  stirred	  for	  24	  hours.	   	  After	  24	  hours	  an	  additional	  10	  mL	  of	  ultra	  pure	  MQ	  water	  was	  added	  to	  the	  mixture	  and	  the	  solution	   was	   stirred	   uncovered	   for	   another	   24	   hours	   to	   allow	   the	   ethyl	   ether	   to	  evaporate	  .	  	  The	  resulting	  polymer	  capped	  nanoparticles	  were	  purified	  of	  excess	  free	  polymer	   in	   solution	  using	  ultracentrifugation	   (40,000	  rpm	   for	  3	  hours,	   twice)	  and	  filtered	   out	   using	   syringe	   filter	   (0.45	   uM,	  Whatman	  NYL).	   	   The	   clear	   and	   cleaned	  nanocrystal	  pellet	  was	  recovered	  and	  resuspended	  in	  ultra	  pure	  MQ	  water.	  	  
4.2.11. 	  Poly(maleic	  anhydride-­‐alt-­‐1-­‐octadecene)	  (PMAO)-­‐	  poly(ethylene	  
glycol)	  (PEG)	  methyl	  ethers	  (mPEG-­‐NH2)	  (PMAO-­‐PEG)	  coating	  
The	  PMAO-­‐PEG	  polymer	  coating	  method	  was	   followed	  and	  modified	  by	   the	  reported	   procedure.221	   PMAO	   (Mn=30,000-­‐50,000)	   was	   reacted	   with	   mPEG-­‐NH2	  (Mw	   2,000)	   in	   chloroform	   overnight	   to	   make	   PMAO-­‐PEG	   amphiphilic	   polymer	  (molar	  ratio	  of	  PMAO/PEG,	  1:5	  to	  1:30).	  	  
The	  varied	  ratios	  of	  PMAO-­‐PEG	  polymer	  per	  nanocrystal	  were	  prepared	  by	  adding	  1	  to	  7	  mL	  (20	  mg/)	  were	  mixed	  with	  1mL	  nanocrystal/	  chloroform	  solution	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(typically	  1,500	  to	  4,000	  mg/L	  of	  Fe	  ion	  concentration).	  	  The	  mixture	  was	  stirred	  for	  24	  hours	  and	   then	   the	   chloroform	  was	  allowed	   to	  evaporate	  using	  vacuum	  or	  air.	  	  After	   adding	   0.1	  M	   sodium	   bicarbonate	   solution	   (10	  mL),	   the	  mixture	  was	   probe	  sonicated	   (60	  %	   amplitude)	   for	   10	  minutes.	   	   The	   resulting	   solution	   was	   purified	  with	   ultracentrifugation	   (40,000	   rpm	   for	   3	   hours,	   twice)	   and	   filtered	   out	   with	  syringe	   filter	   (0.45	   uM,	  Whatman	  NYL).	   	   The	   purified	   nanocrystals	  were	   acquired	  and	  resuspended	  in	  ultrapure	  MQ	  water.	  The	  phase	  transfer	  yields	  were	  calculated	  based	  on	   the	  concentration	  of	  Fe	  metal	   ions	   in	   the	  purified	  sample	  divided	  by	   the	  original	  Fe	  ion	  concentration	  as	  determined	  using	  inductive	  coupled	  plasma–optical	  emission	  spectroscopy	  (ICP-­‐OES).	  
4.2.12. 	  MR	  relaxivity	  measurements	  
MR	  relaxivity	  measurement.	  	  Various	  concentrations	  of	  nanoparticles	  were	  prepared	   by	   the	   dilution	   from	   the	   stock	   solution	   of	   nanoparticles	   with	   different	  coatings	   for	   MR	   relaxivity	   measurement.	   To	  measure	   r2	   of	   iron	   oxide	   and	   ferrite	  nanoparticles,	   the	   MR	   relaxometer	   (NMR	   analyzer,	   mq	   60,	   Bruker)	   was	   used	   at	  1.41T.	   	   To	   get	   an	   accurate	   r2	   values	   of	   different	   coating	   of	   iron	   oxide	   and	   ferrite	  aqueous	  solution,	  various	  concentration	  of	  nanoparticle	  solution	  were	  prepared	  and	  r2	  values	  were	  come	  out	  from	  the	  slope	  between	  1/T2	  and	  concentrations.	  	  	  
MR	   phantom	   imaging.	   To	   get	   MR	   phantom	   imaging,	   the	   MRI	   clinical	   3T	  scanner	  was	  used.	  For	  this	  measurement,	  the	  different	  size/coatings/composition	  of	  iron	  oxide	  aqueous	  solution	  were	  used.	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4.2.13. Cell	  culture	  and	  MTS	  assay	  
Cell	   culture:	   Human	   derman	   fibroblast	   (HDF,	   Cambrex)	   were	   used	   and	  cultured	  in	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM,	  ATCC,	  Manassas,	  VS)	  with	  10	  %	  fetal	  bovine	  serum	  (FBS)	  and	  1	  %	  penicilin-­‐streptomycin	  (PS).	  	  The	  cells	  were	  floated	  by	  trypsin-­‐EDTA	  and	  re-­‐suspended	  in	  media	  (DMEM	  with	  10%	  FBS	  and	  1%	  PS)	  solution	  for	  the	  passaging.	  	  
Cell	  viability	  test	  (MTS	  assay):	  	  To	  determine	  the	  nanoparticle	  cytotoxicity	  the	  standard	  colorimetric	  assay,	  MTS	  (CellTiter	  96,	  Promega)	  was	  used.	   	  HDF	  cells	  were	  placed	  and	  grown	  in	  96	  well	  culture	  plates	  with	  over	  80	  %	  confluency.	   	  Each	  set	   was	   prepared	   with	   different	   concentrations	   of	   nanocrystal	   solutions.	   One	   set	  was	   treated	   as	   a	   blank	   (no	   nanocrystals)	   and	   last	   set	  was	   used	   for	   the	   untreated	  control	   (ethanol).	   	   The	   treated	   cells	   with	   nanocrystal	   aqueous	   solution	   were	  incubated	   for	   24	   hours.	   	   After	   then,	   the	   solution	  was	   suctioned	   out	   and	   replaced	  with	  100	  uL	  fresh	  media	  (DMEM	  with	  FBS	  10%	  and	  1%	  PS)	  solution	  and	  20	  uL	  MTS	  agent	  to	  each	  well.	  	  After	  incubating	  for	  1	  hour	  at	  37	  °C	  and	  5	  %	  CO2,	  the	  absorbance	  at	  490	  nm	  of	  the	  solution	  was	  measured	  by	  using	  a	  plate	  reader	  (Spectra	  Max,	  M2,	  Molecular	  devices).	  	  The	  experiment	  was	  repeated	  three	  times	  for	  to	  determine	  the	  average.	  The	  LD50	  for	  each	  sample.,	  which	  gives	  the	  lethal	  dose	  required	  for	  half	  of	  the	  cells	  to	  die,	  was	  calculated	  by	  the	  percentage	  of	  cell	  viability.	  	  	  
	   148	  	  
4.2.14. 	  Instruments	  and	  characterization	  
Transmission	   electron	   microscope	   (TEM).	   To	   determine	   the	   average	  diameter	  and	  size	  variation	  for	  the	  nanocrystal	  samples	  a	  JEOL	  2100	  field	  emission	  TEM	   operating	   at	   200	   kV	   with	   a	   single	   tilt	   holder	   was	   used.	   TEM	   samples	   were	  prepared	   by	   evaporating	   one	   drop	   of	   nanocrystals	   solution	   on	   an	   ultrathin	   400	  mesh	  copper	  grid	  (Ted	  Pella	  Inc.).	  	  The	  size	  and	  size	  histograms	  of	  each	  sample	  were	  determine	  by	  using	  Image-­‐Pro	  Plus	  5.0	  (Media	  Cybernetics,	  Inc.,	  Silver	  Spring,	  MD)	  to	  detect	  edges,	  smooth	  holes	  and	  determine	  the	  diameter	  for	  at	  least	  500	  particles	  per	  sample.	  
Dynamic	   light	   scattering	   (DLS)	   and	   zeta	   potential.	   	   The	   hydrodynamic	  diameter	  (nm)	  and	  zeta	  potential	  (mV)	  of	  all	  synthesized	  and	  surface	  functionalized	  materials	  measured	  on	  a	  ZEN-­‐3600	  Zetasizer	  Nano	  (Malvern,	  UK)	  equipped	  with	  a	  HeNe	  633nm	  laser	  .	   	  The	  average	  hydrodynamic	  size	  (nm)	  and	  zeta	  potential	  (mV)	  were	  the	  average	  of	  five	  replicates	  for	  each	  sample.	  	  
Inductive	  coupled	  plasma-­‐optical	  emission	  spectroscopy	  (ICP-­‐OES).	   	  To	  measure	   the	   concentration	   of	   iron,	   Perkin	   Elmer	   ICP-­‐OES	   equipped	   with	   auto	  sampler	   was	   used.	   	   Samples	   were	   prepared	   for	   ICP-­‐OES	   by	   acid	   digestion	   using	  nitric	  acid	  (HNO3	  ,	  70	  %)	  and	  hydrogen	  peroxide	  (H2O2	  ,	  30	  %).	  	  
Matrix	  assisted	   laser	  desorption	   ionization	  time-­‐of-­‐flight	  (MALDI-­‐TOF)	  
mass	   spectroscopy.	  To	  measure	   the	  molecular	  weight	  of	  polymers	  a	  MALDI-­‐TOF	  mass	   spectroscopy,	   Bruker	   Autoflex	   II	   ToF-­‐ToF	   equipped	   with	   a	   nitrogen	   laser	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operated	   at	   337	   nm,	   was	   used.	   Polymer	   solutions	   were	   prepared	   in	  acetonitrile:water	  (4:1)	  and	  0.1%	  (v/v)	  triflouroacetic	  acid	  and	  1	  uL	  of	  the	  sample	  was	   added	   on	   the	   plate.	   As	   a	   matrix,	   a	   saturated	   sample	   of	   α-­‐cyano-­‐4-­‐hydroxycinnamic	   acid	   was	   prepared	   in	   acetonitrile:water	   (4:1)	   and	   0.1%	   (v/v)	  triflouroacetic	  acid.	   	  After	  evaporating	  the	  sample	  solution,	  1	  uL	  of	  matrix	  solution	  was	  overlaid	  on	  sample	  spot	  and	  allowed	  to	  dry.	  	  
Total	  organic	  carbon	  (TOC).	   	  A	  Shimadzu	  TOC-­‐L	  was	  used	  to	  measure	  the	  carbon	  concentration	  for	  surface	  functionalized	  gadolinium	  nanoparticles	  in	  water.	  	  Three	   replicates	   of	   each	   sample	   were	   prepared	   by	   adding	   1	   ml	   of	   the	   stock	  nanoparticle	   sample	   and	  diluting	   to	  8.5	  mL	  with	  Milli-­‐Q	  18	  MΩ	  pure	  water.	   	   Each	  sample	  was	  run	  on	  a	  total	  nonpurgeable	  organic	  carbon	  (NPOC)	  assay	  with	  triplicate	  50	   μL	   injections.	   The	   calibrations	   from	   0.5	   to	   60	   ppm	  were	   prepared	   using	   TOC	  standard	  solution	  (Sigma-­‐Adrich)	  (R2	  =	  0.998).	  
Calculation	  of	  grafting	  density	  (GD).	  	  The	  calculation	  of	  grafting	  density	  (σ)	  was	   calculated	   from	   TOC	   data	   using	   the	   equation	   below,	   similar	   to	   previously	  published	  method.167	  	  	  	  	  
𝜎 = 𝐶 ∗𝑀𝑊!𝑀𝑊! ∗ 𝐶! ∗ 𝑁𝑃 ∗ (4𝜋𝑟!"#$! )	  
The	   nonpurgeable	   organic	   carbon	   concentration	   ([C])	   from	   TOC	   analysis	  must	  be	  converted	   from	  mg/L	  (ppm)	  to	  mol/liter	  (molarity)	  by	  considering	  molar	  mass	  of	  carbon	  (12,010	  mg/mol).	  To	  determine	  the	  number	  of	  polymer	  molecules	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the	   carbon	   concentration	   is	   multiplied	   by	   the	   molecular	   weight	   of	   the	   monomer	  (MWn)	   and	  divided	  by	   the	  polymer	  molecular	  weight	   (MWp)	   times	   the	  number	   of	  carbons	  per	  monomer	  (Cn).	  By	  dividing	  by	  the	  molar	  concentration	  of	  nanoparticles,	  [NP],	  and	  the	  surface	  area	  of	  the	  particle	  the	  resulting	  grafting	  density	  is	  achieved.	  	  	  
4.3. Result	  and	  discussions	  
4.3.1. 	  Synthesis	  of	  size	  tunable	  iron	  oxide	  and	  ferrites	  nanocrystals	  
We	   have	   synthesized	   very	   uniform	   and	   high	   crystalline	   iron	   oxide	  nanocrystals	   with	   a	   wide	   range	   of	   size	   from	   4	   nm	   to	   33	   nm	   via	   thermo-­‐decomposition	   of	   iron	   precursors	  with	   oleic	   acid	   and	   1-­‐octadecene	   (ODE)	   at	   high	  temperature	   (320	  °C).51	   	  Moreover,	  by	  adding	  different	  metal	   ion	  (Al,	  Mn,	  and	  Zn)	  precursors	   into	   iron	  precursors,	  we	  prepared	  different	  compositions	  of	   iron	  based	  magnetic	   nanocrystals.	   Figure	   4-­‐1(A-­‐D)	   shows	   the	   TEM	   images	   of	   monodisperse	  iron	  oxide	  nanocrystals	  with	  different	  core	  diameters	  (4.0	  ±	  0.6,	  10.2	  ±	  0.7,	  16.0	  ±	  1.4,	  and	  33.1	  ±	  2.5	  nm).	  The	  experimental	  factors	  such	  as	  molar	  ratio	  of	  FeOOH/oleic	  acid,	  monomer	  concentration,	  and	  reaction	  time	  were	  varied	  to	  achieve	  the	  range	  of	  core	   diameters	   and	   uniformity.	   	   In	   order	   to	   have	   different	   compositions	   of	   iron	  based	   magnetic	   crystals,	   Al,	   Mn,	   and	   Zn	   metal	   oleates	   were	   introduced	   into	   the	  mixture	  of	  iron	  precursors	  by	  adding	  more	  surfactant	  (oleic	  acid)	  and	  solvent	  (ODE)	  based	  on	  the	  previous	  report.51	  The	  TEM	  images	  of	  different	  composition	  of	  ferrite	  samples	   include	  AlFe2O4,	  MnFe2O4,	   ZnFe2O4,	   and	  MnZnFeO4	   (Figure	   4-­‐1	   E-­‐H).	   The	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Figure	  4-­‐1	  TEM	  images	  of	  iron	  oxide	  nanoparticles	  with	  different	  core	  diameters	  (A-­‐D)	  and	  compositions	  (E-­‐H).	  TEM	  images	  of	  monodisperse	  iron	  oxide	  nanoparticles	  with	  different	  core	  diameters	  (A-­‐D);	  the	  core	  diameters	  are	  4.0	  ±	  0.6	  (A),	  10.2	  ±	  0.7	  (B),	  16.0	  ±	  1.4	  (C),	  and	  33.1	  ±	  2.5	   nm	   (D),	   respectively.	   	   The	   TEM	   images	   of	   different	   composition	   of	   ferrite	  samples	   including	   AlFe2O4,	   MnFe2O4,	   ZnFe2O4,	   and	   MnZnFeO4	   (E-­‐H);	   the	   core	  diameters	   are	   8.8	   ±	   0.7	   (E),	   8.9	   ±	   0.8	   (F),	   10.4	   ±	   1.0	   (G),	   and	   9.1	   ±	   0.6	   nm	   (H),	  respectively.	  	  All	  scale	  bars	  are	  20	  nm.	  	   Magnetic	   properties	   are	   dependent	   on	   the	   size	   of	   iron	   oxide	   nanocrystals.	  When	  the	  particle	  size	  is	  small	  (<	  30	  nm),	  the	  superparamagnetism	  occurs.100	  In	  the	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presence	  of	  an	  external	  magnetic	  field	  superparamagnetic	  nanocrystals	  respond	  and	  exhibit	   high	   saturation	   of	   magnetism	   whereas	   they	   have	   no	   remanence	   when	  magnetic	   field	   is	   removed.	   	   The	   Langevin	   equation	   can	   describe	   their	   magnetic	  properties.100	  	  
𝑀𝑀! = coth𝛼 − 1𝛼    𝛼   = 𝜇!𝑚𝐻 𝐾!𝑇 	  
Where,	  𝛼	  is	   the	   ratio	   of	   magnetic	   to	   thermal	   energy,	  m	   is	   magnetic	   moment	   of	   a	  single	  particle,	  and	  H	  is	  magnetic	  field.	  	  When	  the	  particle	  size	  is	  very	  small	  (<	  4	  nm),	  the	  individual	  particles	  have	  very	  small	  magnetic	  moments	  (  !!!"!!! 	  <<	  1)	  and	  show	  a	  linear	   relationship	   between	  magnetization	   and	  magnetic	   field	   !!! = !!!"!!!! .	   This	   is	  paramagnetic	   property	   and	   means	   that	   high	   saturation	   magnetism	   needs	   a	   high	  magnetic	   field.	   If	   the	   particle	   size	   is	   high	   (>40~50	   nm),	   the	   magnetic	   moment	  (!!!"!!! >>1)	  is	  high	  and	  the	  magnetic	  saturation	  occurs	  (!!!~1).	  	  It	  is	  ferromagnetism	  and	  it	  has	  remanence	  and	  coercivity	  in	  the	  absence	  of	  magnetic	  field.	  	  If	  the	  particle	  size	   range	   keeps	   a	   superparamagetism	   in	   a	   single	   domain,	   the	  magnetic	   property	  increases	   with	   increasing	   the	   size	   and	   the	   particle	   has	   no	   remanence	   at	   zero	  magnetic	  field.	  	  	  
The	  magnetic	  properties	  of	  iron	  oxide	  nanocrystals	  can	  also	  be	  controlled	  by	  their	   compositions.100,197,218,222	   The	   iron	   oxide	   magnetite	   (Fe3O4)	   has	   an	   inverse	  spinel	   structure,	   consisting	   of	   face-­‐centered	   cubic	   packed	   lattice	   of	   oxygen	   atoms	  with	   the	   tetrahedral	   sites	   (Td)	   occupied	   by	   Fe3+	   ions	   and	   octahedral	   sites	   (Oh)	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occupied	   by	   Fe2+	   and	   Fe3+	   ions.	   When	   applying	   an	   external	   magnetic	   field,	   the	  magnetic	  spins	  of	  ions	  at	  the	  Oh	  sites	  are	  parallel	  to	  the	  magnetic	  field	  but	  those	  at	  Td	  sites	  are	  antiparallel	  to	  the	  field.	  Thus,	  the	  magnetic	  moment	  of	  Fe3+	  (high	  spin	  state,	  d5	   configuration)	  at	  different	  sites	   (Td	  or	  Oh)	  cancel	   the	  magnetism	  and	   leave	  Fe2+	  (d6	  configuration)	   in	  Oh	  site	  showing	  4	  µB	  of	   total	  magnetic	  moment	  per	  unit.197,218	  The	   Fe2+	   in	   the	   structure	   of	   (Fe3+)Td(Fe2+Fe3+)OhO4	   can	   be	   replaced	   with	   divalent	  transition	  metal	   ions	   from	  Mn2+	  and	  Zn2+.	  The	  Zn2+	  divalent	  metal	   ion	  has	  high	  Td	  preference	   and	   the	   structure	   is	   normal	   spinel	   structure.223	   The	  magnetic	  moment	  dramatically	   increases	   with	   increasing	   doping	   ratio	   of	   Zn	   (x=0.4)	   until	   a	   certain	  level.	   	  Mn2+	  can	  be	  in	  Td	  or	  Oh	  sites	  and	  has	  mixed	  spinel	  structure	  possessing	  high	  magnetic	   moment	   of	   5	   µB.197,218	   Moreover,	   the	   trivalent	   Al	   ions	   (Al3+)	   can	   be	  replaced	  with	  Fe3+	  in	  either	  Td	  or	  Oh	  sites.	  Therefore,	  different	  compositions	  of	  iron	  oxide	  nanocrystals	  such	  as	  AlFe2O4,	  MnFe2O4,	  ZnFe2O4,	  and	  MnZnFeO4	  have	  different	  magnetic	  moments.	  
4.3.2. Surface	  coatings	  of	  iron	  based	  magnetic	  nanoparticles	  
The	   hydrophobic	   iron	   oxide	   nanocrystals	   with	   a	   wide	   range	   of	   sizes	   and	  compositions	   are	   transferred	   into	   aqueous	   solutions	   using	   various	   phase	   transfer	  agents	   (e.g.	   oleic	   acid	   bilayer,	   PAA-­‐OA,	   PAMPS-­‐LA,	   and	   PMAO-­‐PEG).	   In	   schematic	  diagram	  in	  Figure	  4-­‐2,	  these	  various	  phase	  transfer	  agents	  have	  different	  molecular	  weight	   ranges	   (283~50,000)	  and	   functional	   groups,	   such	  as	   carboxylic	   (COOH)	  or	  sulfuryl	  ends	  (SO3H).	   	  Oleic	  acid	  and	  other	  polymer	  coated	  iron	  oxide	  nanocrystals	  kept	   their	   same	   core	   diameters	   and	  morphology	   after	   being	   transferred	   to	  water	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(Figure	  4-­‐3).	  	  These	  water-­‐soluble	  iron	  oxide	  nanocrystals	  were	  non-­‐aggregated	  and	  retained	  a	  single	  core	  and	  small	  hydrodynamic	  size.	  	  
	  
Figure	   4-­‐2	   The	   schematic	   diagram	   of	   various	   phase	   transfer	   agents	   (oleic	   acid	  bilayer,	  PAA-­‐OA,	  PAMPS-­‐LA,	  and	  PMAO-­‐PEG)	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  Figure	  4-­‐3	  TEM	  images	  of	  water-­‐soluble	  iron	  oxide	  nanocrystals	  	  The	  water-­‐soluble	   iron	  oxide	  nanocrystal	   suspensions	  using	  oleic	   acid	  bilayer	   (A),	  PAA-­‐OA	  (B),	  PAMPS-­‐LA	  (C),	  and	  PMAO-­‐PEG	  polymers	  (D);	  the	  core	  diameters	  were	  4.1	  ±	  0.8,	  10.4	  ±	  1.2,	  16.6	  ±	  0.8,	  and	  33.4	  ±	  2.3	  nm,	  respectively	  (A-­‐D).	  	  All	  scale	  bars	  were	  20	  nm.	  
	   Dynamic	  light	  scattering	  (DLS)	  analysis	  shows	  that	  the	  core	  sizes	  and	  surface	  coatings	   influence	   the	   hydrodynamic	   sizes	   of	  magnetic	   nanocrystals.	   	   As	   the	   core	  size	  increased	  from	  4	  to	  33	  nm	  the	  bilayer	  of	  oleic	  acid	  increased	  the	  hydrodynamic	  size	   from	  17	   nm	   to	   41	   nm,	  with	   an	   average	   coating	   thickness	   of	   3.75	   nm	   (Figure	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4-­‐4).	   Polymer	   capping	   agents	   tended	   to	   have	   larger	   molecular	   weights	   and	  thicknesses	  therefore	  showed	  a	  greater	  increase	  in	  hydrodynamic	  size	  when	  applied	  to	   the	   nanocrystals;	   from	   20	   to	   68	   nm.	   Moreover,	   as	   coating	   agents	   varied	   from	  small	   molecules	   (oleic	   acid	   (298	   g/mol)	   to	   large	   polymers	   (PMAO-­‐PEG	   30,000-­‐50,000	  g/mol),	  hydrodynamic	  sizes	  of	  iron	  oxide	  nanocrystals	  with	  4	  nm	  core	  were	  increased	   from	   17	   nm	   to	   38	   nm.	   	   Various	   iron	   oxide	   nanocrystal	   suspensions	  showed	  negative	  zeta	  potentials	  (-­‐40	  to	  -­‐60	  mV),	  which	  means	  that	  they	  were	  well	  dispersed	  and	  not	  aggregated.	  	  
The	   commercial	   polymers	   including	   poly	   (ethylene	   glycol)	   (PEG)	   with	  different	  molecular	   range	   (200,	   1,000,	   10,000	   g/mol),	   poly	   vinyl	   pyrolidone	   (PVP,	  1,000	   g/mol),	   and	   poly	   acrylic	   acid	   (PAA,	   15,000)	   were	   also	   used	   and	  measured	  their	  hydrodynamic	  sizes	  with	  10	  nm	  iron	  oxide	  nanocrystals.	  They	  kept	  in	  a	  small	  hydrodynamic	   range	   around	   30	   nm	   but	   the	   hydrodynamic	   size	   was	   slightly	  increased	  with	   increasing	  molecular	  weight.	   	  The	  PEG	  coated	  particles	  had	  a	  weak	  negative	   surface	   charge	   (-­‐10	  mV)	  and	   compared	   to	   the	  other	  polymers	  with	   large	  net	  negative	  potentials	  (-­‐30~-­‐40	  mV).	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Figure	  4-­‐4	  	  The	  hydrodynamic	  sizes	  and	  zeta	  potentials	  of	  iron	  oxide	  nanoparticles	  (A)	   The	   hydrodynamic	   size	   of	   iron	   oxide	   nanoparticles	   of	   different	   core	   diameter	  and	  surface	  coatings,	  (B)	  the	  hydrodynamic	  size	  of	  iron	  oxide	  (10	  nm)	  with	  different	  commercial	  polymers,	  (C)	  The	  zeta	  potential	  (mV)	  of	  iron	  oxide	  nanoparticles	  with	  different	  sizes	  and	  coatings,	  (D)	  The	  zeta	  potential	  values	  (mV)	  of	  iron	  oxide	  (10	  nm	  core)	  with	  different	  commercial	  polymers	  	  
Except	  at	  low	  pH	  (pH	  3)	  or	  high	  ionic	  strength	  CaCl2	  conditions	  the	  iron	  oxide	  nanocrystal	   suspensions	   with	   various	   coatings	   were	   stable	   and	   all	   samples	   were	  stable	   in	   biological	   cell	   media	   solutions,	   different	   pH	   (5~10),	   and	   NaCl	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concentrations	  from	  0.05M	  to	  0.5M	  (Figure	  4-­‐5).	  Especially,	  PAMPS-­‐LA	  coated	  iron	  oxide	   nanocrystals	   showed	   the	   greatest	   stability	   even	   at	   low	  pH	   (pH=3)	   and	  high	  CaCl2	  (0.05	  to	  0.5	  M)	  conditions.	  	  
	  
Figure	  4-­‐5	  	  The	  hydrodynamic	  sizes	  of	  various	  iron	  oxide	  nanoparticles	  at	  different	  conditions	  of	  (A)buffers,	  (B)	  pH,	  (C)	  NaCl,	  and	  (D)CaCl2.	  	   The	  grafting	  density,	  or	  the	  number	  of	  bound	  polymers	  per	  surface	  area	  of	  a	  nanocrystal	   can	   be	   determined	   by	   total	   organic	   carbon	   analysis	   (TOC).167	   It	   is	  strongly	   dependent	   on	   the	   molecular	   weight	   of	   polymers	   and	   decreases	   with	  increased	   polymer	  molecular	   weight.167	   Large	  molecular	   weight	   polymers	   do	   not	  
	   159	  	  
fully	  cover	  the	  nanoparticle	  surface	  and	  have	  low	  grafting	  densities,	  which	  allow	  for	  a	   high	   permeability/flexibility	   of	   water	   molecules.	   TOC	   evaluations	   of	   our	  nanomaterials	   were	   used	   to	   determine	   the	   grafting	   densities	   of	   various	   coating	  agents	   (bilayer	   oleic	   acid,	   PAA-­‐OA,	   PAMPS-­‐LA	   and	   PMAO-­‐PEG).	   The	   molecular	  weights	  of	  these	  coating	  agents	  (oleic	  acid,	  PAA-­‐OA,	  PAMPS-­‐LA,	  and	  PMAO-­‐PEG)	  are	  283,	   2783,	   4615,	   30,000-­‐50,000	   g/mol,	   respectively	   from	   theoretical	   or	  experimental	   values	   (Figure	   4-­‐6	   and	   Table	   4-­‐1).	   With	   10	   nm	   core	   iron	   oxide	  nanocrystals,	  the	  grafting	  densities	  of	  these	  polymers	  showed	  the	  values	  of	  12.1,	  4.1,	  3.7,	  and	  0.004	  molecules/nm2,	  respectively	  (Figure	  4-­‐7).	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Figure	  4-­‐6	  The	  MALDI-­‐TOF	  of	  PAMPS-­‐LA	  polymer.	  The	  average	  m/z	  of	  PAMPS-­‐LA	  is	  4615	  g/mol.	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Table	  4-­‐1	  The	  grafting	  densities	  of	  various	  phas	  transfer	  agents	  
Iron	  oxide	  (10	  nm)	   Oleic	  acid	  coating	   PAA-­‐OA	  	  coating	   PAMPS-­‐LA	  coating	   PMAOPEG	  coating	  
Molecular	  weight	  (theoretical)	   283	   2783	   -­‐	   30,000-­‐50,000	  
Molecular	  weight	  (experimental)	   	   	   4615	   	  
Grafting	  density	  (GD)	   12.13	   4.11	   3.67	   0.00362	  
	  
	  
Figure	  4-­‐7	  The	  grafting	  densities	  of	  various	  phase	  transfer	  agents	  (oleic	  acid,	  PAA-­‐OA,	  PAMPS-­‐LA,	  and	  PMAO-­‐PEG)	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4.3.3. 	  MR	  relaxation	  dynamics	  
The	  magnetic	   nanocrystals	   can	   induce	   inhomogeneous	   local	  magnetic	   field	  when	   an	   external	  magnetic	   field	   is	   applied.	   The	  magnetic	   interaction	   of	  magnetic	  nanoparticles	  with	  water	  protons	  can	  be	  explained	  by	  outer	  sphere	  (OS)	  spin-­‐spin	  relaxation	  model.100,203	  The	  diffusion	  time	  (𝜏! = 𝑟! 𝐷)	  is	  defined	  by	  the	  particle	  size	  (r)	  and	  diffusion	  coefficient	  of	  water	  (D).	  	  The	  r2	  relaxation	  time	  (1/T2)	  is	  given	  by:	  
𝑅! = 1𝑇! = 64𝜋135000 𝛾!𝑁!𝑀𝜇!!𝜏!𝑟!   =      64𝜋135000 𝛾!𝑁!𝑀𝜇!!𝑟𝐷             (1)	  
𝑣   = !! 𝜋𝑟!𝑁!𝑀×10!!,        	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (2)	  
Δ𝜔! ! = (!!)𝛾!𝜇!!   𝑟!	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (3)	  
𝑅! = !! 𝑣𝜏! Δ𝜔! !        	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (4)	  
where,	  𝑁!	  is	   Avogadro’s	   number,	  𝛾	  is	   gyromagnetic	   ratio,	   M	   is	   the	   particle	  molarity	   (mol/L),	  𝜇! 	  is	   the	   magnetic	   moment	   of	   the	   nanoparticle,	   r	   is	   radius	   of	  particle,	  1/Δ𝜔! 	  is	   the	   angular	   phase	   shift	   induced	  by	   the	  magnetic	   nanoparticle	   at	  the	  equator	  line	  on	  its	  surface,  𝜏!	  is	  the	  diffusion	  time	  (the	  time	  scale	  of	  fluctuation	  in	   the	  particle-­‐water	  proton	  magnetic	  dipolar	   interaction	  arising	   from	   the	   relative	  diffusive	  motion	  (D)	  of	  a	  particle	  with	  respect	  to	  water	  molecules),	  and	  D	  is	  diffusion	  coefficient	   of	   water	   molecule.	   	   According	   these	   equations,	   the	   R2	   relaxivity	   value	  increases	  when	  the	  particle	  volume	  (v)/size	  (r)	  increases	  since	  magnetic	  moment	  is	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proportional	   to	   the	  magnetic	   particle	   size.	   Regarding	   the	   relationship	   between	  R2	  and	   diffusion	   time	   and	   particle	   size	   (𝑅! ∝ 𝑣,	  𝑅!   ∝ 𝜏! ∝ 𝑟! 𝐷),	   three	   theoretical	  regimes	  of	  R2	  can	  be	  explained	  depending	  their	  size	  and	  diffusion	  time:	  the	  motional	  averaging	  regime	  (MAR),	  static	  dephasing	  regime	  (SDR),	  echo-­‐limiting	  regime	  (ELR)	  or	   slow	   motion	   regime	   (SMR).200,202,204,208	   	   In	   MAR,	   the	   relaxivity	   values	   (R2)	  increased	  sharply	  with	  increasing	  particle	  size	  (r2,	  r	  (hydrodynamic	  size)<	  45	  nm).	  	  In	  SDR,	   the	  R2	  value	   is	  maximum	  and	   is	  not	  dependent	  on	   the	  size	  (r0).	  Moreover,	  the	  R2	  value	  is	  decreased	  when	  the	  particle	  size	  is	  quite	  large	  (>	  60	  nm,	  r-­‐1)	  in	  ELR.	  	  In	  order	  to	  optimize	  R2	  values	  for	  magnetic	  nanocrystals,	  the	  hydrodynamic	  size	  (<	  55	  nm)	  should	  be	  in	  a	  range	  of	  maximum	  of	  MAR	  or	  early	  SDR.	  	  
The	  relaxivity	  values	  (r2)	  of	  various	  iron	  oxide	  nanocrystals	  were	  determined	  from	  the	  slope	  in	  a	  plot	  of	  1/T2	  and	  Fe	  ion	  concentrations	  (1/T2	  =	  1/T0	  +	  r2	  [Fe])	  as	  shown	  in	  Figure	  4-­‐8.	  From	  these	  evaluations	  the	  highest	  r2	  value	  was	  510	  mM-­‐1S-­‐1	  of	  oleic	  acid	  bilayered	  iron	  oxide	  nanocrystal	  (33	  nm	  core)	  (Table	  4-­‐2).	  The	  relaxivity	  r2	   is	   strongly	  dependent	  on	   the	  magnetic	  moment	   (𝜇),	  which	   is	   dependent	  on	   the	  size	   and	   composition.190,197,201,218	   Regarding	   to	   these	   size	   effects,	   the	   r2	   values	   of	  oleic	   acid	   coated	   iron	   oxide	   nanocrystals	   were	   11,	   51,	   160,	   and	   510	   mM-­‐1S-­‐1,	  respectively	  when	  the	  core	  sizes	  increased	  to	  4,	  10,	  16,	  and	  33	  nm.	  (Figure	  4-­‐9)	  In	  this	  plot,	  the	  oleic	  acid	  coated	  33	  nm	  iron	  oxide	  nanocrystals	  showed	  the	  highest	  r2	  value	  (510	  mM-­‐1S-­‐1).	  	  
The	  hydrodynamic	  size	  of	  oleic	  acid	  coated	  33	  nm	  iron	  oxide	  nanocrystal	  was	  41	  nm,	  which	  kept	  a	  single	  core	  without	  agglomeration	  and	  a	  high	  r2	  value	  in	  SDR.	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Due	   to	   the	   magnetic	   dipole	   interaction	   and	   remanence,	   large	   core	   size	   magnetic	  nanocrystals	  (>30	  nm)	  are	  easily	  aggregated	  and	  have	  very	  large	  hydrodynamic	  size	  (over	  200	  nm).202	  When	  the	  hydrodynamic	  size	  passed	  over	  a	  limit	  of	  SDR	  (>	  55	  nm)	  and	  reached	  to	  ELR,	  the	  r2	  value	  dramatically	  decreased.202,208	  If	  the	  hydrodynamic	  size	  is	  over	  100	  nm,	  the	  particles	  are	  taken	  up	  by	  phagocytosis.	  224,225	  In	  contrast,	  if	  the	  hydrodynamic	  size	  is	  extremely	  small,	  the	  particles	  can	  easily	  pass	  through	  the	  renal	  filtration	  and	  be	  excreted.	  	  For	  biological	  effect	  the	  optimal	  nanomaterial	  size	  is	  between	  5~60	  nm,	  where	  the	  particles	  will	  be	  able	  to	  travel	  the	  blood	  vessels	  and	  have	   longer	   blood	   circulation	   time	   since	   they	   can	   escape	   phagocytosis.224,225	  Therefore	  large	  single	  core	  magnetic	  nanocrystal	  with	  small	  oleic	  acid	  coating	  which	  possess	   high	   r2	   in	   MAR/SDR	   would	   be	   ideally	   suited	   for	   biological	   used	   because	  their	   biodistribution	   is	   optimum	   for	   longer	   blood	   circulation	   time	   and	   enhance	  permeability	  and	  retention	  (EPR)	  effect	  in	  vivo	  tumor	  targeting.	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Figure	  4-­‐8	  Plots	  of	  r2	  values	  of	  iron	  oxide	  nanoparticles	  Plots	  of	  r2	  values	  of	  iron	  oxide	  nanoparticles	  depending	  their	  core	  diameters	  (4	  to	  33	  nm)	  and	  surface	  coatings	  (oleic	  acid,	  PAA-­‐OA,	  PAMPS-­‐LA,	  and	  PAMO-­‐PEG)	  (A-­‐D)	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Table	  4-­‐2	  The	  r2	  relaxivities	  of	  iron	  oxide	  nanocrystals	  with	  different	  core	  sizes	  and	  coatings	  




)	  at	  1.5T 
Sample Oleic	  acid PAA-­‐OA PAMPS-­‐LA PMAO-­‐PEG	   
4	  nm	  Iron	  oxide 11.1	  ±	  	  3.1 81.9	  ±	  	  6.4 108.7	  ±	  	  3.9 126.6	  ±	  3.1 
10	  nm	  Iron	  oxide 50.5	  	  ±	  	  2.8 158.9	  	  ±	  	  5.9 152.4	  ±	  	  7.2 201.1	  	  ±	  	  5.7 
16	  nm	  Iron	  oxide 159.8	  ±	  	  10.7 327.7	  	  ±	  12.5 385.2	  ±	  	  10.1 260.4	  ±	  12.9 
33	  nm	  Iron	  oxide 510.3	  ±	  18.8 301.2	  ±	  	  10.4	   355.1	  ±	  6.7 339.9	  	  ±	  8.3 
	  	  	  	  	  Table	  4-­‐3.	  Surface	  effects	  on	  MR	  relaxivity	  (r2)	  
Surface	  effect	   Average	  r2	  (mM
-­‐1S-­‐1)	  at	  1.5T	  
Sample	   PEG	  200	   PEG	  1K	   PVP	  10K	   PEG	  10K	   PAA	  15K	  
10	  nm	  Iron	  oxide	   101.5	  ±	  	  1.3	   105.7	  ±	  	  3.0	   138.6	  ±	  	  5.3	   195.7	  	  ±	  	  6.7	   202.3	  	  ±	  	  6.9	  	  
	   167	  	  
	  
Figure	  4-­‐9	  Plots	  of	  r2	  values	  of	  iron	  oxide	  nanoparticles	  Plots	  of	  r2	  values	  of	  iron	  oxide	  nanoparticles	  depending	  their	  core	  diameters(A)	  and	  hydrodynamic	  size	  (B).	   	  The	  r2	  values	  of	  10	  nm	  core	  iron	  oxide	  nanoparticles	  with	  different	  molecular	  weight	  of	  polymers	  (C)	  and	  their	  hydrodynamic	  size	  (D)	  	   As	  changing	  molecular	  weights	  of	  polymers	  from	  oleic	  acid	  to	  PMAO-­‐PEG,	  r2	  relaxivities	   of	   4	   nm	   iron	   oxide	   nanocrystals	   increased	   from	   11	   to	   127	   mM-­‐1S-­‐1	  (Figure	  4-­‐9	  (A)	  and	  (B)).	  	  Moreover,	  r2	  values	  of	  10	  nm	  iron	  oxide	  nanocrystals	  also	  increased	   from	  51	   to	   201	  mM-­‐1S-­‐1.	   In	  MAR,	   the	   r2	  values	   proportionally	   increased	  with	  hydrodynamic	  size.	  Furthermore,	  when	  increasing	  the	  molecular	  weight	  of	  PEG	  from	   200	   to	   10,000	   g/mol,	   PVP	   10,000,	   and	   PAA	   15,000	   g/mol,	   the	   r2	   values	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increased	  from101	  to	  202	  mM-­‐1S-­‐1	  (Figure	  4-­‐9	  (C)	  and	  (D)	  and	  Table	  4-­‐3).	  	  If	  the	  iron	  oxide	  nanocrystals	  have	  small	  core	  (4	  or	  10	  nm)	  and	  small	  hydrodynamic	  size	  (<50	  nm),	  r2	  dynamics	  are	  strongly	  dependent	  on	  the	  magnetic	  moments	  in	  MAR.	  	  	  
High	   molecular	   weights	   of	   polymers	   provide	   larger	   hydrodynamic	   sizes,	  which	  reach	  to	  the	  limitation	  of	  SDR.	  	  When	  the	  hydrodynamic	  size	  was	  over	  SDR	  (>	  60	  nm)	  the	  r2	  values	  dramatically	  decrease	  (Figure	  4-­‐10).	  	  At	  16	  nm	  core	  size,	  the	  r2	  values	   of	   oleic	   acid,	   PAA-­‐OA	   and	   PAMPS-­‐LA	   coated	   iron	   oxide	   nanocrystals	  increased	  to	  160,	  328,	  and	  385	  mM-­‐1S-­‐1.	  	  However,	  the	  r2	  value	  of	  PMAO-­‐PEG	  coated	  iron	  oxide	  nanocrystals	  decreased	  to	  260	  mM-­‐1S-­‐1.	  The	  hydrodynamic	  size	  of	  PMAO-­‐PEG	  coated	  iron	  oxide	  nanocrystals	  was	  around	  60	  nm	  in	  ELR,	  where	  r2	  followed	  to	  1/r.	  	  The	  size	  regime	  theory	  (MAR,	  SDR,	  and	  ELR)	  explained	  that	  r2	  relaxivity	  of	  33	  nm	   iron	  oxide	  nanocrystals	  dramatically	  decreased	  with	   increasing	  hydrodynamic	  sizes	  in	  ELR	  (Figure	  4-­‐10).	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Figure	   4-­‐10	   The	   plots	   of	   r2	   relaxivities	   of	   iron	   oxide	   nanocrystals	   with	   different	  cores	  (A-­‐D).	  	  The	  points	  indicate	  the	  surface	  coatings	  (left,	  oleic	  acid,	  PAA-­‐OA,	  PAMPS-­‐LA,	  PMAO-­‐PEG).	  	  	  	  
The	  relaxivity	  value	  (r2)	  can	  be	  also	  affected	  by	  surface	  coating.	  	  If	  the	  coating	  is	  a	  permeable	  polymer	  matrix	  where	  water	  can	  easily	  diffuse	  the	  water	  inside,	  the	  R2	  follows	  this	  equation100:	  
𝑅! = 1𝑇! = 256𝜋
!𝛾!405 𝑉𝑀!!𝑎!𝐷∗                                                                                         (5)	  
where	  D*	  is	  the	  effective	  diffusion	  coefficient	  of	  water	  molecules.	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If	   the	  polymer	   is	   permeable	   and	  has	   low	  grafting	  density	   (e.g.	   PMAO-­‐PEG),	  the	  diffusion	  rate	  increased	  and	  the	  time	  of	  diffusion	  was	  faster.	  While	  keeping	  same	  hydrodynamic	  size,	  and	  changing	  only	  the	  type	  of	  polymer	  coated	  on	  an	  iron	  oxide	  nanocrystal	  there	  were	  different	  r2	  relaxivity	  values	  (Figure	  4-­‐11).	  	  For	  example,	  at	  a	   hydrodynamic	   size	   between	   30~40	   nm	   in	   MAR,	   the	   r2	   values	   were	   strongly	  dependent	   on	   their	   coatings	   and	   decreased	   with	   increasing	   molecular	   weight	   of	  polymers.	   	  We	   confirmed	   the	   grafting	   densities	   of	   oleic	   acid,	   PAA-­‐OA,	   PAMPS-­‐LA,	  and	   PMAO-­‐PEG	   were	   12.1,	   4.1,	   3.7,	   and	   0.004,	   respectively	   (Figure	   4-­‐7).	   As	   the	  grafting	  densities	  decrease,	   the	  permeability	  and	  diffusion	  rate	   increase	  and	  the	  r2	  value	  decreased.	  	  	  
	  
Figure	  4-­‐11	  The	  surface	  coating	  effects	  at	  same	  hydrodynamic	  size.	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Figure	  4-­‐12	  showed	  the	  T2	  weighted	  MR	  phantom	  images	  for	  (A)	  three	  sizes	  of	  iron	  oxide	  particles	  at	  two	  concentrations	  and	  (B)	  six	  different	  coating	  and	  three	  different	  compositions	  of	  iron	  oxide	  nanocrystals	  on	  the	  same	  core	  (10	  nm).	  	  As	  the	  particle	  size	  increased	  from	  4	  nm	  to	  33	  nm	  with	  small	  oleic	  acid	  coating,	  the	  T2	  MR	  images	  get	  darker.	  Also,	  increasing	  molarity	  (M)	  (0.1	  mM)	  of	  iron	  resulted	  in	  much	  darker	  images	  than	  0.05	  mM.	  	  Increasing	  the	  molecular	  weight	  of	  polymer	  capping	  agents	  on	  a	  10	  nm	  iron	  oxide	  nanocrystals	  increased	  the	  hydrodynamic	  size	  in	  MAR	  which	  resulted	  in	  darker	  MR	  contrast	  images	  (Figure	  4-­‐12	  (B)).	  	  
	  
Figure	  4-­‐12	  T2	  weighted	  MR	  images	  of	  iron	  oxide	  nanocrystals	  (A)	  T2	  weighted	  MR	  image	  of	  iron	  oxide	  nanocrystals	  depending	  on	  their	  sizes	  (4,	  16,	  33	  nm)	  at	  different	  concentration	  of	  Fe	  ions	  (0.05	  mM,	  0.1	  mM),	  and	  (B)	  T2	  weighted	  MR	   image	   of	   iron	   oxide	   nanocrystals	   (10	   nm	   core)	   depending	   on	   their	  coatings/compositions.	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The	   different	   compositions	   of	   iron	   based	   nanocrystals	   (AlFe2O4,	   ZnFe2O4,	  Fe3O4)	  with	  PAMPS-­‐LA	  coating	  are	  shown	  in	  Figure	  4-­‐12(B).	  Table	  4-­‐3	  and	  Table	  4-­‐4	  showed	   the	   r2	   values	   of	   iron	   oxide	   nanocrystals	   with	   various	   coatings	   and	  compositions.	   The	   different	   compositions	   of	   MFe2O4	   iron	   oxide	   nanocrystals	  resulted	  in	  lower	  r2	  values	  (Figure	  4-­‐13).	  It	  was	  assumed	  that	  the	  ratio	  of	  Fe	  to	  the	  divalent	  or	  trivalent	  metal	  ions	  (Mn2+,	  Zn2+,	  and	  Al3+)	  within	  a	  crystals	  would	  affect	  the	  magnetic	  moment	  and	  change	  the	  r2	  values.100	  	  In	  order	  to	  get	  high	  r2	  values,	  the	  ratio	  of	  Fe	   to	  other	  metal	   ions	  needs	   to	  be	  optimized.	   	  The	   r2	   values	  with	  various	  coatings	   were	   examined	   at	   various	   conditions	   including	   buffers,	   pH,	   and	   ionic	  strengths	   (Figure	   4-­‐14).	   Especially,	   PAMPS-­‐LA	   coatings	   were	   stable	   at	   acidic	  condition	  (pH=3)	  and	  high	  ionic	  strengths.	  Thus	  it	  would	  be	  very	  useful	   in	  cellular	  environments	  because	  they	  can	  prevent	  the	  release	  of	  metal	  ions	  and	  cell	  damages.	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Figure	  4-­‐13	  The	  r2	  relaxivites	  of	  different	  compositions	  of	  iron	  oxide	  nanocrystals	  	  
Table	  4-­‐4	  Composition	  effects	  on	  MR	  relaxivity	  (r2)	  




)	  at	  1.5T 




















 16.8	  	  ±	  1.3 48.3	  ±	  2.2 27.4	  ±	  0.7 32.1	  	  ±	  0.4 
10	  nm	  MnZnFeO
4
	   37.9	  ±	  2.2 11.3	  	  ±	  2.2	   13.0	  ±1.8 7.1	  	  ±	  2.9 	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Figure	   4-­‐14	   The	   r2	   values	   of	   iron	   oxide	   nanoparticles	   with	   different	   coatings	   at	  various	  conditions	  of	  buffers	  (A),	  pH	  (B),	  NaCl	  (C),	  and	  CaCl2	  (D).	  	  
4.3.4. In	  vitro	  cell	  toxicology	  study	  
The	   toxicological	   study	   is	   very	   important	   to	   apply	   in	   vivo	   MR	   imaging.	   To	  examine	  the	  toxicological	  issue	  of	  iron	  oxide	  nanocrystals	  depending	  on	  their	  sizes,	  coating,	   and	   compositions,	   we	   performed	   in	   vitro	   cell	   viability	   test	   using	   human	  dermal	   fibroblast	   (HDF).	   Figure	   4-­‐15	   shows	   the	   percentage	   of	   cell	   viability	   with	  increased	  nanoparticle	  concentration	  measure	  from	  the	  amount	  of	  Fe	  ions	  in	  an	  acid	  digested	   sample.	   Figure	   4-­‐15	   (A)	   confirmed	   that	   for	   bilayer	   oleic	   acid	   coated	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particles	   the	  percentage	  of	   cell	  viability	  decreased	  as	  core	  size	   increased.	   	  Smaller	  hydrodynamic	  diameters	  would	  allow	  the	  particles	  to	  be	  internalized	  into	  the	  cells	  quicker,	  which	  result	  in	  increased	  toxicological	  effects.	  	  For	  iron	  oxide	  nanoparticle	  with	   the	  same	  core	  size	   (10	  nm)	  and	  various	  polymer	  coatings	   (oleic	  acid	  bilayer,	  PAA-­‐OA,	   PAMPS-­‐LA,	   PMAO-­‐PEG,	   and	   PEG	   10K)	   only	   the	   bilayer	   oleic	   acid	   coated	  particles	  showed	  any	  toxicity	  up	  to	  6000	  uM	  Fe	  (Figure	  4-­‐15	  (B)).	  	  	  
The	   bilayer	   oleic	   acid	   coating	   resulted	   in	   higher	   toxicity	   than	   any	   other	  polymer	  coating.	  	  The	  nanocrystals	  were	  densely	  covered	  with	  oleic	  acid	  but	  coating	  thickness	   is	  so	  small	   (2~4	  nm)	  so	   that	   the	  core	  (iron	  oxide)	  was	  more	  exposed	  to	  the	   cell	   surface.	   	   Small	   hydrodynamic	   size	   would	   give	   more	   stress	   to	   the	   cells.	  Polymer	   coated	   materials	   were	   prepared	   by	   encapsulation.	   The	   larger	  hydrodynamic	  sizes	  of	  these	  materials	  prevent	  their	  accumulation	  within	  the	  cells.	  	  The	   oleic	   acid	   coated	   nanocrystals	   were	   non	   toxic	   up	   to	   1200	   uM	   of	   iron	   and	  polymer	  coated	  iron	  oxide	  suspensions	  were	  safe	  even	  at	  the	  highest	  concentrations	  tested	  (6,000	  uM).	  Ferrite	  nanocrystals	  show	  greater	   toxicity	   to	  cells	   than	  pristine	  iron	  oxide	  nanocrystals	  (Figure	  4-­‐15	  (C)	  and	  (D)).	  Comparing	  both	  bilayer	  oleic	  acid	  coated	   and	   PMAO-­‐PEG	   coated	   MnFe2O4,	   ZnFe2O4,	   and	   Fe3O4,	   the	   MnFe2O4	  nanocrystals	  were	  more	  toxic	  with	  an	  LD50	  values	  of	  600	  uM	  for	  the	  more	  toxic	  oleic	  acid	  bilayer	  materials.	  	  The	  ZnFe2O4	  and	  Fe3O4	  nanocrystals	  showed	  similar	  toxicity	  with	   LD50	   of	   1200	   uM	   with	   oleic	   acid	   bilayer	   coatings	   however	   with	   PMAO-­‐PEG	  coatings	   the	   ZnFe2O4	   or	   MnFe2O4	   nanocrystals	   were	   more	   toxic	   than	   Fe3O4.	   The	  toxic	  metal	  ions	  (Mn	  and	  Zn)	  gave	  more	  toxicological	  effects	  to	  the	  cells.	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Figure	  4-­‐15	  In	  vitro	  cell	  toxicological	  studies	  In	  vitro	  cell	  toxocological	  study	  (A)	  cell	  viability	  tests	  of	  oleic	  acid	  coated	  iron	  oxide	  nanocrystals	  with	  different	  cores.	  (B)	  cell	  viability	  tests	  of	  iron	  oxide	  nanoparticles	  with	  various	  surface	  coating,	  (C)	  cell	  viability	  tests	  of	  the	  oleic	  acid	  coated	  iron	  oxide	  and	  ferrite	  nanoparticles,	  (D)	  cell	  viability	  tests	  of	  PMAO-­‐PEG	  coated	  iron	  oxide	  and	  ferrite	  nanoparticles	  
4.4. Conclusion	  
In	  order	  to	  see	  the	  effects	  on	  MR	  relaxivity	  values,	  we	  prepared	  size	  tunable	  iron	  oxide	  nanocrystals	  from	  4	  to	  33	  nm	  with	  various	  surface	  coating	  agents	  (oleic	  acid,	   PAA-­‐OA,	   PAMPS-­‐LA,	   and	   PMAO-­‐PEG).	   These	   surface-­‐coated	   iron	   oxide	  suspensions	  gave	  good	  colloidal	  stability	  and	  kept	  small	  hydrodynamic	  size	  so	  that	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Chapter 5	  
Characterization and Optimization of 
the Fluorescence of Nanoscale Iron 
Oxide/Quantum Dots Complexes  
In	  this	  work,	  nanoscale	  iron	  oxide/quantum	  dots	  complexes	  were	  formed	  in	  an	  efficient	  and	  versatile	  reaction	  that	  relied	  on	  the	  nucleation	  of	  chalcogenides	  on	  preformed	   iron	  oxide	  nanocrystals.	   Iron	  oxide	  nanocrystals	   acted	  as	   seeds	   for	   the	  growth	  of	  CdSe	  quantum	  rods	  (QRs),	  CdSe	  quantum	  dots	  (QDs),	  and	  CdSe@ZnS	  QDs.	  A	   zinc	   sulfide	   (ZnS)	   shell	   was	   added	   to	   protect	   the	   CdSe	   core	   in	   the	   complex	  chemically	  and	  to	  provide	  a	  reasonable	  fluorescence	  quantum	  yield	  (~	  5	  %).	  High-­‐resolution	  transmission	  electron	  microscopy	  (HRTEM)	  revealed	  that	  QDs	  shared	  an	  interface	  with	  iron	  oxide,	  yielding	  structures	  that	  resemble	  pincushions	  with	  QDs	  or	  QRs	   studding	   the	   surface	   of	   iron	   oxide.	   These	   complexes	   only	   formed	   under	  conditions	   of	   temperature,	   injection	   rate,	   and	   surfactant	   composition	   that	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minimized	   the	   formation	   of	   unbound	  QDs.	   	   Because	   iron	   oxide	   is	   a	   ferromagnetic	  material,	   it	   provided	   a	   high	   purity	   (~89	   %)	   of	   complexed	   materials	   without	  unbound	  QDs.	   The	   quantitative	   photoluminescence	   quantum	   yields	   (PLQY)	   of	   the	  purified	   complexes	   correlated	   with	   the	   number	   of	   QD	   per	   iron	   oxide.	   The	   size	  dependent	   optical	   and	   magnetic	   properties	   of	   each	   component	   were	   retained	   in	  these	  nanoscale	  complexes.	  	  	  
5.1. Introduction	  
Multifunctional	   nanostructures	   consisting	   of	   two	   or	   more	   functional	  components	  represent	  a	  new	  class	  of	  material	  with	  potential	  applications	  including	  multimodal	   imaging	   and	   simultaneous	   detection	   and	   therapy.33,36,111,112,226-­‐234	  Specifically,	   magnetic-­‐fluorescent	   hybrid	   nanostructures	   are	   recognized	   as	   a	  powerful	   class	   of	   multifunctional	   nanostructures	   because	   they	   combine	   both	  magnetic	   and	   fluorescent	  properties.36,111,230,232	  Magnetic	   iron	  oxide	  nanoparticles,	  possessing	  super	  paramagnetic	  property	  have	   found	  a	  variety	  of	  applications	  such	  as	  magnetic	  resonance	  imaging	  (MRI)	  contrast	  agents,44,235,236	  magnetic	  cell	  sorting	  and	  separation,237,238	  and	  magnetic	  drug	  delivery.239,240	  	  Fluorescent	  materials	  such	  as	  quantum	  dots	   (QDs)	  offer	  size-­‐tunable	  optical	  properties	  and	  high	   fluorescence	  quantum	   yield.25	   As	   a	   fluorescent	   probe,	   QDs	   have	   important	   biomedical	  applications	   including	   in	   vivo	   cell	   targeting,	   imaging,	   and	   multiplexed	   biological	  detection.32,53,65-­‐67	  These	  magnetic-­‐fluorescent	  hybrid	  nanostructures	  can	  open	  new	  capabilities	   such	   as	   optical	   imaging	   combined	   with	   MRI,107,209,211,241-­‐244	   visible	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multiple	   cell	   tracking	   and	   separation.68,108,245	   	   	   However,	   progress	   in	   these	   hybrid	  nanostructures	   is	   limited	   by	   many	   demands	   (stability,	   product	   yields,	   and	   size	  tunability)	   that	   biomedical	   applications	   place	   on	   the	   material.	   	   Ideally,	   these	  assemblies	  would	  be	  prepared	   in	  high	  yield,	  of	   limited	  hydrodynamic	  size	   (d	  <	  50	  nm),	   and	   with	   controlled	   stoichiometry.	   	   Three	   strategies	   have	   been	   explored	   to	  date:	  polymer	  encapsulation,	  ligand	  cross-­‐linking,	  and	  direct	  seed	  nucleation.36	  	  	  The	   first	   strategy	  relies	  on	   the	  encapsulation	  of	   the	  magnetic	  nanoparticles	  including	  iron	  oxide	  and	  QDs	  or	  fluorescent	  dyes	  inside	  of	  larger,	  often	  sub-­‐micron,	  polymeric	  capsules	  or	  porous	  silica	  beads.70,246-­‐257	  This	  method	  is	  relatively	  simple	  and	   is	   suitable	   for	   in-­‐vitro	   applications	   such	   as	   multimodal	   imaging	   and	   drug	  delivery.72-­‐74,211,244,258,259	  But,	  the	  resulting	  materials	  are	  relatively	  large	  (>100	  nm)	  and	  easily	   aggregated.	   	  The	   second	   set	  of	  work	  examines	   the	  use	  of	  direct	   linking	  agents	   to	   coordinate	   magnetic	   particles	   and	   QDs	   or	   fluorescent	   dye.77-­‐82,260-­‐262	  Simply,	  iron	  oxide	  nanoparticles	  are	  covalently	  linked	  to	  the	  fluorescent	  dye	  or	  QDs	  via	   m-­‐2-­‐3-­‐dimercaptosuccinic	   acid	   (DMSA)	   ligand	   or	   dodecylamine	   (DDA)	   cross	  linkers.77,80	  The	  cross-­‐linkers	  can	  directly	  affect	  the	  conjugation	  so	  that	  the	  particle	  size	   remains	   small.	   	   However,	   it	   is	   limited	   by	   its	   low	   product	   yield	   and	   the	  complicated	   functionality	   of	   linkers.	   	   	   The	   third	   strategy	   exploits	   the	   observation	  that	  QDs	   can	  nucleate	  directly	   on	   some	  kinds	  of	  magnetic	  nanoparticles	   including	  iron	   oxide	  nanocrystals.83-­‐90,263-­‐267	   This	  method	   can	  be	   extended	   to	  many	   kinds	   of	  hybrid	   nanostructures	   including	   metal-­‐metal,	   metal-­‐semiconductor,	   metal	   oxide-­‐metal,	   and	   metal	   oxide-­‐semiconductor	   and	   offers	   products	   with	   small	   size,	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homogeneous	   structures,	   and	   tunable	   stoichiometry.91-­‐96,268-­‐271	   Here,	   we	   focus	   on	  this	  direct	  nucleation	  route,	  specifically,	  magnetic-­‐semiconductor	  hetero	  structures	  that	  provide	  small	  and	  tunable	  properties.	  The	   direct	   nucleation	   of	   QDs	   on	   iron	   based	   magnetic	   nanostructure	   could	  reach	   to	   high	   purity	   and	   high	   yields	   of	  magnetic-­‐quantum	   dot	   complex	  materials	  through	   the	   conventional	   high	   temperature	   metal	   precursor	   decomposition	  method.83-­‐90,263-­‐267,272-­‐275	   More	   specifically,	   prior	   works	   have	   examined	   the	  formation	   of	   magnetic-­‐semiconductor	   hetero	   structures	   by	   using	   a	   magnetic	  nanoparticle	   as	   a	   seed	   for	   the	   nucleation	   of	   semiconductor	   materials.	   Kwon	   and	  McDaniel	   et	   al	   described	   the	   synthesis	   of	   iron	   oxide/CdS	   heterostructures	   and	  examined	  the	  size	  dependence	  on	  growth	  rate	  and	  the	  effects	  of	  lattice	  mismatch	  on	  the	   heterojunctions.272-­‐275	   	   Gu	   and	  Gao	   et	  al	  developed	   FePt-­‐CdS,	   FePt-­‐CdSe,	   FePt-­‐ZnS	  heterodimer	  nanoparcticles	  and	  explored	  the	  morphology	  of	  the	  structures	  by	  controlling	   various	   experimental	   conditions.84,276,277	   Recently,	   they	   demonstrated	  the	  intracellular	  manipulation	  of	  FePt-­‐CdSe	  nanoparticles.109	  Selvan	  et	  al	  developed	  Fe2O3-­‐CdSe	   nanocomposites	   and,	   by	   fluorescence	   imaging,	   showed	   internalized	  silica-­‐coated	  magnetic	  quantum	  dots	  in	  a	  live	  cancer	  cell.234,278-­‐280	  	  Generally,	   direct	   nucleation	   produces	   both	   complexed	   materials	   and	   self	  nucleation	  of	  secondary	  materials	  as	  an	  excess.	   	   Ideally,	  a	   reaction	  would	  produce	  mostly	   complexed	   materials	   as	   opposed	   to	   isolated	   nanoparticles	   when	   the	  efficiency	   of	   the	   complex	   formation	   is	   optimized.	   	   In	   order	   to	   achieve	   optimal	  conditions,	   a	   quantitative	   method	   should	   be	   developed	   to	   understand	   favorable	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conditions	  that	  minimize	  the	  formation	  of	  unbound	  QDs.	  	  Moreover,	  an	  unanswered	  question	   is	   the	   extent	   to	  which	   the	   complex	   reduces	  photoluminescence	  quantum	  yield	  (PLQY),	  and	  related	  issue	  of	  strategies	  to	  minimize	  quenching.	   	  The	  PLQYs	  of	  magnetic/QDs	  complexes	  through	  direct	  seed	  nucleation	  are	  generally	  estimated	  to	  be	   3	   to	   38	  %.83,87,109,278-­‐280	   Because	   the	   QDs	   are	   in	   direct	   contact	   with	   the	   metal	  surface	  of	  magnetic	  nanoparticles,	  the	  PLQY	  of	  the	  complex	  decreases	  as	  compared	  with	  stand	  alone	  QDs.75,76,83,87,90,109,278,279	  	  	  Moreover,	  excess	  unbound	  QDs	  also	  affect	  the	   PLQY	   of	   the	   complex	   so	   that	   it	   should	   be	   removed	   to	   attain	   an	   exact	   value.	  	  Precise	  measurement	  is	  needed	  for	  an	  accurate	  PLQY	  value	  of	  the	  complex	  from	  the	  possible	  presence	  of	  excess	  unbound	  QDs.	  	  	  Here	   we	   optimized	   the	   synthesis	   of	   nanoscale	   iron	   oxide/quantum	   dots	  (QDs)	  complexes	  that	  possess	  both	  good	  responsiveness	  to	  external	  magnetic	  fields	  and	  a	  PLQY	  value	   in	  excess	  of	  5	  %.	   	  The	  optimized	  synthesis	  permits	  the	  type	  and	  number	   of	   QD	   to	   be	   controlled.	   	   Because	   iron	   oxide	   is	   a	   strong	   ferromagnetic	  material,	   the	   complexes	   can	   be	   separated	   from	   unbound	   QDs	   with	   an	   external	  magnetic	   field.	   	  This	  magnetic	  capture	  allows	   for	  a	  measure	  of	   reaction	  yields	  and	  for	   the	  optimization	  of	  conditions	   to	  minimize	  excess	  unbound	  QDs.	   	  Also	   through	  this	  magnetic	  capture,	  the	  PLQY	  of	  complexes	  can	  be	  accurately	  determined	  because	  excess	   unbound	   QDs	   are	   removed.	   	   Although	   the	   photoluminescence	   of	   iron	  oxide/QDs	  complexes	  is	  lower	  than	  that	  found	  for	  pure	  QDs,	  it	  is	  non-­‐bleaching	  and	  high	  enough	  to	  be	  easily	  visualized.	  	  Additionally,	  the	  PLQY	  correlates	  well	  with	  the	  number	  of	  QD	  per	  iron	  oxide	  nanoparticle.	  	  This	  work	  illustrates	  an	  efficient	  method	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to	   control	   the	   synthesis	   of	   magnetic	   fluorescent	   complexes	   that	   possess	   variable	  morphology,	  improved	  fluorescent	  emission,	  and	  high	  quantum	  yield.	  
5.2. Experimental	  sections	  
5.2.1. 	  Chemicals	  
Iron	   oxide,	   hydrate	   (FeO(OH),	   catalyst	   grade	   30-­‐50	  mesh	   99%),	   oleic	   acid	  (OA,	   technical	   grade	   90%),	   1-­‐octadecene	   (ODE,	   technical	   grade	   90%),	   cadmium	  oxide	   (CdO,	   powder	   99.99%),	   selenium	   (Se,	   100	  mesh	   99.5%),	   sulfur	   (S,	   powder	  99.98%),	   zinc	   oxide	   (ZnO,	   powder	   99%),	   trioctylphosphine	   (TOP,	   technical	   grade	  90%),	  octadecylamine	  (ODA,	  97%),	  hexadecylamine	  (HDA,	  99%),	  trioctylphosphine	  oxide	  (TOPO,	  99%),	  hexadecane	  (reagent	  plus,	  99%)	  and	  phenyl	  ether	  (reagent	  plus,	  99%)	  were	   all	   purchased	   from	   Sigma-­‐Aldrich.	   	   All	   nanocrystals	  were	   synthesized	  under	   ultra-­‐high	   purity	   nitrogen	   (N2,	   99.99	  %).	  Methanol	   (99.8	  %),	   acetone	   (99.5	  %),	  hexanes	  (98.5	  %),	  sodium	  bicarbonate	  (99.7	  %),	  and	  dimethylformamide	  (DMF,	  99.8	   %),	   nitric	   acid	   (HNO3,	   70	   %)	   and	   hydrogen	   peroxide	   (H2O2,	   30	   %)	   were	  purchased	   from	   Fisher	   Scientific.	   All	   chemicals	   were	   used	   without	   further	  purification.	  	  
5.2.2. Synthesis	  of	  iron	  oxide	  nanocrystals	  
The	  iron	  oxide	  nanocrystals	  were	  synthesized	  based	  on	  the	  previous	  work.51	  Specifically,	   0.178	   g	   of	   FeO(OH)	   was	   added	   to	   2.26	   g	   oleic	   acid	   and	   5	   g	   of	   1-­‐octadecene	  and	  this	  mixture	  was	  heated	  to	  120	  °C	  for	  2	  hours	  to	  evaporate	  residual	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water.	   The	   temperature	   further	   increased	   to	   260	   °C	   for	   30	   minutes.	   Finally,	   the	  mixture	  was	  allowed	  to	  reflux	  at	  320	  °C	  for	  2	  hours	  and	  the	  solution	  became	  black.	  	  The	   iron	   oxide	   nanocrystals	  were	   purified	   and	   concentrated	   by	   first	   precipitating	  the	  product	  using	  methanol	  and	  acetone	  followed	  by	  centrifugation	  at	  4150	  rpm	  for	  30	   minutes	   (5	   ml	   colloidal	   solution,	   20	   ml	   methanol,	   and	   20	   ml	   acetone).	   This	  process	   was	   repeated	   5	   or	   6	   times	   resulting	   in	   purified	   iron	   oxide	   nanocrystal	  solutions	  with	  minimal	  residual	  surfactants.	  	  The	  purification	  step	  is	  very	  important	  to	   make	   QD/iron	   oxide	   magnetic-­‐optical	   complexes	   since	   unpurified	   iron	   oxide	  nanocrystals	  may	  prevent	  the	  nucleation	  and	  growth	  of	  QDs	  on	  the	  surface	  of	   iron	  oxide	   nanocrystals.	   The	   purified	   iron	   oxide	   solution	   was	   stored	   in	   hexanes	   at	   a	  concentration	  typically	  of	  6,000	  mg/L.	  Typically,	  nanocrystals	  diameters	  was	  10	  nm	  (±	  1.5	  nm).	  	  A	  series	  of	  iron	  oxide	  nanocrystals	  with	  various	  diameters	  from	  8	  to	  17	  nm	  was	  synthesized	  by	  controlling	  the	  ratio	  between	  FeO(OH)	  and	  OA	  from	  1:3	  to	  1:6.	  	  The	  purified	  iron	  oxide	  nanocrystal	  solution	  was	  stored	  in	  hexanes.	  
5.2.3. 	  Synthesis	  of	  iron	  oxide/CdSe	  QDs	  nanoparticles	  
To	   synthesize	   iron	   oxide/CdSe	   QDs	   complexes,	   CdO	   (0.0386	   g,	   0.3	   mmol),	  ODA	  (3	  g,	  11	  mmol),	  and	  ODE	  (10	  g,	  40	  mmol)	  were	  mixed	  in	  a	  three-­‐neck	  flask	  and	  heated	   to	   200	   °C	   for	   1	   hour.	   After	   cooling	   down	   to	   60	   °C,	   purified	   iron	   oxide	  nanocrystals/hexanes	  (1	  ml,	  6,000 mg/L of Fe)	  solution	  was	  added	  and	  the	  mixture	  was	  heated	  to	  100°C	  for	  30	  min	  to	  remove	  the	  hexanes	  completely.	  Afterwards,	  the	  reaction	  mixture	   was	   heated	   to	   reflux	   at	   280	   °C	   for	   1	   hour	   under	   N2	   flow.	   After	  cooling	  down	  to	  220	  °C,	  Se	  (0.9	  mmol)	  dissolved	  in	  2	  ml	  of	  TOP	  was	  slowly	  added	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into	  the	  mixture	  solution	  (0.4	  ml/min).	  The	  mixture	  was	  kept	  at	  250	  °C	  to	  allow	  for	  the	   growth	   of	   CdSe	  QDs	   at	   different	   time	   intervals	   (1	  min	   to	   25	  min).	   Aliquots	   of	  growth	  solution	  were	  quenched	  in	  10	  ml	  hexanes.	  	  
5.2.4. Preparation	  of	  precursors	  for	  shell	  growth	  
The	   preparation	   of	   precursors	   and	   the	   shell	   growth	   for	   QDs	  was	  modified	  from	   published	   procedure.62	   The	   zinc	   precursor	   stock	   solution	   (0.04	   M)	   was	  prepared	  by	  dissolving	  ZnO	  (0.39	  g)	   in	  oleic	  acid	  (10.83	  g)	  and	  1-­‐ODE	  (108	  ml)	  at	  250	   °C.	   The	   sulfur	   precursor	   stock	   solution	   (0.04	  M)	  was	   prepared	   by	   dissolving	  sulfur	  powder	  (0.128	  g)	  in	  1-­‐ODE	  (100	  ml)	  at	  200	  °C.	  	  Both	  precursor	  solutions	  were	  prepared	   under	   N2	   flow	   and	   clear	   solutions	   were	   acquired.	   The	   Zn	   precursor	  solution	  was	   preheated	   to	   ensure	   complete	   dissolution	   before	   injection.	   To	  make	  the	  shell,	  a	  specific	  amount	  of	  a	  stock	  solution	  was	   introduced	  via	  syringe	   into	  the	  hot	  reaction	  mixture.	  
5.2.5. Synthesis	  of	  iron	  oxide/CdSe@ZnS	  QDs	  nanoparticles	  
To	  synthesize	  iron	  oxide/CdSe@ZnS	  core/shell	  QDs	  complexes,	  the	  solution	  of	  the	  iron	  oxide/CdSe	  QDs	  complexes	  (growth	   for	  20	  minutes)	  without	  purification	  was	  allowed	  to	  cool	  down	  to	  room	  temperature	  and	  reheated	  to	  220	  °C	  to	  deposit	  ZnS	  shell	  onto	  CdSe	  QDs.	  	  At	  220	  °C,	  1	  ml	  of	  the	  Zn	  precursor	  (0.04	  M	  ZnO/OA	  in	  ODE)	  was	  slowly	  injected	  into	  the	  solution	  and	  allowed	  to	  stir	   for	  10	  minutes.	  The	  same	  volume	  of	  sulfur	   in	  ODE	  was	  sequentially	   injected	  into	  the	  reaction	  and	  stirred	  for	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20	   minutes.	   Afterwards,	   the	   reaction	   mixture	   was	   cooled	   down	   to	   60°C	   and	  dispersed	  in	  hexanes.	  	  
5.2.6. Synthesis	  of	  iron	  oxide/CdSe	  QRs	  nanoparticles	  
For	  synthesizing	  iron	  oxide/CdSe	  QRs	  complexes,	  CdO	  (0.0386	  g,	  0.3	  mmol),	  ODA	  (3	  g,	  11	  mmol),	  and	  ODE	  (10	  g,	  40	  mmol)	  were	  mixed	  and	  heated	  to	  200	  °C	  for	  1	   hour.	   After	   cooling	   down	   to	   60°C,	   purified	   iron	   oxide	   nanocrystal	   (0.023	   g,	   0.1	  mmol)	   solution	   was	   added	   and	   heated	   to	   100	   °C	   for	   30	   minutes	   to	   remove	   the	  hexanes.	  Afterwards,	  the	  reaction	  mixture	  was	  heated	  and	  refluxed	  at	  300	  °C	  for	  1	  hour	  under	  N2	  to	  decompose	  the	  precursors.	  After	  cooling	  down	  to	  200	  °C,	  Se	  (0.9	  mmol)	  dissolved	   in	  TOP	   (2	  ml)	  was	   slowly	   injected	   into	   the	  mixture	   solution	   (0.4	  ml/min).	  After	   injection,	   this	  solution	  was	  allowed	  to	  keep	  at	  250	  °C	   for	  1	  hour	  to	  synthesize	   the	   iron	   oxide/CdSe	   QRs	   complexes.	   Finally,	   the	   solution	   was	   cooled	  down	  and	  dispersed	  in	  hexanes.	  	  	  
5.2.7. 	  Magnetic	  capture	  purification	  
To	   determine	   the	   product	   yield	   (i.e.	   how	   much	   Cd	   converted	   to	   the	   QDs	  attached	   on	   iron	   oxide	   nanoparticles),	   iron	   oxide/QDs	   complexes	  were	   separated	  and	  were	  purified	  from	  unbound	  QDs	  with	  the	  help	  of	  a	  magnetic	  force.	  First,	   iron	  oxide/QDs	   complexes	   were	   purified	   from	   excess	   QD	   precursor,	   surfactant,	   and	  solvent	   with	   three	   cycles	   of	   centrifugation	   by	   adding	   the	   methanol	   (20	   ml)	   and	  acetone	  (20	  ml)	  at	  4150	  rpm	  for	  30	  minutes.	  	  Afterwards,	  a	  strong	  handheld	  magnet	  (1/8	   inch	   diameter,	   1/8	   inch	   long	   NdFeB	   rod	   magnet,	   United	   Nuclear	   Scientific	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Equipment	  &	  Supplies)	  was	  placed	  for	  12	  hours	  in	  proximity	  to	  the	  purified	  solution	  in	   hexanes.	   In	   this	  magnetic	   capture	  process,	   the	   iron	   oxide/QDs	   complexes	  were	  separated	   from	   the	   excess	   unbound	  QDs.	   	   This	   process	  was	   repeated	   three	   times.	  The	   cadmium	   (Cd)	   concentrations	   of	   the	   captured,	   supernatant,	   and	   non-­‐treated	  original	   solution	   were	   analyzed	   by	   inductive	   coupled	   plasma-­‐optical	   emission	  spectroscopy	  (ICP-­‐OES).	  The	  magnetic	  capturing	  efficiency	  (MCE)	  was	  calculated	  by	  the	  equation	  below.	  	  
𝑀𝐶𝐸   % = 𝐶𝑑!"#$%&'𝐶𝑑!"#$%&'  !!"#$%&'('&( ×  100          (𝑒𝑞. 1)	  	  
5.2.8. 	  Instruments	  and	  characterization	  
Ultraviolet-­‐visible	   (UV-­‐Vis)	   absorption	   spectroscopy:	   Ultraviolet-­‐visible	  absorption	   spectra	   were	   measured	   by	   using	   a	   Varian	   Cary	   5000	   UV-­‐VIS-­‐NIR	  spectrophotometer.	  	  
Photoluminescence	   spectroscopy	   and	   photoluminescence	   quantum	  
yield	   determination:	   Photoluminescence	   (PL)	   spectra	   of	   the	   iron	   oxide/QDs	  complexes	   were	   measured	   on	   a	   Jobin	   Yvon	   Spex	   Fluorolog	   3	   fluorescence	  spectrophotometer	  (USA).	  The	  absolute	  value	  of	  the	  iron	  oxide/QDs	  complexes	  was	  determined	   by	   the	   comparison	   of	   the	   PL	   integrated	   intensity	   of	   QDs	   at	   the	   same	  cadmium	  (Cd)	  concentration.	  The	  concentration	  of	  Cd	  was	  determined	  by	  ICP-­‐OES.	  The	   absolute	   photoluminescence	   quantum	   yield	   (PLQY)	   was	   calculated	   by	   the	  gradient	  method	  of	  comparing	  the	  PL	  integrated	  intensity	  of	  the	  CdSe	  QDs	  and	  that	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of	   the	   solution	   of	   rhodamine	   6G	   (R6G)	   in	   ethanol.	   The	   absorption	   spectra	   of	   iron	  oxide/QDs	  complexes,	  CdSe	  QDs,	  and	  R6G	  were	  recorded	  at	  480	  nm	  excitation,	  with	  the	  optical	   intensities	  of	  all	   samples	  below	  0.10	  absorbance.	  The	  equation	  used	   to	  calculate	  the	  quantum	  yield	  follows.117	  	  
Φ!  ! = Φ! ∙ 𝐴!𝐴! ∙ 𝐼!𝐼! ∙ 𝑛!!𝑛!! ∙ 𝐷!𝐷!                 (𝑒𝑞. 2)	  At	  room	  temperature,	  Φx	  and	  Φr	  are	  the	  absolute	  quantum	  yield	  of	  the	  CdSe	  QDs	  and	  rhodamine	  6G.	  The	  Φr	  of	  R6G	  in	  ethanol	  is	  95	  %.	  Ar	  and	  Ax	  are,	  respectively,	  compared	  to	  the	  absorption	  value	  at	  the	  excitation	  wavelength,	  e.g.	  480	  nm	  in	  this	  study.	   	   Ir	  and	   Ix	   are	   the	   intensities	   of	   excitation,	   and	   those	   of	   the	   sample	   in	   our	  experiment	   are	   equal	   to	   the	   values	   of	   the	   standard	   sample.	   nr	   and	   nx	   are	   the	  refractive	   indicies	   of	   the	   solvents.	   Ethanol	   (n=1.359)	   and	   hexanes	   (n=1.372)	   are	  used	  in	  this	  study.	  Dx	  and	  Dr	  are	  the	  PL	  integrated	  intensities	  excited	  at	  480	  nm	  of	  the	  CdSe	  QDs	  and	  R6G.	  	  	  For	   the	   calculation	  of	   PLQY	  of	   the	   iron	  oxide/QDs	   complexes,	   the	   equation	  was	  modified.	  The	  Φx	  and	  Φr	  are	  the	  absolute	  quantum	  yields	  of	  the	  iron	  oxide/QDs	  complexes	   and	   the	   calculated	   quantum	   yield	   of	   CdSe	   QDs	   by	   comparison	   with	  rhodamine	  6G.	  The	  calculated	  value	  of	  CdSe	  QDs	  in	  hexanes	  was	  10	  %.	  Ar	  and	  Ax	  are	  the	  absorption	  values	  of	   iron	  oxide/QDs	  complexes	  and	  CdSe	  QDs	  with	  equivalent	  Cd	   concentration	   at	   same	   excitation	   wavelength.	   Ir	   and	   Ix	   are	   the	   intensities	   of	  excitation,	  and	  those	  of	  the	  sample	  in	  our	  experiment	  are	  equal	  to	  the	  values	  of	  the	  standard	   sample.	   nr	   and	   nx	   are	   the	   refractive	   indicies	   of	   the	   solvents.	   All	   iron	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oxide/QDs	  complexes	  and	  CdSe	  QDs	  are	  both	  dispersed	   in	  hexanes.	  The	  refractive	  index	  n	  term	  was	  equal	  in	  this	  calculation.	  
Transmission	   electron	   microscopy	   (TEM):	   The	   TEM	   specimen	   was	  examined	  by	   JEOL	  2100	   field	   emission	  TEM	  operating	   at	  200	  kV	  with	   a	   single	   tilt	  holder.	  The	  TEM	  sample	  was	  made	  by	  evaporating	  one	  drop	  of	  purified	  solution	  in	  hexanes	  onto	   an	  ultra	   thin	   carbon	   type-­‐A	  400	  mesh	   copper	   grids	   (Ted	  Pella	   Inc.).	  Energy-­‐filtering	   transmission	   electron	   microscopy	   (EFTEM)	   provided	   the	   high-­‐resolution	   images	   showing	   a	   crystalline	   structure	   and	   gatan	   imaging	   filter	   (GIF)	  gave	  the	  quantitative	  elemental	  maps	  (Fe	  and	  Cd)	  of	  a	  sample	  within	  narrow	  energy	  ranges.	   	   Energy-­‐dispersive	   x-­‐ray	   spectrometry	   (EDXS)	   detected	   the	   chemical	  compositions	   of	   the	   complexes.	   The	   average	   diameter	   was	   obtained	   by	   counting	  over	   1000	   individual	   nanocrystalline	   particles	   using	   Image-­‐Pro	   Plus	   5.0	   (Media	  Cybernetics,	  Inc.,	  Silver	  Spring,	  MD).	  	  
Inductively	  coupled	  plasma	  optical	  emission	  spectroscopy	  (ICP-­‐OES):	  To	  determine	   the	   product	   yield	   and	   quantum	   yield	   of	   iron	   oxide/QD	   complexes,	   a	  Perkin	   Elmer	   ICP-­‐OES	   equipped	   with	   auto	   samplers	   was	   used	   to	   measure	   the	  concentration	   of	   Cd.	   Purified	   iron	   oxide/QDs	   complexes	   solution	  was	   digested	   by	  using	  nitric	  acid	  (HNO3,	  70	  %)	  and	  hydrogen	  peroxide	  (H2O2,	  30	  %)	  for	  the	  analysis.	  	  
X-­‐ray	  diffraction	   (XRD):	   	  The	  XRD	  patterns	  were	  recorded	  using	  a	  Rigaku	  D/Max	   Ultima	   II	   with	   a	   zero-­‐back	   ground	   sample	   holder	   and	   analyzed	   by	   JCPDS	  card.	  The	  2θ	  range	  was	  measured	  from	  10	  to	  80	  degrees	  with	  Cu	  Kα	  radiation.	  The	  x-­‐rays	  were	  generated	  at	  40	  kV	  and	  40	  mA.	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5.3. Result	  and	  discussions	  
5.3.1. Synthesis	  of	  iron	  oxide/QD	  complexes	  
5.3.1.1. Synthesis	  of	  iron	  oxide/CdSe	  QD	  complexes	  
Nanoscale	  iron	  oxide/QDs	  complexes	  were	  synthesized	  by	  the	  nucleation	  and	  growth	   of	   QDs	   on	   preformed	   iron	   oxide	   nanocrystals.	   	   Monodisperse	   iron	   oxide	  nanocrystals	  were	  used	  as	  seeds	  for	  the	  nucleation	  sites	  of	  QDs.	  	  As	  shown	  in	  Figure	  5-­‐1	   (A),	   the	   monodisperse	   iron	   oxide	   nanocrystals	   with	   narrow	   size	   distribution	  (<15	  %)	  were	   produced	   using	   a	   thermal	   decomposition	  method,	   reported	   in	   this	  group;	   briefly,	   nanocrystals	   were	   stabilized	   with	   oleic	   acid	   (OA)	   surfactant	   and	  purified	   by	   repeated	   precipitation-­‐centrifugation-­‐redispersion	   using	   methanol,	  acetone,	   and	   hexanes.51	   	   To	   promote	   the	   synthesis	   of	   iron	   oxide/QDs	   complexes,	  cadmium	   oxide	   (CdO)	   was	   added	   to	   colloidal	   iron	   oxide	   nanocrystal	   solution	  forming	   an	   amorphous	   CdO	   shell	   around	   the	   iron	   oxide	   surface	   and	   then	   was	  converted	   to	   a	   cadmium	   precursor	   in	   the	   presence	   of	   octadecylamine	   (ODA)	  surfactant	   (see	   experimental	   section).	   	   From	   the	  TEM	  analysis,	  we	   confirmed	   that	  the	   iron	   oxide	   nanocrystals	   were	   covered	   by	   the	   amorphous	   CdO	   shell	   and	  were	  aggregated.	  When	  the	  Se-­‐trioctylphosphine	  (Se-­‐TOP)	   introduced	  to	   iron	  oxide-­‐CdO	  shell,	  the	  QDs	  nucleated	  and	  grew	  onto	  the	  surface	  of	  iron	  oxide	  nanocrystals	  under	  optimized	   conditions	   (Figure	   5-­‐1).	   We	   speculated	   that	   due	   to	   a	   large	   lattice	  mismatch,	  the	  CdSe	  amorphous	  shell	  broke	  down	  and	  all	  CdSe	  nucleations	  occurred	  directly	   on	   the	   surface	   of	   iron	   oxide	   through	   de-­‐wetting	   process	   at	   high	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temperature.272,273,276	   The	   heterogeneous	   nucleation	   of	   QDs	   on	   iron	   oxide	  nanocrystal	  resulted	  in	  a	  pincushion	  structure	  as	  shown	  in	  Figure	  5-­‐1	  (B).	   	  A	  high-­‐resolution	  transmission	  electron	  microscope	  (HRTEM)	  with	  gatan	  image	  filter	  (GIF)	  analytical	  mapping	  confirmed	  that	  the	  QDs	  nucleated	  directly	  at	   the	   interface	  with	  iron	  oxide,	  resulting	  in	  crystalline	  structures	  (from	  Figure	  5-­‐2	  to	  Figure	  5-­‐5).	  	  	  	  
	   	  Figure	  5-­‐1	  Synthesis	  of	  iron	  oxide	  nanocrystals	  and	  iron	  oxide/CdSe	  QDs	  complexes.	  	  The	   nanoscale	   iron	   oxide/QDs	   complexes	   were	   synthesized	   by	   using	   a	   high	  temperature	   decomposition	   that	   utilizes	   the	   nucleation	   of	   QDs	   on	   preformed	   iron	  oxide	   nanocrystals.	   The	   TEM	   images	   of	   (A)	   iron	   oxide	   nanocrystals	   and	   (B)	   iron	  oxide/CdSe	  QDs	  complexes	  (B)	  are	  shown,	  respectively.	  	  The	  size	  of	  iron	  oxide	  is	  9.1	  nm.	  The	  width/length	  of	  CdSe	  QDs	  is	  3.0/3.4	  nm.	  	  The	  scale	  bars	  are	  50	  nm.	  	  
	   192	  	  
	  
Figure	  5-­‐2	  The	  high	  resolution	  TEM	  images	  of	  (A)	  iron	  oxide/CdSe	  QDs	  complexes	  and	  (B)	  iron	  oxide/CdSe/ZnS	  QDs	  complexes.	  	  The	  Fe3O4	  iron	  oxide	  region	  shows	  the	  (111)	  plane	  with	  lattice	  spacing	  of	  0.458	  nm	  (white	  line)	  and	  (220)	  plane	  with	  lattice	  spacing	  of	  0.245	  nm	  (red	  line).	   	  The	  CdSe	  QD	  region	  shows	  the	  (100)	  plane	  with	  lattice	  spacing	  0.32	  nm	  (blue	  line).	  The	  scale	  bars	  are	  2	  nm.	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Figure	  5-­‐3	  The	  powder	  XRD	  patterns	  of	  iron	  oxide/QD	  complexes	  (A)	  iron	  oxide	  (Fe3O4)/CdSe	  QDs	  complexes,	  (B)	  CdSe	  QDs	  (wurzite),	  and	  (C)	  Fe3O4	  iron	  oxide	  nanocrystals	   (face-­‐centered	  cubic).	  The	  reference	  peak	  of	   face-­‐centered	  cubic	  Fe3O4	  (blue	  line)	  and	  wurzite	  CdSe	  QDs	  (red	  line)	  were	  identified	  from	  JCPDS	  card	  19-­‐0629	  and	  02-­‐0330,	  respectively.	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  Figure	  5-­‐4	  The	  GIF	  mapping	  of	  iron	  oxide/QD	  complexes	  (A)	  The	  GIF	   frame	   image,	   (B)	  of	   iron	   (Fe)	  mapping	   (red),	   (C)	  Cd	  mapping	   (green),	  and	  (D)	  mixed	  mapping	  image	  of	  iron	  oxide/QDs	  complexes.	  From	  these	  images,	  the	  iron	   oxide	   nanocrystals	  were	   used	   as	   a	   core	   and	  QDs	  were	   grown	  on	   the	   surface.	  	  The	  scale	  bar	  is	  10	  nm.	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  Figure	  5-­‐5	  (A)	  STEM	  image	  and	  (B)	  EDAX	  of	  iron	  oxide/QDs	  complexes	  The	   chemical	   components	   of	   Fe,	   Cd,	   and	   Se	  were	  detected	   in	   the	   iron	  oxide/CdSe	  QDs	   complexes.	   (C)	   The	   STEM	   image	   and	   (D)	   EDAX	   analysis	   of	   iron	  oxide/CdSe@ZnS	  QDs	  complexes;	   the	  chemical	  components	  of	  Fe,	  Cd,	  Se,	  Zn	  and	  S	  were	  shown	  in	  the	  iron	  oxide/CdSe@ZnS	  QDs	  complexes.	  
	  
5.3.2. 	  Shape	  control	  of	  iron	  oxide/CdSe	  QD	  complexes	  
The	  versatile	  method	  that	  produced	  heterogeneous	  nucleation	  of	  QDs	  on	  iron	  oxide	   nanocrystals,	   also	   controlled	   both	   the	   shape	   (iron	   oxide	   studded	  with	   core	  CdSe	   QDs,	   core/shell	   CdSe@ZnS	   QDs,	   and	   CdSe	   quantum	   rods	   (QRs))	   and	   the	  composition	  (Figure	  5-­‐6).	   	  Various	  experimental	  reactions	  provided	  different	  types	  of	  iron	  oxide/QDs	  complexes	  such	  as	  core	  CdSe	  QDs	  and	  core/shell	  CdSe@ZnS	  QDs.	  	  For	   example,	   a	   zinc	   sulfide	   (ZnS)	   shell	   can	   be	   formed	  on	   iron	   oxide/CdSe	  QDs	   by	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modified	  the	  successive	  ion	  layer	  adsorption	  and	  reaction	  (SILAR)	  method62	  which	  resulted	  in	  CdSe@ZnS	  QDs	  attached	  magnetic	  material	  with	  a	  fluorescence	  quantum	  yield	   (PLQY)	   of	   about	   5	  %.	   	   The	   improved	   quantum	   yield	   could	   be	   due	   to	   a	   ZnS	  wider	  band	  gap	  effect.60-­‐62,281,282	  The	  ZnS	  shell	  that	  has	  a	  higher	  band	  gap	  than	  CdSe	  QDs,	  provides	  efficient	  quantum	  confinement	  of	  electron-­‐hole	  pair	   inside	   the	  core.	  	  Due	   to	   the	   high	   photochemical	   stability	   of	   the	   ZnS	   shell,	   core/shell	   QDs	   exhibit	  stronger	  luminescence	  and	  higher	  quantum	  yield	  (3	  times	  higher	  than	  that	  of	  core	  CdSe	  QDs).	   	   For	   biological	   and	   environmental	   applications,	   a	   ZnS	   coating	   on	  CdSe	  QDs	  protects	  from	  the	  possible	  release	  of	  toxic	  cadmium	  from	  CdSe	  QDs.	  In	  addition,	  optimized	   experimental	   conditions	   (reaction	   temperature	   and	   growth	   time)	  prepared	   CdSe	   QRs	   on	   iron	   oxide	   nanoparticle.	   The	   injection	   of	   Se-­‐TOP	   into	  CdO/iron	  oxide	  solution	  at	  200	  °C	  and	  a	  growth	  time	  of	  60	  minutes	  prepared	  CdSe	  QRs	  on	  iron	  oxide	  surface	  even	  though	  surfactants	  such	  as	  octadecylphosphonic	  acid	  (ODPA)283	  or	  hexylphosphonic	  acid	   (HPA)284,	  generally	   required	   for	  QR	   formation,	  were	  not	  added.	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  Figure	  5-­‐6	  Types	  of	  the	  iron	  oxide/QDs	  complexes.	  The	  TEM	  images	  of	  (A)	  iron	  oxide/CdSe	  QDs,	  (B)	  iron	  oxide/CdSe@ZnS	  QDs,	  and	  (C)	  iron	  oxide/CdSe	  QRs	   are	   shown.	  The	   iron	  oxide	  nanocrystal	  with	  12	  nm	  diameter	  was	   used	   as	   a	   core	   material.	   The	   diameter	   of	   CdSe	   QDs	   in	   (A)	   is	   3.5/4.4	   nm	  (width/length)	   and	   CdSe/ZnS	  QDs	   is	   4.9/6.7	   nm	   (width/length),	   respectively.	   The	  size	  of	  CdSe	  QRs	  (C)	  is	  3.7/7.8	  nm	  (width/length).	  The	  scale	  bars	  in	  A-­‐C	  were	  20	  nm.	  The	  CdSe	  QRs	  were	  prepared	  from	  long	  time	  growth	  of	  QDs.	  Some	  free	  QDs	  from	  the	  reaction	  are	  seen	  in	  the	  TEM	  images,	  but	  they	  can	  be	  removed	  by	  magnetic	  capture	  purification.	  	  All	  iron	  oxide/QDs	  complexes	  exhibited	  crystalline	  structure	  as	  shown	  in	  high-­‐resolution	  TEM	  images	  in	  D-­‐F.	  The	  scale	  bars	  in	  D-­‐F	  are	  5	  nm.	  
	  In	   these	   complexes,	   an	   increase	   in	   the	   diameter	   of	   iron	   oxide	   nanocrystals	  provided	  more	  nucleation	  sites	  for	  fluorescent	  QDs	  (Figure	  5-­‐7	  and	  Figure	  5-­‐8).	  	  In	  forming	  this	  complex,	  the	  effective	  lattice	  mismatch	  and	  the	  presence	  of	  coincidence	  lattice	   sites	   are	   important	   to	   promote	   the	   formation	   of	   hetero	   structures.273,274	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When	   the	   crystal	   structures	   are	   compatible	   and	   the	   lattice	   parameters	   of	   two	  crystalline	   phases	   are	   well	   matched,	   the	   core/shell	   nanostructures,	   such	   as	  CdSe/CdS	  QDs	  and	  CdSe/ZnS	  QDs	  are	   favored.60-­‐62,281,282	   	   If	   the	   lattice	  mismatch	   is	  large,	  the	  interfacial	  lattice	  strain	  may	  prevent	  the	  nucleation	  of	  the	  second	  material	  on	   the	   first	   material’s	   surface.	   	   Even	   with	   a	   large	   lattice	   mismatch,	   if	   preferred	  coincidence	  sites	  between	  two	  crystalline	  materials	  exist,	  then	  the	  hetero	  structure	  can	   be	   formed.109,272-­‐280	   We	   examined	   how	   the	   diameter	   of	   initial	   iron	   oxide	  controlled	   the	   number	   of	   nucleation	   sites	   of	   CdSe	   QDs	   (Figure	   5-­‐7).	   	   As	   the	   iron	  oxide	  core	  size	  increased,	  multiple	  nucleations	  of	  QDs	  occurred	  because	  of	  the	  large	  interfacial	  strain	  effect.	  	  As	  the	  initial	  size	  of	  iron	  oxide	  nanocrystals	  ranging	  from	  8	  to	  17	  nm	  increased,	  the	  numbers	  of	  nucleation	  sites	  of	  QDs	  also	  increased	  from	  4	  to	  10.	  	  As	  a	  result,	  more	  QDs	  nucleated	  and	  grew	  on	  multiple	  sites	  on	  larger	  iron	  oxide	  core.	  	  Also,	  since	  these	  iron	  oxide/QDs	  complexes	  maintained	  their	  innate	  magnetic	  and	   optical	   properties,	   they	   responded	  well	   to	   an	   external	   handheld	  magnet	   and	  showed	   red	   fluorescence	   under	   UV	   excitation	   (e.g.	   365	   nm)	   (Figure	   5-­‐9).	   	   The	  absorption	  (575	  nm,	  black)	  and	  emission	  (604	  nm,	  red)	  spectra	  also	  supported	  the	  sustained	  optical	  property	  of	  iron	  oxide/QDs	  complexes.	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  Figure	  5-­‐7	  The	  stoichiometry	  of	  iron	  oxide/QDs	  complexes	  (A-­‐D)	   shows	   the	   TEM	   images	   of	   monodisperse	   iron	   oxide	   nanocrystals	   with	  diameters	  of	  10	  nm,	  12	  nm,	  14	  nm,	  and	  17	  nm,	  respectively.	  The	  scale	  bars	  are	  20	  nm.	   (E-­‐H)	   indicates	   the	   TEM	   images	   of	   iron	   oxide/QDs	   complexes	   using	   different	  diameters	  of	   iron	  oxide	  nanocrystals	   from	  10	  nm	  to	  17	  nm.	  The	  scale	  bars	  are	  10	  nm.	   The	   number	   of	   nucleation/growth	   sites	   for	   QDs	   (4	   to	   10)	   directly	   increased	  with	  the	  diameter	  of	  iron	  oxide	  nanocrystals	  from	  10	  to	  17	  nm	  (A-­‐D).	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Figure	  5-­‐8	  The	  histograms	  of	  different	  iron	  oxide/QD	  complexes	  (A-­‐D)	  shows	  the	  size	  histograms	  of	  iron	  oxide	  nanocrystals	  with	  diameter	  of	  (A)	  10	  nm,	   (B)	   12	   nm,	   (C)	   14	   nm,	   and	   (D)	   17	   nm,	   respectively.	   (E-­‐F)	   described	   the	   size	  histograms	  of	  CdSe	  QDs	  in	  the	  complexes	  from	  4	  QDs	  per	  iron	  oxide	  to	  10	  QDs	  per	  iron	  oxide.	  	  The	  width/length	  of	  CdSe	  QDs	  in	  the	  complexes	  was	  (E)	  3.1/3.7	  nm,	  (F)	  3.2/4.0	  nm,	  (G)	  4.0/4.7	  nm,	  and	  (H)	  3.1/3.6	  nm,	  respectively.	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  Figure	  5-­‐9	  The	  optical	  and	  magnetic	  properties	  of	  iron	  oxide/QDs	  complexes.	  (A)	   The	   iron	   oxide/CdSe@ZnS	   QDs	   complexes	   were	   easily	   collected	   by	   handheld	  strong	  magnet.	   (B)	  The	   fluorescent	  emission	  was	  retained	   in	   the	  complexes	  under	  the	   ultraviolet	   light.	   	   (C)	   The	   absorption	   (575	   nm,	   black	   line)	   and	  photoluminescence	  (604	  nm,	  red	  line)	  spectra	  illustrate	  the	  optical	  property	  of	  the	  complexes.	  	  
5.3.3. Magnetic	  capture	  purification	  for	  the	  optimization	  
	  	  A	   simple	   magnetic	   capture	   process	   is	   an	   important	   step	   to	   measure	   the	  product	  yield	  of	  iron	  oxide/QDs	  complexes;	  the	  magnetic	  property	  of	  the	  complexes	  removed	   excess	   unbound	   QDs	   during	   purification	   (Figure	   5-­‐10).	   The	   removal	   of	  homogeneous	   QDs	   performed	   via	   a	   strong	   hand-­‐held	   magnet	   (NdFeB,	   1.25~1.28	  Tesla).	   For	   the	   calculation	   of	   the	   yields	   of	   complexed	  materials	   (iron	   oxide/QDs),	  magnetic	   capture	   efficiency	   (MCE)	  was	   used.	   MCE	   calculates	   the	   percent	   product	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yields	  with	  the	  Cd	  concentration	  of	  the	  magnetically	  captured	  materials	  to	  initial	  Cd	  concentration	   measured	   by	   ICP-­‐OES.	   This	   calculation	   was	   based	   how	   much	   Cd	  converted	  to	  the	  QDs	  attached	  on	  iron	  oxide	  nanoparticles.	  	  	  Figure	  5-­‐10	  shows	  the	  supernatant	  and	  magnetically	  captured	  solutions	  before	  and	  after	   this	  purification	  step.	   	   As	   the	   amount	   of	   unbound	   QDs	   decreased,	   fluorescence	   emissions	  sequentially	  decreased	  in	  the	  captured	  sample	  (complexed	  materials).	  	  From	  the	  bar	  graph,	  with	  the	  original	  Cd	  amounts	  of	  non-­‐captured	  sample	  regarded	  as	  100	  %,	  the	  supernatant	   Cd	   amounts	   of	   unbound	   QDs	   gradually	   decreased	   (from	   15	   to	   3	   %)	  during	   the	   magnetic	   purification.	   The	   MCE	   suggested	   a	   quantitative	   way	   to	  determine	   the	   yields	   of	   iron	   oxide/QDs	   complexes,	   in	   good	   comparison	   to	   TEM	  measurements	  (Figure	  5-­‐11).	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Figure	  5-­‐10	  The	  magnetic	  capture	  process.	  The	   photographs	   of	   supernatant	   solutions	   after	   1st,	   2nd,	   and	   3rd	  magnetic	   capture	  process	   under	   (A)	   the	   fluorescent	   light	   and	   (B)	   the	   ultraviolet	   light.	   	   The	  supernatants	  consist	  of	  unbound	  QDs	  in	  the	  solution.	  	  The	  photographs	  of	  captured	  samples	   after	   1st,	   2nd,	   and	   3rd	  magnetic	   capture	   process	   under	   (C)	   the	   fluorescent	  and	   (D)	   the	   ultraviolet	   light.	   	   The	   captured	   samples	   contained	   iron	   oxide/QD	  complexes	   with	   no	   unbound	   QDs.	   	   The	   unbound	   QDs	   decreased	   with	   multiple	  capturing	   processes.	   	   (E)	   The	   product	   yields	   of	   iron	   oxide/QDs	   complexes	   were	  determined	  via	  magnetic	  capturing	  process.	   	  The	  yields	   from	  1st	   to	  3rd	  capture	  are	  84	  %,	  74	  %,	  and	  68	  %,	  respectively.	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Figure	   5-­‐11	   The	   TEM	   images	   of	   iron	   oxide/CdSe	  QDs	   complexes	   during	  magnetic	  capture	  process	  The	   TEM	   images	   of	   iron	   oxide/CdSe	   QDs	   complexes	   were	   shown	   with	   (A)	   non-­‐captured,	   (B)	  1st	  magnetic	  capture,	   (C)	  2nd	  magnetic	  capture,	  and	  (D)	  3rd	  magnetic	  capture,	   respectively.	   	   As	   the	  magnetic	   capturing	   process	   increased,	   the	   unbound	  QDs	  were	   significantly	   reduced.	   	   Finally,	   purified	   iron	   oxide/CdSe	  QDs	   complexes	  were	  obtained.	   (E)	  The	  graph	  shows	   the	   relative	  percentages	  of	   the	  complexes	  by	  counting	  the	  numbers	  from	  the	  TEM	  images.	  The	  isolated	  iron	  oxide	  nanoparticles	  were	  not	  found	  in	  the	  TEM	  images.	  	  The	  scale	  bars	  are	  20	  nm.	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The	   iron	  oxide/QDs	  complexes	  had	  high	  productive	  yield	  depending	  on	   the	  optimized	   experimental	   conditions	   of	   high	   temperature	   (280	   °C),	   the	   additive	  (octadecylamine	  (ODA)),	  and	  the	  molar	  ratio	  between	  iron	  oxide	  and	  Cd	  precursor,	  as	  shown	  in	  	  Figure	  5-­‐12.	  	  The	  numerical	  values	  of	  product	  yield	  of	  iron	  oxide/QDs	  complexes	  were	  determined	  by	  MCE.	   	  Briefly,	  the	  growth	  temperature	  of	  280	  °C	  led	  to	  the	  highest	  product	  yield	  and	  promoted	  the	  formation	  of	  well-­‐defined	  structures.	  	  In	   fact,	   at	   the	   low	   temperatures	   (200-­‐230	   °C)	   QD	   precursors	   did	   not	   decompose	  fully	  and	  too	  high	  of	  a	   temperature	  (300	  °C)	   led	  to	  a	  high	  ratio	  of	  excess	  unbound	  QDs.	  	  	   In	   the	  second	  optimized	  condition,	   the	  use	  of	  ODA	  as	  an	  additive	   linked	  Cd	  precursors	  to	  the	  iron	  oxide	  surface,	  with	  15	  mmol	  of	  ODA	  giving	  the	  highest	  yield	  of	  complexes	   (72	   to	   89	   %).	   ODA	   is	   generally	   used	   as	   a	   ligand	   for	   high	  photoluminescence	  of	  core/shell	  nanocrystals	  because	  the	  alkylamine	  forms	  a	  weak	  and	   labile	   bond	   to	   the	   surface	   of	   the	   CdSe	   core	   and	   has	   good	   capping	   ability	   to	  prevent	   photo-­‐oxidation.61,62	   In	   this	   complex	   system,	   ODA	   helped	   to	   bind	   QD	  precursors	  to	  the	  surface	  of	  iron	  oxide	  with	  a	  hydrophobic	  interaction.	  	  	  Lastly,	  the	  molar	   ratio	   of	   iron	   oxides	   to	   Cd	   atoms	   was	   also	   optimized	   to	   minimize	   excess	  unbound	  QDs.	   	   In	   fact,	  when	  the	  molar	  ratio	  between	  iron	  oxide	  and	  Cd	  precursor	  increased	  from	  1:4	  to	  3:4,	  iron	  oxide/QD	  complexes	  were	  produced	  with	  high	  yields	  (up	  to	  72	  %).	   	  At	  the	  higher	  ratio	  over	  3:4,	  it	  kept	  the	  high	  yields	  of	  the	  complexes	  but	  excess	  isolated	  iron	  oxide	  nanoparticles	  were	  left,	  showing	  low	  PLQY	  value.	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  Figure	  5-­‐12	  The	  optimization	  of	  iron	  oxide/QDs	  complexes	  via	  magnetic	  capture.	  By	   magnetic-­‐capturing,	   the	   iron	   oxide/QDs	   complex	   formation	   can	   be	   optimized.	  The	  product	  yields	  are	  shown	  at	  (A)	  the	  initial	  temperatures	  from	  200	  °C	  to	  300	  °C,	  (B)	  the	  amounts	  of	  octadecylamine	  (ODA),	  and	  (C)	  the	  molar	  ratio	  of	  iron	  oxide/Cd.	  	  (D)	   The	   solvents,	   (E)	   the	   surfactant	   compositions,	   and	   (F)	   the	   injection	   speeds	  contributed	  to	  the	  reaction	  of	  complexes.	  	  The	  solvents	  included	  phenyl	  ether	  (PE),	  1-­‐octadecene	   (ODE),	   and	  1-­‐hexadecane	   (HDE).	   	  The	  numerical	   values	   are	   given	   in	  Table	  5-­‐1.	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The	   highest	   product	   yields	   (about	   80-­‐89	   %)	   of	   the	   complexes	   were	   also	  optimized	   by	   pure	   iron	   oxide	   (without	   excess	   oleic	   acid)	   and	   right	   surfactant	  compositions	  with	   longer	   carbon	   chain	   surfactant	   (ODA)	   (	  Figure	  5-­‐12	   (E),	   Figure	  5-­‐13,	  and	  Figure	  5-­‐14).	  	  The	  nucleation	  of	  QDs	  on	  preformed	  iron	  oxide	  nanocrystals	  only	  occurred	  when	  the	  iron	  oxide	  surface	  was	  completely	  purified	  from	  excess	  iron	  salts	   and	   oleic	   acid.	   	   Unpurified	   iron	   oxide	  materials	   prevented	   the	   nucleation	   of	  secondary	   crystalline	   formation	   of	   QDs	   on	   the	   surface	   and	   promoted	   the	  homogenous	  nucleation	  of	  QDs	  instead	  (Figure	  5-­‐13).	  	  Furthermore,	   surfactant	   composition	   affected	   the	   formation	   of	   the	   iron	  oxide/QDs	  complexes	   (	  Figure	  5-­‐12	   (E)	  and	  Figure	  5-­‐14).	   	   For	  example,	  oleic	   acid	  (OA)	  irreversibly	  coated	  and	  interfered	  with	  the	  existing	  OA	  stabilizer	  of	  iron	  oxide	  so	   that	   OA	   blocked	   the	   deposition	   and	   nucleation	   of	   QDs	   on	   iron	   oxide	   surface.	  Instead	   of	   OA,	   the	   organoamine	   surfactant,	   ODA	   or	   hexadecylamine	   (HDA),	   was	  introduced	  to	  conjugate	  the	  QDs	  to	  iron	  oxide	  surface,	  providing	  a	  good	  passivation	  and	  chemical	   stability	   to	   the	   surface.	   	   In	   comparison	  with	  HDA,	  ODA	  had	  a	   longer	  hydrophobic	   chain	   and	   showed	   even	   higher	   yields	   than	   HDA.	   	   Yet,	   adding	  trioctylphosphine	  oxide	  (TOPO)	  as	  a	  co-­‐surfactant,	  the	  product	  yields	  (74	  %	  and	  70	  %)	  were	   lower	  than	  that	  of	  ODA	  (85	  %)	  or	  HDA	  (71	  %).	  Organoamines	  and	  TOPO	  did	   not	   interfere	   each	   other	   but	   it	   may	   have	   competed	   for	   the	   binging	   sites	  producing	  some	  defects	  on	  the	  surface	  (Figure	  5-­‐14).	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Figure	  5-­‐13	  The	  purity	  of	  iron	  oxide	  nanocrystals	  for	  iron	  oxide/QD	  complexes	  (A)	   and	   (B)	   show	   the	  TEM	   images	  of	   iron	  oxide/QDs	  mixtures	  using	   incompletely	  purified	   iron	   oxide	   (twice	   washing)	   and	   completely	   purified	   iron	   oxide	   (6	   times	  washing),	   respectively.	   (C)	   described	   the	   product	   yields	   of	   iron	   oxide/QDs.	   The	  yields	  are	  16	  %	  (A)	  and	  83	  %	  (B),	  respectively.	  	  The	  scale	  bars	  are	  20	  nm.	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  Figure	   5-­‐14	   The	   TEM	   images	   of	   iron	   oxide/QD	   mixtures	   with	   various	  surfactants	  (A)	   and	   (B)	   show	   the	  TEM	   images	   of	   iron	   oxide/QDs	  mixtures	   in	   the	   presence	   of	  oleic	  acid	  (OA)/octadecylamine	  (ODA)/1-­‐octedecence	  (ODE)	  and	  only	  ODE	  without	  OA	  and	  ODA,	  respectively.	  The	  yields	  of	  captured	  iron	  oxide/QDs	  were	  (A)	  3	  %	  and	  (B)	   11	   %,	   respectively.	   	   (C)	   and	   (D)	   show	   the	   TEM	   images	   of	   iron	   oxide/QDs	  complexes	   using	   ODA/ODE	   and	   ODA/ODE/trioctylphosphine	   oxide	   (TOPO),	  respectively.	   	   The	   yields	   were	   (C)	   85	  %	   and	   (D)	   74	  %,	   respectively.	   	   (E)	   and	   (F)	  indicate	   the	   TEM	   images	   of	   iron	   oxide/QD	   complexes	   in	   the	   presence	   of	  hexadecylamine	   (HDA)/ODE	   and	  HDA/TOPO/ODE.	   	   The	   yields	   of	   complexes	  were	  (E)	  71	  %	  and	  (F)	  70	  %,	  respectively.	  	  The	  scale	  bars	  are	  20	  nm.	  
	   210	  	  
Another	   sensitive	   function	   to	   obtain	   improved	   product	   yield	   of	   iron	  oxide/QDs	   complexes	   was	   the	   slow	   and	   drop-­‐wise	   addition	   of	   Se-­‐TOP	   at	   high	  temperature	  (	  Figure	  5-­‐12	  (F)	  and	  Figure	  5-­‐15).	  	  	  Figure	  5-­‐12	  (F)	  shows	  the	  product	  yields	   of	   the	   complex	   depending	   on	   the	   addition	   speed	   of	   Se-­‐TOP	   into	   the	   iron	  oxide/CdO	  solution.	  A	  fast	  and	  burst	  injection	  (2	  ml/sec)	  caused	  a	  fast	  homogeneous	  nucleation	  of	  CdSe	  QDs	  rather	  than	  a	  passive	  continuous	  growth	  of	  QDs	  on	  the	  iron	  oxide.	   	   However,	   a	   slow	   and	   drop-­‐wise	   addition	   of	   Se	   precursor	   (0.4	   ml/min)	  minimized	  the	  formation	  of	  homogeneous	  QD	  nucleation,	  with	  optimized	  formation	  (46-­‐76	  %),	  to	  let	  QDs	  deposit	  and	  nucleate	  on	  the	  iron	  oxide	  surface.	  	  By	  decreasing	  rate	  of	  addition	  of	  Se	  precursor	  slowly	  deposited	  QDs	  on	   iron	  oxide	  surface.	   	  As	  a	  result,	  QDs	  nucleated	  and	  grew	  continually	  on	  the	  specific	  sites	  of	   iron	  oxide	  even	  though	   large	   interfacial	   strain	   and	   lattice	  mismatch	   effect	   is	   possible.	   	   This	   lattice	  mismatch	  and	  strain-­‐induced	  contribution	  depends	  on	  the	  presence	  of	  defects	  and	  dislocations	  of	   the	   surface,	  which	  may	  vary	  under	   the	   conditions	   tested	   (purity	  of	  iron	  oxide,	  surfactant	  compositions,	  speed	  of	  Se-­‐TOP	  addition,	  and	  etc.).	  The	  product	  yields	  of	  iron	  oxide/QDs	  complexes	  were	  quantitatively	  measured	  by	  MCE	  and	  were	  listed	  in	  Table	  5-­‐1.	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  Figure	  5-­‐15	  The	  TEM	  images	  of	  iron	  oxide/QD	  complexes	  with	  slow	  and	  fast	  injections	  at	  different	  molar	  ratios	  (A-­‐D)	   The	   TEM	   images	   of	   iron	   oxide/QDs	   complexes	   with	   slow	   injection	   at	   the	  different	  molar	  ratio	  (iron	  oxide/CdO/Se-­‐TOP=	  1:3:6	  (A),	  1:3:9	  (B),	  1:3:15	  (C),	  and	  1:3:30	  (D));	  the	  slow	  injection	  showed	  the	  good	  attachment	  of	  QDs	  on	  the	  iron	  oxide	  surface.	  The	  yields	  of	  iron	  oxide/QDs	  complexes	  from	  (A)	  to	  (D)	  were	  76,	  87,	  55,	  and	  46	  %,	   respectively.	   (E-­‐H)	  The	  TEM	   images	  of	   iron	  oxide/QDs	   complexes	  with	   fast	  injection	  at	  the	  different	  molar	  ratio	  (iron	  oxide/CdO/Se-­‐TOP	  =	  1:3:6	  (E),	  1:3:9	  (F),	  1:3:15	  (G),	  and	  1:3:30	  (H));	  the	  fast	  injection	  showed	  the	  poor	  attachment	  of	  QDs	  on	  iron	  oxide	  surface.	  The	  yields	  from	  (E)	  to	  (H)	  were	  42,	  24,	  17,	  and	  7	  %,	  respectively.	  	  The	  scale	  bars	  are	  20	  nm.	  




	   212	  	  
	  
Table	  5-­‐1	  Magnetic	  capture	  efficiency	  (%)	  of	  the	  iron	  oxide/CdSe	  QDs	  complexes	  at	  various	  conditions	  
Sample	   Magnetic	  Capture	  (Yield	  %)	   Molar	  ratio	  (iron	  oxide:	  Cd:Se)	   Molar	  ratio	  (iron	  oxide/Cd)	   Slow	  injection	   Fast	  injection	   Initial	  Temparature	  (degree	  C)	   OA(g)	   ODA	  (g)	   HDA(g)	   TOPO	  (g)	   ODE(g)	   PE	  (g)	   HDE	  (g)	  
1	   17	   1:3:9	   1:3	   O	   	   200	   	   4	   	   	   10	   	   	  2	   24	   1:3:9	   1:3	   O	   	   230	   	   4	   	   	   10	   	   	  3	   75	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  4	   40	   1:3:9	   1:3	   O	   	   300	   	   4	   	   	   10	   	   	  5	   10	   1:3:9	   1:3	   O	   	   280	   	   2	   	   	   10	   	   	  6	   23	   1:3:9	   1:3	   O	   	   280	   	   3	   	   	   10	   	   	  7	   72	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  8	   43	   1:3:9	   1:3	   O	   	   280	   	   6	   	   	   10	   	   	  9	   25	   1:4:12	   1:4	   O	   	   280	   	   4	   	   	   10	   	   	  10	   38	   1:2:6	   1:2	   O	   	   280	   	   4	   	   	   10	   	   	  11	   71	   3:4:12	   3:4	   O	   	   280	   	   4	   	   	   10	   	   	  12	   10	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   	   10	   	  13	   89	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  14	   23	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   	   	   10	  15	   3	   1:3:9	   1:3	   O	   	   280	   1	   4	   	   	   10	   	   	  16	   11	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  17	   85	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  18	   74	   1:3:9	   1:3	   O	   	   280	   	   4	   	   2	   10	   	   	  19	   71	   1:3:9	   1:3	   O	   	   280	   	   	   4	   	   10	   	   	  20	   70	   1:3:9	   1:3	   O	   	   280	   	   	   4	   2	   10	   	   	  21	   76	   1:3:6	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  22	   87	   1:3:9	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  23	   55	   1:3:15	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  24	   46	   1:3:30	   1:3	   O	   	   280	   	   4	   	   	   10	   	   	  25	   42	   1:3:6	   1:3	   	   O	   280	   	   4	   	   	   10	   	   	  26	   24	   1:3:9	   1:3	   	   O	   280	   	   4	   	   	   10	   	   	  27	   17	   1:3:15	   1:3	   	   O	   280	   	   4	   	   	   10	   	   	  28	   7	   1:3:30	   1:3	   	   O	   280	   	   4	   	   	   10	   	   	  OA-­‐oleic	  acid	  (C18H34O2)	  ODA-­‐octadecylamine	  (CH3(CH2)17NH2)	  HDA-­‐hexadecylamine	  (C16H35N)	  TOPO-­‐trioctylphosphine	  oxide	  ([CH3(CH2)7]3PO)	  ODE-­‐1-­‐octadecene	  (CH2=CH(CH2)15CH3)	  PE	  –	  phenyl	  ether	  (C12H10O)	  HDE-­‐	  1-­‐hexadecene	  (C16H34)	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5.3.4. 	  Quantitative	  PLQY	  measurements	  of	  iron	  oxide/QD	  complex	  
The	  synthesized	   iron	  oxide/QD	  complexes	   still	  maintained	  optical	  property	  even	   though	   QDs	   were	   attached	   on	   the	   surface	   of	   an	   iron	   oxide	   nanocrystal.	  However,	   the	   PLQY	   of	   the	   QDs	   in	   the	   complexes	   is	   an	   order	   of	   magnitude	   (1/8)	  lower	   than	   that	   of	   pure	   QDs	   because	   QDs	   were	   attached	   directly	   to	   iron	   oxide	  nanocrystals.	  Figure	  5-­‐16	  shows	   the	   results	  of	  PLQY	  of	   iron	  oxide/QDs	  complexes	  and	   isolated	  QDs.	   	   Iron	  oxide/QDs	   complexes	  had	   relatively	   lower	  PLQY	   (1~3	  %)	  than	  stand	  alone	  QDs	  (10~20	  %).	  Because	  of	  the	  direct	  contact	  to	  the	  metal	  surface,	  the	   metal	   nanoparticles	   quench	   the	   fluorescence	   of	   QDs	   gradually.70,75,76	   Many	  researchers	  reported	  the	  PLQY	  value	  of	  the	  magnetic-­‐QD	  materials	  ranging	  from	  2	  to	  38	  %.83,87,90,109,277-­‐280	  	  	  In	  a	  seed-­‐mediated	  method,	  excess	  unbound	  QDs	  may	  affect	  the	   PLQY	   value.	   Therefore,	   we	   developed	   the	   MCE	   method	   to	   separate	   iron	  oxide/QDs	   complex	   only	   and	   used	   it	   before	   measuring	   PLQY	   value	   in	   order	   to	  eliminate	  excess	  QDs	  neighboring	  effect.	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Figure	  5-­‐16	  The	  PLQY	  of	  iron	  oxide/QDs	  complexes.	  The	  PLQY	  values	  of	  iron	  oxide/QDs	  complexes	  at	  (A)	  the	  type	  of	  QD,	  (B)	  the	  number	  of	  QD	  per	   iron	  oxide,	  and	   (C)	   surfactant	   composition.	   	  The	  deposition	  of	  ZnS	  shell	  onto	  CdSe	  QDs	  improved	  the	  PLQY	  to	  5	  %.	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The	   iron	   oxide/QDs	   (CdSe	   QRs	   and	   CdSe	   QDs)	   complexes	   have	   low	   PLQY	  coming	  from	  structural	  effect.	  	  However,	  the	  PLQY	  was	  enhanced	  by	  the	  deposition	  of	  a	  ZnS	  shell	  on	  the	  complex.	  	  	  Generally,	  the	  quantum	  yield	  of	  CdSe	  QRs	  (1-­‐3	  %)	  is	  much	   lower	   than	   that	   of	   CdSe	   QDs	   (10-­‐20	   %).285,286	   Due	   to	   quenching	   effect	   of	  metallic	   iron	  oxide,	   the	  PLQY	  of	   iron	  oxide/CdSe	  QRs	  complexes	  was	  0.1	   to	  0.5	  %,	  which	  is	  much	  lower	  than	  that	  of	  iron	  oxide/CdSe	  QDs	  complexes	  (1-­‐3	  %).	  	  Although	  the	  iron	  oxide/QDs	  complexes	  have	  a	  low	  quantum	  yield	  (<	  3	  %),	  the	  deposition	  of	  ZnS	   shell	  would	  protect	   the	  CdSe	  QDs	  on	   iron	  oxide	   chemically	   and	   improved	   the	  PLQY	  up	  to	  5	  %	  (Figure	  5-­‐16A).	   	   If	  the	  shell	  has	  a	  higher	  band	  gap	  than	  CdSe	  core	  and	   the	  band	  offsets	  of	   the	   core/shell	   structures	   are	   type	   I	   (where	   the	   core	  has	   a	  lower	   conduction	   band	   and	   a	   higher	   valence	   band	   in	   comparison	   to	   those	   of	   the	  shell),	   the	   photon	   generating	   an	   electron	   and	   hole	   inside	   the	   nanocrystals	   are	  mostly	   confined	   in	   the	   core.281	   	   Therefore,	   core/shell	   QDs	   exhibit	   enhanced	   PLQY	  and	  are	  more	  stable	  against	  photooxidation.	  	  	  For	  CdSe	  QDs	  (band	  gap	  1.75	  eV),	  the	  CdS	  (2.5	  eV),	  ZnS	  (3.7	  eV),	  or	  ZnSe	  (2.7	  eV)	  which	  have	  higher	  band	  gaps	  can	  be	  used	  as	  shell	  materials	  with	  small	   lattice	  mismatch.60,61,282,287	  In	  the	  complex,	  although	  a	  ZnS	  shell	  gives	  an	  environmentally	  stable	  surface	  to	  prevent	  the	  release	  of	  toxic	  Cd	  to	  the	  outside,	  multilayered	  ZnS	  shells	  were	  not	  successful	  due	  to	  large	  lattice	  strain	  effect	  (data	  not	  shown).	  	  	  	  	  	  Furthermore,	   both	   the	   number	   of	   QDs	   per	   iron	   oxide	   and	   surfactant	  composition	  also	  affected	  the	  PLQY	  value	  of	  iron	  oxide/QDs	  complexes	  (Figure	  5-­‐16	  (B)	  and	  (C)).	  	  	  As	  shown	  in	  Figure	  5-­‐16	  (B),	  the	  PLQY	  value	  slightly	  decreased	  as	  the	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number	   of	   QD	   per	   iron	   oxide	   increased.	   Though	   not	   entirely	   understood,	   we	  speculate	  that	  many	  nucleation/growth	  of	  QDs	  on	  certain	  surface	  area	  may	  produce	  more	   defects	   and	   dislocations,	   leading	   to	   self-­‐quenching	   effect	   in	   both	   iron	  oxide/CdSe	   QDs	   and	   iron	   oxide/CdSe@ZnS	   QDs	   systems.	   	   Figure	   5-­‐16	   (C)	   shows	  that	   ODA	   surfactant	   gave	   the	   highest	   PLQY	   value	   (~5	  %).	   	   However,	   addition	   of	  TOPO	  as	  a	  co-­‐surfactant	  may	  displace	  and	  form	  a	  competitive	  bonding	  of	  QDs	  to	  the	  iron	  oxide	  surface	  forming	  the	  defects.	   	  As	  a	  result,	  the	  PLQY	  was	  low	  in	  both	  core	  (0.7~1	  %)	  and	  core@shell	  iron	  oxide/QDs	  complexes	  (2~3	  %)	  comparing	  to	  those	  of	   ODA	   (5	  %)	   and	  HDA	   (4.5	  %)	   stabilized	   complexes.	   	   In	   short,	   the	   organoamine	  surfactants	   (ODA	   and	   HDA)	   gave	   the	   most	   favorable	   environment	   for	   the	  nucleation/growth	  of	  CdSe	  QDs	  and	  CdSe@ZnS	  QDs.	  	  	  	  
5.4. 	  Conclusion	  
In	  summary,	  we	  have	  synthesized	  nanoscale	  iron	  oxide/QDs	  complexes	  using	  high	  temperature	  decomposition	  of	  QD	  precursors.	  Under	  optimized	  conditions,	  the	  nucleation	   of	   metal	   chalcogenides	   occurred	   only	   on	   preformed	   iron	   oxide	  nanocrystals.	   The	   increase	   of	   the	   diameter	   of	   iron	   oxide	   nanocrystals	   promoted	  more	   nucleation	   sites	   for	   fluorescent	   QDs	   in	   these	   complexes.	   The	   purification	   of	  iron	  oxide/QD	  complexes,	  through	  a	  magnetic	  capture	  process,	  allowed	  us	  to	  tailor	  the	  synthetic	  conditions	  in	  order	  to	  minimize	  excess	  unbound	  QDs	  formation.	  Even	  though	  the	  PLQY	  of	  the	  QDs	  in	  these	  complexes	  is	  an	  order	  of	  magnitude	  lower	  than	  that	  of	  pure	  QDs,	  the	  PLQY	  of	  these	  complexes	  was	  greatly	  improved	  by	  a	  ZnS	  shell	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in	   comparison	   to	   those	   in	   the	   literature.	   	  Moreover,	   the	   PLQY	  of	   these	   complexes	  was	   a	   sensitive	   function	   of	   the	   number	   of	   QD	   per	   iron	   oxide,	   type	   of	   QD,	   and	  surfactant	   stabilizer.	   The	   combination	   of	   optical	   and	  magnetic	   properties	   in	   these	  nanoscale	   iron	   oxide/QDs	   complexes	   make	   it	   possible	   to	   tailor	   the	   synthesis	   for	  potential	  biological	  applications,	  such	  as	  specific	  cell	  separation	  and	  drug	  delivery.	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Chapter 6	  
A strategy for Visualizing Magnetic 
Separations: QDs/Iron Oxide Materials  
Real-­‐time	  quantification	  and	  visualization	  of	  magnetic	  separation	  processes	  involving	   nanoscale	   particles	   can	   be	   a	   challenge	   as	   these	  magnetic	  materials	   lack	  optical	  signatures.	  Here	  we	  address	  this	  problem	  by	  forming	  magnetic	  nanocrystals	  with	   quantum	   dots	   (QDs)	   materials	   affixed	   to	   their	   surfaces.	   These	   materials,	  termed	  here	  magnetic-­‐optical	  complexes,	  consist	  of	  iron	  oxide	  cores	  decorated	  with	  smaller	   cadmium	   selenide	   (CdSe	   core)	   or	   cadmium	   selenide/zinc	   sulfide	   QDs	  (CdSe/ZnS	   core	   shell).	   	   Once	   nucleated	   on	   the	   surface	   of	   iron	   oxide	   nanocrystals,	  QDs	   can	   be	   grown	   to	   diameters	   that	   provide	   tunable	   emission	   throughout	   the	  visible.	   	   After	   phase	   transfer,	   the	   resulting	   aqueous	   suspensions	   of	   the	  magnetic-­‐optical	  complexes	  were	  fluorescent	  (quantum	  yields	  of	  1	  –	  5	  %)	  over	  a	  range	  of	  pH,	  ionic	   strength,	   and	  buffer	   conditions.	  The	   size-­‐dependent	   separation	  of	   iron	  oxide	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cores	  could	  be	  easily	  visualized	  as	  larger	  magnetic	  cores	  tagged	  with	  red	  QDs	  came	  to	   dominate	   emission	   in	   the	  magnetic	   fraction	   of	   a	   starting	  mixture	   that	   included	  smaller	   cores	   tagged	   with	   green	   QDs.	   Additionally,	   optical	   detection	   could	   be	  applied	  to	   the	  problem	  of	  detecting	  small	  amounts	  material	  collected	  magnetically	  onto	  surfaces	  from	  dilute	  suspensions.	  	  For	  example,	  while	  sub	  nanomolar	  solutions	  of	   complexes	   had	   no	   detectable	   emission,	   complex	   emission	   could	   be	   quantified	  from	  surfaces	  used	  for	  magnetic	  collection	  and	  pre-­‐concentration.	  	  
6.1. 	  Introduction	  
The	  combination	  of	  magnetic	  and	   fluorescent	  properties	   in	  one	  nanocrystal	  has	   been	   recognized	   as	   an	   important	   goal	   for	   nano	   chemistry	   with	   applications	  ranging	   from	   material	   science	   to	   biotechnology.33,36,111,112,226-­‐228,232,234,288	   Such	  complexes	   have	   been	   applied	   to	   in	   vitro	   and	   in	   vivo	   cell	   imaging	   with	   MRI,	   drug	  delivery,	   analytical	   multi-­‐cells	   tracking,	   sorting,	   manipulation,	   and	  separations.68,72,73,82,107,108,209,211,237,240-­‐242,262,289-­‐294	  	  Of	  specific	  interest	  in	  this	  work	  is	  the	   development	   of	   materials	   that	   can	   allow	   for	   the	   visualization	   of	   magnetic	  separation	   processes.	   	   External	  magnetic	   fields	   can	   be	   used	   to	   separate	  magnetic	  materials,	   including	   nanocrystals,	   from	   stable	   dispersions.	   This	   principle	   is	   at	   the	  heart	  of	  the	  use	  of	  larger	  magnetic	  beads	  in	  bioanalytical	  applications,	  and	  has	  also	  motivated	  the	  use	  of	  smaller	  nanocrystals	   in	  magnetic	  cell	  sorting,	  separation,	  and	  enrichment.108,237,238,240,288	  By	   including	  a	   fluorescent	  probe	  such	  as	  an	  organic	  dye	  or	  quantum	  dot	  on	  the	  particle,	  visualization	  capability	  allows	  easy	  detection	  of	  the	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target	   molecules.68,73,107,209,242,245,293	   For	   example,	   Wang	   et	   al	   used	  superparamagnetic	  Fe2O3	  bead	  binding	  with	  CdSe/ZnS	  QDs	   to	  separate	  and	  detect	  MCF-­‐7	  breast	  cancer	  cells	  from	  serum.289	  	  Also,	  fabricated	  mesoporous	  dye-­‐dopped	  silica	  nanocrystals	  immobilized	  with	  multiple	  magnetic	  nanocrystals	  may	  be	  applied	  simultaneously	  to	  enhance	  cell	  detection	  with	  MRI,	  fluorescence	  imaging,	  and	  drug	  delivery.72	  	  
Currently,	  most	  researchers	  have	  generated	  magnetic-­‐fluorescent	  complexes	  by	   relying	   on	   the	   encapsulation	   magnetic	   and	   optical	   components	   into	   a	   larger	  structure.70,74,244,247,250-­‐252,254-­‐259,261,295-­‐297	   	   What	   results	   are	   normally	   micron-­‐sized	  polymer	   or	   silica	   beads	  which	   contain	   internally	   the	   active	   nanostructures.	   Using	  such	  materials,	  specific	  target	  (e.g.	  therapeutic	  cells,	  lectins,	  and	  drugs)	  sorting	  and	  detection	   with	   fluorescence	   have	   been	   reported.74,295	   It	   is	   also	   possible	   to	   enrich	  samples	  with	  one	  magnetic	  fraction	  and	  visualize	  this	  by	  fluorescence.247,250,290,298,299	  By	   incorporating	  QDs	  with	   tailored	   emission	   colors,	   it	   is	   also	  possible	   to	   optically	  encode	  materials	   for	  multiplexed	   detection.24,65-­‐67,300,301	   	   This	   work	   illustrates	   the	  great	  value	  of	  combining	  optical	  emission	  with	  magnetic	  responsiveness;	  however,	  the	   strategies	   adopted	   to	  mix	   optical	   and	  magnetic	  materials	   in	   larger	   structures	  cannot	  easily	   translate	   to	   the	  separation	  of	   single	  nanocrystals	  with	  much	  smaller	  diameters.	  	  	  	  	  
To	  address	   the	   specific	   challenge	  of	   creating	  magnetic-­‐optical	   complexes	  of	  small	   diameter	   	   (e.g.	   <	   25	  nm),	   several	   groups	   have	  developed	   strategies	   to	   grow	  emissive	   quantum	   dots	   (QDs)	   directly	   on	   magnetic	   nanocrystals.83,87-­‐89,109,265-­‐
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267,273,276-­‐278,302-­‐305	   	   The	   process	   relies	   on	   the	   nucleation	   of	   QDs	   onto	   iron	   oxide	  surfaces	  and	  can	  provide	  for	  highly	  controlled	  QD	  growth	  and	  hence	  a	  wide	  range	  of	  well-­‐defined	  emission	  colors.83,87,88,276,277,303,304	  While	  this	  direct	  nucleation	  process	  has	  the	  downside	  of	  lowering	  QD	  quantum	  yields	  as	  compared	  to	  isolated	  products,	  because	  multiple	  QD	  attach	  to	  a	  single	  particle	  it	  can	  still	  be	  a	  very	  bright	  object	  with	  stable	  emission	  relatively	   insensitive	   to	  bleaching.	   	  Applications	  of	   these	  materials	  to	  visualizing	  magnetic	  separations	  in	  relevant	  biological	  environments	  have	  not	  yet	  been	  reported.	  
Several	  materials	  issues	  must	  be	  addressed	  to	  realize	  this	  goal.	  	  Certainly,	  as	  is	   true	   for	   the	   larger	   beads	   it	   is	   important	   to	   be	   able	   to	   tag	   different	   kinds	   of	  magnetic	   materials	   with	   different	   colors	   to	   offer	   multiplexed	   optical	  detection.67,70,74,295	  Also	  possible	  is	  the	  ability	  to	  do	  multiplexed	  separation,	  or	  to	  in	  one	  separation	  collect	  several	  material	  fractions	  simply	  by	  varying	  the	  applied	  field	  strength.306-­‐308	   	   Colloidal	   stability	   is	   also	   a	   critical	   issue;	   the	   complexes	   must	   be	  coated	  with	   the	   appropriate	   polymers	   to	   allow	   for	   non-­‐bleaching	   QD	   emission	   as	  well	   as	   non-­‐aggregation	   in	   biological	   media.109,278	   Finally,	   the	   size	   dependent	  magnetic	   properties	   of	   the	   complex	   suggest	   great	   advantages	   in	   multiple	   cells	  separation	   and	   enrichment	   because	   of	   its	   selectivity	   and	   sensitivity	   to	   a	  magnetic	  response.	  	  In	   this	   work	   we	   applied	   strategies	   to	   form	   nanoscale	   magnetic-­‐optical	  complexes	   of	   iron	   oxide	   and	   quantum	   dots	   (QDs)	   to	   developing	   water-­‐soluble	  materials	   that	   allowed	   for	   the	   visualization	   of	   magnetic	   separations.	   	   Briefly,	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purified	   iron	   oxide	   nanocrystals	  were	   used	   as	   nucleation	   sites	   for	   QDs	   leading	   to	  iron	  oxide	  crystallites	  studded	  with	  one	  or	  more	  QDs.	  	  The	  resulting	  complexes	  were	  highly	  uniform,	  tunable	  in	  both	  core	  and	  QD	  dimensions,	  with	  striking	  pin-­‐cushion	  type	   structures.	   	   High-­‐resolution	   TEM	   and	   EELS	   data	   reveal	   that	   the	  QDs	   directly	  nucleate	   at	   the	   interface	   of	   the	   iron	   oxide	   crystallite,	   and	   that	   these	   nanocrystals	  grow	   steadily	   over	   time.	   	   The	  distinctive	   fluorescence	   emission	  of	   the	  QDs	   can	  be	  tailored	  through	  the	  manipulation	  of	  the	  reaction	  time,	  and	  quantum	  yields	  can	  be	  optimized	   through	   the	   addition	   of	   ZnS	   shells.	   	  Water-­‐soluble	   complexes	   could	   be	  formed	   using	   a	   variety	   of	   amphiphilic	   polymers	   in	   a	   conventional	   phase	   transfer	  process.	   	   Applications	   of	   these	  materials	   in	   a	  multiplexed	  magnetic	   separation	   as	  well	  as	  a	  magnetic	  enrichment	  are	  demonstrated.	  	  	  
6.1. 	  Experimental	  sections	  
6.1.1. 	  Chemicals	  
Iron	  oxide,	  hydrate	   (FeO(OH),	  30-­‐50	  mesh),	  oleic	  acid	   (OA,	   technical	  grade,	  90	  %),	  1-­‐octadecene	  (ODE,	  technical	  grade	  90	  %),	  cadmium	  oxide	  (CdO,	  99.99	  %),	  selenium	   (Se,	   99.99	   %),	   sulfur	   (S,	   99.5	   %),	   zinc	   oxide	   (ZnO,	   99.99	   %)	   ,	  trioctylphosphine	  oxide	  (TOP,	  technical	  grade	  90	  %),	  and	  octadecylamine	  (ODA,	  97	  %)	   were	   all	   purchased	   from	   Sigma-­‐Aldrich.	   	   All	   nanocrystals	   were	   synthesized	  under	   ultra-­‐high	  purity	   nitrogen	   (N2	  ,	   99.99	  %).	  Hexanes	   (95	  %),	   acetone	   (99	  %),	  ethanol	   (99.5	   %),	   and	   methanol	   (99	   %)	   were	   obtained	   from	   Sigma-­‐Aldrich.	   All	  chemicals	  were	  used	  as	  received.	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6.1.2. 	  Synthesis	  of	  iron	  oxide	  nanoparticles	  
The	  iron	  oxide	  nanocrystals	  were	  synthesized	  based	  on	  the	  previous	  work.51	  Specifically,	   0.178	   g	   of	   FeO(OH)	   was	   added	   to	   2.26	   g	   oleic	   acid	   and	   5	   g	   of	   1-­‐octadecene	  and	  this	  mixture	  was	  heated	  to	  120	  °C	  for	  2	  hours	  to	  evaporate	  residual	  water.	  The	  temperature	  further	  increased	  to	  260	  °C	  for	  30	  minutes.	  During	  this	  time	  the	   iron	   oxyhydroxide	   dissolved	   and	   formed	   iron-­‐oleate	   precursors.	   Finally,	   the	  mixture	  was	  allowed	  to	  reflux	  at	  320	  °C	  for	  2	  hours	  and	  the	  solution	  became	  black.	  
The	   iron	   oxide	   nanocrystals	   were	   purified	   and	   concentrated	   by	   first	  precipitating	  the	  product	  using	  methanol	  and	  acetone	  followed	  by	  centrifugation	  at	  4150	   rpm	   for	   30	   minutes	   (5	   ml	   colloidal	   solution,	   20	   ml	   methanol,	   and	   20	   ml	  acetone).	   This	   process	  was	   repeated	   5	   to	   6	   times	   resulting	   in	   purified	   iron	   oxide	  nanocrystal	   solutions	   with	   minimal	   residual	   surfactants.	   The	   purification	   step	   is	  very	  important	  to	  make	  QD/iron	  oxide	  magnetic-­‐optical	  complexes	  since	  unpurified	  iron	   oxide	   nanocrystals	   may	   prevent	   the	   nucleation	   and	   growth	   of	   QDs	   on	   the	  surface	   of	   iron	   oxide	   nanocrystals.	   The	   purified	   iron	   oxide	   solution	  was	   stored	   in	  hexanes	   at	   a	   concentration	   typically	   of	   6,000	   mg/L.	   Typically,	   nanocrystals	  diameters	  was	  10	  nm	  (±	  1.5	  nm).	  	  The	  larger	  iron	  oxide	  nanocrystals	  (17	  nm)	  were	  prepared	  by	  increasing	  the	  amount	  of	  oleic	  acid	  relative	  to	  iron	  (FeOOH:	  oleic	  acid	  =	  1:5).	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6.1.3. Synthesis	  of	  iron	  oxide/CdSe	  QD	  nanoparticles	  
CdO	  (0.3	  mmol),	  ODA	  (11	  mmol),	  and	  ODE	  (40	  mmol)	  were	  added	  in	  a	  50	  mL	  three	   neck	   flask.	   This	  mixture	  was	   ramped	   to	   200°C	   and	   held	   there	   for	   one	   hour	  under	  nitrogen	  (N2)	  flow.	  	  After	  cooling	  down	  to	  room	  temperature,	  1	  mL	  iron	  oxide	  nanocrystal	  solution	  stored	   in	  hexanes	  at	   the	  concentration	  of	  6,000	  mg/L	  Fe	  was	  injected	  into	  the	  mixture	  and	  the	  mixture	  was	  heated	  to	  100	  °C	  for	  30	  minutes	  for	  the	   evaporation	   of	   hexanes	   completely.	   Afterwards,	   the	   reaction	   mixture	   was	  allowed	   to	   heat	   at	   280	   °C	   for	   one	   hour	   under	   nitrogen	   (N2)	   flow.	   Se	   (0.9	   mmol)	  dissolved	  in	  trioctylphosphine	  (TOP,	  2	  ml)	  was	  slowly	  injected	  into	  the	  solution	  with	  the	  speed	  of	  0.4	  ml/min	  at	  lower	  temperature	  220	  °C	  and	  the	  temperature	  was	  set	  to	  250	  °C	  allowing	  to	  grow	  CdSe	  QDs	  on	  the	  iron	  oxide	  surface.	  By	  taking	  aliquots	  at	  the	   different	   time	   intervals	   from	   1	   to	   25	   minutes,	   the	   CdSe	   QDs/iron	   oxide	  magnetic-­‐optical	  complexes	  emitted	  multiple	  fluorescence	  colors	  from	  green	  to	  red	  were	  obtained.	  The	  aliquots	  of	  growth	  solution	  were	  quenched	  in	  hexanes.	  
6.1.4. 	  Synthesis	  of	  iron	  oxide/CdSe@ZnS	  	  core/shell	  QD	  nanoparticles	  
Following	  the	  procedure	  of	  Peng’s	  group,	  a	  ZnS	  shell	  was	  deposited	  onto	  the	  CdSe	   QDs	   by	   introducing	   calculated	   amounts	   of	   Zn	   and	   S.62	   	   The	   zinc	   precursor	  solution	  (0.04	  M)	  was	  made	  by	  dissolving	  ZnO	  (0.39	  g)	   in	  oleic	  acid	  (10.83	  g)	  and	  ODE	   (108	   ml)	   at	   250	   °C.	   	   The	   sulfur	   stock	   solution	   (0.04	   M)	   was	   prepared	   by	  dissolving	   sulfur	   powder	   (0.128	   g)	   in	   ODE	   (100	   ml)	   at	   200	   °C.	   	   Both	   precursor	  solutions	  were	  prepared	  under	  nitrogen.	  The	  zinc	  precursor	  solution	  requires	  pre-­‐
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heating	  to	  ensure	  complete	  dissolution	  before	  injection.	  	  For	  each	  injection	  to	  make	  a	  shell,	  a	  certain	  amount	  of	  stock	  solution,	  found	  via	  calculation,	  was	  introduced	  to	  the	  reaction	  via	  a	  syringe.	  The	  CdSe	  QD/iron	  oxide	  magnetic-­‐optical	  complexes	  with	  green	   and	   red	   fluorescence	   colors	  were	   synthesized	   by	   the	   procedure	   above.	   The	  resulting	   complexes	   were	   heated	   to	   220	   °C	   for	   the	   preparation	   of	   CdSe@ZnS	  QDs/iron	  oxide	  complexes	  and	  1	  ml	  of	  Zn	  precursor	  (0.04	  M	  ZnO/OA	  in	  ODE)	  was	  slowly	   injected	  and	  stirred	   for	  10	  min	  at	   this	   temperature.	  The	   same	  amount	  of	   S	  precursor	   solution	   was	   sequentially	   injected	   into	   the	   reaction	   and	   stirred	   for	   15	  min.	  	  Then,	  the	  reaction	  mixture	  was	  cooled	  down	  to	  60	  °C	  and	  dispersed	  in	  hexanes	  solution.	  The	  resulting	  CdSe@ZnS	  QDs/iron	  oxide	  (10	  nm	  diameter	  core)	  materials	  had	   a	   green	   fluorescence	   while	   the	   CdSe@ZnS	   QDs/iron	   oxide	   (17	   nm	   diameter	  core)	  with	  red	  emission	  were	  prepared	  by	  these	  procedures.	  	  
6.1.5. Magnetic	  capture	  purification	  
	  The	   complexes	   could	   be	   purified	   via	   magnetic	   capture;	   specifically	  unattached	  QDs	  could	  be	  removed	  from	  the	  mixture	  as	  they	  were	  not	  magnetically	  responsive.	   	   To	   accomplish	   this,	   15	   mL	   of	   methanol	   was	   added	   to	   the	   hexanes	  solution	  of	  the	  complexes	  (5	  mL).	  	  This	  led	  to	  some	  degree	  of	  aggregation	  and	  faster	  interaction	  with	   the	  strong	  handheld	  magnet	   (NdFeB	  rod	  magnet	  with	  1.25	  ~1.28	  Tesla	  (T),	  United	  Nuclear	  Scientific	  Equipment	  &	  Supplies)	  positioned	  near	  the	  vial	  wall.	   	   After	   one	   to	   three	   minutes,	   the	   QD/iron	   oxide	   magnetic-­‐optical	   complexes	  were	  concentrated	  on	  the	  side	  of	  the	  vial	  leaving	  behind	  any	  surfactant,	  unattached	  QDs,	  and	  unreacted	  precursors	  in	  the	  solution,	  which	  was	  discarded.	  	  5mL	  hexanes	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were	  added	   to	  dissolve	   complex	   solution	  and	  more	  methanol	   (15	  ml)	  was	   further	  added.	   	   The	   solution	  was	   shaken	   and	   the	   cycle	   of	  magnetic	   capture	  was	   repeated	  three	   to	   five	   times.	   It	   is	   notable	   that	   this	   process	   is	   much	   faster	   than	   the	  conventional	   purification,	   which	   relies	   on	   introduction	   of	   methanol	   followed	   by	  centrifugation.	  	  The	  magnetically	  purified	  QDs/iron	  oxide	  magnetic-­‐optical	  complex	  solution	  was	   dispersed	   in	   hexanes	   solution	   and	   stored	   under	   ambient	   conditions	  using	  dark	  vials	  and	  aluminum	  foil.	  
6.1.6. Phase	  transfer	  of	  iron	  oxide/QD	  using	  oleic	  acid	  
This	  phase	  transfer	  method	  was	  modified	  from	  that	  reported	  by	  Prakash	  et.	  al.165	  	  Various	  amounts	  of	  oleic	  acid	  (2~20	  uL,	  6	  to	  64	  µM)	  were	  added	  to	  the	  1	  ml	  of	  QDs/iron	   oxide	   magnetic-­‐optical	   complexes	   ethyl	   ether	   solution	   (typically,	   Fe	   50	  mg/L,	  Cd	  200	  mg/L)	  and	  stirred	  24	  hours	  without	  sonication.	  	  Afterwards,	  the	  same	  volume	  of	  0.05	  M	  NaOH	  solution	  was	  added	   to	   the	  solution.	   It	  was	  allowed	   to	  stir	  gently,	  leading	  to	  the	  evaporation	  of	  the	  organic	  solvent	  (ethyl	  ether)	  over	  24	  hours.	  	  Purification	   of	   as-­‐prepared	   water-­‐soluble	   QDs/iron	   oxide	   complexes	   was	   carried	  out	  using	  ultracentrifugation	   (Optima	  L-­‐90K	  ultracentrifuge,	  BECKMAN	  COULTER)	  at	   35,000	   rpm	   for	   3	   h,	   followed	   by	   syringe	   filtration	   (pore	   size	   of	   0.45	   µm,	  WHATMAN-­‐NYL).	   	  This	  purification	  process	  was	  repeated	  2	  to	  3	  times.	  Finally,	  the	  QDs/iron	   oxide	   magnetic-­‐optical	   complexes	   were	   stored	   in	   ultrapure	   water	  (MILLIPORE,	  18.2	  MΩ·cm).	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6.1.7. 	  Magnetic	  column	  separation	  
The	  iron	  oxide	  nanocrystals	  (10	  and	  17	  nm)	  and	  QDs/iron	  oxide	  complexes	  with	  different	   iron	  oxide	   cores	   (10	  and	  17	  nm)	  and	   fluorescent	   colors	   (green	  and	  red)	   were	   used	   to	   visualize	   size-­‐dependent	   magnetic	   separations.	   Magnetic	  separation	   were	   used	   with	   L-­‐1CN	   S.G.	   Frantz	   Canister	   Separator	   High	   Gradient	  Magnetic	  Separator	  (HGMS)	  equipped	  with	  a	  stainless	  steel	  canister	  column	  (6.3	  x	  25.4	   x	   222.3	   mm,	   35.5	   cm3)	   packed	   with	   stainless-­‐steel	   wool	   (~50	   µm	   wire	  diameter),	  with	  a	  packing	  volume	  of	  5	  %	  of	  the	  canister	  (~15	  g	  stainless-­‐steel	  wool).	  Different	  sizes	  of	   iron	  oxide	  or	   iron	  oxide/QD	  complexes	  were	  passed	  through	  the	  HGMS	  at	  magnetic	   fields	   varying	   from	  0	   to	  1.4	  T	   to	  determine	  how	  efficiently	   the	  samples	   were	   retained	   in	   the	   column,	   similar	   to	   previous	   methods.306-­‐308	   The	  samples	   in	  both	  hexanes	   and	  water	   (typically,	   10	  mL	  volume,	   concentration	  of	   Fe	  500	  mg/L)	  were	  gravity	  fed	  (~1	  min)	  loaded	  into	  the	  column	  packed	  with	  stainless	  steel	   wool.	   The	   iron	   contents	   of	   initial,	   retained,	   and	   effluent	   solutions	   were	  quantitatively	  determined	  by	   a	  PerkinElmer	  Optima	  4300	  DV	   Inductively	  Coupled	  Plasma-­‐Optical	  Emission	  Spectrometer	  (ICP-­‐OES).	  	  
6.1.8. Magnetic	  enrichment	  
Different	  concentrations	  of	  QDs/iron	  oxide	  solutions	  were	  used	   to	  evaluate	  the	  pre-­‐concentration	  of	  magnetic	  materials.	  	  To	  compare	  the	  magnetic	  enrichment	  effect,	  10	  ml	  of	  QD/iron	  oxide	  complex	  solution	  was	   loaded	  onto	  the	  glass	  slide	   in	  the	   small	   round	   shape	   petri	   dish,	   where	   placed	   on	   the	   top	   of	   a	   strong	   magnet	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(NdFeB	  rod	  magnet,	  1.25	  ~1.28	  T)	   for	  12	  hours	  while	   the	  control	  was	  set	  nearby.	  	  The	   fluorescent	   signals	   of	   both	   samples	   were	   detected	   using	   fluorescence	  microscope	   (Zeiss	   Axioimager	   Z2	   upright	   microscope)	   and	   the	   concentrations	   of	  atomic	   Fe	   and	   Cd	   were	   measured	   by	   ICP-­‐OES.	   The	   numeric	   values	   for	   the	  fluorescence	  intensity	  and	  populations	  were	  calculated	  by	  the	  integration	  of	  pixels	  (~106	  pixels)	  of	  the	  signals	  correcting	  for	  the	  background.	  	  	  
6.1.9. 	  Instruments	  and	  characterization	  
Ultraviolet-­‐visible	   (UV-­‐Vis)	   absorption	   spectroscopy:	   Ultraviolet-­‐visible	  absorption	   spectrum	   was	   measured	   by	   a	   Varian	   Cary	   5000	   UV-­‐VIS-­‐NIR	  spectrophotometer.	  Diluted	  solutions	  of	  iron	  oxide/QDs	  complexes	  in	  hexanes	  were	  placed	  in	  1	  cm	  quartz	  cuvette	  and	  their	  absorption	  spectra	  were	  acquired.	  
Photoluminescence	  (PL)	  spectroscopy:	  Photoluminescence	  (PL)	  spectra	  of	  the	   iron	   oxide/QDs	   complexes	   were	   recorded	   on	   a	   Jobin	   Yvon	   Spex	   Fluorolog	   3	  fluorescence	  spectrophotometer.	  	  
Transmission	   electron	  microscopy	   (TEM):	   TEM	   specimens	  were	   carried	  out	   by	   JEOL	   2100	   field	   emission	   gun	   TEM	   operating	   at	   200	   kV	   with	   a	   single	   tilt	  holder.	  The	  TEM	  sample	  was	  made	  by	  evaporating	  one	  drop	  of	  purified	  solution	  in	  hexanes	  on	  ultra	  thin	  carbon	  type-­‐A	  400	  mesh	  copper	  grids	  (Ted	  Pella	  Inc.).	  The	  size	  and	   size	   distribution	   data	   were	   obtained	   by	   counting	   over	   500	   individual	  nanocrystalline	   particles	   using	   Image-­‐Pro	   Plus	   5.0	   (Media	   Cybernetics,	   Inc.,	   Silver	  Spring,	  MD).	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High	   angle	   angular	   dark	   field-­‐scanning	   transmission	   electron	  
microscopy	   (HAADF-­‐STEM)	   and	   electron	   energy	   loss	   spectroscopy	   (EELS)	  
spectrum	  imaging:	  The	  HAADF-­‐STEM	  investigation	  was	  carried	  out	  in	  TEM-­‐2100F	  (JEOL)	  fitted	  with	  a	  spherical	  aberration	  corrector	  (CEOS	  GmbH)	  and	  a	  Gatan	  Enfina	  Electron	  Energy	  Loss	  Spectroscopy	  (EELS)	  spectrometer.	  The	  operating	  voltage	  was	  200	  kV.	  The	  EELS	  spectrum	   images	  were	  recorded	  with	  an	  energy	  resolution	   (full	  width	  at	  half-­‐maximum	  of	  the	  zero	  loss	  peak)	  of	  1	  eV.	  
Inductively	  coupled	  plasma	  optical	  emission	  spectroscopy	  (ICP-­‐OES):	  To	  determine	   the	   concentration	   of	   sample,	   the	   PERKIN	   ELMER	   ICP-­‐OES	   instrument	  equipped	  with	  auto	  sampler	  was	  used.	  For	  the	  phase	  transfer	  efficiency,	  the	  atomic	  concentrations	   (Fe	   and	   Cd)	   of	   water-­‐soluble	   QDs/iron	   oxide	   solution	   added	   with	  different	  amounts	  of	  OA	  were	  compared	  from	  the	  concentrations	  of	  original	  hexanes	  solution.	   	   Moreover,	   the	   percentage	   of	   the	   retention	   by	   magnetic	   separator	   was	  calculated	  by	  dividing	   the	  atomic	   (Fe)	   concentration	   in	   retained	  solution	   from	   the	  concentration	   measured	   for	   the	   initial	   (unseparated)	   solution.	   The	   iron	   oxide	  nanocrystals	  and	  QDs/iron	  oxide	  materials	  were	  digested	  by	  nitric	  acid	  (HNO3,	  70	  %)	  and	  hydrogen	  peroxide	  (H2O2,	  30	  %).	  	  	  	  
Fluorescence	   microscope	   imaging:	   Zeiss	   Axio	   imager	   Z2	   upright	  microscope	   (Excitation:	   BP	   530-­‐585,	   538	   nm,	   Beam	   splitter	   FT	   600,	   Emission:	  LP615)	  was	  used	  for	  getting	  the	  fluorescence	  images	  of	   iron	  oxide/QDs	  complexes	  with	   captured	   samples	   on	  magnetic	   field	   and	   without	   the	   field.	   The	   fluorescence	  images	  were	  acquired	  using	  CCD	  camera	  and	  processed	  by	  the	  software	  Axio	  Vision.	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6.2. 	  Result	  and	  discussions	  
6.2.1. 	  Synthesis	  of	  the	  size	  tunable	  iron	  oxide/QD	  complexes	  
Magnetic-­‐optical	  complexes	  consisting	  of	  iron	  oxide	  core	  and	  CdSe	  QDs	  were	  synthesized	  by	  seed-­‐mediated	  growth	  method	  at	  high	  temperatures	  (280	  °C).	  Figure	  6-­‐1	   shows	   that	   the	   resulting	   pincushion	  magnetic-­‐optical	   complexes	   have	   tunable	  optical	  properties	  and	  collect	  at	  the	  site	  of	  a	  hand-­‐held	  magnet	  (NdFeB	  rod	  magnet,	  1.25	   ~1.28	   T).	   During	   synthesis,	   the	   preformed	   iron	   oxide	   nanocrystals	   act	   as	  nucleation	   sites	   for	   QDs,	   under	   a	   specific	   set	   of	   conditions	   established	   using	   pre-­‐determined	   surfactant	   compositions,	   reaction	   temperatures,	   and	   injection	   speeds.	  The	   magnetic-­‐optical	   complexes	   only	   form	   when	   the	   selenium	   precursor	   was	  injected	   drop-­‐wise	   to	   CdO/iron	   oxide	   mixture	   in	   the	   presence	   of	   octadecylamine	  (ODA)	  at	  high	  temperatures	  (220	  °C)	  (Figure	  6-­‐1(A)).	  The	  high	  angle	  angular	  dark	  field-­‐scanning	   transmission	   electron	   microscopy	   (HAADF-­‐STEM)	   image,	   Figure	  6-­‐1(B)	  clearly	  shows	  that	  QDs	  directly	  nucleated	  and	  grew	  directly	  on	  the	  surface	  of	  the	   iron	   oxide	   nanocrystals.	   	   Electron	   energy	   loss	   spectroscopy	   (EELS)	   elemental	  mapping	   was	   used	   to	   confirm	   that	   magnetic-­‐optical	   complexes	   were	   pincushion	  structures	  that	  stud	  QDs	  onto	  iron	  oxide	  surface	  (Figure	  6-­‐2).	  EELS	  spectrums	  were	  also	  used	  to	  confirm	  the	  position	  and	  chemical	  composition	  of	  Fe	  for	  the	  iron	  oxide	  and	  Cd	  for	  the	  QDs	  features	  (Figure	  6-­‐3).	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Figure	  6-­‐1	  The	  QDs/iron	  oxide	  materials	  and	  their	  optical	  &	  magnetic	  properties.	  TEM	   images	   of	   (A)	   CdSe	   QDs/iron	   oxide	   materials	   and	   (B)	   HAADF-­‐STEM	   image	  (scale:	  21.2	  nm	  x	  21.2	  nm).	  	  The	  diameter	  of	  iron	  oxide	  nanocrystals	  was	  12	  nm.	  The	  size	  of	  CdSe	  QD	  was	  3.8/5.3	  nm	  (width/length).	  The	  scale	  bars	  were	  20	  nm.	  (C)	  The	  photographs	   of	   CdSe	   QDs/iron	   oxide	   under	   the	   fluorescent	   light	   and	   ultraviolet	  light.	   	  By	  controlling	   the	  growth	   time	   from	  1	   to	  25	  minutes,	   the	  size	   tunable	  CdSe	  QDs/iron	   oxide	   materials	   showed	   multiple	   fluorescence	   colors.	   (D)	   and	   (E)	   The	  CdSe	  QDs/iron	  oxide	  materials	  collected	  by	  strong	  handheld	  magnet	  showed	  orange	  and	  red	  fluorescent	  colors.	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Figure	  6-­‐2	  HAADF-­‐STEM	  images	  and	  EELS	  mappings	  of	  magnetic-­‐optical	  complexes	  (A)	  The	  HAADF-­‐STEM	   image,	   (B)	   iron	   (Fe)	  mapping,	   (C)	   the	  HAADF-­‐STEM	   image,	  and	  (D)	  its	  cadmium	  (Cd)	  mapping	  were	  acquired,	  respectively.	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Figure	   6-­‐3	   (A)	   EELS	   spectrum	   image	   and	   (B)	   and	   (C)	   chemical	   identification	  spectrums	  at	  the	  cross	  beam	  of	  (A)	  image.	  	  The	  iron	  (Fe)	  and	  cadmium	  (Cd)	  were	  detected	  at	  721	  eV	  and	  404	  eV,	  respectively.	  	  The	  iron	  oxide	  core	  region	  in	  the	  complexes	  did	  not	  contain	  cadmium	  (Cd).	  (D)	  EELS	  spectrum	  and	  (E)	  and	  (F)	  the	  chemical	  identification	  spectrums	  from	  the	  cross	  beam	  of	  (D)	  image.	  Iron	  (Fe)	  was	  not	  detected	  from	  the	  QDs	  area	  in	  the	  complexes.	  	  
The	  diameters	  of	  QDs	  grown	  on	  the	  surface	  of	  12	  nm	  iron	  oxide	  nanocrystals	  can	  be	  tuned	  from	  2.2	  to	  4.3	  nm,	  resulting	  in	  samples	  with	  a	  range	  of	  distinct	  fluorescence	  emission	   colors.	   The	   resulting	   diameter	   of	   CdSe	   QDs	   in	   the	   complexes	   increased	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causing	   the	  emission	  wavelength	   for	   the	  sample	  aliquot	   to	  red	  shift	   from	  543-­‐605	  nm	   (Figure 6-4).	   The	   size	  dependent	   emission	   spectra	  of	  QDs	   can	  be	   explained	  by	  quantum	  confinement	  and	  band	  gap	  energy	  theory.54,118,282,309	  The	  exciton	  transition	  shifted	   to	   higher	   energy	   with	   an	   increase	   of	   molar	   absorption	   coefficient	   as	   QD	  diameters	   decreased.	   	   The	   size	   dependent	   optical	   properties	   of	  QDs	  were	  used	   to	  produce	   complex	   samples	   that	   emit	   at	   green	   (2.2	   nm),	   yellow	   (3.0	   nm),	   yellow-­‐orange	   (3.3	   nm),	   orange	   (3.8	   nm),	   red-­‐orange	   (4.0	   nm),	   and	   red	   (4.3	   nm)	   (Figure 
6-5).	   	   Being	   able	   to	   achieve	   tunable	   optical	   property	   is	   critical	   for	   designing	  magnetic-­‐optical	   complexes	   for	   biological	   applications	   such	   as	   multiplexed	  detection	  or	  multi-­‐cell	  sorting.1d,	  24,62,66,310	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Figure	  6-­‐4	  (A)	  Absorption	  spectra	  of	  CdSe	  QDs/iron	  oxide	  at	  different	  growth	  time.	  	  The	   absorption	   peaks	   were	   red-­‐shifted	   from	   528	   nm	   to	   589	   nm.	   (B)	  Photoluminescence	   (PL)	   spectra	  of	  CdSe	  QDs/iron	  oxide	  materials	   at	   the	  different	  growth	  time.	  The	  peaks	  of	  the	  photoluminescence	  were	  red-­‐shifted	  from	  543	  nm	  to	  605	  nm.	  (C)	  and	  (D)	  the	  emission	  peak	  positions	  and	  average	  TEM	  sizes	  of	  CdSe	  QDs	  in	  complexes	  were	  increased	  as	  the	  growth	  time	  increased	  from	  1	  to	  25	  min.	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Figure	   6-­‐5	   (A)-­‐(F)	   The	   TEM	   images	   of	   CdSe	   QDs/iron	   oxide	   materials	   as	   the	  different	  growth	  time	  (1,	  5,	  10,	  15,	  20,	  and	  25	  min).	  The	  sizes	  of	  QDs	  were	  corresponded	  to	   the	  emission	  colors.	   	  The	  diameter	  of	   iron	  oxide	  was	  11	  nm.	  The	  diameter	  of	  CdSe	  QD	  in	  the	  complexes	  was	  2.2	  nm	  (green),	  3.0	  nm	  (yellow),	  3.3	  nm	  (light	  orange),	  3.8	  nm	  (orange),	  4.0	  nm	  (deep	  orange),	  and	  4.3	  nm	  (red),	  respectively.	  The	  scale	  bars	  were	  20	  nm.	  	  
6.2.2. Phase	  transfer	  of	  iron	  oxide/QD	  complexes	  
Water-­‐soluble	  magnetic-­‐optical	  complexes	  were	  achieved	  by	  injecting	  phase	  transfer	   agents	   such	   as	   poly(maleic	   anhydride-­‐alt-­‐1-­‐octadecene)	   (PMAO,	   Mn	   =	  50,000),	   poly(maleic	   anhydride-­‐alt-­‐1-­‐octadecene)(PMAO)-­‐co-­‐poly(ethylene	   glycol)	  (PEG,	  Mw	  =	  2,000)	  amphiphilic	  polymers,	  and	  oleic	  acid	  (OA,	  Mw=	  282	  g/mol).165,221	  Among	   them,	   only	  OA	   coated	  magnetic-­‐optical	   complex	   suspensionsretained	   their	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fluorescence	   (Figure	  6-­‐6	  and	  Figure	  6-­‐7).	  With	   the	   colloidal	   stability	   in	  water,	   the	  magnetic-­‐optical	  complexes	  need	  to	  keep	  their	  optical	  and	  magnetic	  properties	  after	  transferring	   to	   water.	   	   However,	   PAMO	   and	   PMAO-­‐PEG	   coated	   magnetic-­‐optical	  complexes	   lost	   their	   optical	   properties	   when	   transferred	   to	   water	   (Figure	   6-­‐6).	  When	  the	  large,	  bulky	  polymers	  were	  introduced	  to	  the	  magnetic-­‐optical	  complexes,	  a	   thin	   ZnS	   shell	   and	   polymer	   agglomeration	   caused	   magnetic-­‐optical	   complexes	  defects	  on	  the	  surface	  and	  led	  to	  the	  quenching	  of	  fluorescence.	  We	  speculated	  that	  a	  thin	  ZnS	  shell	  does	  not	  protect	  the	  surface	  of	  CdSe	  QDs	  densely	  and	  result	  in	  the	  failure	   to	   trap	   the	  excitons	   in	   the	  CdSe	  QDs	  core.	   	   In	  contrast,	   small	   fatty	  acid,	  OA	  coated	   CdSe@ZnS	   QDs/iron	   oxide	   magnetic-­‐optical	   complexes	   retained	   the	  fluorescence	  without	  any	  loss	  in	  aqueous	  solution.	  
	  
	  
Figure	  6-­‐6	  	  The	  photographs	  of	  phase	  transfer	  from	  organic	  to	  aqueous	  phase	  using	  various	  surface	  modification	  methods	  under	  the	  ultraviolet	  light.	  	  	  The	   phase	   transfer	   coating	   were	   used	   (A)	   PMAO-­‐PEG	   amphiphilic	   polymer,	   (B)	  PMAO	  polymer,	   and	   (C)	   oleic	   acid	   (fatty	   acid).	   	   The	  oleic	   acid	   coating	   showed	   the	  fluorescence	  in	  both	  solutions.	  
	   238	  	  
	  Figure	  6-­‐7	  Phase	  transfer	  of	  QDs/iron	  oxide	  materials.	  Oleic	   acid	   as	   was	   used	   as	   a	   phase	   transfer	   agent	   to	   bring	   hydrophobic	   QDs/iron	  oxide	  materials	  to	  water	  phase.	  The	  CdSe@ZnS	  QDs/iron	  oxide	  dispersed	  in	  hexanes	  and	  water	  under	  (A)	  the	  fluorescent	  and	  (B)	  the	  ultraviolet	   light.	   	   (C)	  The	  transfer	  yields	  of	  complexes	  as	  the	   increasing	  amounts	  of	  oleic	  acid.	  (D)	  The	  TEM	  image	  of	  CdSe@ZnS	  QDs/iron	  oxide	  materials	  dispersed	  in	  water.	  	  The	  scale	  bar	  was	  20	  nm.	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OA-­‐coated	  magnetic-­‐optical	  complexes	  dispersed	  in	  water	  did	  not	  change	  in	  diameter	   or	   morphology	   and	   remained	   fluorescent	   (Figure	   6-­‐7).	   The	   average	  hydrodynamic	  diameter	  of	   the	   complexes	  was	  30-­‐35	  nm,	  which	  accounted	   for	   the	  10	  nm	  of	  iron	  oxide,	  9	  nm	  of	  QDs,	  and	  11-­‐16	  nm	  for	  the	  surface	  coating	  agents.	  	  The	  ration	  of	  OA	  per	  complex	  was	  varied	  to	  achieve	  the	  greatest	  transfer	  yield	  (~75	  %).	  Figure	  6-­‐7	  (C)	  shows	  that	   low	  concentration	  of	  OA	  (from	  1	  to	  10	  uM)	  had	  transfer	  yields	   of	   30	   –	  60	  %	  because	   there	  was	  not	   enough	  OA	   to	   fully	   cover	   the	   complex	  surface.	   	  However,	  increasing	  the	  concentration	  of	  OA	  (from	  30	  to	  65	  uM)	  resulted	  in	   cloudy	   solution	   with	   low	   transfer	   yields	   (20–30	   %)	   due	   to	   the	   formation	   of	  micelles.311	  We	  found	  that	  75	  uM	  OA	  per	  1	  mL	  sample	  (CdSe@ZnS	  QDs/iron	  oxide,	  Fe:	  50	  mg/L,	  Cd:	  200	  mg/L)	  resulted	   in	   the	  best	   transfer	  yield	  (75	  %)	  (Figure	  6-­‐7	  (C)).	   The	   OA	   coated	  magnetic-­‐optical	   complexes	   retained	   their	  morphology,	  were	  water-­‐soluble,	  and	  were	  colloidal	  stable	  (Figure	  6-­‐7	  (D)).	  	  
The	   optical	   property	   of	   the	   OA	   coated	   hydrophilic	   magnetic-­‐optical	  complexes	  were	  maintained	   in	  biologically	   relavant	   solutions.	  The	   absorption	   and	  fluorescence	  spectra	  of	  magnetic-­‐optical	  complexes	  did	  not	  shift	  while	  transferring	  from	  organic	  to	  aqueous	  phase	  (Figure	  6-­‐8).	  The	  colloidal	  and	  fluorescence	  stability	  of	  OA	  coated	  magnetic-­‐optical	   complexes	  were	  evaluated	   in	  a	   range	  of	  buffers,	  pH	  (from	  3	  to	  11),	  and	  ionic	  strength	  solutions	  (Figure	  6-­‐9).	  	  Neutral	  and	  basic	  solutions	  from	  7	  to	  11,	  did	  not	  alter	  the	  fluorescence	  of	  magnetic-­‐optical	  complexes.	  However,	  in	   acidic	   conditions	   (pH	   3	   and	   5),	   the	   suspensions	   became	   cloudy	   due	   to	  precipitation	  and	  resulted	  in	  a	  loss	  of	  fluorescence.	  The	  magnetic-­‐optical	  complexes	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were	  stable	  in	  a	  range	  of	  ionic	  strengths	  from	  0.01	  M	  to	  0.5	  M	  NaCl	  and	  in	  various	  biological	   relavant	   buffers	   (phosphate	   buffered	   saline	   (PBS),	   borate,	   and	   sodium	  bicarbonate).	  	  
	  Figure	  6-­‐8	  The	  absorption	  and	  photoluminescence	  spectra	  of	  QD/iron	  oxide	  complexes	  in	  hexanes	  and	  water.	  	  (A)	   the	  absorption	  spectra	   (582	  nm)	  and	   (B)	   the	  photoluminescence	   spectra	   (595	  nm)	  of	  CdSe@ZnS	  QDs/iron	  oxide	  materials	  in	  hexanes	  (black)	  and	  water	  (red).	  The	  absorption	   and	   photoluminescence	   spectra	   of	   complexes	   were	   not	   changed	   after	  phase	  transfer.	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  Figure	  6-­‐9	  The	  QDs/iron	  oxide	  suspensions	  under	  various	  conditions	  (A)	  and	  (B)	  The	  QDs/iron	  oxide	  suspensions	  under	  various	  pH	  conditions	  (pH	  3,	  5,	  7,	  8,	  9,	  11)	  under	  the	  fluorescent	  and	  ultraviolet	  light.	  	  At	  low	  pH,	  the	  samples	  were	  precipitated	  or	  cloudy.	  	  It	  showed	  the	  best	  stability	  in	  basic	  solution	  (pH	  9-­‐10).	  	  (C)	  and	   (D)	   The	   QDs/iron	   oxide	   complex	   suspensions	   under	   the	   different	   ionic	  strengths	   in	   NaCl	   (0.01M,	   0.05M,	   0.1M,	   0.25M,	   0.5M)	   under	   the	   fluorescent	   and	  ultraviolet	   light.	  At	   higher	   ionic	   strengths	   in	  NaCl,	   the	   suspension	  was	   cloudy.	   (E)	  and	   (F)	   The	   QDs/iron	   oxide	   suspensions	   under	   various	   buffer	   conditions	   (PBS	  buffer,	  Borate	  buffer,	  NaHCO3	  buffer).	  These	  photographs	  were	  taken	  after	  7	  days	  of	  the	  treatment.	  	  
	   242	  	  
6.2.3. Visualized	  magnetic	  separation	  of	  iron	  oxide/QD	  complex	  
Size	  dependent	  magnetic	  separation	  showed	  that	  larger	  particles	  have	  higher	  retention	   in	  a	  column	   for	  bare	   iron	  oxide	  and	  magnetic-­‐optical	  complex	  materials.	  Figure	  6-­‐10	  shows	  the	  percent	  retention	  of	  bare	  and	  complexes	  prepared	  from	  iron	  oxide	  nanoparticles	  of	  10	  nm	  and	  17	  nm	   in	  organic	  and	  aqueous	  solution.	  Using	  a	  conventional	   high	   gradient	   magnetic	   separator	   (HGMS)306-­‐308,	   we	   compared	   the	  percentage	   of	   retention	   for	   a	   sample	   as	   the	   applied	  magnetic	   field	  was	   increased	  from	  0.01	  to	  1.4	  T.	  	  As	  expected,	  for	  all	  samples	  the	  larger	  iron	  oxide	  nanoparticles	  (17	  nm)	  had	  a	  higher	  percent	  of	  material	  retained	  within	  the	  column.	  The	  magnetic-­‐optical	   complexes	   in	   either	   solution	   were	   retained	   in	   the	   magnetic	   column	   at	   a	  lower	   percentage	   than	   the	   same	   core	   iron	   oxide	   nanocrystals;	   indicating	   that	   the	  magnetic	   properties	   of	   the	   complexes	   are	   affected	   by	   the	   surrounding	   QDs.	   The	  difference	   in	   retention	   for	   the	   magnetic-­‐optical	   complex	   was	   found	   to	   be	   more	  drastic	   in	   aqueous	   solutions,	   most	   likely	   due	   to	   the	   agglomeration	   effect	   of	   the	  double	  layer	  OA	  surface	  coatings.	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  Figure	   6-­‐10	   Size	   dependent	   magnetic	   separation	   with	   bare	   iron	   oxides	   and	  QDs/iron	  oxide	  materials	  in	  hexanes	  and	  water.	  	  	  (A)	   Size	   dependent	   magnetic	   retention	   of	   iron	   oxide	   (10	   nm	   and	   17	   nm)	   and	  QDs/iron	  oxide	  dispersed	  in	  hexanes	  using	  column	  magnetic	  separator	  (B)	  Magnetic	  retention	   of	   oleic	   acid	   coated	   iron	   oxide	   and	   QDs/iron	   oxide	  materials	   soluble	   in	  water	   using	   magnetic	   column	   separator.	   	   Retained	   fractions	   in	   a	   column	   were	  digested	  in	  5%	  nitric	  acid	  and	  their	  concentration	  of	  iron	  (Fe)	  was	  analyzed	  by	  ICP-­‐OES.	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Size	   dependent	   magnetic	   separations	   selectively	   isolate	   larger	   magnetic-­‐optical	   complexes	   from	   a	   mixture.	   Different	   sizes	   of	   magnetic-­‐optical	   complexes	  were	  prepared	  where	  a	   large	   iron	  oxide	  nanocrystals	   (17	  nm)	  were	   studded	  with	  4.3	   nm	   QDs	   (red)	   and	   smaller	   (10	   nm)	   ones	   were	   conjugated	   with	   2.1	   nm	   QDs	  (green).	  	  Figure	  6-­‐11	  shows	  the	  schematic	  diagram	  of	  the	  HGMS	  and	  TEM	  images	  of	  the	   (A)	  mixed,	   (B)	   retained,	   and	   (C)	   effluent	   samples	   during	  magnetic	   separation.	  First,	   the	  smaller	  green	  fluorescent	  complexes	  were	  mixed	  with	   large	  red	  emitting	  complexes	  in	  a	  1:2	  (v/v)	  ratio.	  	  The	  prepared	  mixture	  was	  passed	  through	  a	  packed	  column	   with	   an	   applied	   magnetic	   field	   of	   0.09	   T.	   	   Due	   to	   the	   size-­‐dependent	  magnetic	  properties	  of	  the	  core	  iron	  oxide,	  most	  of	  larger	  (17	  nm)	  magnetic-­‐optical	  complexes	  were	  retained	  in	  the	  magnetic	  column,	  while	  the	  smaller	  complexes	  were	  eluted.306-­‐308	   While	   some	   QDs	   were	   found	   to	   detach	   from	   the	   core	   iron	   oxide	  nanocrystals	   when	   passed	   through	   the	   magnetic	   column,	   most	   (>	   80	   %)	   of	   the	  recovered	   complexes	   were	   stable	   and	   intact.	   The	   separation	   efficiency	   was	  evaluated	   by	   TEM	   images	   and	   their	   histograms	   of	   retained	   (B)	   and	   effluent	   (C)	  samples,	  as	  shown	  in	  Figure	  6-­‐11.	  	  The	  average	  separation	  efficiency	  was	  80	  %.	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  Figure	  6-­‐11	  Schematic	  diagram	  of	  magnetic	  column	  separator	  and	  TEM	  images	  (A-­‐C)	  of	  mixed,	  captured,	  and	  effluent	  samples.	  The	   bare	   iron	   oxide	   and	   QDs/iron	   oxide	   solution	   are	   loaded	   through	   the	   column	  packed	   with	   stainless	   steel	   wool.	   The	   strength	   of	   magnetic	   field	   (T)	   can	   be	  controlled	  with	  the	  power	  supply.	  After	  turning	  off	  the	  magnetic	  field,	  the	  retained	  samples	   in	   the	   column	   are	   outflowed	  using	   clean	   hexanes	   or	  water.	   	   TEM	   images	  showed	  (A)	  the	  mixed	  solutions	  of	  green	  emitted	  QDs/iron	  oxide	  (10	  nm)	  and	  red	  emitted	  QDs/iron	  oxide	   (17	  nm)	   (B)	   the	   captured	   samples	   in	   the	   column,	   and	   (C)	  outflowed	   samples	  when	   the	  magnetic	   field	  was	   applied.	   	   The	   scale	   bars	  were	  20	  nm.	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Fluorescence	  of	  the	  QDs	  allowed	  for	  ease	  of	  visualization	  for	  the	  separation	  of	  the	  two	  sizes	  of	  complexes.	  	  Figure 6-12	  shows	  the	  visualized	  magnetic	  separation	  of	  the	  magnetic-­‐optical	  complexes,	  which	  was	  a	  more	  effective,	  fast,	  and	  time	  saving	  technique	   since	   the	   materials	   can	   simply	   be	   monitored	   through	   their	   unique	  fluorescence	  spectra,	  instead	  of	  relying	  on	  imaging	  and	  counting	  the	  population	  via	  TEM.	  	  Figure 6-12	  shows	  the	  fluorescence	  spectra	  of	  the	  magnetic-­‐optical	  complexes	  (A	  &	  B)	   isolated,	   (C)	  mixed,	   and	   (D	  &	   E)	   after	  magnetic	   separation.	   The	   emission	  peak	  positions	  for	  the	  green	  and	  red	  magnetic-­‐optical	  complexes	  were	  574	  nm	  and	  610	   nm	   before	   the	   separation	   (Figure 6-12	   (A)	   and	   (B)).	   These	   complexes	   were	  mixed	  together	  in	  a	  vial	  and	  the	  binary	  emission	  peaks	  are	  shown	  in	  Figure 6-12	  (C).	  
Figure 6-12	   (D)	   and	   (E)	   show	   the	   peak	   positions	   of	   these	   outflowed	   and	   retained	  samples	  were	  573	  nm	  and	  607	  nm,	  respectively,	  verifying	  the	  results	  found	  through	  TEM	  analysis	  of	   the	   same	  samples.	  This	   fluorescent	  measurement	  was	  simple	  and	  allowed	  for	  separation	  of	  two	  sizes	  of	  magnetic-­‐optical	  complexes	  from	  a	  mixture.	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Figure	  6-­‐12	  The	  photoluminescence	  (PL)	  spectra	  of	  two	  different	  complexes	  before	  and	  after	  magnetic	  separation.	  	  (A)	  and	   (B)	   the	  photoluminescence	   (PL)	   spectra	  of	  green	  QDs/iron	  oxide	   (10	  nm)	  and	  red	  QDs/iron	  oxide	  (17	  nm)	  materials	  before	  doing	  magnetic	  capture.	   	  The	  PL	  spectra	  of	   (A)	  and	  (B)	  showed	  the	  maximum	  at	  574	  nm	  and	  610	  nm,	  respectively.	  	  	  (C)	   The	   PL	   spectrum	   of	   mixed	   samples.	   	   (D)	   and	   (E)	   the	   PL	   spectra	   of	   collected	  sample	   by	   strong	   magnet	   and	   supernatant.	   	   The	   PL	   spectra	   of	   (D)	   and	   (E)	   were	  maximum	  at	  573	  nm	  and	  607	  nm,	  respectively.	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6.2.4. Magnetic	  enrichment	  
Nanomolar	   concentrations	   of	   magnetic-­‐optical	   complexes	   can	   be	  fluorescently	   detected	   on	   a	   surface	   with	   the	   help	   of	   an	   external	   magnetic	   field	  (Figure	   6-­‐13).	   Innate	   magnetic	   properties	   of	   magnetic-­‐optical	   complexes	   enable	  them	  to	  move	  towards	  an	  external	  magnetic	  field	  and	  are	  very	  useful	  for	  enrichment	  of	  a	  sample	   for	   low-­‐level	  detection.	  Figure	  6-­‐13	  shows	  that	   these	  materials	  can	  be	  easily	  collected	  using	  an	  external	  magnetic	  field	  (NdFeB	  handheld	  magnet,	  1.25-­‐1.28	  T)	   and	   produce	   a	   visual	   signal	   even	   at	   extremely	   low	   concentrations	   (nanomolar	  level).	   The	   fluorescence	   microscope	   (Zeiss	   Axioimager	   Z2	   upright	   microscope	  (excitation:	  530-­‐538	  nm,	  emission:	  615	  nm)	  can	  be	  used	   to	  detect	   the	  signals.	   	  To	  compare	   the	   magnetic	   enrichment	   by	   applying	   the	   external	   magnetic	   field,	  magnetic-­‐optical	   complexes	   were	   diluted	   from	   50	   to	   5000	   times	   of	   the	   starting	  sample	  concentration	  (Fe:	  90	  uM,	  Cd:	  200	  uM).	   	  The	  concentrations	  were	  based	  on	  the	   ionic	   concentrations	  of	  Fe	  and	  Cd	   in	   the	   complex	  determined	  by	   ICP-­‐OES.	   	  An	  external	  magnet	  was	  placed	  below	  three	  of	  the	  six	  samples	  (right	  images	  in	  Figure	  6)	   for	  12	  hours	   and	   then	   the	   surfaces	  were	   imaged.	  As	   shown	   in	  Figure	  6-­‐13,	   the	  magnetically	  concentrated	  samples	  were	  fluorescently	  more	  populated	  compared	  to	  the	   control	   samples	   prepared	   at	   the	   same	   concentration.	   As	   a	   result,	   the	  magnetically	  enriched	  samples	  could	  be	  detectable	  down	  to	  the	  nanomolar	  level.	  
Moreover,	   the	   fluorescent	   signal	   from	   the	   microscope	   images	   can	   be	  quantified	   through	   integration	   of	   the	   pixels	   compared	   to	   the	   background.	   These	  values	   are	   indicated	   on	   the	   bar	   line	   of	   the	   figure	   showing	   that	   the	   signal	   from	   a	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magnetically	   concentration	   samples	   is	   enhanced	   at	   least	   2	   fold	   at	   each	  concentration.	   The	   lowest	   detectable	   concentration	   of	   the	   magnetic-­‐optical	  complexes	  was	   10-­‐9	  mol/L	   (nM)	   level;	   Fe	   and	   Cd	   ionic	   concentrations	   of	   the	   final	  diluted	   sample	   (5,000	   times)	   were	   18	   and	   40	   nM,	   respectively.	   	   Therefore,	   the	  magnetic	   enrichment	   of	   magnetic-­‐optical	   complexes	   offers	   the	   possibility	   of	  enriching	   the	   materials	   at	   a	   target.	   From	   this	   study	   we	   have	   shown	   that	   these	  magnetic-­‐optical	  complexes	  can	  be	  used	  as	  a	  convenient	  and	  sensitive	  sensing	  probe	  for	  biological	   applications,	   such	   as	  multiple	   cell	   separation,	  multiplexed	  detection,	  and	  target	  enrichment	  with	  high	  sensitivities.	  	  
	   250	  	  
	  Figure	  6-­‐13	  Magnetic	  enrichment.	  The	  fluorescence	  images	  of	  CdSe@ZnS	  QDs/iron	  oxide	  materials	  were	  acquired	  with	  a	   Zeiss	   Axioimager	   Z2	   upright	   microscope	   (excitation:	   BP	   530-­‐538	   nm	   beam	  splitter:FT	  600,	   emission:	   LP	  615).	   	   These	  materials	  were	  placed	  on	   the	  handheld	  strong	  magnet	  for	  12	  hours.	  The	  magnetically	  enriched	  samples	  (right)	  were	  more	  concentrated	   in	   comparison	   of	   that	   with	   no	   magnetic	   field	   (left).	   	   (A)-­‐(C)	   the	  fluorescent	   images	   of	   QDs/iron	   oxide	  materials	  were	   shown	   as	   the	   concentration	  was	  decreased.	  	  The	  concentration	  of	  iron	  (Fe)	  in	  complexes	  was	  (A)	  1.8	  uM,	  (B)	  180	  nM,	  and	  (C)	  18	  nM,	  respectively.	  The	  concentration	  of	  cadmium	  (Cd)	   in	  complexes	  was	  (A)	  4	  uM	  (A),	  (B)	  400	  nM,	  (C)	  40	  nM,	  respectively.	  	  The	  diameter	  of	  iron	  oxide	  and	  QDs	  were	  12	  nm	  and	  4.3/4.7	  nm	  (width/length).	  	  The	  scale	  bar	  was	  20	  um.	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6.3. Conclusion	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Chapter 7	  
    Summary and Future Outlook 
I	   have	   studied	   the	   design,	   synthesis,	   and	   their	   applications	   of	   biomedical	  nanocrystal	   agents	   from	   fundamental	   nanocrystals	   to	   multifunctional	  nanocomplexes.	  	  Using	  diameter	  controlled	  gadolinium	  oxide	  nanocrystals	  and	  iron	  oxide	  nanocrystals	  with	  various	  biocompatible	  coatings,	  the	  r1	  and	  r2	  MR	  relaxation	  were	   optimized	   and	   explored	   the	   effects	   of	   size,	   coating,	   and	   composition.	  Especially,	   the	   PAMPS-­‐LA	   and	   PAA-­‐OA	   coated	   ultrasmall	   gadolinium	   oxide	  nanoparticles	  (<	  2	  nm)	  showed	  extremely	  high	  r1	  relaxivity	  (50-­‐	  60	  S-­‐1mM-­‐1),	  which	  is	  10-­‐15	  fold	  higher	  than	  that	  of	  commercial	  Gd(III)	  chelates	  (4.3	  ~4.6	  S-­‐1mM-­‐1).	  	  In	  
vitro	   toxicological	   studies	   showed	   that	   polymer	   coated	   nanocrystals	   suspensions	  had	  no	  significant	  effect	  at	  high	  concentration.	  	  	  
As	  a	  multi-­‐modal	  imaging	  probe,	  iron	  oxide/QDs	  complexes	  have	  size	  tunable	  optical	  properties	  and	  variable	  QDs	   features	  helped	   to	  visualize	  and	   remove	   large	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iron	  oxide	  materials	   in	   a	  magnetic	   separation.	   For	   clinical	  uses	  of	   these	  biomecial	  nanocrystal	   agents	   in	   the	   future,	   long-­‐term	   toxicity,	   in	   vivo	   targeting,	   and	   bio-­‐distribution	   should	   be	   clearly	   addressed.	   To	   conclude,	   the	   development	   of	  biomedical	  nanocrystal	  agents	  and	  exact	  investigations	  of	  their	  properties	  will	  give	  great	  uses	  for	  diagnosis,	  detection,	  and	  therapy	  of	  diseases	  in	  near	  future.	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